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 This dissertation is a study of multi-generational pharmaceutical monopolies in early 
modern France. It explores the unexpected links between the rise of chymical medicine, the 
arrival of exotic plant substances in Europe, and the de-individualization of therapeutics that 
undergirded the production of pharmaceuticals sold for large-scale consumption in the years 
1680-1740. Through a series of case-studies built around individual proprietary drugs, namely 
Robert Talbor’s remède anglois for intermittent fevers; the Contugi family’s poison antidote, 
orviétan; the Helvétius family’s poudre spécifique against dysentery; and the Guiller-Lajutais 
poudre febrifuge, this dissertation demonstrates that a coterie of medical entrepreneurs sold 
proprietary drugs—often called secret remedies (remèdes secrets)—under the protection of 
royally-sponsored monopoly privileges. Some of these entrepreneurs became medical contractors 
for “corporate consumers,” including the French fiscal-military state as well as the long-distance 
trading companies and missionary organizations of the first global age. These included the 
growing army and navy of France as well as the French East Indies Company and the Paris 
Foreign Missions Society.  
 At the heart of these developments was the concept of medicinal specifics: therapeutic 
substances which were believed to cure a given disease over large patient populations despite the 
peculiarities of individual constitutions. The rise of medicinal specifics was closely tied to the 
rise of chymical medicine as well as the arrival of new plant substances in Europe: theoretical 
innovations in Helmontian medicine and the so-called acid-alkali theory converged with the 
therapeutic effects of substances like cinchona bark and ipecacuanha root to problematize the 
categories of traditional Galenic pharmacology. In addition to exploring these transformations in 
pharmacological theory, the dissertation also emphasizes practical pharmacy, the concrete 
iii 
 
processes of drying, grinding, distillation, and extraction that constituted the medical secrets 
which stood at the heart of pharmaceutical monopolies. By exploring medicinal specifics, state-
sponsored monopolies, large-scale pharmaceutical production, and the “corporate consumption” 
of drugs in the decades around 1700, this dissertation contributes to our understanding of the 
question of de-individualization in therapeutics, the ongoing re-evaluation of the early modern 
medical marketplace, and to the place of European proprietary remedies in a global context. 
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 This dissertation began as an inquiry into the history of medical regulation in 
seventeenth-century Paris, but over time it became a study of early pharmaceutical 
monopolists in the context of the “court capitalism” associated with the development of 
the French fiscal-military state. In pursuing the initial project, I cast a wide net through 
the judicial archives, looking for the stories of practitioners whom the university-
educated physicians demeaned as “empirics.” Although some learned physicians saw 
such practitioners as a possible wellspring of medical innovation, the medical 
establishment believed that they practiced dangerously by trial-and-error, without any 
appeal to the causal reasoning that was the hallmark of university medical learning. As 
my investigations moved into the final decades of the seventeenth century, I discovered 
to my surprise that a handful of these supposed “empirics” began to look far less like 
fringe practitioners of folk medicine, and far more like entrepreneurs and pharmaceutical 
monopolists.  
 These seventeenth-century “empirics” might more justly be called “privileged 
vendors” of so-called secret remedies (remèdes secrets), that is, proprietary 
pharmaceuticals. The terms “secret remedies” and “proprietary remedies” are not 
completely interchangeable: the early modern notion of remèdes secrets emphasized the 
medical secret of a drug, understood to include its recipe, preparation, and the identity of 
its main ingredients.1  “Proprietary remedies” by contrast, as used by historians today, 
emphasizes the legal status of monopoly, which restricts its sale to a specific vendor. The 
                                                 
1 These terminological distinctions build on Matthew Ramsey, “Traditional Medicine and Medical 
Enlightenment: The Regulation of Secret Remedies in the Ancien Régime,” in La médicalisation de la 




remedies that form the subject of this dissertation were protected by monopoly privileges, 
and therefore “proprietary,” and in most cases their preparations were also concealed, at 
least initially, by the shroud of trade secrecy. The two terms, however, converge insofar 
as both legal monopolies and medical secrets could be sold, inherited, and otherwise 
transmitted as property.  
 Because they were protected by legal monopolies and medical secrecy, these 
drugs stood apart from those normally compounded by apothecaries.2 The drugs of the 
apothecaries came in two general types: they were either officinal, meaning they were 
prepared according to a standard, publically available formula from an established 
(usually printed) pharmacopoeia, and were often stocked ready-made in their boutiques; 
or they were magistral, tailored to fit an individual case from the personal prescription of 
a physician.3 The lines between secret remedies and the drugs compounded by 
apothecaries could of course be blurred: as, for instance, when a secret recipe was made 
public and incorporated into the pharmacopoeia. But on the whole, secret remedies 
differed fundamentally from officinal compounds in that their recipes were carefully 
guarded rather than being published; indeed, the condition for granting a monopoly 
                                                 
 2 Long neglected in the historiography of medicine, apothecaries have recently seen a revival of 
interest: see notably Valentina Pugliano, “Botanical Artisans: Apothecaries and the Study of Nature in 
Venice and London, 1550-1610” (PhD dissertation, University of Oxford, 2013); James E. Shaw and 
Evelyn S. Welch, Making and Marketing Medicine in Renaissance Florence, Clio Medica 89 (Amsterdam: 
Rodopi, 2011); Leigh Chipman, The World of Pharmacy and Pharmacists in Mamlūk Cairo (Leiden: Brill, 
2010); Stéphanie Tésio, Histoire de la pharmacie en France et en Nouvelle-France au XVIIIe siècle 
(Québec: Les Presses de l’Université Laval, 2009); Filippo De Vivo, “Pharmacies as Centres of 
Communication in Early Modern Venice,” Renaissance Studies 21, no. 4 (2007): 505–21; Patrick Wallis, 
“Medicines for London: The Trade, Regulation and Lifecycle of London Apothecaries, c.1610-c.1670” 
(PhD dissertation, University of Oxford, 2002); Paula S. De Vos, “The Art of Pharmacy in Seventeenth- 
and Eighteenth-Century Mexico” (PhD dissertation, University of California, Berkeley, 2002); Christian 
Warolin, “Le cadre de vie professionnel et familial des apothicaires de Paris au XVIIe siècle” (Thèse de 
doctorat en Histoire, Université Paris IV-Sorbonne, 1994). 
 3 Jean François Lavoisien, Dictionnaire portatif de médecine, d’anatomie, de chirurgie, de 
pharmacie, de chymie, d’histoire naturelle, de botanique et de physique (Paris: Pierre-François Didot le 
jeune, 1771), 15, 429. 
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privilege over a drug often rested on distinguishing it from those available in the “public 
domain” of the pharmacopoeias. Further, secret remedies differed from magistral 
prescriptions insofar as they were not tailored by a physician to fit the individual 
circumstance of a patient: every patient received the same drug. Somewhat more 
problematically, the term remèdes secrets is sometimes used synonymously with remèdes 
spécifiques or “medicinal specifics,” drugs which targeted a defined disease or condition, 
for instance intermittent fevers, venereal disease, or dysentery.4 The reason for conflating 
the two is that so many privileged secret remedies were also “specifics,” 
pharmacologically speaking. Throughout this dissertation, I will treat “specific” primarily 
as a pharmacological category rather than a legal one. 
 The place of secrets in medicine, alchemy, and various craft traditions has gained 
a prominent place in the history of science, medicine, and technology in the past few 
decades. This literature has extended from a focus on technical and craft knowledge in 
printed “books of secrets” to include embodied artisanal knowledge as well as domestic 
medicine and recipe books.5 This literature has most recently been extended to consider 
materials and practices as well as the utility of re-enactment as a tool for accessing 
                                                 
 4 The category of medicinal specifics is explored in detail in ch. 2. 
 5 See most notably William Eamon, Science and the Secrets of Nature: Books of Secrets in 
Medieval and Early Modern Culture (Princeton, N.J.: Princeton University Press, 1994); Pamela O. Long, 
“Power, Patronage, and the Authorship of Ars: From Mechanical Know-How to Mechanical Knowledge in 
the Last Scribal Age,” Isis 88, no. 1 (1997): 1–41; Pamela O. Long, Openness, Secrecy, Authorship: 
Technical Arts and the Culture of Knowledge from Antiquity to the Renaissance (Baltimore: Johns Hopkins 
University Press, 2001); Pamela H. Smith, The Body of the Artisan: Art and Experience in the Scientific 
Revolution (Chicago: University of Chicago Press, 2004); Allison Kavey, Books of Secrets: Natural 
Philosophy in England, 1550-1600 (Urbana, IL.: University of Illinois Press, 2007); Jo Wheeler, 
Renaissance Secrets, Recipes and Formulas (London: Victoria and Albert Museum, 2009); Elaine Leong 
and Alisha Rankin, Secrets and Knowledge in Medicine and Science, 1500-1800 (Farnham: Ashgate, 
2011); Michelle DiMeo and Sara Pennell, Reading and Writing Recipe Books, 1550-1800 (Manchester: 
Manchester University Press, 2013). 
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artisanal knowledge.6 In this dissertation, I bring attention to a hitherto neglected and yet 
fundamental issue—namely, the way in which medical secrets became entwined with the 
interests of the French fiscal-military state.7 I show that many vendors of secret remedies 
held monopoly privileges over their pharmaceutical inventions, granted by the highest 
possible authority, the crown itself. Far from being marginalized, they were closely tied 
to the world of the royal court at Versailles, held prominent positions in the Parisian 
medical marketplace, and supplied their drugs in bulk to the French state for use by its 
ever-growing army and navy. 
 This direction of research emerged from the archival constraints to my initial 
project on urban medical regulation. Unlike other European jurisdictions, Paris lacks a 
concentrated archival fonds focused on medical licensing and lawsuits. Consequently, I 
had to find my way through the archives in a different way, by following the trail of 
individuals through multiple fonds and archives, rather than systematically examining a 
single fonds. This has led me to tell a different kind of story than that found in much of 
the historiography on early modern medical regulation. That historiography drew 
primarily on archives that were generated by physician-dominated medical tribunals and 
licensing authorities. Such archives form the basis for much of the existing scholarship on 
                                                 
6 See for example Lawrence M. Principe, “‘Chemical Translation’ and the Role of Impurities in 
Alchemy: Examples from Basil Valentine’s Triumph-Wagen,” Ambix 34, no. 1 (1987): 21–30; Pamela H. 
Smith, “In the Workshop of History: Making, Writing, and Meaning,” West 86th: A Journal of Decorative 
Arts, Design History, and Material Culture 19 (2012): 4–31; Pamela H. Smith, Amy R. W. Meyers, and 
Harold J. Cook, Ways of Making and Knowing: The Material Culture of Empirical Knowledge (Ann Arbor: 
University of Michigan Press, 2014). See also the pioneering work of Lawrence M. Principe, “‘Chemical 
Translation’ and the Role of Impurities in Alchemy: Examples from Basil Valentine’s Triumph-Wagen,” 
Ambix 34, no. 1 (1987): 21–30 
 7 Broadly speaking, a “fiscal-military state” is a state that develops systems of taxation and other 
fiscal mechanisms in order to support its military in periods of protracted warfare. For the classic statement, 
see John Brewer, The Sinews of Power: War, Money, and the English State, 1688-1783 (New York: Knopf, 
1989); for a review of the development of the French fiscal-military state, see Joël Félix and Frank Talett, 
“The French Experience, 1661-1815,” in The Fiscal-Military State in Eighteenth-Century Europe Essays in 




medical regulation in Spain, Italy, and England.8 The institutions that generated these 
records were called protomedicati in Spain and Italy, and find structural analogues in 
other jurisdictions, most notably the London College of Physicians. Their records have 
allowed historians to closely follow the efforts of university-trained physicians to repress 
illicit practice (understood both in the sense of unlicensed practitioners as well as 
transgression of the medical division of labor), adjudicate patient complaints, and uphold 
their supervisory powers over the guilds of surgeons and apothecaries. The Protomedicati 
records also offer insight into how physicians licensed and policed those practitioners 
who worked outside the formal communities of the medical guilds and colleges, notably 
midwives, specialist operators, and charlatans. Between the sixteenth and seventeenth 
centuries, these regulatory bodies had come into being in several different ways: some 
emerged out of local medical colleges, while others were initiatives of municipal 
governments or, in the Spanish cases, of the royal physicians associated with the central 
monarchy and its viceroys.9 
 Why was there no equivalent to these institutions in the kingdom of France or in 
the city of Paris? The answer strikes at the heart of how my project transformed. As late 
                                                 
 8 On Spain, see John Tate Lanning and John J TePaske, The Royal Protomedicato: The Regulation 
of the Medical Professions in the Spanish Empire (Durham: Duke University Press, 1985); María Luz 
López Terrada and Àlvar Martínez Vidal, eds., Dynamis, El Tribunal del Real Protomedicato en la 
Monarquía hispànica, 1593-1808, no. 16 (1996); Michele L. Clouse, Medicine, Government and Public 
Health in Philip II’s Spain: Shared Interests, Competing Authorities (Farnham: Ashgate, 2011). On Italy, 
see David Gentilcore, “All That Pertains to Medicine: Protomedici and Protomedicati in Early Modern 
Italy,” Medical History 38 (1994): 121–42; Gianna Pomata, Contracting a Cure: Patients, Healers, and the 
Law in Early Modern Bologna (Baltimore: Johns Hopkins University Press, 1998, ch. 1, 1-24; David 
Gentilcore, Healers and Healing in Early Modern Italy (Manchester: Manchester University Press, 1998); 
Elisa Andretta, Roma medica: anatomie d’un système médical au XVIe siècle (Rome: École française de 
Rome, 2011). On England, see Margaret Pelling and Webster, Charles, “Medical Practitioners,” in Health, 
Medicine and Mortality in the Sixteenth Century (Cambridge: Cambridge University Press, 1979), 165–
235; Harold J. Cook, The Decline of the Old Medical Regime in Stuart London (Ithaca: Cornell University 
Press, 1986); Margaret Pelling, Medical Conflicts in Early Modern London: Patronage, Physicians, and 
Irregular Practitioners, 1550-1640 (Oxford: Clarendon Press, 2003). 
 9 Gentilcore, Healers and Healing, chap. 2; Gentilcore, “All That Pertains to Medicine.” 
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as the 1760s, the physician and jurist Jean Verdier, author of the main legal treatise 
dealing with medicine in Ancien Régime France, began his work by lamenting the 
kingdom’s lack of a separate tribunal and regulatory body.10 In fact, the first efforts to 
create such a body would not come until the very end of the Ancien Régime, with the 
establishment of the Société royale de médecine in 1776.11 This organization aimed at 
coordinating the pharmaceutical licensing and public response to epidemics, but never 
approached the scope of the protomedicati as a licensing bureau and medical tribunal. 
Likewise, within the capital, the Paris Medical Faculty never held jurisdiction like an 
urban protomedicato. Instead of enjoying a separate judicial authority, the physicians of 
the Paris Faculty—as well as the apothecaries’ and surgeons’ guilds—were obliged to 
assert their corporate privileges and bring lawsuits against interlopers in the civil courts 
of the Châtelet and the Parlement.12 
 This French deviation from European trends was rooted in the tension between 
the Paris Faculty and the royal physicians, who represented the two most likely sources 
of such a regulatory initiative. The powers of the Paris Faculty were constantly checked 
by practitioners tied to the French court, who held a traditional privilege to practice not 
                                                 
10 Jean Verdier, La jurisprudence de la medicine en France (Alençon: Malassis le jeune, 1762), 1–
2, 722. 
 11 Caroline Hannaway, “Medicine, Public Welfare and the State in Eighteenth Century France: 
The Société Royale de Médecine of Paris (1776-1793)” (Dissertation, Johns Hopkins University, 1977); 
Charles Coulston Gillispie, Science and Polity in France at the End of the Old Regime (Princeton: 
Princeton University Press, 1980), 118–226; Matthew Ramsey, Professional and Popular Medicine in 
France, 1770-1830: The Social World of Medical Practice (Cambridge: Cambridge University Press, 
1988); Colin Jones, “The Médecins Du Roi at the End of the Ancien Régime and in the French 
Revolution,” in Medicine at the Courts of Europe, 1500-1837, ed. Vivian Nutton (London: Routledge, 
1990), 209–63; Laurence Brockliss and Colin Jones, The Medical World of Early Modern France (Oxford: 
Clarendon Press, 1997), 760–782.  
 12 For all practical purposes, the best guide on the jurisdictions of Paris and the royal house 
remains Michel Antoine et al., Guide des recherches dans les fonds judiciaires de l’Ancien Régime (Paris: 
Imprimerie nationale, 1958); see also J. H. Shennan, The Parlement of Paris (Thrupp, Stroud, 
Gloucestershire: Sutton, 1998); Richard Mowery Andrews, Law, Magistracy and Crime in Old Regime 
Paris: 1735-1789 (Cambridge: Cambridge University Press, 1994). 
7 
 
only at Versailles, Fontainebleau, or wherever else the court might be, but also in the 
capital.13 Many of these court physicians hailed from provincial or even foreign medical 
schools, and the vaunted position of royal first physician typically alternated between 
graduates of the Paris Faculty and its southern rival, the University of Montpellier. The 
centralizing efforts of the Paris Faculty were also resisted by the local surgeons and 
apothecaries. The tension between these various interests had the effect of producing a 
stalemate, which slowed the process of regulatory centralization.  
If comprehensive regulation was never imposed by the Paris Faculty, why did it 
not emerge from above, from the central monarchy, as it did with the Tribunal del 
protomedicato of the continent’s other great absolutist state, Spain? The Tribunal, 
overseen by the Spanish king’s first physician (protomédico), was established quite early 
in 1477 and quickly became a model for other medical regulatory bodies. In the sixteenth 
century, its authority was extended beyond Castile to include the whole Iberian Peninsula 
and Spain’s Italian territories, and eventually the Spanish Americas.14 The jurisdictional 
authority of the Spanish Tribunal was sometimes contested and negotiated with local 
authorities, but it succeeded even in dictating medical curricula and examination 
procedures to the kingdom’s universities—a regulatory feat unparalleled in Europe at this 
time—and survived until the Bourbon reforms of the late eighteenth century.15 
The royal first physicians of France focused primarily on their role as health care 
providers to the king and royal family and oversaw the other practitioners of the royal 
                                                 
 13 Alexandre Lunel, La maison médicale du roi, XVIe-XVIIIe siècles. Le pouvoir royal et les 
professions de santé (Seyssel: Champ Vallon, 2008), 87–92. 
 14 See Clouse, Medicine, Government and Public Health in Philip II’s Spain. On Naples, see 
Gentilcore, Healers and Healing; on New Spain, see Lanning and TePaske, The Royal Protomedicato. 
15 On the Tribunal del protomedicato in Iberia, see Clouse, Medicine, Government and Public 
Health in Philip II’s Spain and López Terrada and Martínez Vidal, eds. Dynamis 16 (1996); for the 
kingdom of Naples, see Gentilcore, Healers and Healing; and for the Spanish Americas, see Lanning and 
TePaske, The Royal Protomedicato. 
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medical household. Alexandre Lunel has demonstrated that the first physicians also 
offered counsel to the state on medical reforms, particularly in the eighteenth century, but 
these projects never led to the creation of a central regulatory bureaucracy with the same 
scope of action as a protomedicato. By the reign of Louis XIV (1643–1715), the first 
physicians had nonetheless accumulated a collection of other important rights, which 
retained a more personal character. These included the regulation of apothecaries in those 
parts of the kingdom where there were no guilds; the supervision of the kingdom’s spas 
and mineral waters; and, for a few decades, the superintendency of the Jardin du Roi.16  
Last but not least, the first physician also recommended the granting of royal monopoly 
privileges for proprietary drugs.17 The growing significance of these drugs, typically 
called “secret remedies,” and the legal privileges surrounding them form the subject of 
this dissertation.  
 These pharmaceutical privileges were granted by the crown with the stated 
interest of rewarding medical innovation, ensuring the good quality of medical care, and 
benefitting the people of France, but as we shall see, many were tied to the patronage of 
prominent figures at court, the venality of the royal first physicians who issued the 
medical recommendations, and the expediencies of state interests in supplying effective 
drugs to the army. These privileges allowed pharmaceutical vendors to assert their 
monopolies by legally pursuing counterfeiters, and allowed them to circumvent urban 
trade regulations throughout the kingdom, most notably the corporate privileges of 
apothecaries. 
                                                 
16 Lunel, La maison médicale du roi, 204–5. Lunel’s book was fundamental in re-orienting the 
direction of my research.  
17 Ibid., 277–281; Brockliss and Jones, The Medical World of Early Modern France, 627–630; 
Ramsey, “Traditional Medicine and Medical Enlightenment,” 217–218. 
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 These privileges guaranteed monopolies over therapeutic substances, rather than 
attesting to the knowledge and skills of practitioners. As such, privilege holders could run 
the full gamut of the medical world and beyond, from learned physicians to street 
charlatans, and from retired soldiers to tobacco controllers. In contrast with the 
predominantly patrilineal transmission of family property and office in early modern 
France, both the privileges and the medical secrets were passed down bilaterally and 
through ties of affinity: the widows, sisters, and daughters of male privilege-holders play 
recurring roles in these familial monopolies, a fact we will encounter repeatedly in this 
dissertation. Far from being marginalized, a handful of these vendors were able to use 
their courtly connections to secure medical monopolies. The most successful even served 
as military-medical contractors, selling their drugs in bulk to the army and navy. They 
became wealthy, were able to secure places for their children within the corporate 
medical community, and most importantly, they established the basis for multi-
generational family medical businesses. Interestingly, they seem at once to be linked with 
the past—the traditional world of medical empiricism and popular medicine—but also to 
look ahead to the future, anticipating a world of government contracting and proto-
industrial pharmaceutical production. 
 I was first alerted to the emergence of an “entrepreneurial” culture in eighteenth-
century French medicine by Laurence Brockliss and Colin Jones, who dedicate a chapter 
to the subject in their foundational survey of the French medical world.18 Although they 
                                                 
18 See Brockliss and Jones, The Medical World of Early Modern France, esp. Ch. 10, “Medical 
Entrepreneurialism in the Enlightenment,” 622–670. In their description of a rise of medical 
entrepreneurialism in the eighteenth century Brockliss and Jones are obviously influenced by Roy Porter, 
particularly Health for Sale: Quackery in England, 1660-1850 (Manchester: Manchester University Press, 
1989), Ch. 4, entitled “Medical entrepreneurship in the consumer society,” 21–59. Although Porter stresses 
the peculiarity of the English experience against that of the Continent, his account of “quack medicine” as 
inherently modern and attuned to “the specific orientation of a commercial capitalist, spectacle-loving, 
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nod to seventeenth-century “precursors” like Adrien Helvétius and Robert Talbor and to 
the “privileged state markets like the court and the army,” Brockliss and Jones follow 
Roy Porter in situating the phenomenon of “entrepreneurialism” primarily within the later 
eighteenth century and link it to the marketplace of individual consumers.19 My 
dissertation examines this phenomenon in much greater detail and also from a new 
perspective: first, it assembles a fine-grained archival picture of some of the most famous 
medical monopolists in order to better understand their emergence and links with state 
power; second, it explores how developments in “secret” and “specific” remedies 
emerged from contemporary intellectual debates related to the rise of chymical medicine 
and the decline of Galenism; and third, it extends the range of the discussion 
chronologically further back into the seventeenth century to show that in the 1680s 
medical entrepreneurialism was already firmly linked to what some historians have called 
“court capitalism.” 
 By “court capitalism” I mean the peculiar ways in which the capitalist market was 
shaped within the framework of an Ancien Régime state whose power was concentrated 
at a royal court, which served as the prime locus of negotiation. This framework included 
the venality of governmental offices, the farming out of important state functions to 
private contractors, and the creation of powerful state-sponsored monopolies.20 Like so 
                                                                                                                                                 
consumer-oriented society,” has been enormously influential in the history of early modern medicine on 
both sides of the Channel. 
19 Brockliss and Jones, The Medical World of Early Modern France, 622–627; Porter, Health for 
Sale, Ch. 4, entitled “Medical entrepreneurship in the consumer society,” 21–59.  
 20 Gail Bossenga, “Markets, the Patrimonial State, and the Origins of the French Revolution,” 
1650-1850: Ideas, Aesthetics, and Inquiries in the Early Modern Era 11 (2005): 443-510, esp. 460–464 and 
480–485. Bossenga draws on and expands the category from George V. Taylor, “Types of Capitalism in 
Eighteenth-Century France,” The English Historical Review 79, no. 312 (July 1, 1964): 478–97. “Court 
capitalism” has also been employed recently by Michael Kwass to explain the Farmers General and the 
tobacco and salt monopolies. See Michael Kwass, “Court Capitalism, Illicit Markets, and Political 
Legitimacy in Eighteenth-Century France: The Salt and Tobacco Monopolies,” in Questioning Credible 
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many other players, pharmaceutical monopolists looked for opportunities in this context, 
and in the years around 1700 several had found in the state not only a powerful 
legitimator of monopoly but also a potentially lucrative consumer of its products, the 
drugs themselves. 
 My dissertation is based on a corpus of sources which included pharmaceutical 
privileges, royal edicts, published pharmacological texts, as well as a host of other types 
of documents assembled around a sequence of case-studies, stretching from the late 
1670s all the way into the first years of the nineteenth century. Besides the cases of the 
so-called Louvre Capuchins and the celebrated medical adventurer Robert Talbor, I look 
particularly closely at three multi-generational familial pharmaceutical monopolies: those 
of the Contugi family, active 1647-1741; the Helvétius family, active 1688-1755; and the 
Guiller-Lajutais family, active 1713-1808. The Contugi family patented an immensely 
popular poison antidote, called the orviétan, and succeeded in defending their privileges 
from rival charlatans and apothecaries for four generations. The Helvétius family for its 
part patented an anti-dysentery medication, called the remède spécifique, based on the 
ground root of ipecacuanha, a plant native to South America, which they later 
supplemented with a whole series of drugs for other ailments. The Helvétius drugs were 
supplied in bulk to the French state for the use of soldiers and peasants. Finally, the 
Guiller-Lajutais family patented an inexpensive poudre fébrifuge, a drug against 
intermittent fevers based on a common European wood spurge, which they touted as an 
equally effective but more economical alternative to importing cinchona from the 
Spanish New World.  
                                                                                                                                                 
Commitment: Perspectives on the Rise of Financial Capitalism, ed. D’Maris Coffman, Adrian Leonard, and 
Larry Neal (Cambridge: Cambridge University Press, 2013), 228–50. 
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 Tracing the outlines of these monopolies through privileges, lawsuits, sales 
records, and notarial acts has necessitated ventures into a variety of different archives. 
These included the surviving fonds of the Paris Faculty and the apothecaries’ guild, held 
at the Bibliothèque interuniversitaire de santé, as well as a variety of judicial fonds at the 
Archives nationales, ranging from the Châtelet up to the extraordinary commissions of 
the Conseil privé; the notarial archives of the Minutier central; and the fonds of the 
central state, most notably the dispatch registers of the Secretary of State for the Royal 
Household, the principal source from which pharmaceutical privileges emanated. Parts of 
this documentation had already treated anecdotally, but this dissertation represents the 
first attempt to investigate it systematically.21 Tracing the sales of these drugs eventually 
led me into the archives of the French army and navy as well as those of the Paris Foreign 
Missions Society and the French East Indies Company, all of which purchased the drugs 
of the Helvétius and Guiller-Lajutais families in bulk quantities. As far as I know, these 
archives are hitherto untapped for material on pharmaceutical monopolies. The research I 
present here is the first exploration in this respect.  
 In addition to tracing the social and economic history of pharmaceutical 
monopolies, this dissertation also shows that their history had important intellectual 
implications. Traditional Galenic medicine targeted humoral imbalances and had to be 
carefully tailored to a patient’s unique individual constitution: the reasoned deliberation 
                                                 
21 See Pierre Julien, “Bibliographie des publications de Maurice Bouvet,” Revue d’histoire de la 
pharmacie 73 (1985): 325–61; Claude-Stéphen Le Paulmier, L’Orviétan. Histoire d’une famille de 
charlatans du Pont-Neuf aux XVIIe et XVIIIe siècles (Paris: Librairie illustrée, 1893); Louis Lafond, La 
dynastie des Helvétius. Les remèdes du Roi. (Paris: Occitania, 1926). In tracing these monopolies from 
archive to archive, I have benefited immensely from a rich body of nineteenth- and early twentieth-century 
secondary literature, produced primarily by pharmacists and physicians who cultivated an avid interest in 
the histories of their professions. Although their work is in some cases over a century old, the collections of 
sources which figures such as Maurice Bouvet, Claude-Stéphen La Paulmier, and Louis Lafond assembled 
furnished me with my earliest leads in extending my own investigations into the archives. They stand as a 
reminder of the invaluable resources which earlier scholarship can offer to present-day historians. 
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that calibrated therapy and regimen for each specific patient was seen as the hallmark of 
learned medicine. The drugs described in this dissertation, by contrast, were often 
categorized pharmacologically as medicinal specifics (spécifiques or specifica): they 
were supposed to respond to a given disease regardless of the peculiarities of an 
individual’s temperament, and could thus be used to the same effect by entire 
populations. This “one-size-fits-all” approach to medicine smacked of medical 
empiricism to Galenic physicians, but found assertive proponents among the newer 
school of chymical medicine or iatrochemistry.22 On an intellectual level, the rise of  
pharmaceutical monopolies is closely tied to the emergence of new spheres of medical 
activity on a mass scale, the arrival of new therapeutic substances in Europe, which 
challenged conventional Galenic pharmacological theories, and the chymical debate 
about the ontological status of disease. 
*** 
This dissertation is divided into six chapters. Chapter 1 explores the social and 
legal basis of the pharmaceutical privilege regime in France.23 The chapter draws on 
royal legislation and a corpus of fifty-six pharmaceutical privileges from 1670 (the date 
of the earliest registers) to 1728, which marks the first attempt to reform the privilege 
                                                 
22 I follow William R. Newman and Lawrence M. Principe in using the archaic “chymistry” and 
the adjective “chymical” to refer to the premodern discipline prior to the exclusion of transmutational 
alchemy. To refer to the medical branch of chymistry, I use “chymical medicine” or “iatrochemistry” 
interchangeably throughout. On this usage see William R. Newman and Lawrence M. Principe, “Alchemy 
vs. Chemistry: The Etymological Origins of a Historiographic Mistake,” Early Science and Medicine 3, no. 
1 (1998): 32–65. 
23 The initial goal of this chapter was to provide for Ancien Régime France what Joseph Gabriel 
has recently provided for the pharmaceutical industry of the nineteenth-century United States: a synthetic 
account of “secret remedies” looking at the interrelations between law, the market, ethical values. See 
Joseph M. Gabriel, Medical Monopoly: Intellectual Property Rights and the Origins of the Modern 
Pharmaceutical Industry (Chicago: University of Chicago Press, 2014). It is also to be hoped that Gabriel’s 
work will elicit further work on the pre-modern antecedents to the modern pharmaceutical industry. 
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system and re-examine existing privileges.24 After 1731, the process of reviewing 
applications was theoretically delegated to a standing commission, but remained a de 
facto right of the royal first physician, subject to his personal recommendation and the 
patronage of prominent figures at court. This chapter also contextualizes pharmaceutical 
privileges as a peculiarly medical form of “court capitalism,” placing it alongside other 
varieties of industrial privilege, which were used as economic tools by the state and often 
served to undercut older urban corporate privileges. 
 Chapter 2 moves to consider the concept of the “medicinal specific” that was 
invoked to explain the action of several of the most prominent proprietary drugs in this 
period and came to form a therapeutic criterion for their evaluation. The chapter 
demonstrates that although the notion of medicinal specifics drew on an older medieval 
tradition, this notion was revived in the seventeenth century by chymical views of 
pathology. The vendors of proprietary remedies often invoked a concept of the 
therapeutic action of  specifics to explain the unique effects of the substances they sold—
effects which often defied the categories of Galenic pharmacology. I argue that the 
production of chymical medicines was patronized by Louis XIV by sponsoring the 
pharmaceutical laboratory of the Louvre Capuchins and purchasing the secret to Robert 
Talbor’s cinchona-based Remède Anglois. I also show that chymical ideas of pathology 
and pharmacology had a substantial influence on the royal first physicians Antoine 
Daquin (1629–1696) and Guy-Crescent Fagon (1638–1718), the principal arbitrators of 
medical privileges.  
                                                 
24 Ramsey, “Traditional Medicine and Medical Enlightenment”; Maurice Bouvet, “Histoire 
sommaire du remède secret,” Revue d’histoire de la pharmacie 45, no. 153 (1957): 57–63; Maurice Bouvet, 
“Les commissions de contrôle des spécialités pharmaceutiques au XVIIIe siècle : suite et fin,” Bulletin de 
la Société d’histoire de la pharmacie 10, no. 36 (1922): 119–24. 
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 By looking closely at Talbor’s cinchona preparation I also show that colonial 
botanical substances were transformed once they arrived in Europe in two ways: 
conceptually, as they were assimilated into existing European understandings of 
pharmacology, and materially, as they were processed through the long and careful works 
of drying, grinding, infusion, and distillation. Like the identities of the ingredients 
themselves, these concrete processes constituted the medical secrets which formed the 
backbone of familial medical monopolies, and are treated in detail in each of the 
following three chapters. 
 Whereas Chapters 1 and 2 provide a general look at the overall legal and 
intellectual framework in which proprietary drugs functioned under the Ancien Régime, 
Chapters 3-5 offer specific case-studies of actual drug monopolies in action over multiple 
generations. Chapter 3 deals with the Contugi family and their poison antidote, orviétan. 
The family patriarch, Christophe Contugi, was a “charlatan” in the classic sense of the 
word (that is, a vendor who peddled his drug through a stage-show in the market square) 
but he and his successors also had surprisingly close relations with the Paris Faculty of 
Medicine, a fact which problematizes the tendency to relegate charlatans to the 
“penumbra” of the medical world.25 Indeed, after passing through three generations of the 
Contugi family, the privilege for orviétan was eventually purchased by the regent doctor 
Charles Dionis, who expanded its sale through a network of sub-vendors who sold it on 
his behalf. On a thematic level, this chapter focuses on the relationship between branding 
                                                 
 25 On the core-penumbra model see Brockliss and Jones, The Medical World of Early Modern 
France, chap. 4, esp. 237; for alternatives, see Gentilcore, Healers and Healing, 1–5. See also the recent 
reassessments of David Gentilcore, “Medical Pluralism and the Medical Marketplace in Early Modern 
Italy,” in Medical Pluralism: Past - Present - Future, ed. Robert Jütte (Stuttgart: Franz Steiner Verlag, 
2013), 45–56; and Matthew Ramsey, “Medical Pluralism in Early Modern France,” in Medical Pluralism: 
Past - Present - Future, ed. Robert Jütte (Stuttgart: Franz Steiner Verlag, 2013), 57–80. 
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and secrecy, particularly the reconfiguration of the royal privilege into a trademark, 
which occurred whenever a medical secret was disclosed in published pharmacopoeia, 
and competing versions of the drug came to be produced by rival charlatans and local 
apothecaries—an early modern parallel to the modern concept of “genericide.”26 
Chapter 4 follows the story of the Dutch-born physician Adrien Helvétius and his 
son Jean-Claude Adrien, whose fortunes rested on the poudre spécifique, a remedy 
against dysentery based on the Brazilian ipecacuanha root. The chapter explores the ways 
in which Adrien was able to leverage his success in private practice among Parisian elites 
and forge close ties with France’s central fiscal and military administration. These ties 
granted him access to hospital patients for clinical trials of his drug, and to military 
populations as the drug’s consumers. He became a bulk supplier of his drugs to the 
French army and to royally-funded poor relief projects in the French countryside. He 
expanded beyond his dysentery remedy to produce a lineup of other pre-packaged drugs, 
distributed in standardized physic chests with printed instructions sheets, which travelled 
out to the provinces through the fiscal infrastructure of the absolutist state and the local 
charitable infrastructure. The main thematic argument of the chapter is that Helvétius’ 
patronage connections made him eminently well-situated to tap into the new possibilities 
of harnessing state networks for the large-scale testing and distribution of proprietary 
drugs in the decades around 1700. 
Chapter 5 follows the poudre fébrifuge, first patented by Ferdinand de Guiller in 
1713 as a more affordable “indigenous” European alternative to exotic cinchona-based 
                                                 
26 “Genericide” describes the passage of a trademarked name into the vernacular as a common 
term of reference for a whole class of competing products: modern examples include jell-o, xerox, and 
kleenex, and in the pharmaceutical industry, adrenaline and aspirin. For a succinct description and 
additional references see Jeremy Greene, Generic: The Unbranding of Modern Medicine (Baltimore: Johns 
Hopkins University Press, 2014), esp. 22, 283n4. 
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drugs. The chapter describes how the remedy came to be widely distributed to the 
military and the French East Indies Company by Guiller’s putative successor, Pierre 
Brodin de Lajutais. The chapter also examines the persistent ambiguities in testing 
standards and the varying opinions on the efficacy of the drug between the 1710s and the 
1770s, as the drug passed through several reforms of the privilege regime. It provides, 
moreover, a case study of the inherent risk of breakdown in the chain of inter-
generational transmission of medical secrets and privileges. Consequently, the thematic 
focus of the chapter is on the challenges a proprietary drug faced as it travelled through 
time—challenges posed by changing regulatory procedures as well as by gaps in the 
transmission of the medicinal knowledge on which it was based.  
Chapter 6 follows these three drugs—orviétan, the remède spécifique, and the 
poudre febrifuge—as they travelled outside of metropolitan France, to consider the role 
that they played in French colonial, missionary, and mercantile endeavors. While most 
studies of medical regulation and pharmaceutical monopolies have a metropolitan and 
urban focus, I have endeavored to demonstrate how far from Paris these French 
proprietary pharmaceuticals could reach in this period. In so doing I have treated the city 
of Paris as a “ville-monde,” whose archives preserve the traces of important political, 
intellectual, and economic connections to the wider world.27 In addition to selling their 
drugs to the state, secret remedies vendors also found other “corporate consumers,” 
notably overseas trading companies and missionary orders, which were likewise 
interested in purchasing bulk quantities of proprietary drugs. In the 1680s, orviétan was 
used by French agents in the wilds of North America from Hudson Bay to the Mississippi 
                                                 
 27 Antonella Romano and Stéphane Van Damme, “Penser les savoirs au large (XVIe-XVIIIe 
siècles),” Revue d’histoire moderne et contemporaine 55, no. 2 (2008): 7–18. 
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valley. By 1693, Helvétius’ drugs could be found in the hands of missionaries in 
Southeast Asia. In the 1730s, the French East Indies Company was shipping Lajutais’ 
poudre fébrifuge to its far-flung posts in the Indian Ocean. In this final chapter, I also aim 
to complement the historiography on colonial bioprospecting, by showing that the in-flow 
of raw plant substances into Europe was accompanied by an out-flow of compounded 
proprietary drugs to the territories of European expansion in the first global age.28 
                                                 
 28 On colonial bioprospecting and the importation of medicinal substances in Europe, see for 
example from a growing literature: Londa Schiebinger, Plants and Empire: Colonial Bioprospecting in the 
Atlantic World (Cambridge, Mass.: Harvard University Press, 2004); Londa Schiebinger and Claudia Swan, 
Colonial Botany: Science, Commerce, and Politics in the Early Modern World (Philadelphia: University of 
Pennsylvania Press, 2005); Harold J. Cook, Matters of Exchange Commerce, Medicine, and Science in the 
Dutch Golden Age (New Haven: Yale University Press, 2007); Patrick Wallis, “Exotic Drugs and English 
Medicine: England’s Drug Trade, c. 1550–c. 1800,” Social History of Medicine 25, no. 1 (2012): 20–46; 
Stefanie Gänger, “World Trade in Medicinal Plants from Spanish America, 1717-1815,” Medical History 




“The means by which empiricism has been tolerated in recent centuries”: 
Royal privileges for secret remedies in early modern France 
 
  On July 3, 1728, the State Council of Louis XV promulgated an arrêt to bring 
order to the medical anarchy then reigning in the capital. Unqualified individuals were 
haphazardly distributing so-called “specific” remedies (remèdes prétendus spécifiques) to 
the sick without regard for differences in their age or sex and without consulting 
physicians.1 At first glance the text of this arrêt reads much like any other early modern 
denunciation of illicit medical practice. But the producers and vendors of these pernicious 
“remèdes prétendus spécifiques” were no ordinary empirics, as the operative portion of 
the edict demonstrates. The State Council and the king’s first physician, Claude Jean 
Baptiste Dodart (1650-1730), had much bigger fish to fry:  
His Majesty wishes that all persons without exception who have heretofore 
obtained brevets, permissions and privileges for the distribution of specific 
and other remedies, whoever they may be, shall be required to bring them 
back or send them to the Lieutenant General of Police of Paris within two 
months, counting from the day the present arrêt is published; so that, 
following the examination of said brevets and the remedies they authorize, a 
verdict maybe be given by His Majesty, be it for the confirmation or 
revocation of said brevets, permissions, and privileges, as the case may be.2 
                                                 
 1 “Sa Majesté etant informé que plusieurs particuliers sans qualité, distribuent dans la ville et 
fauxbourgs de Paris, des remedes pretendus specifiques, dont il peut resulter des inconvenients d’autant 
plus dangereux, que ces particuliers, sans consulter les medecins ny aucunes personnes de l’art, dispensent 
ces remedes au hasard et a des malades de tous ages et de tout sexe,” Arrêt du conseil d’Etat du Roy, qui 
défend à toutes personnes de distribuer des remèdes spécifiques et autres sans en avoir obtenu de nouvelles 
permissions. Du 3 Juillet 1728. (Paris: P. J. Mariette, Imprimeur de la Police, 1728), 1–2. My working copy 
is BnF F- 21107 (117). Cf. AN E 2088, Minutes d’arrêts, Secrétaire d’État de la Maison du Roi, fol. 167r–
168r (3 juillet 1728). For royal edicts and arrêts I will cite printed versions where available, marking the 
ms. copies in the AN Minutes d’arrêts registers only in the first citation. 
 2 “Veut Sa Majesté que toutes personnes sans exception qui ont cy-devant obtenu des Brevets, 
permissions, et privileges, pour la distribution de remedes specifiques et autres, quel qu’ils puissent etre, 
soient tenuës de les raporter ou envoyer dans deux mois à compter du jour de la publication du presente 
Arrest, au Sieur Lieutenant General de Police de Paris, pour après l’examen fait desdits Brevets, 




The attempt on the part of the first physician Dodart to re-examine and, if necessary, 
revoke existing privileges was a response to the fact that a veritable industry of privileged 
vendors had emerged by the early eighteenth century. This arrêt was the first of a series 
which would, between 1728 and 1731, provide increasingly articulate legislation 
regulating the trade in proprietary remedies in France. But the very need for all hitherto 
granted privileges to be re-examined and for the medications they licensed to be tested 
suggests that the practice of granting particularistic privileges for proprietary remedies 
had somehow run off the rails in the first decades of the eighteenth century.  
 What had been the norm before the 1728 legislation? In his 1762 Jurisprudence 
de la médecine, the most extensive treatise on medical regulation in France, the physician 
and lawyer Jean Verdier provides some notion of how the 1728 arrêt came into being, 
and what abuses it was intended to rectify. Verdier observed that the most famous 
empirics had long known that the best way of evading challenges from the faculties and 
other medical corporations in France was to secure a royal privilege. They might petition 
local medical faculties and Parlements for various permissions and certifications, but only 
a royal privilege encompassing the whole kingdom could override the problems they 
would otherwise face when crossing into differing legal jurisdictions. And since kings 
would never grant such privileges without the medical counsel of their first physicians, 
the approbation of specific remedies came, through custom (usage) to constitute an 
                                                                                                                                                 
statué ce qu’il  appartiendra, tant pour la confirmation que pour la revocation desdits Brevets, permission et 
privileges, s’il y échoit,” Ibid., 2. 
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established right (droit établi).3 As Verdier puts it, “Such was the order followed in 
recent centuries, by which means empiricism has been tolerated.”4  
 Like other contemporaries, Verdier admits that the licensing of proprietary 
remedies was in some cases desirable. Pure chance and even charlatanism had enriched 
medicine with new remedies, in his view, and so empiricism could not be rejected 
wholesale.5 This was particularly important in the case of medicinal specifics, whose 
occult virtues could only be identified through the trial-and-error associated with the 
practice of empirics. Writing at the height of the Enlightenment, Verdier saw in empirics 
a potential wellspring for medical innovations, and believed that a careful regime of 
privilege-granting, kept in narrow bounds, could ensure that the true fruits of empiricism 
would be safely reaped while carefully avoiding the abuses that might come with it. 
 In France, Verdier tells us, important steps toward producing such a balanced 
situation came in 1728 following the remonstrances of the royal first physician Dodart: 
M. Dodart, concerned by the abuses that were being committed in the 
distribution of these remedies, even more concerned to find himself forced by 
human respect to encourage these abuses through the infinite number of 
permissions that he could not refuse to grant following the solicitations and 
importunity of the Princes and Lords who continuously persecuted him, came 
to see this authority as embarrassing, and wanted to share it in order to have 
grounds for refusing those who asked him for weapons against humankind. 
To this end he suggested to our Monarch the idea he had conceived of 
appointing a Society in charge of examining medicinal specifics.6 
                                                 
 3 “Tel a été l’ordre suivi dans les derniers siècles, au moyen duquel l’empirisme étoit toléré,” Jean 
Verdier, La jurisprudence de la medicine en France (Alençon: Malassis le jeune, 1762), 150–151. 
 4 Ibid., 152. 
 5 “Il est pourtant vrai que l’Empirisme est le premier principe de la médecine, et que hasard et 
même le Charlatanisme l’ont enrichie de remèdes très-précieux; l’Empirisme ne doit donc point être rejeté 
tout-à-fait,” ibid., 147.  
 6 “M. Dodart touché des abus qui se commettoient dans la distribution de ces remèdes, plus touché 
encore de se voir forcé par le respect humain, de les fomenter lui-même, par le nombre infini de 
permissions qu’il ne pouvoit refuser à la sollicitation et l’importunité des Princes et des Seigneurs dont il 
étoit persécuté continuellement, regarda cette autorité comme gênante, et voulut la partager, pour avoir lieu 
de refuser ceux qui lui demandoient des armes contre le genre humain. Pour cela il suggéra à notre 





Verdier provides an image of a first physician with his hands tied, imposed upon by 
various court interests to gratify their respective medical clients by licensing their 
medications regardless of the fact that many were veritable “weapons against 
humankind.” Although he describes these privileges as infinite in number, Verdier points 
out that the medical secrets behind most privileged remedies tended to die with their 
inventors without enriching the art of medicine. Leaving these aside, Verdier cites the 
two most prominent examples of multi-generational royal support for proprietary 
remedies vendors: namely, the Helvétius and Contugi families, who have gone on to 
become commonplaces in the history of medicine in France.7 Their notoriety and the 
longevity of their respective monopolies have generated a wealth of documentary 
evidence in judicial and government archives, some of which was diligently collected and 
published by late nineteenth- and early twentieth-century historians of pharmacy.8 The 
goal of this chapter is to contextualize these prominent cases by looking at the peculiar 
phenomenon that the 1728 arrêt sought to reform, namely, the granting of exclusive sales 
privileges to the vendors of proprietary “secret” or “specific” remedies. As we shall see, 
there was indeed cause for Dodart’s concerns, but despite his efforts and those of his 
successor, Pierre Chirac (1650-1732), the granting of privileges continued largely 
unchanged after the 1728-1731 reform efforts. 
 This chapter shows that the granting of royal brevets, letters patent, and pensions 
to the vendors of proprietary remedies in effect constituted a parallel licensing regime, 
underwritten by royal authority, which offered an alternative to that of the urban 
                                                 
 7 Ibid., 152–160. 
 8 See most notably Claude-Stéphen Le Paulmier, L’Orviétan. Histoire d’une famille de charlatans 
du Pont-Neuf aux XVIIe et XVIIIe siècles (Paris: Librairie illustrée, 1893); Louis Lafond, La dynastie des 
Helvétius. Les remèdes du Roi. (Paris: Occitania, 1926). 
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faculties, colleges, and trade corporations. It also emphasizes the regulation of therapeutic 
substances, and to a lesser extent, of the tools and workspaces (chymical furnaces and 
laboratories) which enabled their production. Both topics have as of yet received little 
attention in the historiography of medical regulation, which tends to focus on 
practitioner-based licensing.9 
The chapter takes the 1728 reforms as its point of departure: what state of affairs 
did it respond to? What kinds of privilege had been granted before 1728? (1) I begin to 
answer these questions by contextualizing these peculiarly medical privileges within the 
broader notions of privilege in the Ancien Régime, focusing on the privileges of royal 
servants, industries, and the phenomenon of “court capitalism.” (2) The second section 
provides a tripartite division of the ways in which the crown could reward or protect 
vendors. Each of these means is then granted its own section. These include: (3) granting 
them monopoly privileges over the sale of the drug; (4) providing chymical furnace and 
laboratory privileges; and (5) granting pensions for the sale and publication of medical 
secrets. The chapter concludes with a final section (6) which returns to the 1728-1731 
reforms to ask whether or not they succeeded in changing the first-physician centered 
                                                 
 9 See most notably Gianna Pomata, Contracting a Cure: Patients, Healers, and the Law in Early 
Modern Bologna (Baltimore: Johns Hopkins University Press, 1998); David Gentilcore, Healers and 
Healing in Early Modern Italy (Manchester: Manchester University Press, 1998); Margaret Pelling, 
Medical Conflicts in Early Modern London: Patronage, Physicians, and Irregular Practitioners, 1550-
1640 (Oxford: Clarendon Press, 2003); Michele L. Clouse, Medicine, Government and Public Health in 
Philip II’s Spain: Shared Interests, Competing Authorities (Farnham: Ashgate, 2011).   
 Although it never created a central tribunal or bureaucracy to enforce them, France also witnessed 
kingdom-wide attempts at practitioner-based licensing in this period, culminating in the 1707 Edict of 
Marly, aimed at standardizing minimum educational requirements in the medical faculties and ensuring that 
physicians had to present their degrees to local magistrates in order to practice even in towns without 
medical colleges or faculties: see Laurence Brockliss and Colin Jones, The Medical World of Early Modern 
France (Oxford: Clarendon Press, 1997), 485–499; and Alexandre Lunel, La maison médicale du roi, 
XVIe-XVIIIe siècles. Le pouvoir royal et les professions de santé (médecins, chirurgiens, apothicaires) 
(Seyssel: Champ Vallon, 2008), 221–234, on the relative ineffectiveness of these attempts. 
24 
 
privilege regime, and to assess the continuities that exist in privilege-granting for secret 
remedies before and after these reform attempts. 
 The 1728-1731 reforms have received little attention in the historiography of 
medicine in early modern France. They are duly mentioned in most major surveys, most 
recently in Brockliss and Jones, but usually are allotted only a few pages.10 Even in more 
specialized works, such as Alexandre Lunel’s recent study of the reform efforts of the 
“royal medical household,” scarcely more than four pages are dedicated to the subject.11 
Matthew Ramsey, who has written several important articles tracing the regulation of 
“secret remedies” in France from the Ancien Régime through the nineteenth century, has 
likewise only treated the 1728-1731 arrêts in passing before moving on to the better-
documented regulatory regime of the Société royale de médecine after 1776.12 Indeed, as 
the work of Ramsey and of Brockliss and Jones demonstrates, the source of reference for 
this first attempt to regulate secret remedies is still Maurice Bouvet’s short 1922 article 
on the topic, made up primarily of extensive quotations from the arrêts themselves.13 
                                                 
 10 Brockliss and Jones, The Medical World of Early Modern France, 628–629. 
 11 Lunel, La maison médicale du roi, 280–281, 288–289. 
 12 Matthew Ramsey, “Traditional Medicine and Medical Enlightenment: The Regulation of Secret 
Remedies in the Ancien Régime,” in La médicalisation de la société française 1770-1830, ed. Jean-Pierre 
Goubert (Waterloo, Ontario: Historical Reflections Press, 1982), 217–218; see also the sequels to this 
article covering the revolutionary period and the nineteenth century: “Property Rights and the Right to 
Health: The Regulation of Secret Remedies in France, 1789-1815,” in Medical Fringe and Medical 
Orthodoxy, 1750-1850, ed. William F. Bynum and Roy Porter (London: Croom Helm, 1987), 79–105; and 
“Academic Medicine and Medical Industrialism: The Regulation of Secret Remedies in Nineteenth-
Century France,” in French Medical Culture in the Nineteenth Century, ed. Ann La Berge and Mordechai 
Feingold, vol. 25, Clio Medica (Amsterdam: Rodopi B.V., 1994), 25–78. 
 Scholars studying the later eighteenth-century have recently shown that the marketplace for 
licensed proprietary remedies in France extended beyond drugs to include “health foods” and therapeutic 
instruments like steel hernia trusses. See Christelle Rabier, ed. Technology and Culture, Special Issue: 
Fitting for Health, 54, no. 3 (2013), esp. “Introduction: The Crafting of medicine in the Early Industrial 
Age,” 437-459 and Liliane Hilaire-Pérez and Christelle Rabier, “Self-Machinery?: Steel Trusses and the 
Management of Ruptures in Eighteenth-Century Europe,” 460–502, on hernia trusses. On health foods see 
Emma C. Spary, Feeding France: New Sciences of Food, 1760-1815 (Cambridge: Cambridge University 
Press, 2014), chap. 4, “Health foods and the medical marketplace,” 125–166. 
 13 Maurice Bouvet, “Les commissions de contrôle des spécialités pharmaceutiques au XVIIIe 
siècle,” Bulletin de la Société d’histoire de la pharmacie 10, no. 35–36 (1922): 88–94, 119–24. 
25 
 
 If these reforms have received only passing mention in the existing historiography 
of medicine in France, the situation surrounding the pre-1728 regime of privilege-
granting is even worse: here again, beyond the work on the cas célèbres of Helvétius’ 
remède spécifique against dysentery and the Contugi family’s orviétan privilege, the 
phenomenon is often evoked but has never been explored in any depth. The singular 
exception to this rule is, once again, the work of Maurice Bouvet, who wrote over three 
hundred short notices and articles on the history of pharmacy in various periodicals 
between 1920 and 1963, many of which treated privileged secret remedies. Despite his 
considerable archival work, however, Bouvet never provided a synthetic analysis of the 
overall phenomenon of privilege-granting.14 
 There are of course important reasons for the general lack of studies on 
particularistic privileges in Ancien Régime France, the foremost of which is the absence 
of concentrated archival fonds, as mentioned in the introduction. There were no efforts to 
initiate a bureaucratic commission regulating secret remedies until 1728, and no 
systematic record keeping exists until the creation of the Société royale de médecine in 
                                                 
 14 The closest to a synthesis is Maurice Bouvet, “Histoire sommaire du remède secret,” Revue 
d’histoire de la pharmacie 45, no. 153–54 (1957): 57–63, 109–18. Even then, the main goal of the article is 
to follow legislative changes, rather than to excavating broader social, economic, and intellectual aspects of 
the phenomenon.  
 Maurice Bouvet (1885-1964) was a graduate of the École supérieur de Pharmacie de Paris, served 
as a military pharmacist during the First World War, and spent most of his career working for the drug 
manufacturer Les établissements Goy (initially a manufacturer of capsules and tablets, later famous for its 
M.B.C. throat pastilles), becoming president of its administrative council from 1940 until his death in 1964. 
He was also a regular contributor to the Revue d’histoire de la pharmacie and other French pharmaceutical 
and medical journals (for which he provided short historical notices) and was president of the Société 
d’histoire de la pharmacie from 1945 until 1964. On Bouvet’s career see the special issue of the Revue 
d’histoire de la pharmacie (vol. 73 no. 267), which includes a series of biographical articles and a useful 
bibliography: Pierre Julien, “Bibliographie des publications de Maurice Bouvet,” Revue d’histoire de la 
pharmacie 73, no. 267 (1985): 325–61.  
 NB: Bouvet’s articles are often split into installments across several issues of the same 
publication, sometimes with slight variations in titling (and usually followed by “suite” or “suite et fin”), 
which tends to complicate citation. In several cases, the same articles are published in multiple periodicals 
(e.g. many from the Courrier médical can also be found in La pharmacie française). See the Julien 
bibliography mentioned above for the concordance of these versions. 
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1776. Consequently, the records of medical regulation and litigation in Paris are mixed 
pêle-mêle within voluminous judicial and administrative fonds, a fact which makes their 
systematic examination more difficult, but not impossible. 
1. Privilege in Ancien Régime France 
 Monopoly privileges over specific remedies stand as a peculiarly medical 
expression of the much broader phenomenon of economic privilege-granting in this 
period, both in France and throughout Europe.15 Furetière’s Dictionnaire (1690) defines 
privilege as “a particular advantage enjoyed by one person to the exclusion of many 
others, which comes to him by the benefaction of his sovereign.”16 The granting of 
privileges was an attribute of royal sovereignty. They were held by individuals, but also 
by collective entities such as corps, orders, and estates, as well as provinces, cities, and 
seigneuries. Privileges were the ties that bound the king and his subjects, either directly 
or in a mediated way through their membership in corporate bodies ranging from 
religious orders to provincial estates, municipal governments, and trade guilds. In 
concrete terms, privileges permeated every part of an individual’s social and economic 
status, from occupation, tax status, obligations for military service and billeting, to 
political rights, eligibility for given offices, costume, and the right to carry a sword.17 As 
Michael Fitzsimmons has aptly put it, “Under the old regime, privilege was a primary 
                                                 
15 An ongoing project supported by the Agence nationale de la recherche, entitled “Les privilèges 
économiques en Europe, XVe-XIXe siècles: étude quantitative et comparative,” directed by Dominique 
Margairaz, promises to shed light on the broader European phenomenon of privilege granting through the 
creation of a database of economic privileges from the fifteenth to the nineteenth century, including France, 
England, Germany, and Italy. 
 16 “Un avantage particulier dont jouit une personne à l’exclusion de plusieurs d’autres, qui lui 
vient par le bienfait de son souverain.” This definition is closey followed by the 1694 Dictionnaire de 
l’Académie as well as the first sentence of Diderot and d’Alembert’s Encyclopédie, although much of the 
rest of the article is a critique of abuses of privilege. 
 17 For an excellent description of how privilege flows socially and economically through corps, 
orders, and estates, see Gail Bossenga, The Politics of Privilege: Old Regime and Revolution in Lille 
(Cambridge: Cambridge University Press, 1991), 5–7. 
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instrument of government and the chief medium of political exchange between the Crown 
and the corporate entities that comprised much of French society.”18  
 A number of privileges were closely associated with service to the royal 
household. These included the privileges of royal medical practitioners, such as the 
privilege to practice in Paris and anywhere else that the royal court was based (and in 
spite of any local corporate privileges that might otherwise preclude such practice). As 
the court became increasingly sedentary at palaces in the vicinity of Paris, Fontainebleau, 
and Versailles, these privileges became, in effect, a way of both sidestepping the 
privileges of the University of Paris Faculty of Medicine and the guilds of surgeons and 
apothecaries, and gaining access to the lucrative Parisian medical marketplace without 
the hassle of submitting to examination and paying exorbitant fees to the local 
corporations.19 
 The personal exemptions to corporate regulation that were provided to courtly 
medical practitioners were part of a larger set of economic privileges granted to 
merchants and artisans who served the royal household, from artisans such as 
breadmakers, tailors, and wigmakers to musicians, stable masters, palace guards, and 
wolf-catchers, who fell under the legal category of domestiques commensaux, servants of 
the king who “shared his table” (usually in a purely figurative sense).20 Their privileges 
included concrete economic benefits such as exemption from numerous taxes or other 
duties like troop billeting, and the right to do business in the city without impediment 
                                                 
 18 Michael P. Fitzsimmons, The Night the Old Regime Ended: August 4, 1789, and the French 
Revolution (University Park, Pa.: Pennsylvania State University Press, 2003), 18; Michael P. Fitzsimmons, 
The Remaking of France: The National Assembly and the Constitution of 1791 (Cambridge: Cambridge 
University Press, 1994), 4–5. 
 19 Lunel, La maison médicale du roi, 87–92. 
 20 See Sophie de Laverny, Les domestiques commensaux du roi de France au XVIIe siècle (Paris: 
Presses de l’Université de Paris-Sorbonne, 2002). 
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from the local guilds and to decorate their shops with fleur de lys and the arms of the 
Prévôté de l’Hôtel du Roi.21 Along with these privileges and access to all the potential 
connections available at the royal court, exemption from urban guild regulation was in 
fact one of the key incentives for taking on such positions, as their actual wages were 
sometimes relatively modest. 
 Royal privileges were also granted to commercial and industrial interests. 
Alongside the royal manufactures for military supplies (weapons and munitions) and 
luxury goods (tapestries, porcelain, glass), a host of smaller inventors and producers were 
granted privileges to produce steel, iron, copper, and lead, and for machines they had 
invented for everything from textile production and grain winnowing to Blaise Pascal’s 
calculators.22 The granting of royal industrial privileges was part of the larger complex of 
economic policies that historians have called mercantilism, closely associated in French 
historiography with Louis XIV’s famous Controller General of Finances, Jean-Baptiste 
Colbert. Although privilege-granting as an industrial policy dates back to Henri IV, and 
royal privileges also defined the medieval trade corporations, the practice of granting 
limited-term privileges to develop industries greatly accelerated under Colbert’s tenure as 
Controller General of Finances (1665-1683) and Secretary of State for the Royal 
Household (1669-1683), and continued into the eighteenth century.23 In the eighteenth 
                                                 
 21 Ibid., 111–126. 
 22 See especially Liliane Hilaire-Pérez, L’invention technique au siècle des Lumières (Paris: Albin 
Michel, 2000), which compares invention and monopoly in France and England. See also Pierre Deyon and 
Philippe Guignet, “The Royal Manufactures and Economic Progress in France before the Industrial 
Revolution,” Journal of European Economic History 9, no. 3 (1980), 611-632; and the still useful survey of 
privileges provided by Paul-Martin Bondois, “L’organisation industrielle et commerciale sous l’ancien 
régime: le privilège exclusif au XVIIIe siècle,” Revue d’histoire économique et sociale 21, no. 2 (1933): 
140–89. For the 1649 calculator privilege see Blaise Pascal, Oeuvres complètes de Blaise Pascal, vol. 3 
(Paris: Hachette, 1865), 194–196. 
 23 Deyon and Guignet, “The Royal Manufactures,” 619; for royal industrial privileges under Henri 
IV, see Henry Heller, “Primitive Accumulation and Technical Innovation in the French Wars of Religion,” 
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century, they were managed by the Bureau de commerce, which delegated experts (often 
members of the Académie royale des sciences) to inspect inventions and decide whether 
privileges should be allotted.24 The goals of such policies were various. To begin, such 
privileges were usually granted with a limited term of between ten and twenty years. The 
rationale was not to create a perpetual monopoly but simply to ensure a fair return on 
what were sometimes costly ventures for the inventor and financial backers.25 In a 
broader sense, these privileges also aimed to provide the necessary protections until the 
industry was well-established domestically, above all to make sure that it was not 
outcompeted by imports, which mercantilist policy sought to minimize as much as 
possible. The first rationale, that of ensuring a fair return on investments for innovators, 
appears explicitly in the text of many of the privileges analyzed below. As for the second 
rationale, avoiding import dependency on important plant substances like cinchona bark 
and ipecacuanaha had both mercantilist and military overtones. As we shall see in the 
case of the poudre fébrifuge, strategic concerns over the cost and supply of exotic plant 
substances could serve as a powerful motive for both the state and medical entrepreneurs 
to develop indigenous European equivalents. 
 These newer privileges also had the effect of weakening the long-standing 
privileges of the trade corporations, which dated back to the Middle Ages. As Prosper 
Boisonnade put it in his classic study of Colbert, “In order to grow amidst the hostility of 
                                                                                                                                                 
History and Technology 16, no. 3 (2000): 243–62; for a European-wide sketch of the phenomenon, with a 
special emphasis on Venice, see Luca Molà, “Inventors, Patents and the Market for Innovations in 
Renaissance Italy,” ed. Anna Guagnini and Luca Molà, Italian Technology from the Renaissance to the 
Twentieth Century 32 (2014): 7–34.  
 24On the Bureau de commerce and invention see  Hilaire-Pérez, L’invention technique; and 
Philippe Minard, La Fortune du colbertisme: état et industrie dans la France des Lumières (Paris: Fayard, 
1998). Although it regulated the allotment of privileges to numerous other varieties of invention, the 
Bureau de commerce appears not to have been involved in pharmaceutical privilege-granting. 
 25 Prosper Boissonnade, Colbert, le triomphe de l’étatisme: la fondation de la suprématie 
industrielle de la France, la dictature du travail (1661-1683) (Paris: M. Rivière, 1932), 43. 
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the guilds, new enterprises needed the protection of the state: to oppose corporate 
monopoly, the state introduced another kind of monopoly: the privilege.”26 This play of 
privilege against privilege served the centralizing goals of the absolutist monarchy, 
replacing the more mediated local bonds of traditional corporatism with new direct bonds 
between the monarch and the privilege holders, juxtaposing a layer of new agents directly 
loyal to the crown on top of the older layers of municipal or corporate privilege. There 
can be little doubt that the granting of monopoly privileges over secret remedies eroded 
existing corporate medical privileges, particularly those of apothecaries, and the 
expediency of such privileges for the military goals of the centralizing state is particularly 
apparent, as we shall see in the cases of the Helvétius and Guiller-Lajutais families. 
 Jeff Horn has recently developed the theme of privilege granting as a tool of state-
sponsored economic development in the last century and a half of the Ancien Régime. 
Horn has pointed to the ways in which French officials, in “a fit of ‘beautiful madness’” 
deployed privilege to encourage economic development: on the one hand, new 
“privileges of liberty” could be used to minimize risk in innovation for entrepreneurs, and 
how “liberties of privilege” could be used to exempt their holders from other existing 
privilege that were economically cumbersome.27 Horn’s “beautiful madness” of privilege 
granting is closely linked with what other scholars have called “court capitalism” to 
describe the ways in which capitalism operates under the conditions of absolutism where 
                                                 
 26 “Pour grandir au milieu de l’hostilité des jurandes [guilds/corporations], il faut aux entreprises 
nouvelles la protection de l’État [...] Au monopole corporatif, il oppose donc un autre monopole: le 
privilège,” ibid., 42. 
 27 Jeff Horn, Economic Development in Early Modern France: The Privilege of Liberty, 1650-
1820 (Cambridge: Cambridge University Press, 2015), 3–5. 
 The French phrase is “beau délire.” It comes from a 1778 Avis of the deputies of commerce to the 
director general of finances, Jacques Necker, where it is in fact used to describe “unlimited liberty” of 
commerce. See Horn’s article, “‘A Beautiful Madness’: Privilege, the Machine Question and Industrial 
Development in Normandy in 1789,” Past & Present 217, no. 1 (2012): 149–85, 162. 
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markets are shaped to meet the ramshackle needs of the fiscal-military state. As Gail 
Bossenga has defined it, expanding on the earlier usage of George V. Taylor, “court 
capitalism” entailed the venality of state offices, the farming out of important functions 
such as tax collection, and the creation of powerful state-sponsored monopolies, all 
centered on the royal court as their prime sphere of negotiation.28 Monopoly privileges 
for secret remedies, particularly those which were tied to military interests, are one thread 
in this larger tapestry where state goals converged with those of private entrepreneurs. 
 Before moving on to survey the medical privileges themselves, it is useful to 
address one final contextual question: given the close link between monopoly and 
innovation that the secret remedy privileges embody, can they be said to be a sort of 
Ancien Régime pharmaceutical patent? Answering this question requires an appreciation 
of the peculiarity of modern notions of intellectual property. According to Mario Biagioli, 
despite these superficial similarities, privileges and patents have significant differences 
which grow out of their embeddedness in radically different political forms, namely 
absolutism and liberal democracy.29 Privileges were “gifts” that sovereigns bestowed on 
their subjects, while patents emerge from the liberal notion of intellectual property and 
Enlightenment commitments to the dissemination of knowledge. Alongside the question 
of “gift-of-the-sovereign” vs. “right-of-the-citizen,” the key to the modern “patent 
bargain,” which emerged in France and the United States but has since spread to the rest 
of the world, is the specification requirement: an inventor must disclose to the public (via 
                                                 
 28 Gail Bossenga, “Markets, the Patrimonial State, and the Origins of the French Revolution,” 
1650-1850: Ideas, Aesthetics, and Inquiries in the Early Modern Era 11 (2005): esp. 460–464; George V. 
Taylor, “Types of Capitalism in Eighteenth-Century France,” The English Historical Review 79, no. 312 
(July 1, 1964): 478–97. 
 29 Mario Biagioli, “Patent Republic: Representing Inventions, Constructing Rights and Authors,” 
Social Research 73, no. 4 (2006): 1150–72. 
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the patent bureaucracy) the full details of their invention in exchange for the legal and 
financial protections of a temporary monopoly. Privileges, by contrast, did not require a 
public disclosure of the secret behind an invention, proof that it was in fact novel (that is, 
that it was not taking something away from the public that it already had), technical 
examinations or testing, and “specification” understood as a kind of textualization of the 
invention into a series of instructions that ensured its reproducibility by “a person 
reasonably skilled in the art.” Patents were in fact explicitly constructed against earlier 
privilege regimes: as Biagioli puts it, specification requirements were what made the 
patent bargain “politically defensible by distancing it from the ‘odious monopolies’ of the 
Ancien Régime.”30 Likewise, a patent is an attempt to legally define the “idea” of an 
invention through representation (textual or diagrammatic) that could be examined and 
managed by a bureaucracy, whereas privileges were more often than not closely tied to 
actual material inventions, including real substances, working models, and even 
miniatures.31 
 Biagioli builds a stark divide between absolutism and republicanism, Ancien 
Régime and modern liberal democracy; as he himself admits, his approach is “more 
archaeological than historical.”32 The case of pharmaceutical privileges in France points 
instead to a more gradual transition between privilege and patent. As we shall see, certain 
features of specification began to emerge between 1728-1731, well before the end of the 
Ancien Régime and even before the height of the Enlightenment at mid-century. 
 Secret remedy privileges can be seen as the offspring of these two other forms of 
privilege, namely the privileges held by servants of the royal household (including its 
                                                 
 30 Ibid., 1136. 
 31 Ibid., 1156–1159. 
 32 Ibid., 1159. 
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medical practitioners) and the industrial privileges granted by Colbert and his successors. 
The two are even bound together on a functional level: in fact, some vendors began as 
courtly medical practitioners and leveraged their positions to gain additional privileges 
for the sale of secret remedies. Desiderio Descombes, the first Parisian vendor of 
orviétan—perhaps the most famous secret remedy of the Ancien Régime—held a 
privilege as an “Opérateur et distillateur ordinaire du roi.” Adrien Helvétius’s exclusive 
privilege for his remède spécifique depended on the hospital trials he was able to secure 
thanks to his existing court connections, and after he gained his pharmaceutical privilege 
he was able to acquire an appointment as physician to the Duke of Orléans.33 Access to 
the royal court was a crucial condition for acquiring medical privileges, and one privilege 
tended to beget another. 
 The comparison of secret remedy monopoly privileges to industrial privileges is 
likewise instructive. Both often emanated from the same source, namely the Secretary of 
State for the Royal Household (Secrétaire d’État de la Maison du roi), and can often 
even be found alongside one another in the ministerial dispatch registers. It should of 
course be acknowledged that the production of secret remedies, even in the significant 
volumes demanded by the military and other “corporate consumers” was probably far 
less capital-intensive and smaller in scale than, say, casting cannons. Like mechanical or 
metallurgical privileges, however, pharmaceutical privileges are legal monopolies 
identified with the exclusive production and sale of an invention or product. Although 
there is a tendency to treat medicine as a distinct sphere, medical subjects should not only 
be compared temporally and geographically (across different medical licensing regimes 
for instance) but also to contemporary non-medical phenomena. Medicine often operated 
                                                 
33 See below, ch. 4. 
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in ways which were basically analogous to other economic activities: the royal medical 
practitioners can be placed alongside the other privileged servants of the royal household, 
and pharmaceutical privileges bear some resemblance to other industrial privileges. The 
cases of Helvétius and Guiller likewise demonstrate that the military-medical contracting 
played out in analogous ways to other fields of military supply: eighteenth-century 
military rationality demanded increasingly standardized tools and supplies in ever 
growing quantities, and medications have a place in this story alongside food, muskets, 
cannons, powder, and shot. 
 The royal privileges granted to the domestiques commensaux and to various 
manufactures provide useful background for understanding what Brockliss and Jones 
have called “the new forms of medical entrepreneurialism which spanned the traditional 
divide between orthodox practitioners and ‘empirics’ or charlatans’” and which they 
associate with the Enlightenment.34 New commercial imperatives and a new clientele (the 
state) help explain this erosion of boundaries. My suggestion here is that these 
entrepreneurs played a role in the medical dimension of some much larger early modern 
historical developments, including the erosion of medieval corporatism through new 
economic privileges and the rise of the fiscal-military state. These themes will be 
developed in greater detail in the following chapters. In the meantime, the best way into 
the world of medical privileges in this period is by examining the privileges themselves. 
2. Three varieties of pharmaceutical privilege 
 By the last quarter of the seventeenth century, the crown regularly granted 
privileges to support the vendors of “secret” or “specific” medications in three principal 
ways: (1) it could grant a monopoly, leaving the exclusive sale of a given medication in 
                                                 
 34 Brockliss and Jones, The Medical World of Early Modern France, 622. 
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the hands of a given individual, either for a defined period with renewal conditions, or 
life-long with the possibility of inheritance, sale or transfer; (2) it could provide the legal 
right to maintain a furnace and chymical laboratory for the purpose of producing 
medications; and finally, (3) the crown could (in effect) purchase a medical secret 
(disclosing it either to the first physician or publishing it for the benefit of the kingdom) 
in exchange for a fixed annual pension, payable to the “owner” of the secret and his heirs. 
For the sake of simplicity, I will refer to these three modes as (1) exclusive-sale 
privileges, (2) laboratory privileges, and (3) pensions.  
 In total, I have assembled a corpus of sixty pre-1728 medical privileges and 
pensions allotted or the disclosure of a medical secret. I have included privileges within 
the corpus only when I was able to obtain a full copy of the operative letters patent, 
brevet, or certificate.35 With that said, it seems unlikely that this corpus represents 
anything more than a mere fraction of the privileges which were actually granted during 
this period, as the considerations in Appendix 2 make clear. Many of those which I have 
assembled are in fact explicitly described as renewals of earlier privileges which have not 
survived. There are also further limits to the representativeness of the corpus due to gaps 
in the principal fonds in which copies of the privileges have survived, the dispatch 
register of the Secretary of State for the Royal Household (series O1) and the registers of 
the Prévôté de l’Hôtel (V3). With the exception of a single orviétan privilege from 1625 
and two laboratory privileges for 1646 and 1663, all of the pre-1728 privileges I have 
                                                 
 35 This more than doubles the corpus of pre-1728 privileges identified by Bouvet. Restricting our 
count to cases where an actual privilege is cited (rather than simply attested by a another source), in the 
four articles cited above Bouvet had identified copies of seven exclusive sale privileges in series O1 and V3; 
nine laboratory privileges (including two from outside of the sources I examined); and six pensions, for a 
total of twenty-two medical privileges. 
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found are dated after 1670, as very few records have survived from the Secretary of State 
for the Royal Household before 1669. 
 To provide some idea of the distribution of these three types of privilege at the 
outset, the pre-1728 corpus I have assembled is made up of forty-six exclusive-sale 
privileges, ten laboratory privileges, and six pensions.36 The exclusive-sale privileges 
thus predominate, comprising over 3/4 of the privileges under study. 
 Before the bureaucratization of privilege-granting for secret remedies under the 
Société royale de médecine in 1776, all letters patent and brevets were granted through 
the authority of the Secretary of State for the Royal Household on behalf of the king and 
on the recommendation of his first physician. This recommendation is often, but not 
always, mentioned in the text of the privilege itself. To the best of my knowledge, there 
are no documented efforts to develop a systematic process of examination before 1728. 
The corpus I have assembled represents a series of privileges granted on an ad hoc basis, 
not an organized regulatory bureaucracy or judicial authority. In the absence of a 
dedicated fonds, I have had to painstakingly extract these privileges from the voluminous 
dispatch registers of the Secretary of State for the Royal House (see Appendix 2: Sources 
and Methodology). The diverse responsibilities of the Secretary of State for the Royal 
Household in this period included not only overseeing the royal household itself, but also 
the city of Paris (in collaboration with the Lieutenant General of Police), the general 
administration of the interior provinces, and overseeing a host of royal institutions, 
                                                 
 36 The total here exceeds sixty because Helvétius’ privilege is counted twice: he received a joint 
privilege granting him both exclusive sale of his remedy as well as the right to have a laboratory. 
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including the Collège royal, the Bibliothèque du Roi, the Jardin du Roi, the Imprimerie 
royale, and the various Académies.37 
 Pharmaceutical privileges typically take the form of brevets and letters patent. 
While most of the texts I have examined are transcriptions from the dispatch register, the 
original letters patent and brevets were written on large sheets of parchment (see 
Appendix 3, Figure 1). As guarantees of their authenticity, letters patent included both the 
signatures of the Secretary of State and the king as well as a prominent yellow wax seal 
from the royal Chancellor, while brevets included only the two signatures, without any 
seal. Brevets and letters patent were of course not types of document specifically 
produced for the granting of medical privileges of the kind that interest this dissertation; 
they were in fact used for all varieties of royal orders, permissions, and privileges, as we 
shall see below.38 
 Beyond these physical differences, the brevets and the letters patent each follow a 
distinct textual formula. Letters patent begin as follows: “Louis by the grace of God King 
of France and Navarre to our beloved and loyal counselors in the courts of our 
Parlements, bailiffs, seneschals, their lieutenants and to all other officers and upholders of 
the law to whom it concerns, Greetings.”39 The letters subsequently refer to the bearer of 
the privilege as “Our well-beloved subject” and recount how he or she “has very humbly 
petitioned us” (nous a remonstré très humblement) to provide them with protection for 
their remedy, which is then observed to be very useful against a given disease or 
                                                 
 37 Bernard Barbiche, Les institutions de la monarchie française à l’époque moderne (XVIe - 
XVIIIe siècle) (Paris: Presses Universitaires de France, 2012), 239–251. 
 38 For an introduction to letters patent and brevets, see Ibid., 166–170, 190–191. 
39 “Louis par la grâce de Dieu Roy de France et Navarre à notre aimez et féaux conseilleurs dans 




condition, and sometimes to have been tested or to have met with the approval of the first 
physician. This is followed by a series of specific provisions surrounding duration, fines 
for counterfeiters, advertising rights, and permission to subcontract, which I will describe 
in greater detail below. 
 Brevets, by contrast, begin less formally with the word “Today” (Aujourd’huy) 
and provide the date, and the location of the king (usually Versailles or Fontainebleau). 
They then specify that the king has been “well informed” of the remedy or reputation of 
the vendor, with the first physician often mentioned as his source. In consequence of 
these favorable reports, the brevet then states that the king has elected to permit the 
vendor to sell his or her remedy at Paris and in all parts of the kingdom, or, in the case of 
pensions (which are always dispensed via brevets), it specifies a set annual figure, “to be 
paid throughout his life by the keepers of his Royal Treasury present and future.” In the 
case of exclusive-sales privileges, the brevets tend to be much shorter than letters patent 
and provide fewer specifications on the protections afforded by the privilege (most 
notably, they do not always provide a set fine for infractions). Historically, the issue of 
royal brevets was simply a provisional step taken before full letters patent were issued, 
and as such they were “legally imperfect.”40 By the early modern period, however, they 
had become, “the form which, above all others, was suited to liberalities, and to the 
distribution of rewards and favors,” and were no longer superseded by subsequent letters 
patent.41 But for the purposes of medical brevets, I have found no evidence that they were 
treated any differently than letters patent: beyond the difference in formula, the main 
                                                 
 40 Barbiche, Les institutions de la monarchie française, 190–191. 
 41 “Le brevet […] est la forme par excellence qui convient aux libéralités, à la distribution des 




difference between the two seems to be that letters patent provide more detail in 
specifications than the brevets. 
 The third type of document, certificates from the first physician, usually surround 
mineral waters, medicinal syrups, or oils. Rather than being stand-alone privileges of 
their own, they are dependent upon a privilege held personally by the first physician, who 
also held the title of superintendant of mineral and medicinal waters in the kingdom.42 As 
such, the permissions to sell mineral and medicinal waters in Paris and elsewhere were 
granted by virtue of his own letters patent as superintendent. In other cases, such as that 
of Cosme Damien Barré’s 1678 laboratory privilege, the certificate from the first 
physician was a temporary authorisation for six months, registered with various courts, 
and then replaced before the elapsed time by genuine letters patent. 
 With a single exception, that of the brevet granted to Ferdinand Guiller in 1713, 
the texts of the letters, brevets, and certificates assembled in my corpus are all taken from 
transcriptions in dispatch registers or registres d’entregistrement.43 The originals would 
of course have been kept by their holders, and as such have disappeared. They appear 
periodically in images of charlatans from the period, however, and the original parchment 
certificates, with dangling seals, would have served as material guarantors of the medical 
legitimacy of their holders, alongside the medallions they were occasionally given by 
civil authorities (see Appendix 3, Figures 11 and 12).44 
  
                                                 
42 Lunel, La maison médicale du roi, 192–200, 208–209, 319–322. 
 43 For the original Guiller brevet, see AN V7 246 (6) dossier 3, item 2. The preservation of this 
brevet is a historical accident. See below, ch. 5, sect. 1 and Appendix 3, Figure 1. 
 44 See below, ch. 3, sect. 3, on the golden medallion which the charlatan Christophe Polony 
received along with his privileges from the Languedoc Estates in 1654. 
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3. Exclusive-sales privileges for secret remedies: protections and conditions 
 Beyond these formal divergences, the most important details of the privileges in 
both brevets and letters patent are broadly similar among the exclusive-sales privileges 
(see Appendix Table 1 for a list of the privileges). All exclusive-sales privileges grant the 
bearer the right to sell his or her remedies—regardless of whether or not they hold any 
formal medical qualifications—to the exclusion of all others, including physicians, 
surgeons, and apothecaries. Most, however, also specify other conditions, rights, and 
obligations. This section provides a breakdown of how these and other features are 
distributed within the corpus, including the most common types of drugs for which 
privileges were granted; the duration of the privilege, the penalties specified for 
counterfeiters; the presence or absence of rights to establish franchises or sub-contractors 
to sell the substance on the vendor’s behalf; provisions for advertisements, including the 
right to use the royal arms as a trade mark (a common privilege for merchants following 
the court); and, finally, various conditions sometimes attached to the privileges. These 
conditions sometimes included organized clinical testing (occasionally in hospitals), 
price-fixing or the creation of special exceptions to the monopoly for military hospitals, 
and, much more rarely, the provision of notarized cure certificates as a condition for the 
privilege’s renewal. 
3.1. Varieties of remedy  
 What kinds of medications were protected by privileges in the France of Louis 
XIV and XV? Antidotes form the largest contingent, with a total of twelve (nearly ¼ of 
the total), including orviétan, the antidote de France of Pierre Obelin de Quercetan, and 
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other contrepoisons.45 Five of these are renewals of the Contugi orviétan privilege, but 
even excluding these, antidotes would be tied with venereal disease remedies as the most 
numerous type of remedy in the corpus. The prominence of antidotes is hardly surprising 
given their important uses against plague, rabies, snake-venom, and intentional poisoning 
with chemical substances like arsenic, as well as their prominent place in the history of 
medicinal specifics.46  
 In second place following antidotes are seven drugs against venereal disease, 
which are especially prevalent in the early decades of the eighteenth century.47 Next are 
febrifuges (three privileges), followed by cancers remedies, hernia plasters, and 
Helvétius’ dysentery specific, which occupy two privileges each.48 Disease categories 
with only a single remedy include gout, rheumatism, hydropsy, and apoplexy. The 
remainder either do not specify a condition to which the remedy responds, or list a variety 
of complaints. Three, for example, are for elixirs whose exact purposes remain 
unspecified in the text of the privileges. Some were panaceas, most notably the famous 
“Elixir de Garrus” devised by the Montpellier doctor Joseph Garrus, a panacea 
supposedly based on Paracelsus’ elixir proprietatis and containing an array of exotic 
simples from the Indian Ocean.49 Seven remedies fall under the category of mineral 
waters, syrups, and oils. Perhaps the most unusual of these is the “Gabian oil” sold by 
                                                 
 45 See Appendix 1, Table 1: Descombes (1625), Contugi (1686, x2), Obelin de Quercetan (1689) 
Lescot (1689), Contugi (1694), Contugi (1700), Contugi (1716), Fournier de la Flotte (1716), Toscano 
(1716), Gerauldy (1721) and Toscano (1727). 
 46 See below, ch. 2 and 3 for the role played by antidotes as models for the kind of therapeutic 
action assigned to medicinal specifics in the later seventeenth century. 
 47 See Appendix, Table 1: Montroche (1693), Meunier (1715), Legrand (1716), Frechon (1721), 
Granger (1722), Huber (1725), and Mauman (1727). 
 48 Ibid. For febrifuges, see Auby (1683) and Guiller (1713 and 1724); for cancer treatments, see 
Alliot (1683) and Jouen (1691); for hernia plasters, see Veuve de Jean de Vaux (1700) and Bols (1722). 
 49 The elixir was made up of aloe from the island of Socotra (south of the Arabian peninsula), 
saffron, myrrh, Ceylonese cinnamon, cloves and nutmeg. See Pierre Labrude, “L’elixir du Docteur Garrus. 
Medicament ou liqueur de table? Formule originale ou imitation?” Histoire des sciences médicales 41, no. 
3 (2007): 315–16. 
42 
 
Sébastien Matte La Faveur (1629-1714) and Jean-Baptiste Daumont, which was in fact 
petroleum from a natural seep near the town of Gabian in the Languedoc, first discovered 
in 1608 and commercialized by the local bishop. The petroleum was ingested or used 
topically against a variety of illnesses including gout, asthma, tumors, gall, or skin 
problems.50 Among other non-plant-based substances, there is an instance of potable gold 
in the form of the “drops” (gouttes) of the General La Motte.51 Where some remedies are 
left vague in their applications, others are very precisely defined: for example, Gerauldy’s 
“opiate for use during dental operations,” and Roger Lasalle’s “remedy against calluses 
and inflations in the neck of the bladder.”52 Many of these remedies appear to have been 
based on plants native to metropolitan France. Canada (maidenhair ferns), Brazil 
(ipecacuanha), Peru (cinchona bark), and the islands of the Indian Ocean (aloe, spices 
such as saffron, cinnamon, cloves, nutmeg) are among the most exotic sources for the 
simples which entered into these proprietary remedies. 
3.2. Duration of privilege.  
 Laboratory privileges and pensions appear to have been life-long, and make no 
specifications on duration. Likewise, the exclusive sales privileges typically do not 
provide a duration, with some notable exceptions: two that I have found indicate a 
provisional trial period of one year or less, after which time the holder must return and 
provide proof—in the form of official certificates from medical personnel—attesting to 
                                                 
50 See Cécile Raynal, “Le Gabianol, huile de Gabian,” Revue d’histoire de la pharmacie 93, no. 
348 (2005): 655–58; Robert Jacobus Forbes, Studies in Early Petroleum History (Leiden: Brill, 1958), 1–
12; Maurice Bouvet, “L’huile de Gabian,” Revue d’histoire de la pharmacie 27, no. 105 (1939): 5–12. 
 51 On La Motte, see below in this chapter, esp. section 5; see also Maurice Bouvet, “La spécialité 
pharmaceutique au XVIIIe siècle : Les gouttes du général de la Motte,” Revue moderne de pharmacie 12, 
no. 1 (1922): 7–15. On potable gold, one of the most powerful symbols of medical alchemy in the Middle 
Ages, see Chiara Crisciani and Michela Pereira, “Black Death and Golden Remedies: Some Remarks on 
Alchemy and the Plague,” in The Regulation of Evil: Social and Cultural Attitudes to Epidemics in the Late 
Middle Ages, ed. Agostino Paravicini Bagliani and Francesco Santi (Florence: Sismel, 1998), 7–39. 
 52 See Appendix 1, Table 1: Gerauldy (1700) and Lasalle  (1716). 
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the effectiveness and celebrity of their remedy in order to be awarded a more long-term 
privilege.53 Two others specify a fifteen-year duration, and three specify a twenty-year 
duration.54 Only four of the remaining thirty-five exclusive-sale privileges explicitly 
specify that the privilege is to be held “as long as he/she lives” (sa vie durant), but in 
practice all privileges without a specified time-limit appear to have been treated as life-
long privileges.55  In many cases they were extended even further, being renewed by 
successors, typically widows and descendants.  
3.3. Penalties for counterfeiters and adulterators.  
 The exclusive-sales privileges consistently specify that their bearers should be 
“neither troubled nor impeded” in the exercise of their privilege, often singling out 
physicians, surgeons, and apothecaries specifically as the source of potential 
challenges.56 Many also specified a penalty for counterfeiting or adulteration, “under 
pretext of augmentation, reduction, or some other change” (sous pretexte 
d’augmentation, diminution ou autre changement). The most common penalty being the 
seizure of the counterfeited drugs, the payment of legal costs and damages, and, in some 
cases (eighteen out the forty-six pre-1728 exclusive-sales privileges) a specified fine of 
between 1,000 and 3,000 livres tournois, to be split evenly in half or into thirds (see 
Appendix 1, Tables 4 and 5). For example, one common model splits the fine three ways, 
with one third for the king, one third for the bearer of the privilege, and one third for the 
                                                 
53 See Ibid., Barré (1678) and Fronville (1700). 
 54 See Ibid., for fifteen-years, see Helvétius (1688) and (1703); for twenty-years, Guyet 
(1688), Leroux (1693) and Leroux/Lasalle (1716). 
 55 Ibid., Contugi (1694), Contugi (1694), Toscano (1716) and Fournier de la Flotte (1716). 
 56 “Fait Sa Majesté très expresses défenses a tout Médecin, Chirurgien, Apotiquaire et à toutes 
personnes de quelque qualité et condition qu’elles soient de luy donner aucun trouble ny empeschement.” 
The June 29, 1716 privielge of Pierre Le Grand for his venereal disease remedy went a step further with 
proscrptions against other proprietary vendors as well: “Faisant defenses à toutes Medecins, Chirurgiens, et 
apotiquaires de luy donner à cet égard aucun trouble ny empechement mesme sous pretexte des privileges 
qu’ils pourroitent avoir obtenu pour la guerison des memes maladies,” O1 60, fol. 95v. 
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nearest Hôtel-Dieu. Three even provide a reward for the “denonciateur” who reported the 
infraction.  
3.4. Franchise rights 
 Fines were steep for counterfeiters, but at least some of the vendors of proprietary 
remedies seem to have been willing to share the wealth with authorized distributors if it 
meant expanding their markets. One specification that crops up rarely (only six times) 
within the pre-1728 corpus but that would become crucial in later privileges is the 
allowance for what might be called “franchises” or “subcontractors,” as in Helvétius’ 
1688 privilege, which permitted him “to have whichever persons he should see fit to 
distribute his specific in his name,” and in others which note that the remedy can be sold 
only by the holder or the brevet or someone else with their “express permission.” In other 
cases, franchise vendors are simply implied by provisions for multiple boutiques or 
bureaux de distribution, as in the case of Guiller’s 1713 febrifuge privilege.  
 One of the most notable instances of long-distance franchising is that of the 
Montpellier chymist Sébastien Matte La Faveur and his Parisian distributor, Jean-
Baptiste Daumont.57 Matte La Faveur had fought against the restrictions of the 
Montpellier apothecaries’ corporation and gained a local privilege from the Parlement of 
Toulouse in 1663, enabling him to practice chymistry and produce “essences, waters, and 
oils.” He became a prominent iatrochemist and chymical “demonstrator” to the students 
of the Montpellier Faculty of Medicine, publishing a Pratique de chymie, dedicated to the 
                                                 
 57 See Michel Bougard, “La Pratique de Chymie de Sebastien Matte La Faveur : un épisode 
méconnu des démonstrations publiques de chimie au XVIIe siècle,” in Alchemy, chemistry and pharmacy: 
Proceedings of the XXth International Congress of History of Science (Liège, 20-26 July 1997), ed. Michel 
Bougard, De diversis artibus, 61 (Turnhout: Brepols, 2002), 77–98; Roy G. Neville, “The Pratique de 
Chymie of Sébastien Matte La Faveur,” Ambix 10 (1962): 14–28. 
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royal first physician Antoine Daquin, in 1677.58 Matte La Faveur was famous for his 
Queen of Hungary water—allegedly based on a recipe devised by a fourteenth-century 
Hungarian queen—which he advertised as effective against gout, paralysis, rheumatism, 
various obstructions, bad breath, and burns.59 In 1678 he obtained a joint privilege with 
his Parisian distributor, Daumont, which permitted them to supply Queen of Hungary 
water and other medicinal waters to courtly and Parisian clients.60 These privileges were 
granted personally by the authority of Daquin, by virtue of his own prerogative over the 
kingdom’s mineral waters. The other substances included in the privilege were mineral 
waters from the spring of Sète in the Languedoc, the aforementioned Gabian oil,61 and 
capillary (maidenhair fern) syrups from Montpellier and Canada.62 With the exception of 
the Canadian capillary syrup, most of these products were from Provence or the 
Languedoc, and Matte La Faveur collaborated with Daumont to bottle and transport them 
to Paris and Versailles for courtly clients which included the famous courtly epistolarist 
Madame de Sévigné.63 
 In the post-1728 period, the proprietary remedy franchising phenomenon would 
reach new heights with Pierre Dionis, doctor regent in the Paris Faculty and purchaser of 
the orviétan privilege from the Contugi family. Dionis’ 1741 privilege, issued jointly in 
                                                 
 58 Sébastien Matte la Faveur, Pratique de chymie, divisée en quatre parties (Montpellier: Daniel 
Pech, 1671). 
59 J. Worth Estes describes this substance as an antispasmodic made of rosemary distilled in wine. 
See “Hungary (Queen of ) Water,” in J. Worth Estes, Dictionary of Protopharmacology: Therapeutic 
Practices, 1700-1850 (Canton, MA: Science History Publications, USA, 1990), 97; Bougard, “La Pratique 
de Chymie de Sebastien Matte La Faveur,” 83–84. 
 60 AN V3 189, fol. 10 r°-v° (8 August 1678). See also V5 1245, 118r°-121v° (January14, 1682) 
 61 See above in this chapter, section 3 “Varieties of remedy.” 
62 A syrup used against coughs and other lung conditions and as an aperitif; also held to be capable 
of provoking menstruation. The Montpellier variety was eventually outmoded by the Canadian variety, 
which was beleived to be more effective. See Stéphanie Tésio, Histoire de la pharmacie en France et en 
Nouvelle-France au XVIIIe siècle (Québec: Les Presses de l’Université Laval, 2009), 158; Nicolas Lémery, 
Traité universel des drogues simples (Paris: Laurent d’Houry, 1698), 12, “Ils sont pectoraux, aperitifs, ils 
excitente le crachat, ils adoucissent les acretez du sang, ils provoquent les mois aux femmes.” 
 63 Bougard, “La Pratique de Chymie de Sebastien Matte La Faveur,” 84. 
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his name and that of his wife, stipulates the usual 1,000 livre fine against any distributor 
“who does not have the consent of the Sieur and Dame Dionis.” In the decades following 
1760, this consent appears to have been granted with a surprising frequency. As we shall 
see in Chapter 3, Dionis was careful to provide written permission to each of his 
commissionaires, and these permission certificates were then registered with the Prévôté 
de l’Hôtel. The Prévôté registers for the 1740s do not include any Dionis orviétan 
franchisees—although this could simply mean that Dionis had not yet made registering 
them part of his modus operandi—and those for the 1750s have not survived, but by the 
1760s Dionis was farming out his privilege to a steadily growing number of vendors each 
year. In 1763, for instance, eight were licensed; in 1764, there were another ten; in 1765, 
another twelve. Who were these franchise vendors? Pierre Baron has provided a 
breakdown of the composition of this group for the period 1762-1783, and found that out 
of a total of two-hundred and sixteen permissions, forty-five specified that they were 
surgeons, thirty-six were operators, and thirty-two were dentists, followed by sixteen 
botanists, and a smattering of other occupations, from chymists to innkeepers.64 
3.5. Advertising rights.  
 Six of the pre-1728 privileges include provisions that either imply or explicitly 
indicate that the holder has the right to advertise their remedy on posters and printed 
broadsheets. The Sieur Aubry, for instance, was permitted by his 1683 privilege “to have 
posters (affiches) placed wherever he should see fit.”65 Trademarks are closely linked to 
                                                 
 64 Pierre Baron, “La vente de l’orviétan en France à la fin du XVIIIe siècle,” St. Honoré les Bains, 
6-8 June 1997, Actes de la Société française d’histoire de l’art dentaire, accessed May 10, 2014, 
http://www.biusante.parisdescartes.fr/sfhad/vol2/debut.htm; see also Brockliss and Jones, The Medical 
World of Early Modern France, 640–642; and the list of commissionaires in Le Paulmier, L’Orviétan, 
Pièce LII, 233–246. 




advertising in the privileges. Privilege holders were permitted to sell and advertise their 
medications using the arms of the royal court as their mark; the 1691 privilege of the 
oculist Louis Jouën for his cancer cure includes provisions not only permitting him to 
advertise using posters and printed broadsheets (affiches et placards) but also to make 
use of a tableau (probably a large sign on wood or canvas) with the royal arms, which he 
can place above his door “for the facility of the public.”66 As a privileged merchant 
following the court, Daumont, Matte La Faveur’s Parisian vendor of syrups and mineral 
waters, was likewise permitted to use the royal arms in his advertising, and to use the 
fleur de lys as mark of authenticity on his bottles of mineral waters.67 
3.6. Testing  
 The 1728-1731 legislation regulating medical privileges would put a strong accent 
on the empirical testing of the medications in question, but to what extent was testing 
already going on? Out of the corpus of forty-six pre-1728 exclusive-sales privileges, only 
thirteen make specific mention of successful trials (épreuves), usually supervised directly 
by the first physician or by other doctors appointed as commissioners on his behalf; and 
out of these thirteen, a mere four explicitly underline that they were granted following 
hospital trials on multiple patients. These are the 1677 privileges for the delousing 
sachets of the Duc de Bouillon,68 the 1688 and 1703 privileges for Helvétius’ remède 
spécifique,69 and Louis Jouën’s 1691 privilege for his remedy against cancer, scirrhus, 
and malignant ulcers. Jouën, who was an oculist by trade, was granted his privilege based 
                                                 
 66 AN O1 35, fol. 258v-259r, Privilege pour la guérison des cancers en faveur de Louis Joüen 
(September 18, 1691). 
 67 AN V3 189, fol. 10r-v, Permission de Daquin pour Sébastien Matte La Faveur et Jean-Baptiste 
Daumont (August 8, 1678); see also Daumont’s printed affiches in BnF Res Z-THOISY- 325, fol. 487-489. 
 68 AN O1 21, fol. 202r-203r, Privilege pour des sachetzs contre la vermine, en faveur de Monsieur 
le Duc de Bouillon (September 17, 1677). 




not only on the result of trials (épreuves) on several (plusieurs) patients at the Paris 
Hôpital général, but also “after having seen the attestations of other cures he made of said 
conditions in other towns of the kingdom.”70 Just beyond the pre-1728 period, the 1730 
brevet for the “gouttes” of General La Motte was also granted following hospital trials at 
the Hôtel des Invalides.71 
3.7. Price-fixing 
 Another condition sometimes specified in the exclusive-sales privileges is price 
fixing. The 1678 and 1682 privileges granted by Antoine Daquin to Jean-Baptiste 
Daumont specified that his “veritables syrops de capillaires de Canada et de Montpellier” 
were to be sold in four different bottle sizes fixed at 15 sols, 20 sols, 30 sols and one écu; 
and Helvétius’s privileges for 1688 specified a “modest price” of three Louis d’or for his 
remède spécifique. The exclusive-sales privilege and pension for the elixirs of the 
General La Motte, later granted to his widow, likewise specified set prices and 
volumes.72 Once fixed by the privilege, the prices appear to have remained constant over 
time, even in subsequent renewals. In the case of Helvétius, the price for the elixirs 
specified in La Motte’s initial privilege of January 1, 1730, was still the same twelve 
years later in the 1742 privileges granted to his widow, Simone Morcet. It should be 
mentioned, however, that the La Motte exclusive-sales privileges had another important 
condition: their elixirs could also be produced and distributed at the Hôtel des Invalides 
                                                 
 70 AN O1 35, fol. 258v-259r, Privilege pour la guérison des cancers en faveur de Louis Joüen 
(September 18, 1691). 
 71 See below, sect. 5. 
 72 The privilege specifies 25 livres per phial of the yellow elixir and 20 livres for a phial of the 
white elixir, with each containing a minimum of two and a half gros of liquid. See AN O1 86, p. 216-220, 
Lettres patentes portant privilège d’un Élixir sous le nom de Goutes du General de la Mothe à la veuve La 
Mothe concurremment avec la maison de St. Cyr (May 3, 1742). 
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and other military hospitals without any payment to La Motte, and, later, to his widow. 
They were compensated for this inconvenience with a generous 4,000 livre pension. 
4. Laboratory privileges and the 1682 poison edict 
 Ten privileges for chymical laboratories and furnaces, granted for the express 
purpose of producing medicines, can be found in the dispatch registers of the Secretary of 
State for the Royal Household and the Prévôté de l’Hôtel. These laboratory privileges 
have a history that stands somewhat apart from that of the exclusive-sales privileges, and 
any account of the laboratory privileges must first begin with a digression into the history 
of one of the most fascinating scandals of seventeenth-century France: the Affair of the 
Poisons (1677-1682). The affair opened when Mademoiselle de la Grange and her lover, 
the abbé Nail, were accused of poisoning her patron, the lawyer Jean Faurye, and of 
forging a marriage certificate so that she would inherit Faurye’s estate. These events—
which followed an earlier case of poisoning in 1675, wherein the Marquise de Brinvilliers 
was accused, along with her lover, of poisoning her father and brothers in order to inherit 
their estates—precipitated a massive investigation by the chief of the Paris police, 
Gabriel Nicolas de la Reynie, and the creation of a special tribunal, the Chambre de 
l’Arsenal, which uncovered a massive underworld of criminal magicians, diviners, and 
poisoners-for-hire reaching all the way into the inner circle of the king. In the most 
famous case, the midwife La Voisin (later executed as a sorceress) implicated Louis 
XIV’s own mistress, Madame de Montespan, in the purchase of aphrodisiacs and in the 
arrangement of a number of black masses officiated by the abbé Etienne Guibourg. 
Between 1677 and 1682, the investigation led to numerous arrests, tortures, and over 
three dozen executions, including those of several chymists. The affair surrounding 
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Madame de Montespan was hushed, the Chambre de l’Arsenal was eventually dissolved, 
and an edict was finally promulgated in July of 1682 to bring closure to the affair.73 
 This edict provided a new rationale for laboratory licensing, and is cited in almost 
all of the laboratory privileges. Despite its first-order importance for chymical regulation, 
recent accounts of the Affair of the Poisons give little attention to the role of medicine 
and chymistry, focusing instead on the role of black magic. The accounts of Arlette 
Lebigre and Lynn Mollenauer dedicate only a few pages to the chymical regulations of 
the 1682 edict.74 Beyond its opening articles regulating divination, the edict is remarkable 
as an early instance of legal controls being placed on the circulation of toxic substances, 
notably arsenic, orpiment, and mercury sublimate, all of which would henceforth be sold 
only to persons who needed to employ them as part of their professions, notably 
physicians, apothecaries, and tradesmen such as goldsmiths and dyers. Detailed registers 
of the names and addresses of all purchasers would need to be kept by the vendors of 
such chemicals (including spicers and haberdashers), and the purchasers would 
themselves need to keep registers of the use of the substance, including the quantities 
held and used for different activities. But for my purposes here, the most important part 
of the edict is its eleventh article: 
We expressly prohibit all persons of whatever profession or condition—
excepting approved physicians, and in the places of their residence, 
professors of chymistry, and master apothecaries—to have any 
laboratories for working at any preparations of drugs or distillations, under 
pretext of producing chymical remedies, experiments, or particular secrets, 
of searching for the Philosophers’ Stone, converting, multiplying, or 
                                                 
 73 See Jean-Christian Petitfils, L’affaire des Poisons. Crimes et sorcellerie au temps du Roi-Soleil 
(Paris: Perrin, 2010); Lynn Wood Mollenauer, Strange Revelations: Magic, Poison, and Sacrilege in Louis 
XIV’s France (University Park, Pa.: Pennsylvania State University Press, 2007); Arlette Lebigre, L’affaire 
des poisons , 1679-1682 (Bruxelles: Editions Complexe, 1989); Claude Quétel, L’affaire des poisons: 
crime, sorcellerie et scandale sous le règne de Louis XIV (Paris: Tallandier, 2015). 




refining metals, or of preparing crystals or colored stones, and for other 
similar pretexts, without having first obtained permission to have such 
laboratories from us in the form of  letters of the Great Seal and having 
presented and declared them to our judges and officers of police of each 
given place.75  
 
Following this edict, private chymical laboratories were licensed by the Secretary of State 
for the Royal Household. It should however be noted that this edict should not be seen as 
a royal condemnation of chymical medicine more generally. Chymical medicine had a 
long history of royal patronage, particularly through the laboratories, courses, and chair 
in chemistry at the Jardin du Roi. Even at the height of the Affair of Poisons, the crown 
also maintained a chymical laboratory explicitly dedicated to the production of chymical 
remedies, operated by the Capuchins Nicolas Aignan (aka Père Tranquile) and Henri de 
Montbazon (aka Père Rousseau), whose case will be discussed in Chapter 2.  
 Some privileges for laboratories appear to have been granted even before the 1682 
edict: those of Cosme Damnien Barré, for instance, as well as Henri de Rochas and 
Marguerite Charpentier. These privileges emanated from the Cour des monnaies, the 
court charged with the surveillance of coin-making and the prosecution of counterfeiting 
and other methods of debasing the currency. Helvétius’ exclusive sales privileges were 
registered with the Cour des monnaies because of their provisions for furnaces and 
                                                 
 75 “Faisons très-expresses defenses à toutes personnes de quelque profession et condition qu’elles 
soient, excepté aux Medecins approuvez, et dans le lieu de leur residence, aux Professeurs en Chimie, et 
aux Maistres Apothicaires d’avoir aucuns laboratoires, et d’y travailler à aucunes preparations de drogues 
ou distillations, sous pretexte de remedes chimiques, experiences, secrets particuliers, recherche de la pierre 
philosophale, conversion, multiplication ou rafinement des metaux, confection de cristaux ou pierre de 
couleur, et autres semblables pretextes, sans avoir auparavant obtenu de nous par Lettres du grand Sceau la 
permission d’avoir lesdites laboratoires, presenté lesdites Lettres et fait declaration en consequence à nos 
Juges et Officiers de Police des lieux,” AN AD XI 21, item 45, Edit du roy pour la punition de differents 
crimes qui sont devins, magiciens, sorciers, empoisonneurs. Regle ceux qui peuvent vendre ou employer les 
drogues dangereuses, et à qui il est permis d’avoir des fourneaux ou laboratoires. Registré en Parlement le 
31 aoust 1682. (Paris: François Muguet, 1682), 5. Professeurs de Chymie is likely a reference to the 
instructors in chymistry at the Jardin du Roi. 
52 
 
laboratories,76 as were several pre-1682 furnace privileges granted for iatrochemical 
purposes; the Cour des monnaies also prosecuted chymists who owned unregistered 
furnaces.77  Parisian distillers in particular had been obliged to request permissions to 
have furnaces from the Cour des monnaies because of their potential use in 
counterfeiting.78 As such, the 1682 edict marks not so much a completely new form of 
regulation as a move from one concern over chymists to another: namely, a shift from 
fears of counterfeiting to fears of poisoning.79 
5. Pensions and the disclosure of medical secrets 
 Some purveyors of medical secrets (six within my corpus) were provided with a 
pension from the royal treasury after disclosing their secrets to the crown. The earliest 
pension I have found is of 1,200 livres for Robert Talbor’s valet, Philippe de la Verdure, 
in exchange for his febrifuge specific in 1680, a case which will be discussed at length in 
Chapter 2. The latest pre-1728 pension was valued at 1,000 livres for the widow of 
Garus, inventor of the famous elixir bearing his name. Among the corpus of six pre-1728 
pension brevets, the average value is 1,500 livres per year. All of these pensions mandate 
the disclosure of the medical secret to the king and his first physician, and some also 
mandate the publication of the secret for the benefit of the general public.  
                                                 
 76 AN Z1B 95, p. 947-950, Helvétius privilege (August 21, 1688). 
 77 See for example AN Z1B 94, Ordonnances et arrêts civils et criminels (1679-1683), fol. 44v-45v, 
furnace privilege for Cosme Damien Barré (October 8, 1679); fol. 214r, furnace privilege for the Écuyer 
Seigneur de Hautebont (November 28, 1677). The Cordelier Jacques Tiran was convicted by the Cour in 
1681 of having an illicit laboratory in the Marais (including furnaces, a matrass, and various phials) in 
which he had produced “oils extracted by chymistry.” See AN Z1B 94, fol. 423r-v (March 6, 1681). 
 78 Robert Scagliola, “Les apothicaires de Paris et les distillateurs” (Thèse de pharmacie, Université 
de Strasbourg, 1943), 36–42. 
 79 My search through the Cour des monnaies fonds was cursory, given time constraints, but 
revealed several interesting cases. As far as I am aware, series Z1B stands as a hitherto unrecognized source 
for state regulation of chymists and chymistry in France. 
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 The “gouttes jaunes” and “gouttes blanches” of the General La Motte provide a 
revealing and amply-documented instance of pension-granting in exchange for the 
disclosure of a medical secret. Antoine Dumut de la Motte (sometimes La Mothe) had 
served as a Major-General of Artillery for the Transylvanian Prince Ragortzi.80 When he 
returned to France, he brought with him a recipe for a golden elixir. Trials on patients at 
the Hôtel des Invalides led to a favorable report from Morand and other physicians, and 
so the king acquired La Motte’s secret in exchange for a pension and an exclusive-sales 
privilege. The only exception to his monopoly were army hospitals and the Hôtel des 
Invalides, which were permitted to produce the medication for the king’s troops. The 
privilege was later held by La Motte’s widow, Simonne Morcet, who renewed it in 1742, 
1750 and 1768.81 La Motte’s brevet was granted January 1, 1730—in the midst of the 
period when the commission for the examination of remedies was forming—and the 
value of his pension was 4,000 livres, over double the value of the average pension.82 
 The most interesting sources surrounding La Motte are two letters, a lengthy pair 
of chymical recipes, and an accompanying mémoire on how to administer the medication, 
bound together in a manuscript compendium at the Bibliothèque nationale. These 
documents shed light on how the process of “secret disclosure” took place. They show 
that the task of examining La Motte’s secret was given to one of the consulting royal 
                                                 
 80Probably Ferenc Rákóczi II (1676-1735), prince of Transylvania, whose rebellion against the 
Habsburgs was subsidized by Louis XIV during the War of the Austrian Succession. Rákóczi was later 
received at Versailles during his exile: see Miklós Molnár, A Concise History of Hungary, trans. Anna 
Magyar (Cambridge: Cambridge University Press, 2001), 133–138; in his French memoirs, Rákóczi makes 
frequent mention of a Colonel La Mothe: see François Rakoczy, Les memoires du prince François Rakoczy 
sur la guerre de Hongrie, depuis 1706 jusqu’à la fin, 5 vols. (The Hague: Jean Neaulme, 1739). 
 81 Bouvet, “Les gouttes du général de la Motte,” 7–8. This story is similar to that of Ferdinand de 
Guiller, who also served in an army in Eastern Europe (Dalmatia in his case) and returned with a medical 
secret which found French military applications (see Chapter 5).  
 82 Mercure de France (March 1730), 555. The prices are the same as those specified in La Motte’s 
widow’s 1742 privilege: 25 livres per phial of the yellow elixir; 20 livres per phial of white elixir. I have 
been unable to find a copy of the original brevet granted to La Motte, but the later renewals survive. 
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physicians, Antoine Sidobre (1672-1747), and that the product of this examination is fifty 
pages of detailed instructions on how to produce the “gouttes d’or” and the “gouttes 
blanches,” signed by La Motte and Sidobre. The instructions report dozens of chemical 
operations, undertaken at different locations (including the royal mint and the personal 
laboratories of La Motte and Sidobre). The “gouttes jaunes” (also known as “gouttes 
d’or”) are revealed to be “une teinture d’or dulcifiée tirée par l’esprit de vin tartarisé et 
alkoolisé,” and are especially extensive, being made up of thirty-five distinct steps. The 
cheaper and simpler to make “gouttes blanche” are “une dissolution de cinabre minerai, 
faite dans l’esprit de vin tartarise et alkoolisé,” requiring only six steps. 83 
 The recipe mémoire was put in the hands of no less than the Cardinal de Fleury 
(1653-1743), tutor and later de facto prime minister of Louis XV, who sent it to one of 
the royal librarians, the abbé Targuy, in the form of a sealed package, with a letter, dated 
October 4, 1729, including the following instructions for the librarian: 
The intention of the King is that the mémoire which contains the method to 
compose the two elixirs of the General de La Motte should be deposited into 
his library. I have put it into a packet (here attached) which cannot be opened 
except by an express order of His Majesty. As regards the mémoire which 
explains the properties of these elixirs, it too should be attached to the sealed 
packet.84 
 
The royal librarian Targuy acknowledged receipt (a draft of his letter is included in the 
package) and confirmed that the package had been placed under lock and key in the 
                                                 
 83 BnF ms. NAF 22162, “Mélanges de médecine et de pharmacie XVIe-XIXe siècle,” fol. 36-67, 
“Quatre pièces relative à l’élixir du General la Motte du mois d’octobre 1729 (deux lettres et deux 
mémoires).”These documents were first noticed by Maurice Bouvet, “Les gouttes du général,” Revue 
d’histoire de la pharmacie 37, no. 124 (1949): 487–89. I plan to return to this source in a subsequent 
publication. 
 84 “L’intention du Roy est que le mémoire qui contient la manière de composer les deux Elixirs du 
General de la Mothe soit mis dans sa bibliothèque en forme de Dépôt. Je l’ai fait mettre dans le pacquet cy 
joint lequel ne pourra être ouvert sans un ordre exprès de Sa Majesté. À l’égard de celuy qui explique les 
propriétés de ces Elixirs, il doit être joint au paquet cacheté,” BN ms. NAF 22162, 37r°-v°. 
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library.85 Although La Motte’s secret was apparently kept, one possible result of royal 
purchase in other cases was the secret’s subsequent publication: as we shall see in 
Chapter 2, the preparation of Robert Talbor’s remède anglois was published after 
Talbor’s death by Nicolas de Blégny in collaboration with Antoine Daquin, the royal first 
physician.  
6. Privileges re-examined: The creation of the Commission (1728-1731) 
 The ad hoc granting of lifetime privileges and pensions did not continue 
indefinitely, as the July 3, 1728 arrêt which opened this chapter makes clear. While the 
previous sections explored the privilege regime which it sought to reform, in this final 
section I will explore how privileges were granted after the reforms of 1728-1731, and 
ask what, if anything, changed in the following decades. 
 Over a month after the deadline for submitting privileges for re-examination had 
passed, Dodart, the architect of the 1728 reforms, pressed the king to grant an extension. 
The rationale was “to leave no pretext for those who have not yet satisfied the 
conditions,” a goal that was reached by providing yet another month from the day the 
new arrêt was published (November 4, 1728 according to the printed version).86 Beyond 
extending the deadline in order to gain a better show of compliance from the privilege 
holders, the new arrêt also specified for the first time that the paperwork and medications 
                                                 
 85 Ibid., 38r°-v°. 
 86 Arrest du Conseil d’Estat du Roy, qui defend à toutes sortes de personnes de distirbuer des 
Remedes sans en avoir obtenu de nouvelles Permissions. Extrait des registres du Conseil d’Estat du Roy. 
Du 25 octobre 1728. (sl: sn, sd). My working copy is BnF F- 21108 (49). Cf. AN E 2089, Minutes d’arrêts, 
Secrétaire d’État de la Maison du Roi, fol. 250r°–252r° (25 octobre 1728). 
 All of the time limits specified in these arrêts begin the day they are published, both in print 
through the circulation of printed copies and broadsides, as well as orally by being called aloud in public 
places at the sound of trumpets and bells by official criers (Jurés-Crieurs du Roi). Because the July 3 arrêt 
was published on the 24 July, this means in fact that the original deadline fell on the 24 September; another 
month passed before the new arrêt was promulgated on 25 October, and several weeks again passed before 
it was published on 4 November, meaning the new deadline would fall on 4 December. As such, with these 
various elapses in time and delays, medical privilege holders had five months to provide their paper work 
and samples of the remedies to the police. 
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would be examined by an eleven-person commission of physicians, surgeons, and 
apothecaries, with Dodart at its head. Together, this set of physicians, surgeons, and 
apothecaries were among the most famous in France: prestigious court practitioners, 
chymists from the Jardin du Roi, members of the Académie royale des sciences, with 
both Paris and Montpellier graduates among their number.87 The new arrêt was also 
careful to specify the distinct roles of each type of practitioner, observing that the 
principal task of examination was left to the physicians and apothecaries; surgeons would 
be involved only in cases where the remedy was surgical in nature. 
 Precious little has survived documenting the work of the 1728 commission, which 
makes it difficult to assess how the commission did its work. We can assume that many 
vendors obeyed the 1728 arrêts. As the deadlines kept being extended, a growing 
collection of drugs and their accompanying privileges must have been deposited with the 
Lieutenant General of Police. At some point, the commissionaires must have convened to 
analyze them. But what was their modus operandi? The only document that I have been 
able to find that offers any trace of the internal workings of the commission is a short, 
                                                 
 87 The other distinguished members were: Jean-Adrien Helvétius, the son of Adrien and recently 
first physician to the queen, Marie Leczinska; Étienne François Geoffroy (1672-1731), chymist at the 
Jardin du Roi and then dean of the Paris Faculty; two royal consulting physicians, Jean-Baptiste Silva 
(1682-1642) and Michel Louis Vernage (1697-1773); Georges Mareschal (1758-1736), the king’s first 
surgeon; three other royal surgeons, Malval, Petit, and François Gigot de Lapeyronie (1678-1747), later 
Mareschal’s successor; and two apothecaries, Claude-Joseph Geoffroy (1685-1752) and Gilles-François 
Boulduc (1685-1731), both members of the Académie royale des sciences.  
 On Vernage, see Isabelle Coquillard, “Vernage, Michel Louis (1697-1773),” Le Monde médical à 
la cour de France. Base de données biographique publiée en ligne sur Cour de France.fr, accessed May 
13, 2014, http://cour-de-france.fr/squelettes-dist/bases/medecine/dictionnaire_fiche.php?numero=55.  
 On Lapeyronie, see Louis-Paul Fischer, Jean-Jacques Ferrandis, and Jean-Éric Blatteau, “François 
de Lapeyronie, de Montpellier (1678-1747), restaurateur de la chirurgie et esprit universel : l’âme, le musc, 
les oeufs de coq,” Histoire des sciences médicales 43, no. 3 (2009): 241–48. 
  On Geofroy and Boulduc, see Gustave Planchon, Dynasties d’apothicaires Parisiens : I. Les 
Geoffroy (Paris: Masson et Cie, ed., 1899); Gustave Planchon, Dynasties d’apothicaires parisiens : II-III. 
Les Boulduc. Les Pia. (Paris: Octave Doin, 1900); Paul Dorveaux, “Apothicaires membres de l’Académie 
royale des Sciences VII : Claude-Joseph Geoffroy,” Revue d’histoire de la pharmacie 20, no. 79 (1932): 
113–26; Christian Warolin, “La dynastie des Boulduc, apothicaires à Paris aux XVIIe et XVIIIe siècles,” 
Revue d’histoire de la pharmacie 89, no. 331 (2001): 333–54. 
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one-page mémoire, dated October 16, 1729, and signed by René Hérault (1691-1740), 
Lieutenant General of Police. It distinguishes three types of remedy: those which are 
dangerous, those which are salutary, and, finally, the pragmatic category of “indifferent 
remedies.” In the latter case, the mémoire observes that the commission should not 
abolish those privileges which it has pleased the king to grant for “indifferent” remedies 
which cause no ill effects. Their vendors were permitted to continue holding privileges 
allowing them to sell such “indifferent” remedies, although—a subsequent note 
clarifies—they should no longer hold the exclusive rights to do so: “In this case the 
exclusion must be abolished, and the apothecaries must be given the liberty to compound 
these remedies.”88 Any monopoly clause should be removed so that the apothecaries will 
likewise be permitted to sell the supposed “medication.” This clause offers the nearest 
thing to an admission of the potential political consequences involved in re-assessing and 
potentially revoking privileges that were likely granted through the intercession of 
powerful patrons at court, including the king himself. 
The remainder of the mémoire expresses the two principal objectives: 
The commission has two important goals which are of the utmost importance: 
1. In the future, to no longer grant privileges for remedies under any 
pretext whatsoever unless they have been analyzed beforehand, and that it be 
evident that the remedy is distinctive, not present in any Pharmacopeia, and 
that it is salutary. 
2. To express the illnesses and circumstances of illnesses where it is 
suitable to make use of the remedies which have been approved or will be 
later. This article is among the most essential and just as worthy as any other 
of the full attention of Messrs the Commissioners.89 
                                                 
 88 BIUS Médecine, Ms 2006, fol. 310r-v. 
 89 “La Commission a deux grands objets ausquels il est necessaire de s’attacher par preference à 
tout : 1. De ne plus accorder a l’avenir sous quelque pretexte que ce soit aucuns Privileges pour des 
remedes que l’analyse n’en ait esté préalablement faite, et qu’il ne soit évident que le remede proposé est 
particulier, qu’il n’est dans aucun Pharmacopée et qu’il est salutaire. 2. D’exprimer les maladies et les 
circonstances des maladies ou il conviendra a faire usage des remedes qui sont approuvées ou qui le seront 
par la suite. Cet article est des plus essentiels et est aussi digne qu’aucun autre de toute l’attention de 




In contrast with the rather opaque statements of the arrêts that privileges would be “re-
examined,” these protocols offer a window into what likely took place in the 
deliberations of the commission: the testing of drugs with the objective of determining if 
they in fact responded to given conditions; the assessment of whether or not a given drug 
was already known in the pharmacopeiae; and, finally, the careful specification of the 
circumstances and conditions of sickness in which the drug should be used. These 
considerations, far more sophisticated than the “approved” vs. “unapproved” or 
“salubrious” vs. “insalubrious” reasoning implied by the text of the 1728 arrêts, would be 
further elaborated in the final March 17, 1731 arrêt that brought the developmental phase 
of the commission to a close and created a clear protocol for the “new regime” of 
privilege-granting. 
 It is of course possible that these apparently new requirements may simply have 
codified the existing practices of the first physicians. Take, for example, the following 
anecdote from Bernard Le Bouyer de Fontenelle’s éloge of Fagon, the first physician who 
preceded the reformer Dodart during the height of the pre-1728 privilege regime. 
According to Fontenelle, Fagon was “no friend to empirics,” although he was interested 
in medical secrets, and had bought several on behalf of the king:  
He wanted these to be true secrets, that is to say, unknown up until that 
point, and consistently useful. He often showed people who believed they 
possessed a treasure that it had already been made public: he would show 
them the book in which it was enclosed—for he read widely—or a 
mémoire that had already turned it to good account.90  
 
                                                 
 90 “Il vouloit qu’il fussent veritablement Secrets, c’est-à dire inconnus jusques-là, et d’une utilité 
constante. Souvent il a fait voir à des gens qui croyoient posseder un tresor, que leur tresor étoit déjà public, 
il leur montroit le Livre où il étoit renfermé, car il avoit une vaste lecture, et une mémoire qui la mettoit 
tout entiere à profit,” Fontenelle, “Eloge de Fagon” Histoire de l’Académie royale des sciences (1718), 99. 
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These comments suggest that Fagon was careful to establish the novelty of a cure before 
recommending a pension or a privilege, lest vendors be rewarded for “secrets” that are 
already in the “public domain” (that is, printed in an existing pharmacopoeia). It seems 
likely that the other steps recommended in the mémoire, including establishing whether 
or not the drug affected the condition for which it had been proposed, was implicit within 
the trials of the medication. 
 Leaving aside the question of whether or not the new protocols merely reflect a 
codification of existing practices, the “new privilege regime” was not yet instantiated at 
Dodart’s death on November 25, 1730. To this was added the death of one of the 
commission’s most prominent members, Geoffroy, on January 6, 1731. These ill-timed 
deaths may have stalled the reform project, but the new first physician, Pierre Chirac, a 
graduate of the University of Montpellier, took up the banner and replaced Geoffroy with 
Hyacinthe-Théodore Baron (1707-1787), the new dean of the Paris Faculty.91 This was 
followed a week later by the March 17, 1731 arrêt, which would be the final word on 
privileges for proprietary medicine in France until 1754, when the commission would be 
renewed, and stands as the most articulate project for regulation until the creation of the 
Société royale de médecine in 1776. 
 The clear intention of the March 17, 1731 arrêt is to put a definitive end to the 
“wild-west” period of privilege-granting and replace it with a more regular model. With 
this goal in mind, it provides nine articles that would henceforth govern the regulation of 
privilege granting. The first specifies that brevets and privileges will no longer be granted 
on the authority of the first physician alone; all must be signed and examined by the 
                                                 
 91 AN E 2111, fol. 215r°-v° (March 11, 1730). No printed version of this arrêt appears to have 




whole commission. The second adds that all brevets and privileges will now have a three-
year expiry date, after which holders must apply for renewal, which will only be granted 
based on certificates of approval from physicians and surgeons of those places where the 
remedies were used. The arrêt is clear on these points: even if three years is not explicitly 
specified in the text of the brevet or letters patent, this is the term limit on all existing or 
future brevets, and violators will face a thousand livre fine (payable to the local hospital). 
Finally, it prohibited all remedies sold under old brevets which had not been re-examined 
by the commission, both those from before 1728 as well as any that failed to secure 
renewal after their three-year term had expired. To these ends, the third article mandated 
careful record-keeping: minutes of the brevets and privileges—presumably a register of 
examinations and approved remedies—were to be kept by the first physician. Any 
affiches or other advertisements for approved remedies must conform only to those 
remedies that were examined and approved by the commission, under penalty of a 500 
livre fine for false advertising. Finally, all privileges will be circulated to faculty and 
college deans in a printed copy, and the deans will be encouraged to report any problems 
or accidents involving privileged medications.  
 Well beyond regulating secret remedies, Chirac also aimed to use the commission 
to lay the groundwork for a broader regulatory system—a proto-Société royale—even if 
it lacked judicial power to enforce its will and was confined to “encouraging” 
cooperation from the medical faculties and corporations in Paris and the provinces. The 
final articles enjoined provincial faculties and other medical corporations to collaborate 
with the commission, notably requesting that they report any “unprivileged” vendors; and 
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specifying that inter-corporate medical conflicts should be reported to the commission.92 
The final article of the 1731 arrêt returns to the question of secret remedies and 
endeavors to anticipate any jurisdictional conflicts: it enjoins all civil officials in the 
towns and provinces not to give permissions to any vendors, charlatans, or operators 
except those approved by the commission. 
 A clear path of development can be discerned through these arrêts from 1728-
1731. The first arrêt (July 3, 1728) simply represents the recognition of a problem (too 
many privileges have been granted, and some may be dangerous) and the beginnings of a 
solution (recalling all brevets and letters patent, having them deposited along with 
samples of their associated drugs in the hands of the Lieutenant-General of Police). The 
second arrêt (October 25, 1728) nominates a commission of eleven experts to examine 
the drugs and their privileges. A mémoire dated October 29, 1729, which identifies 
different kinds of examination outcomes and specifies that the originality of the drug 
must be assessed (qu’il n’est dans aucun Pharmacopée), likewise that the disease or 
condition which it responds to must be specified, as must the circumstances on which it 
should be used. These developments culminate with the March 17, 1731 arrêt, which 
details the new way in which substances will be examined and privileges will be allotted. 
 But did these careful prescriptions coalesce as a functional regulatory regime? 
The reforms initiated by Dodart and continued under Chirac appear to have ended in 
disappointment. A draft copy of an undated “Rapport et requeste” by Chirac and his 
commissioners opens by admitting that, following the March 17, 1731 arrêt, 
Only a small number of individuals appeared with their brevets in hand, 
most not having wanted to submit their remedies and their conduct to a 
                                                 
 92 This role extends only to providing expert advice on the jurisdiction of the three corps; despite 
its ambitions, the commission did not have any real executive role in resolving disputes. 
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new examination, abusing their surreptitious privileges in Paris as well as 
in the provinces, to the prejudice of Your Majesty’s subjects, 
notwithstanding the prohibitions made by the arrêts of Your Council.93 
 
This failure, coupled with a second motive, namely the “mutual usurpations” of the three 
medical corps—physicians, surgeons, and apothecaries—provide the commissioners with 
the rationale for the request. The noncompliance of the secret remedy vendors and 
“mutual usurpations” in the three corps are all seen by Chirac as related phenomena. The 
disintegration of the proper division of medical labor is in fact enabled by the undue 
“license” of the secret remedies vendors and the “colporteurs, chymists, spicers and 
drugists, who furnish them with the means.” To this end, he proposed twenty-four new 
articles for a new arrêt. The first five articles include particularly draconian measures 
against noncompliant secret remedies vendors. Any vendors who continue to sell 
remedies under privileges that were submitted for re-examination but were not re-
authorized following the new arrêts should face the penalty of imprisonment as 
“poisoners of the public” and should be condemned to serve in the galleys. Any brevets 
that were not re-submitted within the three-month deadline of the March 17, 1731 arrêt 
will be declared null and void, and if their holders continue to sell remedies they will face 
the above penalty, as would any individual treating human patients or even livestock 
without a proper brevet. Chirac also specifies that any vendors holding brevets that were 
re-authorized by the commission should face the same penalty if they were selling any 
remedies other than those authorized by their brevet or using them in cases or conditions 
other than those specified by the brevet. Finally, local officers should carefully and 
                                                 
 93 “Il ne se seroit presenté qu’un petit nombre de particuliers pourvûs desdits Brevets, la plus 
grande partie n’ayant voulu soumettre et leurs remedes et leur conduite à un nouvel examen, abusant de ces 
privileges subreptices tant a Paris que dans les provinces, au prejudice de vos sujets, nonobstant les 
deffenses portées par les arrests de votre Conseil,” BIUS Ms 2006, 329r-v. 
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diligently report the results of their inquiries to the local Parlement so that cases against 
the illicit vendors can be prosecuted.94 
 The fact of continued noncompliance with the earlier arrêts, coupled with the 
draconian punishments recommended against the carefully defined offenses of violators 
and the attempt to “restore” the “proper” division of labor among the legitimate medical 
corporations, all converge to give Chirac’s “Rapport et requeste” an overall tone of 
frustration. The twenty-four articles the report recommends never made their way into 
law, and Chirac himself died within a year of writing it. Over the following decades the 
commission continued to meet sporadically, examining remedies and recommending new 
brevets, but the extent to which the 1728 and 1731 arrêts were enforced remains unclear. 
Prosecution may have been contingent upon the desire of a vendor’s adversaries to report 
their infractions: the Contugi orviétan boutique was searched and sealed in 1729 after 
local apothecaries reported Contugi to the Lieutenant General of Police for failing to 
deliver his brevet to be re-examined under the new privilege regime.95 Other examples of 
noncompliance can be found in prominent vendors who sold proprietary drugs for 
decades but appear never to have secured privileges. Some vendors saw obvious 
advantages to securing privileges, particularly if they hoped to sell their remedies to the 
state or other bulk purchasers, but others seem not to have bothered, a fact which 
suggests the arrêts were not consistently enforced in Paris or the provinces.96  
                                                 
 94 Ibid., 331r-332v. 
 95 See below, ch. 3, sect. 5; and Gustave Planchon, “Notes sur l’histoire de l’Orviétan,” Journal de 
Pharmacie et de Chimie 26, no. 3–7 (1892): 293–298; Le Paulmier, L’Orviétan, 86–88. 
 96 Several high-profile vendors appear to have never requested monopoly privileges. Take for 
example the remède universel, a proprietary purgative sold by Jean-Louis Ailhaud (1674-1766), which was 
never protected by a privilege; and the former pilules mercurielles of the army surgeon Augustin Belloste 
(1654-1730). Belloste sold his famous mercurial pills from 1681 onward but appears to have never 
requested a monopoly privilege. The earliest privilege for them appears to have been granted well into the 
career of his son, Michel-Antoine Belloste, in 1756. The Belloste pills stand as a particularly prominent 
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 Lacking a bureaucratic archive or surviving papers from the first physicians, it is 
impossible to assess the degree to which the new commission-based processes were 
implemented. But looking specifically at vendors who actually requested privileges, can 
we say that, following the intentions of Dodart, the “embarrassing authority” of 
examining drugs was now shared with the commission? Evidence suggests that it was 
not. When Pierre Brodin de Lajutais and Etienne Guerin petitioned to renew the privilege 
for the poudre fébrifuge in 1733, it was the patronage of Chirac’s successor, François 
Chicoyneau (1672-1752), that was the deciding factor, and they managed to secure the 
renewal in spite of the vociferous opposition of the commission.97 Guerin likewise 
reports that the cost of a monopoly brevet in this period was around 1,200 livres—
admittedly without specifying exactly to whom the sum needed to be paid—and 
personally worked very hard to ingratiate himself with the first physician through gifts of 
tobacco.98 The members of the commission sat whenever it was convoked, but it 
remained under the aegis of the first physician and its authority could be overridden by 
him or the Secretary of State for the Royal Household. It seems that the personal 
judgment of a man who had literally been entrusted with the health of the monarch was 
quite sufficient to decide whether or not a drug “worked,” whether it was useful to the 
interests of the fiscal-military state, and whether it should be rewarded with a privilege. 
 Other anecdotes likewise suggest that at least some contemporaries continued to 
perceive the first physician’s prerogative of privilege-granting as inherently corrupt all 
                                                                                                                                                 
example of a proprietary drug that was never protected by a pre-1728 and which also appears to have 
passed under the radar of the latter privilege regime. See AN V5 1269 fol. 173. Pascal Clair and Jean-Marie 
Le Minor, “Augustin Belloste (1654-1730), de la chirurgie militaire à la thérapeutique mercurielle,” Revue 
d’histoire de la pharmacie 89, no. 331 (2001): 369–80; Maurice Bouvet, “Le « Remède Universel » Ou 
« Poudre d’Ailhaud,” Courrier Médical, no. 30 October-18 December (1927): 495–96, 511, 523, 535–36, 
551, 567, 579, 591. 
 97 See below, ch. 5, sect. 3. 
 98 AN V7 246, (6), dossier 1, piece 10, Guerin to Lajutais (December 30, 1732). 
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the way up to the creation of the Société royale. Take for example the comments of 
Frédéric-Melchior Grimm on Jean-Baptiste Sénac (1693–1770), the successor to 
Chicoyneau as first physician. In his manuscript newsletter, the Correspondance 
littéraire, Grimm provides what amounts to a posthumous character assassination (the 
very opposite of an éloge), which ends with a description of his gross venality in 
privilege-granting. Grimm observes that Sénac did not really “believe” in medicine, but 
recognized that physicians were the longest-standing “merchants of hope” (marchands 
d’espérance) and so resolved to become one. Grimm adds that Sénac never made eye-
contact while speaking—implying he was dishonest—and that, as a dyed-in-the-wool 
Montpellier doctor, he supported the introduction of inoculation in France simply to give 
grief to the Paris Faculty. According to Grimm, writing in 1771, Sénac had delegated his 
responsibilities in privilege-granting to his wife: 
She directed the Charlatans Department, and enjoyed the attendant profits, 
and in her extreme avarice she wanted to push these profits as far as they 
could go. Every rascal who paid handsomely was sure to get a permit from 
the first physician, delivered by his wife, to sell drugs that were often 
dreadful for the health of the people throughout the kingdom: his reign 
was that of the charlatans. His death opened an important position which 
was close to the royal person, and which circumstances could render 
infinitely interesting. Moreover, the position is lucrative, having 
consistently provided Madame Senac with over one hundred thousand 
livres in revenue annually.99 
 
The reader may evaluate these comments in due measure with Grimm’s other jabs against 
Sénac. What is clear from them is that the practice of privilege-granting continued to 
                                                 
 99 “Elle avait le département des charlatans, et y jouissait des profits attachés, que son extrême 
avarice voulait pousser aussi loin qu’ils pouvaient aller. Tout coquin qui payait grassement était sûr d’avoir 
une permission du premier médecin, délivrée par sa femme, pour vendre et débiter par tout le royaume des 
drogues souvent funestes à la santé du peuple : son règne fut celui des charlatans. Sa mort fait vaquer une 
place importante qui approche de la personne du souverain, et que les circonstances peuvent rendre 
infiniment intéressante. Elle est d'ailleurs très lucrative, et il passe pour assez constant qu’elle a valu tous 
les ans plus de cent mille livres de rente à madame Senac,” Friedrich Melchior Grimm and Denis Diderot, 
Correspondance littéraire, philosophique et critique de Grimm et de Diderot, depuis 1753 jusqu’en 1790., 
ed. Jules-Antoine Taschereau and A. Chaudé, vol. 7 (Paris: Furne, 1829), 168. (January 1771). 
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carry the stigma of charlatanism in spite of the efforts of Dodart and Chirac to reform its 
“abuses.” Grimm’s image of a corrupt first physician whose wife managed the sale of 
brevets in a “department des charlatans” reminds us of the potential for venality and 
patronage inherent in the practice of medical privilege-granting. These innuendos and 
whispers evoke a medical corner of the world of “court capitalism” at Versailles that has 
left little record for historians to analyze, as do Verdier’s comments on the “infinite 
number of permissions” which the first physicians were constantly compelled to grant to 
“empirics” supported by powerful courtly patrons whom they could not dare refuse. This 
situation likely continued even under the Société royale in the final decades of the Ancien 
Régime. Although some historians have taken spokesmen of the Société such as Vicq 
d’Azyr at their word and described it as a model of enlightened medical regulation, Colin 
Jones has astutely suggested that the remedy-licensing practices of the Société continued 
to provide a “powerful lever of potential patronage and self-enrichment.”100  
 My contention in the chapters that follow is that a small but important coterie of 
these “medical entrepreneurs” were much more than mere symptoms of Ancien Régime 
corruption or evidence of a pluralistic medical marketplace rapidly supplanting traditional 
corporatism. Rather, they were aware of current theoretical conversations in learned 
medicine—most notably surrounding the virtues and therapeutic effects of medicinal 
specifics—and in practical terms they worked assiduously to produce innovative new 
preparations, which often formed the basis for their fortunes. These engagements allowed 
them to fill a wholly new and potentially lucrative niche in the constrained Ancien 
Régime medical marketplace by serving the needs of a new class of state and “corporate” 
                                                 
 100 Colin Jones, “The Médecins du Roi at the End of the Ancien Régime and in the French 
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Chymical pathology and therapy at the court of Louis XIV:  
The Louvre Capuchins and Robert Talbor’s remède anglois 
 
 Chapter 1 focused on privilege, what might be called the legal basis for secret 
remedies. This chapter will examine the intellectual basis of such remedies by assessing 
the role of chymical medicine in explaining diseases and their cures in the period 1680-
1700. I argue that Louis XIV patronized the production of chymical remedies and that 
chymical ideas furnished his royal first physicians with a criterion for explaining the 
action of drugs that were deemed medicinal specifics. Previous discussions of the 
fortunes of chymical medicine in seventeenth-century France have focused on the 
reception of Paracelsianism and the vicious debates over the safety of antimonial 
medicines—the century-long “Querelle de l’antimoine,” 1566-1666.1 In this chapter, I 
show that later seventeenth-century chymical medicine also provided powerful models 
for understanding pathological entities (disease semina and fermenta; semences and 
levains), pathological processes (fermentation), and the therapeutic effects of exotic plant 
substances like cinchona bark that otherwise eluded the traditional Galenic qualities.  
 This chapter is organized around the contemporaneous arrival of a group of 
medical outsiders at the court of Louis XIV in the years 1678-1681: first, the Capuchins 
of the Louvre (part 2) and second, Robert Talbor, aka “le médecin Anglois” (part 3). 
                                                 
 1 Laurence Brockliss and Colin Jones, The Medical World of Early Modern France (Oxford: 
Clarendon Press, 1997), 119–138; Didier Kahn, Alchimie et Paracelsisme en France à la fin de la 
Renaissance (1567-1625) (Geneva: Droz, 2007), chap. 4.1, 353–409; Didier Kahn, “Paracelse, l’antimoine 
et le vin émétique” (unpublished conference paper, Les savoirs du vin à la Renaissance 1450-1650, Pessac, 
2013); Elisabeth Labrousse and Alfred Soman, “La querelle de l’antimoine : Guy Patin sur la sellette,” 
Histoire, économie et société, 1986, 31–45; Allen G. Debus, The French Paracelsians: The Chemical 
Challenge to Medical and Scientific Tradition in Early Modern France (Cambridge: Cambridge University 
Press, 1991), 46–99. 
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Although neither the Capuchins nor Talbor received a monopoly privilege, they were 
supported by Louis XIV in other ways and can be seen as precursors of the later medical 
privilege regime. In the first case, the Louvre Capuchins neatly exemplify the extent of 
support the crown was willing to accord to iatrochemistry, manifested most dramatically 
in the provisions made for their pharmaceutical laboratory. In the second case, the 
stunning success and royal endorsement of Robert Talbor’s cinchona-based remède 
anglois provoked intense experimental competition by rival practitioners who sought to 
reverse-engineer its preparation, and it came to serve as a model for subsequent 
proprietary remedies. The remède anglois provided a fertile model in other areas as well, 
notably in the chymical accounts of its therapeutic action provided by Nicolas de Blégny 
(1653-1722) and Antoine Daquin (1629-1696). Blégny was one of the royal physicians in 
ordinary, and held a privilege to publish a vernacular medical journal, the Nouvelles 
découvertes; Daquin was Louis XIV’s first physician from 1672 to 1693. The chymical 
accounts of cinchona which they authored, coupled with the Helmontian and “chymical 
Hippocratic” ideas of the Louvre Capuchins and Talbor, all demonstrate an openness to 
chymical medicine—particularly in the form of the so-called “acid-alkali theory” of 
pathology—at the highest levels of French society.  
 Chymical medicine provided new techniques for preparing drugs, new criteria for 
assessing their therapeutic efficacy, and new models of their internal therapeutic action. 
In the fourth part of this chapter I will show that the chymical account of cinchona’s 
action was also accepted by Guy-Crescent Fagon (1638-1718), Daquin’s successor as 
first physician. The fact that both first physicians endorsed a chymical account of 
cinchona bark—which came to be a kind of “model specific”—is of special importance 
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considering the fact that they were the principal medical arbiters of the secret remedies 
privilege regime at the height of its activity. In a fifth and final section, I consider the 
extent to which this peculiarly chymical account of medicinal specifics is related to the 
“ontological conception of disease” that Walter Pagel associated with the influential 
chymical physician Joan Baptista Van Helmont (1580-1644). 
1. What is a specific remedy? 
 Before moving into the question of chymical medicine at court and chymical 
views of “specifics” like cinchona bark, it is useful to ask just what the term “specific 
remedy” (remède spécifique) meant at the end of the seventeenth century. The 1694 
dictionary of the Académie française defines “spécifique” broadly as “Specially 
appropriate to something,” and offers the following medical use of its substantive, 
“Theriac is a good specific against poison.” A second medical example, added to later 
editions, immediately points to the ways in which the category would expand in this 
period: “Cinchona is a great specific against intermittent fevers.”2 A more technical 
medical definition can be found in the 1682 edition of Castelli’s Lexicon medicum: 
specifics (specifica) are “drugs and their virtues which depend primarily on their whole 
substance (tota substantia) and intrinsic essential form.”3  
                                                 
 2 “Propre spécialement à quelque chose” with examples “La theriaque est un bon specifique contre 
le poison” (1694); and “Le quinquina est un grand spécifique contre la fièvre intermittente” (1762). See Le 
dictionnaire de l’Académie françoise, 1st ed. (Paris: la veuve de Jean Baptiste Coignard, 1694), 395; 
Dictionnaire de l’Académie françoise., 4th ed. (Paris: veuve de Bernard Brunet, 1762), 758.  
 3 “Specificus non solum dicitur de medicamentis, et eorum virtutibus, a tota substantia et forma 
intrinseca essentiali, primariò dependentibus; atque idem est, quod [gk Idiosyncrasia] Vide ldiosyncrasia: 
Item Occultus. Hinc Ruland et Iohnson ita descripserunt, quod Specificum formale sit, quod speciem per 
formales proprietates saltem refert; Et licet materiales quoque virtutes concurrant, formales tamen 
excellunt, et illae potissimum elaborando respiciuntur; Tales sunt Tinctura, et Oleum: Verum etiam 
Paracels. non veritus est extendere ad aegritudines, eas apellando Specificas, que sperma suum peculiare 
habent in corpore, Paramir. l. 2. c. 7 De Specificis vero medicamentis lege eundem Achidox. l. 7 Imo et 
Medicorum sectam quadam constituit, quos vocavit Specificas, qui alias Experimentales, et Empirici 
vocantur, in Paramiro de 5. entib. morbor. prolog. 3,” Bartolomeo Castelli and Jakob Pancraz Bruno, 
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 The embryo of Castelli’s definition can be traced back to the first book of 
Avicenna’s Canon. Following Galen’s De simplicium medicamentorum, Avicenna 
observes that ingested substances can change the body in three ways: either (1) through 
their manifest qualities (i.e. those discernible by the senses, e.g. hotness, coldness, 
wetness, dryness), which affect the body without being absorbed into it through 
digestion; (2) through their matter after it is assimilated into the body via digestion, as 
with food; or (3) through their whole substance (tota substantia). The “whole substance” 
did not act therapeutically through its manifest qualities, but rather through an unseen 
(occult) virtue, which could be recognized only empirically from its effects, rather than 
identified through the causal reasoning based on manifest qualities.4 The virtues of 
medicines which act per totam substantiam in this way can thus be learned only through 
experience.5 
 The concept of action by the “whole substance” was most commonly associated 
with compound medicines, which were supposed to be able to acquire a wholly new 
“specific form” (forma specifica) through a process of “fermentation” of their various 
ingredients. This new form could not be predicted through an assessment of the manifest 
qualities of the individual constituent substances. Michael McVaugh has argued that 
although Galen acknowledged that some drugs work per totam substantiam, “he would 
certainly have felt this sort of activity to be definitely subordinate to the regular and 
predictable effects of drugs, whereas for Avicenna just the opposite was true. From the 
                                                                                                                                                 
Castellus renovatus; hoc est, Lexicon medicum, (Nuremberg: Johannis Danielis Tauberi, 1682), 1069–
1070. See below, sect. 3.3 on the latter half of this entry, drawn from Ruland’s Lexicon Alchemiae. 
 4 The best description of these concepts is Michael McVaugh, “The Development of Medieval 
Pharmaceutical Theory,” in Arnaldi de Villanova Opera Medica Omnia. II. Aphorismi de Gradibus 
(Granada: Seminarium Historiae Medicae Granatensis, 1975), esp. 17–19. McVaugh cites the 1507 
Venetian edition of the Liber Canonis Avicenne, fols. 33v-34v. Cf. Galen, De simplicium medicamentorum 
temperamentis ac facultatibus, in Kühn ed. Opera omnia, vol. xi (Hildesheim: G. Olms, 1965), 705. 
5 McVaugh, “The Development of Medieval Pharmaceutical Theory,” 19. 
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thirteenth century on it was surely Avicenna who symbolized the unpredictable element 
in pharmacology and Galen who symbolized its regularity.”6  
 Avicenna pointed to the magnet and the torpedo fish as examples of occult 
causation, but in pharmacy the example par-excellence was theriac. This complex 
antidote originated in classical antiquity and was attributed to Andromachus, physician to 
the Emperor Nero. Frederick Gibbs has argued that in late medieval pharmacology, 
poisons (venena) came to acquire a distinct ontological status that cast them as 
fundamentally harmful to the human body. This contrasts with the classical notion of 
pharmaka, which placed remedy and poison on a spectrum and saw poisoning as a 
subjective change which depended relationally on the nature of the “poison” and the 
“poisoned” body. In the new medieval view, a poison came to have its own forma 
specifica, as did its antidote.7 No longer situated on a continuum, poison and antidote 
became diametric opposites at the ontological level. 
 This formal complementarity of specific disease with specific remedy—already 
latent in Avicenna and developed in a localized way around poison antidotes by late 
medieval toxicology—would later expand beyond theriac to include other diseases and 
their “specifics.” In the seventeenth century theriac and other poison antidotes 
(sometimes called alexipharmaca) would continue to serve as models for medicinal 
specifics: the entry for “spécifique” in the 1689 second edition of the Dictionaire 
pharmaceutique cross-references directly to alexipharmaca, and cites theriac first and 
                                                 
 6 Ibid., 19n11. 
 7 Frederick W. Gibbs, “Specific Form and Poisonous Properties: Understanding Poison in the 
Fifteenth Century,” Preternature: Critical and Historical Studies on the Preternatural 2, no. 1 (2013): 19–
46; see also ch. 2 of Frederick W. Gibbs, “Medical Understandings of Poison circa 1250-1600” 




foremost among the “specific” alexipharmaca.8 By this time, the category of diseases 
which could be treated by specifics had expanded beyond the traditional poisons (venins), 
to include other diseases as well, as exemplified in the Dictionaire’s inclusion of 
intermittent fevers among the ailments the could be cured by alexipharmaca. 
 The forma specifica and tota substantia tradition were attractive to physicians that 
encountered diseases and cures which defied explanation through Galenic temperament 
and manifest qualities. Notable in this regard is the renowned Paris physician Jean Fernel 
(1497-1558) who contributed to this extension of the theriac-poison model to other 
diseases. Fernel saw poisonous, contagious, and pestilential diseases as diseases of the 
total substance; consequently, he argued that they required remedies of the total 
substance. Linda Deer Richardson has found that few faculty physicians took up Fernel’s 
position: the Galenic emphasis on temperament and manifest qualities was firmly 
integrated into the broader existing Aristotelian natural philosophic consensus. Fernel’s 
emphasis on occult causes of diseases pointed to occult remedies, identifiable only 
through trial and error rather than causal reasoning—a practice too close to that of the 
empirics.9 
 Although these ideas failed to catch on among the learned establishment in the 
sixteenth century, they found more traction among Paracelsian and Helmontian chymists 
in the seventeenth. The Fernelian critique and the Avicennan category of “specifics” were 
                                                 
 8  “Ces mots Alexipharmaques et Alexiteres sont tirez du Grec. Les François s’en servent aussi 
bien que les Latins pour signifier des médicaments qui ont une vertu très particulière de résister aux venins 
dont les uns sont internes et les autres externes. Les internes remédient proprement à la peste aux fièvres 
malignes et aux poisons pris au dedans et les externes à la morsure et à la piqueure des bêtes vénéneuses.” 
See De Meuve, Dictionaire pharmaceutique ou apparat de medecine, pharmacie et chymie, 2nd ed. (Paris: 
Laurent d’Houry, 1689), 558, 23. Interestingly. the first (1677) edition contains no entry for specific at all. 
 9 Linda Deer Richardson, “The Generation of Disease: Occult Causes and Diseases of the Total 
Substance,” in The Medical Renaissance of the Sixteenth Century, ed. Andrew Wear, Roger K. French, and 
Iain M. Lonie (Cambridge: Cambridge University Press, 1985), 175–194. 
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appropriated and reconfigured by the chymical tradition. Much of its terminology, 
especially surrounding “occult” causes and tota substantia, was discarded. The vendors 
of “specifics” in the 1680s and the first physicians Daquin and Fagon instead make use of 
a distinctly chymical theoretical language. Despite this shift in terminology, many of the 
same themes reappear, however. Most notable in this respect are: (1) a deep skepticism of 
the view that disease is cured by restoring complexional balance; (2) an insistence on the 
importance of an unseen form or ideal (rather than manifest qualities) in both diseases 
and remedies; (3) a view of a direct ontological relationship between an identified disease 
entity and the medicinal substance; and (4) the concept of fermentation, albeit in a much-
expanded chymical form. 
 Among chymical authors, the category of specifics overlaps considerably with the 
Paracelsian notion of arcana, particularly in its emphasis on form. Paracelsus likewise 
argued that “humor causes no disease. Disease is made by something else, namely 
substantiae ens,” a distinct entity.10 An arcanum is the non-material formal manifestation 
of the virtue of a given substance, which responds to the form of the disease-being.11 The 
conceptual overlap with arcanum is apparent in Castelli’s secondary definition of 
“specific,” which is itself taken from the chymist Martin Ruland the Younger’s definition 
of specificum formale in his Lexicon alchemiae: a specific is there defined as restoring 
health “by means of its formal properties” (per formales proprietates), and Ruland 
                                                 
 10 Paracelsus, Paracelsus (Theophrastus Bombastus von Hohenheim, 1493-1451): Essential 
Theoretical Writings, ed. Andrew Weeks (Leiden: Brill, 2008), 330–331, Opus Paramirium 1:3. Weeks 
adds, “Ens substantiae signals that the cause of disease is not an insubstantial imbalance of alien humors 
but a disease-engendering substance, entity, or agency, hidden beneath outer physical appearances.” 
 11 Weeks defines it (following Ruland): “the arcanum is an occult and eternal incorporeal entity 
embodying the exalted virtue of an object or herb. It can be extracted in certain forms,” Ibid., 195n1. 
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likewise points to the term’s identification with tinctures and oils.12 This emphasis on the 
formal aspects of the drug also has some overlap with later Helmontian usage of the term 
specific: according to the Helmontian chymist George Thomson, specifics “sully, marr, 
or quite expunge the Idea or Image of a Disease.”13 
 Alongside the emphasis on form, the most important carry-over from the 
Avicennan definition to the more chymical view of “specifics,” however, is that they do 
not cure by helping to re-balance the humors through their own manifest qualities. They 
are not a response to humoral imbalance (dyscrasia). Indeed, the traditional therapeutic 
armamentarium is filled with what we might call “unspecifics,” drugs which were 
thought to provoke predictable reactions through their manifest qualities. These 
“unspecifics” aimed to restore a humoral balance peculiar to the individual, but could be 
used in various arrangements against a variety of different illnesses. To offer but one 
example, there is nothing therapeutically specific about bloodletting: it is a tool that could 
be used in a host of different conditions, often with different rationales, and used 
alongside a broad variety of ancillary therapies. The traditional therapeutic 
armamentarium of bloodletting, purgatives, emetics, diaphoretics, diuretics, etc. were 
intended to provoke physiological responses calibrated to alter the body’s temperament 
through their own manifest qualities.  
 Perhaps the most defining aspect of “specifics” as remedies was that they did not 
work by provoking reactions that had the ultimate goal of re-balancing the humors. A 
                                                 
 12 Castelli and Bruno, Castellus renovatus, 1069–1070. See above, this chapter, n. 3 for the full 
entry. The Lexicon also points out that specificus can also refer to diseases (aegritudines specificae), a 
category used by Paracelsus to refer to diseases “inborn” or innate to an individual, something like 
diathesis. On which see Weeks, ed. Paracelsus, Essential Theoretical Writings, 484–487. 
 13 George Thomson, Orthometodos Iatrochymike: Or the Direct Method of Curing Chymically 
(London: B. Billingsley and S. Crouch, 1675), A6r. 
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host of wholly different concepts were invoked to explain their action. Among authors 
influenced by chymical medicine in this period, these tended to center on acid and alkali 
ferments. Specifics were thought to respond in a “radical” way to these ferments—
striking at the “root cause” of a disease—which was itself seen as having a distinct 
formal entity. As we have seen, this view of therapy had been latent in the western 
medical tradition since the time of Avicenna, but would find a new, much expanded 
application when it was taken up by chymically-inclined practitioners in the final decades 
of the seventeenth century. Some of these chymical practitioners found a propitious 
environment at the court of Louis XIV. 
2. Court support for chymical medicine: The chymical Capuchins of the Louvre, 
1678-1679  
 
 In June 1678 the curious readers of the Mercure galant—the most widely 
circulating periodical in late seventeenth-century France—learned (among many other 
things) that two Capuchin fathers had recently established a pharmaceutical laboratory in 
the palace of the Louvre.14 According to the Mercure, these Capuchins had spent time in 
Egypt and Ethiopia, and their courtly medical practice was aimed toward acquiring 
patronage for their prospective mission to save the Christians there from the “heresy of 
Dioscorus” (monophysitism).15 In the meantime they prepared their chymical remedies 
                                                 
 14 Mercure galant (June 1678), 187–192. The six-page notice detailing the activities and ambitions 
of these chymical Capuchins was innocuously nestled between an amusing tale of suspected cuckoldry in a 
garrison town and a short notice on the appointment of a royal organist to the Chapelle royale 
 15 The Ethiopian Church and other churches of Oriental Orthodox Christianity were labelled 
“monophysites” by Roman Catholic and some Orthodox theologians for rejecting the Council of Chalcedon 
and were thought to maintain that Christ possessed an exclusively divine nature. Jesuit missionary projects 
to bring Ethiopian Christians back into communion with Rome date to the mid sixteenth century. Following 
the expulsion of the Jesuits from Ethiopia in 1632, the Sacred Congregation for the Propagation of the Faith 
sent Franciscans and Capuchins to replace them. French Capuchins in particular were sent through Cairo, 
and two were martyred in Ethiopia as early as early as 1638. See Andreu Martínez d’Alòs-Moner, 
“Capuchins,” Encyclopaedia Aethiopica (Wiesbaden: Harrassowitz, 2003); and his monograph on the 




for the use of the court and the poor. The author highlights the efficacy and gentleness of 
their cures, particularly for fevers and vapours. Far from dismissing them as clerical 
“empirics,” as some contemporaries and much later historiography has done, the Mercure 
in fact goes to some length to illustrate that they are quite learned and rest their practice 
on their own maxims as well as secrets culled from a variety of prominent authors: 
They have their own maxims which they follow as rules, without submitting 
themselves to the sentiments of Hippocrates, who they have not neglected to 
read but in his complete purity, without having been altered by Galen. They 
undertook a very serious study of Paracelsus and Van Helmont, and have said 
that few of their secrets are unknown to them.16 
 
The Mercure cast the Capuchins as anti-Galenic readers of Hippocrates who also delved 
into the secrets of Paracelsus and Van Helmont, the two most famous iatrochemists of the 
age. To these credentials the Mercure added that Plato was their “principal philosopher,” 
that they had mastered Arabic during their time in the East, and that knowledge of this 
language had allowed them to make many medical discoveries. 
 The chymical Capuchins of the Louvre are among dozens of unorthodox 
practitioners who are deployed, often superficially, as colorful furniture in survey texts on 
French medicine in the age of Louis XIV. The most common reference in such accounts 
are the letters of Madame de Sévigné (1646-1705), the famous courtly epistolarist, who 
was a prominent supporter of the Louvre Capuchins and avid consumer of their 
medications, particularly their “baume tranquille.”17 The two Capuchins were Henri 
Rousseau de Montbazon (1643-1694), aka Père Rousseau, and Nicolas Aignan (1644-
1709), aka Père Tranquille, who shared his name with their famous balm. In spite of the 
                                                 
 16 “Ils ont leurs maximes qu’ils suivent pour regles, sans s’assujettir aux sentimens d’Hippocrate, 
qu’ils ne laissent pas d’avoir leû, mais dans son entière pureté, et sans estre alteré par Gallien. Ils ont fait 
une étude très-sérieux de Paracelse et de Van Elmon, et ont dit que peu de leurs secrets leur sont inconnus,” 
Mercure galant (June 1678), 189–190. 
 17 Madame de Sévigné, Correspondance, ed. Roger Duchêne (Paris: Gallimard, 1972), e.g. 1:705. 
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prominent news coverage they were given in the Mercure, the Capuchins have almost 
been completely ignored by modern medical historiography. They are usually evoked 
anecdotally, to add colorful background characters to the medical world of Louis XIV’s 
court, or to illustrate the prominence of medical “empirics” among the regular clergy.18 
The singular exception is the 1938 work of Joseph Tournier, Le clergé et la pharmacie, 
which includes a full chapter on the Capuchins with ample citations, clears up a number 
of biographical and bibliographical errors, and forms the background of my discussion.19 
Most importantly, their relation to contemporary iatrochemical thought has never been 
elucidated, leaving the impression that, in spite of their court connections, they were 
merely stand-alone “empirics”  separate from the major intellectual currents of late 
seventeenth-century medicine. In order to situate them within the broader currents of late 
seventeenth-century chymical medicine, this section draws on the Capuchin Aignan’s 
L’ancienne médecine à la mode, ou Le sentiment uniforme d’Hippocrate et de Galien sur 
les acides et les alkalis (1693) and on an earlier letter the two Capuchins wrote in the 
early 1680s. The support they received provides a barometer of courtly interest in 
chymical medicine at the end of the 1670s, leading up to the arrival of another “empiric” 
outsider, Robert Tabor, inventor of the famous “English remedy” for intermittent fevers, 
at the same time as the famous Affair of Poisons (1677-1682). 
 At the time of their eighteen-month stay in the Louvre Palace (June 1678 to 
November 1679), the Capuchins had not yet published any writings on chymical 
                                                 
 18 To provide a recent example, Laurence Brockliss and Colin Jones refer to them as “the colourful 
Capuchins of the Louvre,” and describe them as examples of clerical medical practice, being “among the 
most successful medical entrepreneurs at the court of Louis XIV”: see Brockliss and Jones, The Medical 
World of Early Modern France, 258–9, 656. 
 19 Joseph Tournier, Le Clergé et la pharmacie. Essai sur le rôle du clergé et plus particulièrement 
des congrégations religieuses dans la préparation et la distribution des remèdes avant la Révolution. 
(Paris: Caffin, 1938), 110–145. 
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medicine.20 Aignan’s first work, L’ancienne médecine à la mode, was not published until 
1693, and was followed by two other works before his death in 1709.21 His partner 
Rousseau did not publish in his lifetime, but two of his works were published 
posthumously by his brother, Rousseau de la Grange-Rouge, in 1697, and went through 
subsequent editions.22 Within this corpus, Aignan’s L’ancienne médecine à la mode is of 
special interest because of the theoretical outlook that it outlines, which locates him 
within the mainstream of late seventeenth-century iatrochemical discourse. Although 
published at some remove from his time at the Louvre, I will show that evidence from 
several contemporary documents suggests that there was a strong continuity between his 
outlook in 1678-79 and the views he expressed in his published work in 1693. As the 
above quotation from the June 1679 Mercure already implies, these sources show that at 
least one of the Louvre Capuchins was thoroughly engaged in contemporary chymical 
thought. 
 Aignan’s L’ancienne médecine à la mode is written as a pair of “lettres en forme 
de dissertation” to his patron and patient, Guillaume-Egon, Cardinal of Fürstenberg 
                                                 
 20 The aforementioned June 1678 issue of the Mercure galant records their arrival. A letter from 
Henri Justel to Robert Boyle dated to 21 May already mentions they are working for the king. Their 
departure is recounted in the December 1679 issue of the Mercure, which also observes that they stayed at 
the Louvre for eighteen months. This lines up as approximately June 1678 to November 1679. 
 21 The lengthy titles of Aignan’s two other published works are worth citing in full, as they neatly 
encapsulate his medical attitudes: Le prestre medecin, ou, Discours physique sur l’établissement de la 
medecine. Avec un traité du caffé et du thé de France, selon le systeme d’Hippocrate (Paris: Laurent 
d’Houry, 1696); and Traité de la goutte dans son etat naturel; ou, L’art de connoistre les vrais principes 
des maladies: avec plusieurs remedes conformes au systême d’Hippocrate, de Galien, et de Vanhelmont, 
qui se trouve dans son vray jour, développé du faux langage et de la fausse opinion (Paris: Claude Jombert, 
1707). On Aignan’s publications see Tournier, Le clergé et la pharmacie 143–144. Also note the confusion 
of names: François Aignan, to whom these works are sometimes erroneously attributed, was the nephew of 
the former Capuchin and Padua doctor Nicolas Aignan (see below on his transfer to the Cluny Benedictines 
and his possible degree from Padua). François for his part was received as doctor by the Paris Faculty in 
1703. 
 22 These are: Henri de Montbazon Rousseau, Secrets et remedes éprouvez : dont les préparations 
ont et́é faites au Louvre, de l’ordre du roy (Paris: Jean Jombert, 1697); Préservatifs et remèdes universels 
tirez des animaux, des végétaux et des minéraux (Paris: Claude Cellier, 1706); and Secrets et remedes 
éprouvez : dont les préparations ont été faites au Louvre, de l’ordre du roy [...] Seconde Edition corrigée et 
aumentée des Préservatifs et Remedes universels, 2nd ed. (Claude Jombert, 1708). 
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(1629-1704), a powerful supporter of Louis XIV in the Rhineland.23 In it, Aignan has two 
interrelated goals: the first is to explain the pathological views and course of therapy he 
has followed in the particular case of the Cardinal’s digestive problems, and the second is 
to defend himself against the charge of being a “modern” by showing that the chymical 
theory that undergirds his pathology and therapy is perfectly supported by ancient 
Hippocratic ideas, which he himself follows in his rejection of the traditional 
Aristotelian-Galenic qualities (hot, cold, wet and dry). 
 The Cardinal apparently suffered from debilitating digestive problems which 
Aignan attributed to a disordered acidic ferment in his stomach, which instead of properly 
digesting his food into chyle, transformed it into a viscous coagulum that corrupted his 
blood and released dangerous vapours throughout his body.24 Having identified the 
nature of the illness as acidic, Aignan followed the basic principle of neutralization in his 
therapy, administering strong alkalis as remedies: these included decoctions of chicory in 
coffee, crystallized salt of wormwood, and “essence of vipers,” all aimed at breaking up 
the coagulum produced by the disordered acidic ferment in the Cardinal’s stomach.25 
 As this brief summary suggests, we can class the Capuchin Aignan as a proponent 
of the then-popular acid-alkali theory. Evan Ragland has recently detailed this theory in 
his dissertation on the long history of experiments surrounding digestion, beginning with 
those of the Leiden medical professor Franciscus Sylvius de le Boë (1614-1672).26 In 
                                                 
23 See Louis Châtellier, “Fürstenberg, Guillaume Egon de,” in Nouveau dictionnaire de biographie 
alsacienne, vol. 12 (Strasbourg: Fédération des Sociétés d’Histoire et d’Archéologie d’Alsace, 1988), 1083. 
 24 Nicolas Aignan, L’Ancienne médecine à la mode, ou le sentiment uniforme d’Hippocrate & de 
Galien sur les acides & les alkalis (Paris: Laurent d’Houry, 1693), 95–98. 
 25 Ibid., 153–154. 
 26 Evan R. Ragland, “Experimenting with Chemical Bodies: Science, Medicine, and Philosophy in 
the Long History of Reinier de Graaf’s Experiments on Digestion, from Harvey and Descartes to Claude 
Bernard” (Dissertation, Indiana University, 2012); for earlier accounts see Marie Boas, “Acid and alkali in 
seventeenth century chemistry,” Archives internationales d'histoire des sciences 9 (1958): 13–28; and 
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broad terms, the acid-alkali theory was based initially on an examination of the chymical 
physiology of digestion that was eventually extended to serve as a flexible alternative to 
traditional humoral pathology. Diseases were understood as an excess of acidity or 
alkalinity produced by a disordered digestive ferment, usually originating in the stomach, 
and therapy was framed as process of neutralization, typically using alkalis to neutralize 
the unnatural acids in the digestive tract. While earlier accounts of the acid-alkali theory 
identified it as being first devised by Sylvius, Ragland has shown that Sylvius in fact 
derived much of it from a “materialist” reading of Van Helmont, whose writings were 
already circulating in manuscript form in the early 1640s.27 I follow Ragland in tracing 
the acid-alkali theory back to Van Helmont and also acknowledge his points about 
important variants in the acid-alkali theory, notably between the versions of Sylvius and 
of the German chymist Otto Tachenius (d. 1670).28 
 Aignan also fits within established chymical currents in his approach to 
legitimizing his medical views. He very explicitly defends himself against the charge of 
being a “modern” innovator with no respect for antiquity through an appeal to what might 
be called “the chymical Hippocrates.” In his work on the Paracelsian Petrus Severinus 
(1542–1602), Jole Shackelford has described this apologetic and exegetical project as 
“the extraction of a chemical Hippocrates,” from the “corrupt base matter of Galenism.”29 
This project began with Severinus in the late sixteenth century and continued to inform 
                                                                                                                                                 
Allen G. Debus, Chemistry and Medical Debate: Van Helmont to Boerhaave (Canton, MA: Science 
History Publications, 2001), 103–137. 
 27 Ragland, “Experimenting with Chemical Bodies,” 25, 82–91. 
 28 Ibid., 361–382. On Tachenius see Marie Boas Hall, “Tachenius, Otto,” in Dictionary of 
Scientific Biography, vol. 13 (New York: Scribners, 1976), 234–35; and Heinz-Herbert Take, Otto 
Tachenius, 1610-1680: ein Wegbereiter der Chemie zwischen Herford und Venedig (Bielefeld: Verlag für 
Regionalgeschichte, 2002). 
 29 Jole Shackelford, “The Chemical Hippocrates: Paracelsian and Hippocratic Theory in Petrus 




iatrochemistry throughout the seventeenth, including such prominent proponents as Van 
Helmont and Tachenius. The goal was to use the Hippocratic corpus itself to challenge 
traditional Galenism and provide a legitimating ancient foundation for contemporary 
iatrochemistry. Like Severinus in is 1571 Idea medicinae, Aignan leans heavily on the 
Hippocratic treatise On ancient medicine (De vetere medicina) to problematize the 
traditional qualities: 
I declare alongside all of antiquity that heat can be neither the origin nor the 
cause of any disease, of whatever nature it might be. On this Hippocrates has 
formally declared himself, maintaining that all that is called disease—without 
excepting even fever, which seems to have a very great fire—are beings 
which subsist independent of cold and heat, which are merely accidents that 
accompany them; that these beings are salts composed of their own matter 
and form, subsisting by themselves without the support of these qualities, 
which indeed make them recognizable, but which do not produce them.30 
 
This passage neatly encapsulates Aignan’s views on the purely accidental nature of 
“qualities,” affirming instead the primacy of bitterness (amarum), acidity (acidus), 
saltiness (salsus) over what he saw as imprecise subjective concepts like “heat.”31 This 
view is supported with two passages from Hippocrates De vetere medicina (15.4, 17.2), 
the latter of which was frequently quoted by Van Helmont and seems to have been a 
Hippocratic touchstone for proponents of chymical medicine seeking to question the four 
qualities.32 The ill-defined quality of “heat” will never truly be defeated by its contrary, 
                                                 
 30 “Je dis avec tout l’antiquité que la chaleur ne peut être le principe ni la cause d’aucune maladie, 
de quelque nature qu’elle puisse être. C’est sur quoy Hippocrate se déclare formellement, prétendant que 
tout ce qui s’appelle maladie, sans en excepter la fièvre même, qui semble avoir un plus grand feu, sont des 
êtres qui subsistent indépendamment du froid et du chaud, qui ne sont que des accidens qui les 
accompagnent; que ces êtres sont de sels qui sont composez de leur matiere et de leur forme, subsistant par 
eux-mêmes sans le secours de ces qualitez, qui les font bien à la verité reconnoître, mais qui ne les 
produisent pas,” Aignan, L’Ancienne médecine à la mode, 15–17. Emphasis added. 
 31 For an exploration of Aristotle’s views on heat, see Gad Freudenthal, Aristotle’s Theory of 
Material Substance: Heat and Pneuma, Form and Soul (Oxford: Clarendon, 1995). 
 32 The passage as quoted by Aignan is: “Non enim calidum est, quod magnam caloris vim habet; 
sed quod acerbum est, lene, caeteraque habet quae diximus, quae et in ipso homine insunt et extra : quod 
puto maximum argumentum esse homines propter calorem calidumve febre non corripi : nec hoc est cur 
male habeant, sed causa est, quod calidum amarum est, acidum, acre, salsum, caeteraque multa.”  
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“cold,” but an acid (acidus) can be neutralized by a bitter (amarum) alkali. Aignan here 
goes so far as to say that he is sure that all the physicians of the French court would 
support him in his contention that the opinion of Hippocrates crushes the “vulgar error” 
of hot and cold as qualities.33 Later, he also supports his position through reference to the 
unusual two-principle theory of water and fire as the constituents of the human body 
expounded the Hippocratic Regimen I (De dieta) by translating them as acid and alkali.34 
 But how and why does neutralization “work” as a therapy? Aignan offers no clear 
answer to the question, but his thinking is at least implicitly corpuscular: the damaging 
points of the acids must be blunted or muffled (émousser) by alkalis,35 a view which 
would be well in keeping with those of Tachenius, François de Saint-André, and Nicolas 
Lémery, who all described points as characteristics of acids and pores as characteristics 
of alkalis.36 This therapeutic neutralization is an effort directed at re-establishing the 
                                                                                                                                                 
 This quotation mixes two passages from De vetere medicina: 15.4 (before the first colon) and 17.2 
in Schiefsky ed. On Ancient Medicine. The context of 17.2 is in fact a discussion of fevers which describes 
heat as a mere adjunct or auxiliary (adiunctum) to more important qualities like bitterness, acidity, etc. (all 
supposedly “secondary” by later Aristotelian and Galenic standards). Rather than the more recent 
transaltion of Anuce Foës (available in multiple editions from 1595 onward), Aignan uses the older 
translation of Fabio Calvo (probably in a later edition than that cited here, from 1526): “Liber de prisca 
medicina,” in Hippocratis coi medicorum omnium longe principis, opera (Basel: Andreas Cratander, 1526), 
10.  
 The latter passage (17.2) is also cited by Van Helmont on at least five occasions: Ortus medicinae 
(Amsterdam: Elzevir, 1648), 153 (“Blas humanum” 52), 320 (“Plura furens” 17), 379 (“Potestas 
medicaminum” 12), 396 (“Ignotus hospes” 52), 424 (“Introductio diagnostica” 11), 741 (“De febribus” 32). 
 Shiefsky renders these passages as follows in his recent translation from the Greek: “For it is not 
the hot that has great power, but the astringent and the insipid and all the other things I have mentioned, 
both inside and outside the human being” (15.4), and “I think it is my strongest piece of evidence that it is 
not simply because of the hot that people are feverish, and that this is not the only cause of harm; rather, 
one and the same thing is both bitter and hot, acid and hot, salty and hot, and myriad other combinations—
and again cold, too, is conjoined with other powers” (17.2), Schiefsky, On Ancient Medicine 94-97. See 
also Les Admirables qualitez du kinkina, 14. On the qualities as mere subjective, human concepts, rather 
than true causes, which emerge from ideas, forms, and seminal principles, see Aignan, 20-21. 
 33 Aignan, L’Ancienne médecine à la mode, 18–19. 
 34 Ibid., 57. 
 35 Ibid., 52, 107. 
 36 Ragland, “Experimenting with Chemical Bodies,” 375; see also Lawrence M. Principe, 
“Revealing Analogies: The Descriptive and Deceptive Roles of Sexuality and Gender in Latin Alchemy,” 
in Hidden Intercourse, ed. Wouter J. Hanegraaff and Jeffrey J. Kripal (Leiden: Brill, 2008), 209–30, on the 
use of sexual analogies by Tachenius to explain this process (“phallic” acids “vacuous” alkalis). 
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normal process of digestion, which itself is driven by the action of a “vital acid” on food 
followed by the introduction of a neturalizing alkali bile from the spleen. 
 Despite this corpuscular language, it cannot be said that Aignan followed a 
strictly materialist version of the acid-alkali theory. As noted in the passage above, 
diseases, including fevers (an important point to emphasize here for the following 
sections), are “beings” (êtres) which subsist “entirely independently of qualities like hot 
and cold.” While in this passage diseases are equated with acid and alkali salts, 
L’ancienne médecine à la mode includes numerous references to non-corporeal entities 
and his explanations of these bear a distinctly Helmontian flavour and vocabulary. As 
Aignan notes a few pages later, only ideas, forms, or “seminal principles” can be 
described as true causes.37 Referring specifically to pathology, he observes “Heat is but 
an effect and not at all the cause of our ills, assuming always a primary being which holds 
the place of seminal principle, which produced in man the bad fruit which we call 
disease.”38 The notion of seminal principles placed in the world by God at creation had 
wide applications in this period, explaining the generation of animals, plants, minerals, 
and even diseases.39 The idea of the seeds of disease (semina morborum) being sown in 
human bodies can be found in earlier Paracelsian authors, most notably Severinus.40 
While essentially formal and non-corporeal, these entities can rearrange matter, 
producing pathological processes in the human body. The semina find an analogue in the 
                                                 
 37 Aignan, L’Ancienne médecine à la mode, 20–21. 
 38 “La chaleur n’est qu’un effet, et non point la cause de nos maux, supposant toujours un être 
premier qui tient lieu de principe seminal, qui produit dans l’homme un mauvais fruit qu’on appelle 
maladie,” Ibid., 33. Emphasis added. 
 39 Although he does not discuss semina morborum in detail, on the broader history of the semina 
concept, see Hiro Hirai, Le concept de semence dans les théories de la matière à la renaissance: de Marsile 
Ficin à Pierre Gassendi (Turnhout: Brepols, 2005). 
40 Jole Shackelford, A Philosophical Path for Paracelsian Medicine: The Ideas, Intellectual 
Context, and Influence of Petrus Severinus (1540/2-1602) (Copenhagen: Museum Tusculanum Press, 
University of Cophenhagen, 2004), 17, 185–194. 
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Helmontian understanding of the occasional cause of disease as the arrival of a “foreign 
guest” in the human body a view which Walter Pagel referred to as an “ontological” 
conception of disease.41 
 Although the concept of disease semina is common to this broader post-
Paracelsian chymical tradition, Aignan’s view of pathology also betrays a number of 
specifically Helmontian features. Most notably, he makes consistent reference to a 
quintessentially Helmontian entity, the archeus (l’archée). According to Van Helmont, 
normal physiological processes as well as pathological processes depended upon a non-
corporeal vital principle called the archeus. Disease is a manifestation of the corporeal 
and non-corporeal interaction between the archeus and the “foreign guest.” Although the 
chief archeus is “seated” in the “mouth of the stomach” and governs digestion, all 
physiological processes and their related organs are likewise governed by lesser archei. 
Disease often begins in the stomach, but the disordered fermentation there soon spreads 
acid salts throughout the body. Disease, produced by the interaction between an archeus 
and the non-material “foreign guest,” then spreads throughout the body, “specifies itself” 
differently (se specifie differemment) depending on which local archei are irritated.42 
Likewise, Aignan acknowledges that some diseases require no material salt whatsoever, 
and can be caused by “an archeus irritated by passions which take the place of salts.”43 
This appears to be Van Helmont’s non-corporeal “idea of indignation” which can spread 
                                                 
 41 Walter Pagel, Joan Baptista van Helmont: Reformer of Science and Medicine (Cambridge and 
New York: Cambridge University Press, 1982), esp. 141–154; Walter Pagel, “Van Helmont’s Concept of 
Disease - To Be or Not To Be? The Influence of Paracelsus,” Bulletin of the History of Medicine 46, no. 5 
(1972): 419–54; for a longer view of this question, see the classic essay by Owsei Temkin, “The Scientific 
Approach to Disease: Specific Entity and Individual Sickness,” in The Double Face of Janus and Other 
Essays in the History of Medicine (Baltimore: Johns Hopkins University Press, 1977), 441–55. 
 42 Aignan, L’Ancienne médecine à la mode, 60–61. 
 43 “ Il est encore vray qu’il y a des maladies qui ne supposent aucun sel, mais seulement un archée 
irrité par des passions qui tiennent lieu des sels,” Ibid., 30–31. 
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to an archeus independent of any material vessel (much like the non-corporeal disease 
semina) and trigger the pathological process which generates the material manifestation 
of a disease.  
 Many of these ideas can also be found in a short letter the Capuchins addressed to 
Henri Justel. Formerly a secretary to Louis XIV, Justel was a Huguenot who immigrated 
to England before the Revocation of the Edict of Nantes, becoming librarian at St James’ 
Palace. The Capuchins likely knew him from their time at the Louvre. The letter was 
written to Justel c. 1681-1686, forwarded on to Robert Boyle, and copied by his 
amanuensis Robin Bacon.44 There the Capuchins express their interest in establishing an 
association with the English curieux in their project to work in common with them to 
reform medicine:  
We must work in concert on a Philosophy of Practice in which Medicine shall 
find a new dawn without changing the system of Hippocrates, Plato, 
Paracelsus, and Van Helmont, which we have reduced to a mutual 
concordance of Thoughts and Operations which will one day surprise many 
people—especially the Faculty of Galen.45 
                                                 
 44 “François Aignan [sic, Nicolas Aignan, see above note] and Henri Rousseau de Montbazon to 
Henri Justel,” in Correspondence of Boyle 6:440-445, citing the original as BL 2, fols. 130-1, where it is 
entitled “Abstract of a letter from two Capucins to Mr. Justel from Nants.”  
 There are some ambiguities in dating this document. The editors of the Boyle correspondence 
associate it with a letter written by Justel to Boyle on 21 May 1678. This letter does in fact mention the 
Capuchins in a postscript, observing “Il y a ici des Peres Capucins que le Roi faict travailler qui ont une 
estime particuliere pour vous et qui voudroient bien pouvoir vous entretenir de ce qu’ils ont decouvert. 
Monsieur Watson estoit leur bon ami. Ils ont connoissance de qu’il a fait dans le Levant,” Correspondence 
of Boyle, 5:90. (The identity of this Watson is unclear).  
 The actual letter from the Capuchins to Justel survives only in a copy made by Boyle’s 
amanuensis Robin Bacon and is dated by the Correspondence editors as c. 1678 because of this reference 
in the letter from Justel to Boyle, but internal and corroborating evidence suggests a later date. The 
Capuchins refer to their departure from the Louvre (“depuis nostre sortie du Louvre”), which occurred in 
November 1679, make reference to being in Brittany, which places it after 1681; and they still sign as 
Capuchins, which places it before 1686, when they were transferred by order of the Pope to the Cluny 
Benedictine order. See Tournier 124-30. Thanks to Lawrence M. Principe for bringing this letter to my 
attention. 
 45 “Nous devions travailler de concert a une Philosophie di [de] Practique ou la Medicine auroit 
Trouvé un nouveau jour sans changer li [le] Systeme d’Hypocrate, de Platon, de Paracelse è [et] 
Vanhelmont, que nous avons reduit a un concours mutuel de Pensees e [et] d’Operations que [qui] 





Since leaving the Louvre, they boast that they had read through the works of Hippocrates 
three times, found in them the means to destroy Galenic medicine “par son propre 
Système,” treated an infinite number of patients, and devised new “Remèdes 
particulieres,” including remedies for all of the fevers “bien plus commode que celuy du 
médecin Anglois,” that is, Robert Talbor, subject of the next section of this chapter.46 The 
Capuchins also refer to a sudorific remedy they have devised which cures gout by 
ensuring that the innate semina of disease remain weak and do not produce any fruit.47 
They pass through their catalogue of remedies, observing that their famous “baume 
tranquille” has important military applications in treating wounds, and could do much 
good for the army and navy. They observe that the public would greatly benefit not just 
from their remedies but also from a course they could teach on “les raisons de la nature et 
de la Phisique,” should it please Louis XIV “or some other prince” to command them to 
deliver it, a qualifier which suggests they were fishing for English patronage. 
 The reporting of the Mercure galant suggests that the testing and distribution of 
their medications to the army, particularly their febrifuge, played an important part in 
their activities while they were staying at the Louvre. Indeed, their febrifuge’s reputation 
for success in Louis XIV’s armies inadvertently led to a scandal over the death of 
Thomas Carpatry, a commis (clerk or official) serving the War Secretary, François-
Michel Le Tellier, Marquis de Louvois (1641-1691). Carpatry, who was suffering from a 
fever, had died while under their care as well as that of several other physicians, and the 
critics of the Capuchins, including at least one of the physicians who was also at 
                                                 
 46 Ibid., 6 :442. 
 47 They refer to “la Semince de ce cruel mal qui est en l’homme auparavant l’ame y demeure 
desormais faible, infeconde, et inutile, sans y produire aucun fruit,” Ibid., 6 :443. 
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Carpatry’s bedside, had blamed his death on their febrifuge. An unnamed bishop, who 
favoured the Capuchins, wrote a public letter to the Mercure asking them to dispel this 
rumour. The Capuchins responded in the pages of the Mercure, offering a detailed 
account of the case. They reported that Carpatry had asked them to his bedside because 
his place in the war office had placed into his hands “an infinite number of letters which 
testify that our febrifuge has worked wonders in the army”48 and that they were very 
reluctant to do so given the gravity of his condition and the presence of the other 
physicians, who had let his blood three times and administered no less than three doses of 
the antimonial vin émétique. Like Van Helmont, the Capuchins were strongly opposed to 
both therapies.  
 Although both previous and subsequent issues of the Mercure depict the 
Capuchins as enjoying the support of the royal court and the people of Paris through their 
charitable practice, the Carpatry controversy shows that by November 1678 they had 
found important critics. The most vocal of these critics was an unnamed physician—
perhaps a young Paris Faculty doctor—that penned attacks on them in the Mercure and 
may also have been involved with the publication of a stand-alone libel against them 
signed under the pseudonym “Alithon,” entitled Réflexions sur la vanité outrée des Pères 
Capucins qui sont au Louvre (1679). This short pamphlet criticized the Capuchins as 
clerics meddling in medicine and specifically targeted an engraving of them in their 
                                                 
 48 “…une infinité de Lettres [...] qui assuroient que nos Febrifuges avoient fait des merveilles dans 
les Armées,” Mercure galant (November 1678), 95. The use of the Capuchins’ remedies in the army is 
corroborated by the previous issue of the Mercure, which likewise observes their febrifuge had been tested 
by surgeons at Fontainebleau and found effective: “On écrit des Hospitaux de l’Armée, que le Remede 
qu’ils appellent Febrifuge, y fait des miracles. Les chirurgiens du roy en font des épreuves à Fontainebleau, 
qui ne laissent aucun lieu de douter de sa bonté,” Mercure galant (September 1678), 246. The Capuchins 




laboratory which had been published as a plate in the Mercure (see Appendix 3, Figure 
2). 
 Like Aignan’s later account of his cure of the Cardinal of Fürstenberg in 
L’ancienne médecine à la mode, the description the Capuchins provided of Carpatry’s 
case in the Mercure implicitly testifies to a iatrochemical theory of disease, and also 
mounts a substantial critique of the use of the vin émétique, which they describe as a 
poison. Indeed, they argue that it was the vin émétique that killed Carpatry, not one of 
their essences. Their critics pointed toward the gangrene found in the patient’s intestines 
during the post-mortem as a sign of the excessive “heat” of their remedies, but the 
Capuchins argued that this sign stands against their accusers (whom they identify as the 
five physicians present) and that their critics must be ignorant in the principles of both 
medicine and chymistry: essences like their febrifuge are volatile and provoke sweating, 
“resolving” and carrying the febrile impurities and excrements upward following the 
habit (l’habitude) of the body itself, not downward, as is proper with substances like the 
vin émétique. To illustrate this point they provide an amusing and quintessentially 
chymical analogy: they suggest that if one of their imprudent critics had taken some of 
their essence in a corked glass vial and placed it somewhere hot, they would find that the 
essence would not fall to the bottom as sediment but rather would rise up as a vapour; 
and that if the vial had pores like the human stomach, it would escape completely and 
leave nothing at all in the bottom.49 The patient is literally depicted as a corked test-tube.  
 The Capuchins offer another illustration, that of their success in treating “ce petit 
prince,” the Duke of Chartres (Philippe II, later Duke of Orléans and Regent, then only a 
few years old), for which the author of the Mercure had praised them a few pages earlier. 
                                                 
 49 Mercure galant (November 1678), 118-123. 
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In that case too, the action of their drugs, in this case their essence de vipère, was nearly 
sabotaged by the physicians repeatedly administering the vin émétique, which in each 
case brought on a series of convulsions that only stopped when they gave the prince more 
of their essence. Then too their rivals accused them of using overly “hot” remedies: to 
this they asked, rhetorically, 
Is it in this case a hot or cold essence which sustains and tempers the violence 
of a caustic and boiling remedy [the vin émétique]? One might say that it is 
viper, which is believed to be one of the hottest medicines in the world; but 
we would say that only we know what it is, and others must judge it by its 
effect.50 
 
The Capuchins argued that their remedies simply elude the simplistic qualities of the 
Galenists, who, without knowing their true “secret,” can only judge them by their 
effects—like empirics. 
 In both of these cases, the Capuchins draw on a decidedly chymical understanding 
of pathological processes which forms the basis of their arguments against the Galenic 
physicians, who were using a violent chemical remedy, the vin émétique, which had since 
1666 been officially accepted even by the doctors of the Paris Faculty.51 The apparent 
contradiction of the reputedly anti-chymical faculty doctors administering a chemical-
based remedy and being opposed by chymical practitioners paints a much more complex 
picture of medicine in Paris and at the French court in the late seventeenth century than 
the existing historiography might suggest. 
                                                 
 50 “Est-ce là une Essence chaude ou froide, qui soûtient et tempere la violence d’un Remede 
caustique et boüillant [the vin emetique]? On dira que c’est du Vipere, qui est crû un des plus chauds 
Médicaments du monde; et nous dirons qu’il n’y a que nous qui sçavons ce que c’est, et que les autres en 
doivent juger par ses effets,” Ibid., 129-130. 
 51 On the “querelle,” see the above note, especially Pascal Pilpoul, La querelle de l’antimoine : 
essai historique, Doctoral thesis. University of Paris. (Paris: Louis Arnette, 1928); Kahn, “Paracelse, 




 The letter to Justel and the pages of the Mercure also presents us with a more 
nuanced picture of the Louvre Capuchins than the one available in the existing 
historiography. Aignan in particular emerges from L’ancienne medecine à la mode not as 
an “empiric” so much as a theoretically articulate iatrochemist, a “chymical Hippocratic” 
informed by the acid-alkali theory and by a distinctly Helmontian theory of disease. Most 
of the Capuchins’ ideas were not particularly original: I have found well-known sources 
for all of those expounded here, in many cases decades if not a century old. They can thus 
be contextualized within the mainstream of seventeenth-century chymical discourse.  
 But what can Aignan and his partner Rousseau’s sojourn at the Louvre tell us 
about the acceptance of chymical medicine at the court of Louis XIV?  The material 
support the Capuchins received from the crown presents a useful starting point. Beyond 
their generous pension of 1,000 livres (a typical figure for court practitioners), they also 
received a laboratory equipped at the crown’s expense. The ledger of the Compte des 
Bâtiments du Roi shows that the total sum spent during the first six months of their time 
at the Louvre, from 30 May to 16 December 1678, is upwards of 3,840 livres, well over 
double the average annual pension for royal physicians in ordinary and members of the 
Académie royale des sciences, with about half of this being spent on laboratory 
equipment and supplies—everything from “drogues, allambics, fiolles de verre” to 150 
bushels of juniper berries.52 
 This laboratory enabled them to produce remedies that could be charitably 
distributed among the poor of Paris, but as the pages of the Mercure make clear, the 
                                                 
 52 Tournier, Le Clergé et la pharmacie, 114–118; Jules Guiffrey, ed., Comptes des bâtiments du 
roi sous le règne de Louis XIV, vol. 1 (Paris: Imprimerie nationale, 1881), 1024, 1108, 1109, 1111; David J. 
Sturdy, Science and Social Status: The Members of the Academie Des Sciences 1666-1750 (Woodbridge, 
Suffolk: Boydell Press, 1995), 153–156. 
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Capuchins also personally treated elite patients, from senior government bureaucrats like 
Carpatry to princes of the blood like the Duke of Chartres, as well as Madame de 
Sévigné, the President of the Paris Parlement, and later the Duke of Chaulnes in Brittany 
(as we shall see). The king himself graciously accepted a small cellar’s worth of their 
remedies, and one of their essences is alleged to have helped him recover from an arm 
injury he sustained while playing tennis. Indeed, the Mercure report on them for 
September 1678 observes that the people of Paris and the “personnes de marque” in 
particular were indebted to the Capuchins and to Talbor (“le Médecin Anglois”) for 
maintaining their health during what was an unusually hot summer, and that they had also 
worked marvels in the army.53 
 The material support that the Louvre Capuchins were provided through their lab 
and pension, for their service to court patients, to the poor of Paris, and to the armies of 
Louis XIV, stands as a hitherto unrecognized example of substantial royal patronage 
being directed to chymical medicine in this period. The laboratory of the Louvre 
Capuchins may stand as one of the most substantial royal investments in iatrochemistry 
in the latter seventeenth century. This places it alongside the courses in chymistry taught 
at the Jardin du Roi since the time of Guy de la Brosse and William Davisson, and the 
chymists like Samuel Cottereau Duclos who were supported by the Académie.54 This is 
particularly notable because it occurred simultaneously with the Affair of Poisons, which 
                                                 
 53 “On écrit des Hospitaux de l’Armée, que le Remede qu’ils appellent Febrifuge, y fait des 
miracles. Les chirurgiens du roy en font des épreuves à Fontainebleau, qui ne laissent aucun lieu de douter 
de sa bonté,” Mercure galant (September 1678), 246. 
54 On the Jardin as a locus for chymistry, see esp. Jean-Paul Contant, Contribution à l’histoire de 
l’enseignement de la pharmacie: l’enseignement de la chimie au Jardin Royal des Plantes de Paris. 
(Cahors: A. Coueslant, 1952). 
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Lawrence M. Principe has shown posed important challenges to the public image of 
chymistry in France during this period.55 
 This raises one final question, that of the reason for the departure of the 
Capuchins from the Louvre in late 1679. While it might be tempting to associate their 
departure with the Affair of Poisons and a general desire on the part of the court to 
disassociate itself from chymistry, increasingly closely associated with poison in the eyes 
of the public, our main sources, namely Madame de Sévigné and the Mercure, attribute 
their departure to other causes. Both indicate that the Capuchins were leaving Paris for 
Egypt or Ethiopia, and Madame de Sévigné also points to their medical critics as culprits: 
“the physicians are cruel and have taken away from the public admirable and 
disinterested folk who were in truth making prodigious cures.”56 The Mercure, however, 
accounts for their departure by laying the emphasis on their planned mission to Ethiopia, 
for which Louis XIV had given them letters of recommendation: their stay in Paris was 
always intended to be temporary, and their practice of medicine was always only an 
accessory to their true goal, namely, to use their medical skills to gain inroads in Ethiopia 
and bring the Christians there into communion with the Church of Rome.57 
                                                 
 55 Lawrence M. Principe, “The End of Alchemy?: The Repudiation and Persistence of 
Chrysopoeia at the Académie Royale Des Sciences in the Eighteenth Century,” Osiris 29, no. 1 (2014): 96–
116. 
 56 “Les médecins sont cruels et ont ôté au public des gens admirables et désintéressées, qui faisait 
en vérité des guérisons prodigieuses,” Madame de Sévigné, Correspondance, 2:742. See also Tournier, Le 
Clergé et la pharmacie, 123. 
 57 The interest of Ethiopian kings in European medicine is also testified to by the case of the 
French explorer and physician Charles Poncet, who travelled to treat the Negus Iya’su I (1682-1706) and 
his son or a “skin ailment” in 1698. See Theodore Natsoulas, “Charles Poncet’s Travels to Ethiopia, 1698-
1703,” in Distant Lands and Diverse Cultures: The French Experience in Asia, 1600-1700, ed. Glenn 
Joseph Ames and Ronald S. Love (Westport, Conn.: Praeger, 2003), 71–95. Citing an account by the 
Scottish explorer James Bruce (75), written seventy years later, Natsoulas also makes reference to two 
Capuchins who are alleged to have cured a Muslim merchant with court connections, Hadji Ali, who 
intended to bring them back to Ethiopia, only to have the French Consul, Bernard de Maillet, send Poncet 
instead. Could these be the Louvre Capuchins? Poncet arrived in Cairo in 1691, well after the period of the 
Capuchins in Egypt, which was probably the early to mid 1670s; they could have made a second journey to 
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 Their mission never got off ground due to financial difficulties and over a year 
later they would be back in Paris for a short time, and from there to Brittany, where they 
found patronage with Charles d’Albert d’Ailly, Duke of Chaulnes and Governor of 
Brittany, and continued producing their remedies. Joseph Tournier and Édouard Guéguen 
have traced their activities in Brittany, where they continued to supply their remedies to 
elite patrons like Madame de Sévigné as well as to the poor, and where they appear to 
have been involved in a conflict with the apothecaries of Vannes, who filled their 
prescriptions with spoilt medication, as is mentioned in a 1684 arrêt of the Brittany 
Parlement.58 While the apothecaries were bound by the Parlement to fill their 
prescriptions correctly, the Capuchins would face greater challenges from the local 
provincial vicar of their order, whose protestations against their practice of medicine 
eventually led to their transfer—by papal intervention—to the more liberal Cluny 
Benedictine order. After this point, they can no longer be called the Louvre Capuchins 
(being neither Capuchins nor based in the Louvre) and are usually referred to as Pères 
Rousseau and Aignan (or Tranquille). Both spent little time at their new abbey, and 
continued practicing medicine. In 1690 they were granted a laboratory privilege in Paris, 
where Aignan appears to have resided. Interestingly, Aignan is listed in Blégny’s 1692 
Livre commode des addresses among the ordinary physicians as a doctor from the 
Faculty of Padua, a distinction which also appears on the cover of his L’ancienne 
médecine à la mode, published at this time, although it is unclear how or when he 
                                                                                                                                                 
Egypt, but attestations of their presence in Brittany through most of the 1680s and Paris in the 1690s would 
seem to preclude this.  
 58 Tournier, Le Clergé et la pharmacie, 124–144; Édouard Guéguen, “Les Pères Capucins du 
Louvre en Bretagne au XVIIe siècle,” Revue d’histoire de la pharmacie 48, no. 164 (1960): 290–92. 
Guéguen cites records of the legal battle with the apothecaries from the AD Ille-et-Vilaine. 
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received this degree.59 Aignan seems to have practiced and published in Paris until his 
death in 1709. Rousseau continued on as a physician to the Duke of Chaulnes, but died 
earlier, in 1694; as mentioned above, his brother published his writings and recipes 
posthumously.60 
 The case of the Chymical Capuchins of the Louvre is useful for establishing the 
prominence of chymical medicine at court on the eve of Robert Talbor’s arrival and 
serves as a reminder not to define chymical medicine narrowly as the use of mineral-
based therapeutic substances. Most of the Capuchin’s cures were plant or animal-based, 
and their chymical ideas emerged most vividly in their accounts of pathology, therapy, 
and physiology, as well as in the laboratory practices through which they processed and 
purified therapeutic substances. Much the same is true of debates surrounding Robert 
Talbor’s cinchona-based remède anglois, as it came to be called in France. 
3. Robert Talbor’s remède anglois in France, 1679-1681 
 Another example of the prominence of chymical theories of disease and therapy at 
the French court is provided by the events and debate surrounding the popularization and 
eventual disclosure of Robert Talbor’s secret remède anglois (the English Remedy) 
against intermittent fevers. The work of the medical journalist and surgeon Nicolas de 
Blégny in collaboration with the first physician Antoine Daquin provides a particularly 
poignant manifestation of the prominence of disease ferments (levains) and acid-alkali 
therapeutics at the highest levels of court medicine in this period. The same set of 
chymical ideas was invoked a decade later in one of the few publications of Daquin’s 
                                                 
 59 Aignan’s status is a Padua doctor is not mentioned in any earlier sources that I have seen, 
including the Mercure reports. The Padua registers have only been published for up to the year 1600, which 
prevents me from being able to easily check whether and when he graduated: see Gaspare Zonta and 
Johanne Brotto, eds., Acta graduum academicorum Gymnasii Patavini, 5 vols. (Padua: Antenore, 1970-). 
60 Rousseau, Secrets et remedes éprouvez, 1697. 
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successor, Fagon, and so it offers us a window onto the pathological and therapeutic 
concepts of the two first physicians who oversaw the pre-1728 privilege regime at the 
peak of its activity. 
 The prominence of chymical ideas in the debates surrounding cinchona more 
generally has gone largely unrecognized, despite the fact that Talbor’s Pyretologia 
includes direct citations of Van Helmont and the subsequent debates surrounding the 
action of the drug were conducted using chymical terms.61 This may be due in part to a 
persistent tendency to assume that chymical medicine is reducible to the therapeutic use 
of mineral substances, which obscures the more complex role that chymical ideas played 
in the reception of exotic plant substances like cinchona bark.62  
The bark itself is of course well known in the history of medicine, thanks in part 
to the later reputation of quinine, the antipyretic alkaloid of which it is the source. 
Cinchona is frequently mentioned in accounts of colonial botany and bioprospecting, and 
the long history of its European reception has been surveyed by Saul Jarcho and others.63 
The latter efforts of French officials to develop French sources of the bark in the 1730s 
                                                 
 61 The sole exception is Fiorella Lopiccoli, who has recently pointed to the role of iatromechanical 
and iatrochemical ideas in these debates, but the topic has not been pursued any further: Fiorella Lopiccoli, 
“Francia 1679-1683: l’uso terapeutico della chinachina tra iatrochimica e iatromeccanica,” Medicina & 
Storia 7, no. 13 (2007): 65–93. Lopiccoli recognizes a link to Thomas Willis and fermentation, but neglects 
the place of this debate within the broader iatrochemical tradition of chymical ferments and the acid-alkali 
theory. 
 62 For example, in Jarcho’s account of cinchona, the only reference to chymical medicine is his 
discussion of antimony, which he paints as the foil and “principal rival” of cinchona as febrifuge, and 
which he estimates was used far more frequently than cinchona in France before the arrival of Talbor’s 
remède anglois. Jarcho also lauds Blégny’s condemnation of Lémery’s acid-alkali theory, but fails to 
acknowledge that it still provides the main source for his own account of the drug’s action (as I will suggest 
below, Blégny doth protest too much). See Saul Jarcho, Quinine’s Predecessor: Francesco Torti and the 
Early History of Cinchona (Baltimore: Johns Hopkins University Press, 1993), 65, 75–78. 
 63 On cinchona’s reception in Europe, see esp. Jarcho, Quinine’s Predecessor; Andreas-Holger 
Maehle, Drugs on Trial: Experimental Pharmacology and Therapeutic Innovation in the Eighteenth 
Century (Amsterdam: Rodopi, 1999), 233–209.  
 The forthcoming monograph of Samir Boumediene, La colonisation du savoir. L’appropriation 
des plantes médicinales américaines par les Européens (1570-1750) (Paris: Alma Éditeur, forthcoming), 
promises to shed much light on the question of cinchona’s appropriation and reception in Europe, but was 
not yet released when this dissertation was submitted. 
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has received recent attention,64 as have Spanish efforts to monopolize the supply of the 
plant in the latter half of the eighteenth century.65 
Although Talbor is typically mentioned in histories of cinchona,66 the remède 
anglois episode usually receives little attention, despite the fact that it helps to explain 
one of the more important features of the bark’s European reception.67 Although 
cinchona had been well-known in Europe for decades, it was held in suspicion by 
physicians because its action could not be explained through traditional Galenic 
pharmacology, and patients who took it were believed to suffer relapses. I argue that the 
dissemination of a chymical model of pathology allowed for more comprehensible 
accounts of cinchona’s therapeutic action than those previously available, a fact which 
helps explain the more favorable reception it found in the 1680s when Talbor “re-
popularized” its use: in intellectual terms, the acid-alkali theory and the chymical critique 
of Galenic qualities had created a more propitious intellectual environment for the 
understanding of cinchona’s therapeutic action. Alongside this shift in pharmacological 
reasoning, I also draw attention to the material processes which transformed raw 
cinchona bark into Talbor’s remède anglois, in order to suggest that Talbor devised what 
                                                 
64 Londa Schiebinger, Plants and Empire: Colonial Bioprospecting in the Atlantic World 
(Cambridge, Mass.: Harvard University Press, 2004), 38–39; James E. McClellan and François Regourd, 
The Colonial Machine: French Science and Overseas Expansion in the Old Regime (Turnhout: Brepols, 
2011), 259–262. 
65 Matthew James Crawford, “Empire’s Experts : The Politics of Knowledge in Spain’s Royal 
Monopoly of Quina (1751-1808)” (Dissertation, University of California, San Diego, 2009). 
66 See for example Jarcho, Quinine’s Predecessor, 49–50, 64–66; Maehle, Drugs on Trial, 237, 
291n8. Jarcho provides a brief but judicious view of Talbor: he observes that Talbor “combined medical 
knowledge with greater pharmaceutical expertness than ordinary physicians are likely to have possessed” 
(48), and credits him for introducing “useful dosage forms such as the tincture” (65), but provides no 
additional details. 
67 The main exception is the recent work of Harold J. Cook, which I will discuss below: see 
Harold J. Cook, “Markets and Cultures: Medical Specifics and the Reconfiguration of the Body in Early 
Modern Europe,” Transactions of the Royal Historical Society 21 (2011): 123–45. 
98 
 
his contemporaries believed was a more effective chymical preparation of the drug than 
had been previously available.  
 Before moving into the Talbor episode, it is useful to recall some details about the 
1650s debate and cinchona’s reception in European medicine. To begin, cinchona, 
sometimes called the “Jesuit’s bark” or “Peruvian bark,” was as its various names suggest 
a bark from a tree native to the Andean forests of South America first introduced in 
Europe through Jesuit channels in the 1630s. The fortunes of cinchona in learned 
European medical circles were deeply affected by a controversy that raged in the early 
1650s. In 1652, Leopold Wilhelm, Archduke of Austria and Governor of the Spanish 
Netherlands, suffered from a tertian fever and was administered cinchona by an attendant 
physician, Jacques Chiflet. The fever disappeared for a time, but the patient suffered a 
relapse a month later. Chiflet then became a critic of the bark and published a short 
treatise against it: citing other cases of relapse, he argued that it did not cure the disease 
but merely extended the fever intervals. This provoked a response by the Jesuit Honoré 
Fabri, who defended the drug, and who was in turn systematically criticized in a treatise 
by the Louvain medical professor Vopiscus Fortunatus Plempius. The “criterion” by 
which cinchona was being assessed was Galenic on both sides of the debate, even for 
Fabri, who wrote in favour of the bark. This controversy set the terms of subsequent 
debates over cinchona: in the first place, it was deemed to be “hot,” and within a 
traditional Galenic mindset, using a hot medication to cure a disease defined by 
preternatural heat seemed paradoxical; second, it was not an evacuant, as they thought a 
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febrifuge ought to be; and third, clinical experience demonstrated that patients who took 
it were prone to relapses.68 
 The suspicions voiced by Chiflet and Plempius seem to have followed cinchona 
wherever it went, particularly in learned circles. In the case of France, Jarcho has drawn 
on a number of sources to show that the bark was not popular, at least among learned 
physicians, either owing to this negative assessment, to difficulties in securing a supply, 
or to both in tandem. The letters of the Parisian physician Guy Patin—admittedly a 
hostile witness in the case of medical novelties—show that he closely followed the 
development of the 1650s polemic, and had nothing good to say about cinchona.69 In a 
1661 letter to André Falconet, he reported that the recently disgraced finance minister, 
Nicolas Fouquet, had taken cinchona but was not cured of his quartan fever. Patin then 
takes the occasion to offer his own estimation of the drug:   
As for cinchona, it makes no miracles here: when the body is well evacuated 
by bleeding and purgatives, it can resolve or absorb the remainder of morbific 
matter through its heat; in any other case, the only thing it does is heat [the 
body]. Even those for whom it abates the fever are not wholly cured, for the 
fever returns, despite their having been well purged.70 
 
Patin instead preferred a simple purgative of senna, administered at the end of the fever 
access. But his assessment of cinchona focused on the quality of heat and its propensity 
toward relapses, well in keeping with the objections of Chiflet and Plempius. 
                                                 
 68 Maehle, Drugs on Trial, 225–230. 
 69 Jarcho, Quinine’s Predecessor, 61–64. 
 70 “Mais à propos de quinquina, il ne fait point ici de miracle : quand le corps est bien déchargé 
par la saignée et les purgatifs, il peut par sa chaleur résoudre ou absorber le reliquat de la matière 
morbifique; à moins que cela, il ne fait qu’échauffer. Ceux mêmes à qui il a fait cesser la fièvre n’en ont 
pas été tout à fait guéris, car elle est revenue, quoiqu’ils eussent été bien purgés,” Guy Patin to André 
Falconet (21 September 1661), L. 713 in Loïc Capron, ed. Correspondance française de Guy Patin (Paris: 




 This situation would change only with the arrival of Talbor’s remède anglois. The 
story of this proprietary drug begins, as its epithet suggests, not in France, but in the 
marshes of Essex across the English Channel. Robert Talbor (1642-1681) apprenticed 
with an apothecary and even began studies at Cambridge in 1663, but appears not to have 
completed a degree. 71 Instead, as he himself recounts, “I planted myself in Essex near to 
the sea side, in a place where Agues [fevers] are the epidemical diseases” to perfect his 
treatment of them through “observation and experiment.”72 His sole publication, the 
seventy-seven page Pyretologia (1672), documents the results of his experiments in the 
Essex marshes: it includes a brief description of human physiology; a defense of his 
methods and sources, which stresses the importance of finding a “golden mean” between 
the rationality of the dogmatic sect in medicine and the experience of the empirics; an 
account of the cause of agues; notes on diagnosis and prognosis; a survey of existing 
therapies, including recipes; an account of his own (superior) method; observations on 
regimen; and four case histories. 
 Like the Louvre Capuchins, Talbor is usually characterized as an “empiric” 
interloper at the French court. Perhaps for this reason, no one has bothered to analyse his 
single publication, which clearly shows that he was influenced by Helmontian ideas. 
                                                 
 71 On Talbor’s biography see Mary J. Dobson, “Tabor, Sir Robert (bap. 1642, D. 1681),” Oxford 
Dictionary of National Biography (Oxford: Oxford University Press, 2004), http://www.oxforddnb.com/ 
view/article/26910 (accessed January 5, 2016); Mary J. Dobson, “Bitter-Sweet Solutions for Malaria: 
Exploring Natural Remedies from the Past,” Parassitologia 40 (1998): 69–81; Rudolph E. Siegel and F. N. 
L. Poynter, “Robert Talbor, Charles II, and Cinchona: A Contemporary Document,” Medical History 6, no. 
1 (1962): 82–85; Maurice Bouvet, “Talbot, vulgarisateur du quinquina en France,” Bulletin des sciences 
pharmacologiques 41 (1934): 165–80.  
 It also bears mention here that Talbor is consistently called “Talbot” in French sources, beginning 
with Blégny in the seventeenth century and continuing up to Bouvet in the twentieth. In his Pyretologia and 
the royal brevet cited below, his name is consistently spelt Talbor, the spelling which I have preferred here, 
although Mary J. Dobson has elected to use “Tabor” in the ODNB. 
 72 Robert Talbor, Pyretologia, a Rational Account of the Cause & Cure of Agues with Their Signes 
Diagnostick & Prognostick. Also Some Specifick Medicines Prescribed for the Cure of All Sorts of Agues 
[...] (London: R. Robinson, 1672), A4v. Ague and fever are synonymous: the former derives from the 
French fièvre aigu, that is, an acute fever. OED. 
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Indeed, Talbor first mentions Van Helmont quite early in the treatise, and he is the only 
medical authority explicitly cited throughout the text. The initial account Talbor provides 
of the spleen and the stomach as the “duumvirate” of human physiology is explicitly 
credited to “the ingenious Van Helmont” and the subsequent account of the action of both 
organs follows Helmontian terms: the spleen “ferments” the blood and produces an acidic 
menstruum for the stomach, where food is transformed into chyle.73 
 Later in the treatise, in his appendix on “Nature’s Method in time of sickness,” he 
provides a general account of chronic diseases as the product of unnatural ferments 
slowly “invading Nature’s Castle,” and uses the same language of siege in his section on 
acute diseases, wherein Nature is able to mobilize more quickly because she has received 
“timely notice of the approach.” As in Van Helmont, sweating is identified as the ideal 
way of expelling the initial morbific matter which forms the occasional cause of disease; 
in so doing, the physician helps Nature, which stands in here for the archeus. On this 
point Talbor directly cites “that true friend of nature, the learned Helmont,” even 
specifying the page number: “Nature being the Physicianess of diseases, she is to be 
strengthened, and comforted, not frightened or disquieted.”74 
 Talbor’s pathological description of fevers agrees with Van Helmont’s in its 
broad strokes, most notably on identifying the spleen as the seat of agues, but it includes 
references to the humors and lacks the Helmontian emphasis on the “foreign guest” as the 
occasional cause of a fever (although, as we have already seen, his view of morbific 
matter literally besieging the castle of Nature resembles the archeus/“foreign guest” 
                                                 
 73 Ibid., 15–18. 
 74 Ibid., 59. This is Talbor’s own translation of “Naturam esse morborum medicatricem, eam 
confortandam ideo non consternandam,” a passage from the “Scholarum humoristarum passiva deceptio,” 
Ortus medicinae (Amsterdam: Elsevier, 1652), 802. 
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relation as the cause of disease). The account of fevers begins in medias res, after the 
disordered fermentation has already begun: the blood is no longer being fermented in the 
spleen, and sufficient acidic digestive ferment is not conveyed by the spleen to the 
stomach; this improper fermentation generates “viscous humours” and chyle that make 
their way into the blood and eventually the heart, where the flow of blood is obstructed, 
intermittently damming it up and releasing it. “Nature” releases the improperly fermented 
matter through transpiration, “till the morbifick matter come round again, continuously 
recruiting itself with fresh supplies from the imperfect digested chyle, till that cause be 
taken away,” either by Nature alone or by Nature with the assistance of drugs. The 
periodicity of the fever depends upon the relative lightness or heaviness of the morbific 
matter (be it phlegm, bile, or black bile), and the duration of the fits depends upon the 
quantity of such matter.75 Clots of such viscous humors were sometimes vomited as 
“Ague-cakes” by his patients in Essex (he diligently weighed and measured several), 
after which they would usually be cured of the fever.76  
 After listing a series of already known remedies for intermittent fevers, Talbor 
describes his own method. He begins with a “specifical Emetocathartick Powder,” 
administered a few hours before an expected fit alongside a cordial for the stomach and 
spleen. But this is merely a first resort. In the case of long quotidians or quartans that do 
not respond to this treatment, he then administers his own “specificks,” the recipes of 
which are, unsurprisingly, not provided.77 The first is intended to provoke sweats and 
urination, the second is a “specifical splenetick medicine.” At the end of this section, he 
then makes the surprising move of explicitly addressing the “Jesuit powder.” He cautions 
                                                 
 75 Ibid., 20–21. 
 76 Ibid., 23. 
 77 Talbor does offer some hints: one is made from four vegetables, two domestic and two foreign. 
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that it can cause frenzies, convulsions, fits, and will only remove the fever temporarily: a 
relapse will occur within a fortnight. To which he adds, however, “Yet is this Powder not 
altogether to be condemned; for it is a noble and safe medicine, if rightly prepared and 
corrected, and administered by a skillful hand; otherwise as pernicious a medicine as can 
be taken.”78 Talbor’s goal here seems to be to throw his reader off track from suspecting 
that cinchona was his secret: as would later be made clear, his own remedy was based on 
cinchona.79 
 Talbor was certainly a reader of Van Helmont: the Pyretologia is in broad 
agreement with Van Helmont in its views of the physiology of the “duumvirate,” his 
notion of the spleen is the seat of intermittent fevers, and his views of assisting Nature by 
provoking sweats. He does, however, downplay the non-corporeal aspects of Van 
Helmont (whither the archeus?) without making the turn into the more materialist acid-
alkali pathology that would be popular in 1678, when he popularized his remède anglois 
in France. 
 This popularization can be best followed through the eyes of Nicolas de Blégny 
(1652-1722), who held a royal privilege to publish an early medical journal, Les 
Nouvelles découvertes sur toutes les parties de la médecine (1679-1683), which was 
translated into Latin and published in Geneva for an international audience as the 
(curiously titled) Zodiacus Medico-Gallicus.80 Although Talbor himself left behind no 
                                                 
 78 Talbor, Pyretologia, 44. 
 79 On the term “specific” itself, see below. Talbor uses it repeatedly throughout the treatise without 
providing any clear definition. He does however link “specifics” to the “arcana” of empirics. He may be 
using “arcana” in the Paracelsian sense here, in which case, it is very likely synonymous with “specific.” 
Ibid, 12-13. 
 80 The main biographical source on Blégny is a 68-page medical dissertation which leaves much to 
be desired: Pierre Jean Tellier, Un aventurier médical au XVIIe siècle, Nicolas de Blégny, Thèse pour le 
doctorat en Médecine, Université de Paris (Paris: Librairie Louis Arnette, 1932).  
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writings beyond his 1672 Pyretologia, Blégny provides ample reporting on the drug 
during Talbor’s period in France in the form of his Découverte de l’admirable remède 
anglois, published as a special issue of his journal.81 Indeed, after Talbor’s death, Blégny 
was selected by Louis XIV to publish the secret of his remedy with the commentary of 
the royal first physician Daquin in 1682, in the form of a special issue (“extraordinaire”) 
of the Nouvelles découvertes, entitled Le remède anglois pour la guérison des fièvres, 
publié par ordre du Roy.82 These two texts by Blégny, the 1680 Découverte and 
particularly the 1682 Le remède anglois (including the sections by Daquin), form the 
basis for my discussion. 
 Talbor first arrived in France in the summer of 1678 to treat the fever of la petite 
Mademoiselle, Marie-Louise d’Orléans, daughter of Monsieur (Philippe I, Duke  of 
Orléans, the brother of Louis XIV) and Henrietta Maria of England. He was already 
famous in England at this point, and had been made physician-in-ordinary to Charles II in 
1672 during a royal visit to Essex, and knighted in 1678. After his success with Marie-
Louise, Talbor treated other important patients and when Marie-Louise married Charles 
                                                                                                                                                 
 By 1689, Blegny had become Médecin du Roi et de Monsieur, director of his Académie de 
Nouvelles découvertes, editor of its journal, proprietor of a Manufacture Royalle des Bandages, and was 
also running his own public infirmary on the rue de Pincourt. Blégny’s surprising successes were 
definitively halted in 1693 when he was imprisoned for false usurpation of noble titles owing to his efforts 
to revive a defunct hospitaller order, l’Ordre du Saint-Esprit, and was also accused of heresy (“des 
conférences qu’il tenait clandestinement chez lui tous les vendredis d’expliquer physiquement les mystères 
de la Religion”), and of combining multiple medical professions. As Tellier notes, the sudden disgrace of 
Daquin, who had previously been his protector, likely played an important role in sealing Blégny’s fate; he 
appears to have been imprisoned until at least 1699, after which time, he seems to have managed to flee 
first to Avignon then to Italy. See Tellier, Un aventurier médical esp. 50–58. 
 81 Nicolas de Blégny, La Découverte de l’admirable remède anglois pour la guérison des fièvres 
au moyen de laquelle chacun pourra se procurer la facilité de guérir à très peu de frais (Paris: C. Blageart 
et L. d’Hourry, 1680); David A. Kronick, “Nicolas de Blégny, Medical Journalist,” in “Devant le deluge” 
and Other Essays on Early Modern Scientific Communication (Lanham, MD: Scarecrow Press, 2004), 1–
11. Reprinted from an article in the Bulletin of the Cleveland Medical Library (1960): 47–56. 
 82 Nicolas de Blégny, Le Remède anglois pour la guérison des fièvres, publié par ordre du Roy, 
avec les Observations de M. le premier médecin de Sa Majesté sur la composition, les vertus et l’usage de 
ce remède (Paris: Veuve d’Antoine Padeloup, 1682). 
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II of Spain in 1679, he accompanied her as her physician, only to return with her to 
France the following year.83 
 It seems that in Talbor’s absence, his former valet or domestique, Philippe de la 
Verdure, claimed to have learned Talbor’s secret while in his service and began 
administering his own remedy at a lower rate (3 louis d’or per patient).84 Although de la 
Verdure appears to have communicated it to Daquin,85 Blégny reports that Talbor denied 
that de la Verdure knew the true secret.86 At any rate, on September 9, 1680, a royal 
brevet for a 1,200 livre annual pension was granted to de la Verdure, “in consideration of 
his having renounced heresy [Protestantism] and for the services he has rendered to the 
public with his specific remedy against fevers,” under the condition that he provide the 
remedy to the public and charge no more than 33 livres per patient.87  
 Talbor’s one-time valet Philippe de la Verdure—who it should be mentioned is 
given the title of médecin in this brevet—was not the only one who sought to discover the 
secret of his remedy and duplicate it. Blégny’s first publication on the remedy, the 1680 
Découverte de l’admirable remède anglois, is in fact an advertisement of the fact that he 
too had acquired a recipe for it and had been able to confirm through a parallel chemical 
analysis that it was identical to Talbor’s. Blégny describes how he received the recipe 
from an English gentleman who was an old friend of Talbor and who disclosed the recipe 
to Blégny out of thanks after having recourse to him during “and indisposition whose 
                                                 
 83 Bouvet, “Talbot, vulgarisateur du quinquina,” 166–169; Dobson, “Tabor, Sir Robert.” 
 84 Incidentally, this is the same price that Helvétius’ privilege would fix for his own “Remède 
spécifique.” 
 85 Bouvet, “Talbot, vulgarisateur du quinquina,” 170. Bouvet cites this from Blégny’s own 
medical periodical, vol. 1, p. 264. 
 86 Blégny, La Découverte de l’admirable remède anglois, 67. 
 87 “…en consideration de l’abjuration qu’il a fait de l’héresie [Protestantism] et des services qu’il a 
rendus au public par les remedes specifiques qu’il a pour la fièvre,” AN O1 24, fol. 232r-v. 
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cure was rather delicate” (perhaps a venereal condition; Blégny had a reputation in this 
field).88 
 He even describes the pains he took to acquire a sample of Talbor’s remedy in 
order to confirm the recipe.89 This was especially difficult as Talbor was careful to 
administer it personally in order to prevent it from falling into the hands of potential 
imitators. As Blégny describes it, a chemical analysis (l’analize chimique) of the 
substance would likely have given him the answers he needed, but  “the English 
physician, who understood that his success depended upon his secret, was secretive to the 
point that he wanted to be the only one who would administer all the doses to every 
patient, without trusting anyone else,” and that if the patient were placed in other hands, 
he would only provide the remedy to another practitioner in exchange for 50 livres, 
which was a high enough cost to discourage investigators like Blégny from buying it for 
the purpose of such an analysis.90 Indeed, according to Blégny, Talbor kept company 
only with his trusted English servants and guests (although, as we have seen, not all of 
these servants could be trusted!). In the end, Blégny got his hands on it by pure chance: 
the valet de chambre of an unnamed foreign prince,91 who had taken ill with fever, called 
Blégny to have his blood let (recall here that he was a surgeon). Blégny did so, and 
discovered that the valet had been given doses of the remède anglois but was unwilling to 
take it, preferring traditional treatments instead. The valet’s master, however, had 
recently been cured of fever by Talbor and had apparently paid for an entire course of 
                                                 
 88 Blégny, La Découverte de l’admirable remède anglois, 10. 
 89 Ibid., 13–17. 
 90 “Le Medecin Anglois, qui avoit compris que sa fortune dépendoit de son secret, estoit 
misterieux au point de vouloir donner luy-mesme toutes les prises à chaque malade, sans le confier à qui 
que ce soit,” Ibid., 8. 
 91 Bouvet 177 identifies him as the prince of Òsnabruch and the valet as one Gaillan, dit Violette. 
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treatment using the drug for his servant. The valet had thus decided to feign taking 
Talbor’s remedy as a sign of respect to his master, while secretly providing his regular 
doses to Blégny!  
 Blégny himself confesses being stupefied both by his luck and by the folly of his 
patient, who was disregarding the reputation of the drug and its inventor, as well as the 
sound judgement of his own master. But Blégny knew better than to look a gift horse in 
the mouth:  
This was a fine occasion to profit from his quirkiness: I asked him to give me 
all the doses that were brought to him, and as he had no use for them, he 
readily consented to share them with me, and he sent them to me so regularly 
that every day I had material on which to perform new experiments.92 
 
To compare the authentic remède anglois to the version he himself had produced from 
the recipe he had been given, Blégny undertook a series of chymical tests before an 
audience of his academicians (presumably members of the academic society associated to 
his journal), including evaporation, solvent tests of the residue, distillation and 
precipitation, all of which showed the two substances to be identical on the level of 
colour, odour, and taste.93 Beyond these chymical tests, Blégny earlier mentions 
successful clinical trials of his version on the poor as well, apparently before he had the 
basis for a chymical comparison, but that he apparently did not consider the clinical 
results to be sufficient to allow him to claim he had duplicated the drug.94 
 Blégny shows discretion and does not publish the secret in full, observing that to 
do so would “damage the art of medicine” because secrets revealed soon fall into disdain 
                                                 
 92 “Ce fut une belle occasion pour profiter de sa bizarrerie: Je le priay de me donner toutes les 
prises qu’on luy apporteroit, et comme il ne le destinoit à aucun usage, il consentit sans peine à m’en faire 
part, et il me l’envoya si exactement, que j’avois chaque jour de quoy en faire de nouvelles experiences,” 
Blégny, La Découverte de l’admirable remède anglois, 15. 
 93 Ibid., 16–17. 
 94 Ibid., 12. 
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among the public, and that this would run counter to the king’s wishes and to his mandate 
as editor of his medical journal.95 He goes so far as to say that the basis of the drug is 
indeed cinchona, which everyone appears to have known already, and which merely 
offered a starting point as it was Talbor’s preparation which was the real key. The full 
disclosure of the secret would have to wait until after Talbor’s death in 1682; in the 
meantime, Blégny simply advertises that he knows the secret and that patients may now 
come to him for it as well.96 
 To quickly summarise the rest of Talbor’s career, he returned to Paris from Spain 
in 1680, and had a number of successes in treating fevers, most notably with the Dauphin 
in November 1680. During this period he acquired two substantial pensions for curing the 
Dauphin and Dauphine, several gratifications, and was naturalized in France. His secret 
had been purchased by the king and was to be published upon his death. Drawing on 
contemporary letters, Bouvet has shown that Talbor’s reputation appears to have fallen 
off in 1681 however: many who had been cured using his febrifuge seemed to be 
relapsing. By September, Talbor had left Paris to return to England, died shortly 
thereafter (although he was only about 40 years old), and was buried on 17 November 
1681, with his monument bearing the epitaph “Febrium malleus,” the hammer of 
fevers.97 
                                                 
 95 “La grace qu’il a plû au Roy de me faire, en me préposant pour la recherché des choses 
utiles à la santé des hommes [that is, in giving him the privilege for his medical journal], m’engage 
à travailler sans cesse pour le bien du public; et je manquerois à ce que je dois à cet égard, si je 
divulgeois un remede qui ne luy peut estre utile sans estre secret,” Ibid., 19. 
 96 Bouvet also adds that Blégny advertised his Découverte with 8,000 affiches, an indication 
perhaps of the value at this point of having duplicated Talbor’s remedy. Bouvet cites BN 8- TE46- 21, with 
no page number; as far as I can tell this is simply another copy of the Découverte which I examined at the 
BIUS and from which I cite here. 
 97 Bouvet, “Talbot, vulgarisateur du quinquina,” 174–176; Madame de Sévigné, Correspondance, 
3:56. Concerning the episode with the Dauphin, Madame de Sévigné observed the following in a letter to 
her daughter: “L’Anglois a promis au Roi, sur sa tête, et si positivement, de guérir Monseigneur dans 
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 Talbor’s Pyretologia reveals that, like the Louvre Capuchins, he was conversant 
in the chymical discourse of the time. His phenomenal success with his remedy, and the 
subsequent re-emergence of cinchona as a subject of learned medical speculation, rested 
on two foundations. First, Talbor personally devised a new preparation of cinchona that 
was considerably different from the common one then available and widely perceived to 
be more effective. Second, in the decades since the Chiflet-Fabri-Plempius polemic, a 
new more propitious chymical-theoretical framework had emerged for understanding 
cinchona’s therapeutic action. These factors neatly exemplify the dialectic between 
economic ambitions and a new intellectual climate which, along with the ingenuity of 
would-be counterfeiters like Blégny, would bring cinchona back to the center of medical 
attention in the 1680s. 
 3.1 Responses to marketplace secrecy: pharmaceutical reverse-engineering 
 Talbor’s success in France provoked a sudden renewal of interest in cinchona. 
Motivated by a combination of intellectual curiosity and economic interest, other 
practitioners, it seems, wanted to reverse-engineer the secret of his preparation. In 
addition to de la Verdure and Blégny, we know that the former army apothecary Henri de 
Rouvière was producing a competing drug,98  and Bouvet has also shown that the Abbé 
Bourdelot (1610-1685), the central figure of one of the pre-Académie scientific circles, 
expressed a keen interest in discovering the secret in these same years.99 This sudden 
renewal of interest is also confirmed by Blégny in his full, royally-mandated  disclosure 
of Talbor’s secret, Le Remède anglois [...] publié par ordre du Roy, published 15 January 
                                                                                                                                                 
quatre jours, et de la fièvre, et du dévoiement, que s’il n’y réussit, je crois qu’on le jettera par les fenêtres,” 
suggesting that even at this stage Talbor’s reputation was precarious (November 8, 1680). 
 98 Bouvet, “Talbot, vulgarisateur du quinquina,” 174. Bouvet cites Blégny’s journal for 7 
September 1680. 
 99 Ibid., 170. 
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1682 as an “extraordinaire” of his Nouvelles découvertes. With Talbor dead and buried, 
the secret of his preparation could be revealed. Blégny’s preface praises Louis XIV for 
having Daquin order him to publish the secret, observing that a more selfish monarch 
may have reserved its enjoyment for his own royal family. Blégny opens with a natural 
and economic history of the drug, and the remainder of the text toggles back and forth 
between excerpts from Talbor’s preparation and Daquin’s instructions on how to 
administer it. Both authors explain the action of the drug through reference to the acid-
alkali theory. 
 Blégny affirms that the ground bark which forms the basis of the remède anglois 
is from Peru and was first brought back to Europe by the Jesuits. He also provides a list 
of authorities who have written on it, from Chifflet in 1653 to the anonymous author 
(François Monginot) of the short treatise entitled De la guérison des fièvres par le 
quinquina (1679), and finally the fourth edition of Lémery’s Cours de chymie (1681). 
After explaining that there are two species of cinchona, one of which is of little use, 
Blégny explains how to identify the right one. This leads him into a discussion of how the 
bark is sometimes adulterated by merchants, and from here his natural history of 
cinchona transfers seamlessly into an economic history of the dramatic fluctuations in the 
price of cinchona bark since the popularization of Talbor’s remedy. 
 Indeed, according to Blégny, Talbor’s remedy caused substantial fluctuations in 
the price of cinchona. When only the Jesuits possessed it, presumably in the 1650s, he 
tells us that it sold at the high price of one écu  (=3 livres) per dose of two drachms.100 On 
the eve of Talbor’s introduction of his remedy, the value of a pound of cinchona had 
diminished to between 22 and 25 francs (synonymous with livres): 
                                                 
 100 Presumably the écu d’argent of 3 livres. 
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As soon as the remède Anglois was in vogue, men on all sides began to 
experiment on cinchona, which greatly increased the price, but these 
experiments alone were not what brought up the price: Talbot, seeing that 
they were preparing febrifuges which came very close to his, and worrying 
that in the end someone would discover it, resolved to remove all the 
cinchona he could find in Paris, and in the other principal cities of France, 
and even England. As the execution of this design made some noise, a 
number of physicians, surgeons, and apothecaries hastened to furnish 
themselves with cinchona.101 
 
In effect Blégny describes a scenario in which the remède anglois created an initial spike 
in demand for cinchona, which made it scarce. If we take him at his word, this spike was 
not due to apothecaries or others using it to compound and sell known cinchona 
preparations: rather, his implication seems to be that people were buying it for “essais,” 
presumably in an effort to replicate the remède anglois. Alarmed by these “essais,” which 
were coming close to replicating his own remedy, Talbor then committed his resources 
(which were by this time probably considerable) to purchasing as much of the cinchona 
supply as he could get his hands on, to forestall ingenious competitors (presumably the 
likes of his former valet de la Verdure and Blégny himself). The unsurprising result, 
again according to Blégny, was that the price of cinchona skyrocketed. French merchants 
began buying it up all the way back to its sources in the ports of Rouen and Bordeaux, 
where there was still a good quantity to be had. At the height of the bubble, the famous 
Parisian apothecaries Andry and Villain were selling it at no less than two hundred francs 
per pound, an 800% increase in price from the period immediately prior to Talbor’s 
                                                 
 101 “Mais à peine le Remede Anglois commança-t’il à estre en vogue, qu’on fit de tous les costez 
des essais sur le Quinquina, qui en augmenterent de beaucoup la chereté : ces essais neanmoins ne furent 
pas ce qui le porta à un plus haut prix. Le sieur Talbot voyant qu’on preparoit des Febrifuges fort 
approchant du sien, et craignant qu’à le fin quelqu’un ne le découvrist, prit resolution de faire enlever tout 
ce qu’il pouroit trouver de Quinquina à Paris, et dans les autres principales Villes de France, et mesme 
d’Angleterre. Comme l’execution de ce dessein fit quelque bruit, plusieurs Medecins, Chirurgiens et 
Apothiquaires, crurent devoir faire leurs diligences pour s’en fournir,” Blégny, Le Remède anglois, 25. 
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introduction of the remède anglois. after which, Blégny tells us, “fifteen days went by in 
which we could not find any, neither with them, nor with any other druggists.”102 
 A trickle of cinchona finally began to arrive in Paris at the end of this period, and 
was sold at one hundred écus per pound. Since that time, Blégny concludes, the price has 
dropped steadily as Talbor’s remedy fell out of fashion and as merchants secured new 
supplies of the bark from Spain and Portugal. At the time of his writing, Blégny says that 
the price has dropped to between fifty and sixty francs per pound, and that he expected it 
to continue dropping: “I have no doubt that in a short time some fleet shall arrive from 
the Indies, and make it even cheaper.”103 
 My suggestion here is that the race to uncover the secret of Talbor’s success 
provided a great stimulus to further investigations of cinchona. To the anecdotal data on 
various imitators and interested parties, we can add Blégny’s account of experimenters 
buying up cinchona to discover Talbor’s secret, and the flurry of publications on 
cinchona in France during the five years following Talbor’s arrival (1679-1684). To 
name just a few, there are multiple editions of Blégny’s works on cinchona (the 1680 
Découverte, the 1681 Connoissance certaine, several editions of the remède anglois, first 
published in 1682 and later reissued under several titles); two editions of a work by Jacob 
Spon responding to Blégny;104 the work of François Monginot (which went through at 
least three editions between 1679 and 1686);105 the work of Jacques Minot (which went 
                                                 
 102 “Il se passa plus de quinze jours sans qu’on en pût trouver, ny chez eux, ny chez aucun de nos 
Droguistes,” Ibid., 26. 
 103 “Je ne doute pas que dans peu quelque flotte arrivée des Indes, ne le rendent encore à beaucoup 
meilleur marché,” Ibid., 27. 
 104 Jacob Spon, Observations sur les fievres et les febrifuges, a l’occasion du livre intitulé, La 
decouverte de l’admirable remede anglois (Lyon: s.n., 1681). 




through four editions between 1684 and 1710);106 the accounts of cinchona in various 
entries of Lémery’s Cours de chymie; and shorter works by Helvétius on therapeutics, 
including the enema delivery method he devised (1684).107 
 These considerations raise questions about the relationship between Talbor’s 
remedy, medical interest in testing and analyzing cinchona, and the European supply-
and-demand for the bark as a commodity. Historians of medicine over the past two 
decades have given considerable attention to the medical marketplace, but have typically 
positioned their work as a social historical alternative to a more traditional intellectual 
history. The quest to unlock the secret of Talbor’s remède anglois demonstrates the 
interest of considering the dialectical relationship between economic factors on the one 
hand and medical-intellectual discourse on the other. Harold J. Cook has recently drawn 
on the case of Talbor and cinchona specifically to suggest that economic and intellectual 
transformations are often intimately linked. Indeed, Cook has suggested that the 
proliferation and commodification of medicinal specifics may be at the root of two other 
trends often observed in this period, namely the move toward more ontological 
conceptions of disease on the one hand and a growing de-individualization of human 
bodies on the other.108  
 Leaving aside the broader implications of Cook’s argument for the time being, in 
the third part of this section (3.3) I will explore the intellectual side of this 
transformation. In the case of Talbor’s remède anglois, this entails a close examination of 
                                                 
 106 Jacques Minot, De la nature et des causes de la fievre, avec quelques experiences sur le 
quinquina, et des reflexions sur l’action de ce remede (Paris: Robert Pepie, 1684). 
 107 Jean-Adrien Helvétius, Methode pour guerir toute sorte de fievres : sans rien faire prendre par 
la bouche. (Paris: veuve de Nicolas Oudot, 1684). 
 108 Harold J. Cook, “Markets and Cultures: Medical Specifics and the Reconfiguration of the Body 
in Early Modern Europe,” Transactions of the Royal Historical Society 21 (2011): 123–45. 
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the new climate fostered by the chymical pathology of the acid-alkali theory, whose 
bearing on the history of cinchona has so far escaped scholarly treatment. In the 
following section (3.2) I highlight a hitherto ignored aspect of the story, namely, Talbor’s 
own practical ingenuity in developing his new preparation for cinchona. 
 3.2 The secret of Talbor’s preparation 
 The new chymical preparation of cinchona which Talbor devised is crucial to 
understanding how his remedy was able to rescue cinchona from obscurity and put it 
back at the forefront of medical discussion in France. Talbor’s recipe, as exposed by 
Blégny’s 1682 Le Remède anglois, can be usefully compared to the so-called “Schedula 
romana,” the principal cinchona recipe available at the time. The “Schedula” is a short, 
page-long set of instructions for preparing and administering the bark, likely based on the 
practices of Jesuit apothecaries in Rome around 1650. It was probably the most common 
preparation in the decades following cinchona’s introduction into Europe, and as such it 
provides a useful barometer for assessing Talbor’s preparation.109 
 Just how innovative was Talbor’s cinchona preparation? Blégny begins by 
observing that the preparation of the remède anglois is relatively simple, contrary to the 
expectations of many of those who sought to duplicate it using too many different 
substances.110 A comparison to the “Schedula,” however, immediately reveals that 
Talbor’s recipe was considerably more complex than the main cinchona recipe then in 
circulation. According to the “Schedula,” two drachms of “finely ground and sieved 
bark” should be placed in a cyathus (45ml) of strong white wine for three hours before 
                                                 
 109 On the “Schedula Romana” see Jarcho, Quinine’s Predecessor, 262–269. 
 110 Blégny, Le Remède anglois, 48. Talbor’s own preparation instructions on preparation covers 
51-107, interspersed with comments by Daquin on administration, almost page for page. 
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the next episode of fever is expected. Compare these simple instructions to Talbor’s 
preparation. First, pulverize a livre (480g) of cinchona, sieve it, soak in a decoction of 
anise and parsley juice (suc de persil), then put it into a 15-pint (14.25l) stoneware jug 
(cruche de grais/grès), filling it with red wine. Then cork it, put it in a dry place away 
from fire for eight days, stirring two or three times daily, being careful to reach the 
bottom in so doing. After which, you filter it through cheese cloth into glass bottles, cork 
it, and store it in a dry still place, where its virtues will be preserved for 2-3 months.111 
 Already at this early stage in Talbor’s preparation there are a number of pertinent 
differences between it and the “Schedula.” These include: the pre-soaking of the 
cinchona in the anise-parsley decoction; the variety of wine (white vs. red); the ratio of 
cinchona to wine (the “Schedula” has 0.15g of cinchona per 1ml of wine while Talbor 
has 0.03g/1ml); the substantial difference in amount of time that the cinchona powder is 
left to soak in the wine (3 hours vs. 8 days); and the importance of regularly stirring the 
solution. It should also be noted that Talbor did not administer uniform doses throughout 
the course of his treatment: he used a staged preparation model that slowly ramped down 
the concentration of cinchona. For his second infusion he would take the residue of the 
first infusion, mix it with a new half livre of cinchona, place it in a jug of the same wine, 
this time for 10 days instead of eight; and for his third infusion, he would take the residue 
of the second infusion and mix it with wine in the jug, this time without adding any new 
cinchona.112 
 We have less information on Talbor’s own technique in administering these 
infusions, and Daquin observes in his commentary that Talbor himself did not always 
                                                 
 111 Ibid., 51–53. 
 112 Ibid., 56–57. 
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follow his own protocols. He specifies that 5-6 onces (1/2 septier, approximately 238ml) 
of the full-concentration first infusion of cinchona wine should be given for adult 
patients, at the end of a fever period, not at the outset, as in the “Schedula.” The same 
dose should then be taken every third hour until the next attack of the fever, except in 
sleeping hours (sleep should never be interrupted). After the next attack or “access” 
concludes, the patient should continue taking a full dose of the first infusion every third 
hour until the fever misses one of its regular attacks, after which the periodicity of doses 
can be reduced to once with breakfast and once with supper rather than every third hour. 
This regimen, using the first infusion, should be followed for 5-6 days; after which, the 
patient should move on to the less concentrated second infusion, taking it once daily in 
the morning for eight days, and then to the third and weakest infusion, to be taken every 
second day for fifteen days. Daquin also stresses the paramount importance of not 
following a dose of the remedy with a purge or bloodletting, and that such “remèdes 
ordinaires” are only necessary in certain cases. Generally, the “specific” is most effective 
when taken alone.113 In this particular instruction—which would be taken up by Fagon a 
decade and a half later—we see the move from using general therapies to rectify a 
humoral imbalance (dyscrasia) toward a view of the remedy as a “specific” that 
suppresses the causative ferment of the disease. 
 The “Schedula” by contrast prescribes a much simpler regimen. When an episode 
of fever begins (ascertained by the patient’s shuddering) the patient should drink the 
whole cinchona-wine infusion. Beyond this it offers few instructions: the administration 
can be preceded by a purge, but no medications should be taken for several days 
afterward. No instructions are provided in the original “Schedula” on additional doses. 
                                                 
 113 Ibid., 74. 
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 In sum, there are a number of important differences between the recipes for the 
“Schedula” and Talbor’s remède anglois. Talbor was using five times less cinchona per 
volume of wine, but was letting it steep for much longer, and regularly stirring it to 
ensure that the virtues of the bark were extracted by the wine. In his administration, 
Talbor was also careful to keep the patient taking regular doses every three hours for 5-6 
days, long after the fever stopped making its regular accesses, and then continued on with 
diminishing concentrations and less-frequent dosage periods for another three weeks.114 
As such, Talbor’s remède anglois was much more than a case of a streetwise charlatan 
repackaging an “already well-known” drug and making it big at court, as Stanis Perez has 
suggested.115 Perez is of course right to point to Talbor’s remedy as an intriguing episode 
in the history of pharmaceutical consumption, and to underline the role of royal bodies as 
powerful arbitrators in pharmaceutical debate.116 But to say cinchona had “already been 
discovered” is an oversimplification, and misses the crucial importance of Talbor’s 
innovations. His preparation and protracted course of treatment represent a substantial 
departure, and his contemporaries, who were well aware of cinchona and concluded that 
                                                 
 114 It is of course impossible to make categorical statements about, for example, just how much of 
what we today identify as the active alkaloid in cinchona, quinine, was present in these different 
preparations. We do not know, for example, specifically what cinchona bark Talbor and others were 
receiving and where it came from (in some cases, as we shall later see, vendors sold “false” cinchona bark; 
see also Maehle, Drugs on Trial, 229 on confusion with Peruvian Balsam tree bark), what effects the 
conditions and duration of transportation might have had, etc. These limitations granted, a laboratory test 
for the relative extraction of quinine following the two recipes might still be interesting, but is beyond the 
scope of my dissertation, not to mention the fact that I have no skills or training in organic chemistry. 
 115 Stanis Perez, “Louis XIV et le quinquina,” Vesalius 9, no. 2 (2003): 25–30. “On constate que la 
‘querelle du quinquina,’ si l’expression n’est pas exagérée, concerne essentiellement des courtisans 
ambitieux, souhaitant avoir la primeur d’une découverte déjà ancienne! Si nouveauté il y a, elle consiste sur 
tout dans l’ampleur de sa diffusion à la Cour : elle atteint le roi en personne” (26). 
 116 Perez casts Louis XIV’s usage of cinchona in the same light as the famous 1658 cure of Louis 
XIV through the vin émétique, which vastly increased the prestige of antimonials and paved the way to the 
revocation of the Parlement’s ban: in both cases, he argues, the king’s own consumption solves disputes 
over therapeutic substances. The problem here is that the king did not use cinchona until 1686, long after 
Talbor was dead. The argument could however be extended to “royal” or “courtly” bodies more generally, 
such as that of the Dauphine, but this raises the chicken-or-the-egg question: did Talbor’s success in the 
Paris market follow from his success at court, or vice versa? And what of his earlier successes in England? 
A simple emulation model for consumer behaviour seems insufficient to explain Talbor’s success. 
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it must be the primary ingredient in his secret remedy, nonetheless recognized the greater 
efficacy of Talbor’s specific preparation and, as we have already seen, endeavoured to 
replicate it. 
 3.3 The court physicians Blégny and Daquin on the action of cinchona  
 The material transformation of cinchona embodied by Talbor’s preparation was 
followed in its wake by an intellectual shift in pharmacological reasoning surrounding the 
drug. The comments of Blégny and Daquin are best understood within the broader history 
of “fermentationist” accounts of fever and of the acid-alkali theory of pathology. It 
should be recalled once again that Le remède anglois includes different sections written 
by Daquin and Blégny, respectively: although both share a common chymical 
vocabulary, in this section I will be careful to note some of their more subtle points of 
disagreement. 
 As Lopiccoli has pointed out, Blégny’s basic definition of fever is in accord with 
that of the English chymical physician Thomas Willis (1621-1675): “Fever is a 
fermentation of the blood; fermentation is a disordered movement of insensible parts.”117 
This already stands starkly against the Galenic definition of fever as preternatural heat. 
Blégny and Willis also agree that bitter (amère, amarus) substances should be used 
                                                 
 117 “La fièvre est une fermentation du sang, la fermentation est un mouvement dereglé des parties 
insensibles (motus intestinus partium insensibilium),” Blégny, Le Remède anglois, 109–110; Thomas 
Willis, Diatribae duae medico-philosopicae quarum prior agit de fermentatione sive de motu intestino 
particularum in quovis corpore, altera de febribus, sive de motu earundem in sangine animalium, 3rd ed. 
(London: J. Martin, 1662), 17, 117.  
 The exact phrase used by Blégny does not appear in Willis, but seems instead to be a mixture of 
two different definitions, one for fermentation and the other for intermittent fevers: the first, “Fermentatio 
est motus intestinus particularum, seu principiorum cuiusvis corporis, cum tendentia ad perfectionem 
eiusdem corporis, vel propter mutationem in aliud” (17); and the second (for fevers): “Quae de febri ex vi 
vocis et etymologia vulgo prosant notiones, hic consulto ommittam: describi potest in hunc modum, quod 
sit motus inordinatus sanguinis, eiusque nimia effervescentia, cum calore, et siti, aliisque praeterea 
symptomatis, quibus oeconomia naturalis varie perturbatur” (117). This passage is also the source for 
Willis’s subtitle. See also Bayle on Sylvius; fermentation may be defined this way by him as well. 
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against such fermentation, and that cinchona is the best of a class of such substances, 
having virtues which are peculiar to it.118 
 But where then did Willis’s notion of fermentation come from? The most obvious 
answer is that he devised it by analogy to alcoholic fermentation. Fermentation of wine 
and beer is consistently referred to by Willis from the preface of De febribus onward, but 
so too are the production of cheese and butter, as well as the rising of bread.119 Willis 
himself acknowledges the link to these crafts, pointing out that he initially intended to 
write a treatise on the use of fermentation in the arts of baking and brewing, but quickly 
realized the subject was much broader, and extended from the works of art to the works 
of nature. In his view, natural fermentation was not just similar to artificial fermentation, 
but the two are one and the same.120 
 The use of tiny quantities of yeast (or rennet in the case of cheese) to produce 
widespread changes in bread, grape must, barley wort, and milk provides the central 
analogy through which tiny quantities of “febrile leaven” could be understood as 
producing a much larger quantity of acidic matter through fermentation. Such everyday 
analogies were also used in transmutational alchemy to explain how a tiny piece of the 
Philosophers’ Stone could transform thousands of times its weight of lead into gold.121 It 
                                                 
 118 Blégny, Le Remède anglois, 28–29; Willis, Diatribae duae, 156. The other substances are 
gentian, centaurea, contrayerva, dragonword (serpentaire), absinth and chervil (cerfeuil) leaves, 
scammony. This passage is taken almost word for word from the corresponding statement in Willis, which 
mentions the same plant and ascribes the quality of bitterness to all of them. Interestingly, Willis also calls 
them alexipharmaca, meaning antidotes. 
 119 Willis, Diatribae duae, 1–4, 82–83, 90. See Ch. 1 (1-4) for reference to wine, beer, and bread; 
Ch. 11 (82-83) and Ch. 12 (90) for cheese and butter. 
 120 Ibid., A6. “Disquisitionem istam aggressus me ad pistrinam detrusum, et solummodo ad 
panificum et cervisiariorum furnos relegatum esse putaram; nec ultra istos limites, nisi sortè raptim, aut 
petita prius venia procedere licere : postquam vero rem penitus intueri coeperam, provinciam longè 
amplissimam nactus videbar; quippe praester isthaec Artis, plurima naturae opera, effectus fermentationi 
non modo similes sed ipsosmet fuisse planè constabat.” 




was from this alchemical lineage that Van Helmont built his own notion of fermentation, 
of which Willis was certainly aware, and which was closely linked to metallic 
transmutation.122 For him, the ferment was an immaterial force capable of impregnating a 
given object and altering the matter which constitutes it in order to make it more similar 
to itself.123 The ferment is thus the agent of the “odor” which carries the seminal idea of a 
given being (its blueprint, to use Pagel’s analogy): the ferment renders matter receptive to 
the idea, re-arranging it in accordance with the “plan” of the seminal idea. In the genesis 
of living things, the ferment then assumes the position of archeus.124 The notion of the 
archeus is of course absent in Willis as well as Blégny and Daquin, but as we shall see, 
other elements remain, especially in the notion of a febrile levain endowed with a power 
to “transmute” normal food into dangerous acids. 
 Moving from the image of disease as disordered fermentation to that of cure as 
neutralization, Blégny’s use of a bitter (alkali) therapeutic substance against a sharp 
(acid) disease has obvious resonances with the then-current acid-alkali pathology 
associated with Sylvius, Tachenius, and others. But following Willis’s lead in the 
Diatribae duae, Blégny is reluctant to openly join a particular medical-philosophical 
camp, including that of the acid-alkali theory (in spite of its numerous affinities with his 
own views), ostensibly wanting to avoid the trap of speculating on causes without first 
having sufficient grasp of the phenomena. After explaining that “bitterness” can suppress 
(supprime) unnatural acidic fermentations, and after brushing aside the Galenic 
physicians who content themselves with saying that cinchona is hot and dry at the 
beginning of the second degree, Blégny directly condemns those who have “introduced 
                                                 
 122 Willis refers directly (if not favourably) to Van Helmont in ch. 9 of the Diatribae duae. 
 123 Pagel, Joan Baptista van Helmont, 79–87. 
 124 Ibid., 71–74. 
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bad principles (méchans principes) into the “New Philosophy,” by simply making 
cinchona an alkali that “arrests” the movement of the fever, here identified as acidic.125 
As Blégny later clarifies, this is a response to the view of the apothecary Nicolas 
Lémery,126 recently expressed in the fourth edition of his popular chymical textbook, the 
Cours de chymie (1681): 
It seems that cinchona arrests and suspends the humor of the fever in more or 
less the same way as an alkali arrests the movement of an acid salt, that is to 
say it holds it and makes a sort of coagulum; this humor remains dormant for 
fifteen days and the patient feels a bit bloated and heavy, especially when he 
has not been sufficiently purged: and then the fever returns because the 
humor, having been agitated by the corporeal spirits or having joined with 
other humors of the same nature that had been made in the fifteen days, rids 
itself of the cinchona and begins fermenting just as it had done beforehand.127 
 
Although this passage is quoted nearly verbatim by Blégny,128 referring to Lémery by 
name, his tune on Lémery’s acid-alkali pathology more generally is less 
condemnatory.129 Blégny observes that “In his new Cours de chymie, M. Lémery is not 
so far from the truth,”130 but believes that Lémery goes wrong when he believes the 
cinchona merely envelops the febrile acidity in a temporary “coagulum.” Blégny argues 
                                                 
 125 “Quelques autres du nombre de ceux qui ont introduit de méchans principes dans la nouvelle 
Philosophie, ont crû mieux dire en avançant que le Quinquina comme un alkali arreste le movement de 
l’acide qui fait la fièvre; mais c’est vouloir expliquer une chose obscure par d’autres qui le sont encore 
d’avantage,” Blégny, Le Remède anglois, 27–28. 
126 On Lémery see esp. Michel Bougard, La Chimie de Nicolas Lemery (Turnhout: Brepols, 1999). 
 127 “II y a apparence que le Kina Kina arreste et suspend l’humeur de la fièvre à peu prés comme 
un Alkali arreste le mouvement d’un sel acide, c’est a dire qu’il la tient liée et qu’il en fait une espece de 
coagulum; cette humeur demeure ordinairement pendant quinze jours en repos et le malade se sent un peu 
gonflé et pesant, principalement quand il n a pas esté assés purgé: ensuite la fièvre revient parce que 
l’humeur ayant esté agitée par les esprits du corps, où s’estant jointe à d’autres humeurs de la mème nature 
qui se font faites pendant les quinze jours, elle s’est débarassée du Quinquina et elle fermente comme 
auparavant,” Nicolas Lémery, Cours de chymie, 4th ed. (Paris: Chez l’auteur, 1681), 582–583. 
 128 “Le Quinquina fixe et coagula l’humeur de la fièvre, à peu près comme un alkali arreste le 
mouvement d’un sel acide,” Blégny, Le Remède anglois, 44. 
129 On Lémery’s permutation of the acid-alkali theory, see esp. Lawrence M. Principe, “A 
Revolution Nobody Noticed? Changes in Early Eighteenth-Century Chymistry,” in New Narratives in 
Eighteenth-Century Chemistry, ed. Lawrence M. Principe (Dordrecht: Springer, 2007), 4–5; John C. 
Powers, “Ars Sine Arte: Nicholas Lemery and the End of Alchemy in Eighteenth-Century France,” Ambix 
45, no. 3 (1998): 515. 
 130 “M. Lemery dans son nouveau Cours de Chimie, ne s’est pas tant éloigné de la verité,” Blégny, 
Le Remède anglois, 44. 
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instead that the principles of the cinchona travel throughout the body and reunite the 
proper parts (propres parties) of the blood, separating them from the febrile matter, 
which, rather than being trapped in a coagulum, is instead expelled insensibly through 
transpiration or urine.131 
 Blégny responds in a similar way to the work of François de Monginot, the 
anonymous author of the 1679 Traité de la guérison des fièvres par le quinquina, which, 
along with Willis and Lémery, is one of the key sources for his reflections on fever and 
cinchona: 
The author of La guérison des fièvres par le quinquina, who makes the cause 
of the fever consist of a certain acid leaven (levain), associates the effects of 
this medicine to the faculty it has to combat, mortify, and resolve this venom; 
but this author has not taken care, for if in fact the cinchona was capable of 
destroying or even expelling the acids in the blood, it could not be taken 
without entirely perverting this liquid, because it would blunt or chase away 
even the natural acids which are part of the blood.132 
 
Here again the key is cinchona’s capacity to separate the good from the bad in blood, the 
normal acid corpuscules from the pathological febrile matter. In spite of his initial 
condemnation of “méchans principes” introduced into the New Philosophy, we can see 
that Blégny’s own contributions are more of the order of modifications and qualifiers to 
those of the more explicit versions of the acid-alkali theory as applied to fever pathology. 
Although he occasionally slips into referring to the cause of the fever as an acid,133 
Blégny generally uses qualitative adjectives “aigre” (sharp) and “amère” (bitter) and their 
                                                 
 131 Ibid., 45. 
 132 “L’Auteur de la guérison des Fièvres par le Quinquina, qui fait consister la cause de la fièvre 
dans un certain levain acide, raporte les effets de ce medicament à la faculté qu’il a de combattre, de 
mortifier, et de resoudre ce venin; mais cet Autheur n’a pas pris garde, que si effectivement le Quinquina 
estoit capable de détruire ou mesme de pousser dehors les acides qui sont dans le sang, il ne pourroit estre 
pris sans pervertir entierement ce liqueur, puis qu’il amortiroit ou chasseroit les acides mesmes qui 
naturellement en font partie,” Ibid., 42–43. 
 133 Ibid., 121. 
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nominalized versions like “aigreur” (sharp) and “amertume” (bitterness), instead of 
referring directly to acids and alkalis.134 
 This semantic variance can perhaps be attributed to Blégny’s avowed 
cautiousness regarding premature speculation about the action of cinchona and his 
avowed desire stick to experience and the observed phenomena. He favourably cites 
Willis’s similar attitude to this effect on two occasions,135 although he is sufficiently 
adventurous to supply corpuscular imagery by describing the different shapes of the 
particles.136 
 Although Daquin and Blégny agree on the basic definition of fever as an 
excessive fermentation of the blood, Daquin’s sections of Le remède anglois have 
important lexical distinctions which point to important differences in emphasis between 
his and Blégny’s accounts both of fever pathology and of the action of cinchona.137 The 
first of these differences is Daquin’s repeated usage of the term levain and, on one 
occasion, fermens. While Blégny reports the use of this term by others (e.g. Monginot), 
he only uses it himself in one of his own explanations on one occasion, usually preferring 
the process-noun, fermentation.138 As such, in Daquin’s account the ferment or levain 
emerges more as a causative agent, literally the catalyst of the process of fermentation, a 
materialist version of Van Helmont’s disease semina. Blégny by contrast describes 
                                                 
 134 Could this be related to the taste-assaying described by Ragland, and usually justified through 
reference to the Hippocratic De vetere medicina? 
 135 Blégny, Le Remède anglois, 28, 38. 
 136 On this imagery see Lopiccoli, “L’uso terapeutico della chinachina.” 
 137 Blégny, Le Remède anglois, 73–105. Daquin’s main observations on the action of cinchona 
appear under two subheadings, “Autres observations tirées des Memoires de Monsieur le premier Medecin 
du Roy” (75-87) and “Remarques tirées de Memoires de Monsieur le premier Medecin du Roy, touchant la 
pratique du sieur Talbot, dans la preparation et dans la distirbution de son Remede” (88-105). Daquin 
published very little, and these two sections may, along with his observations in the royal Journal de santé, 
be his principal surviving writings. 
 138 Ibid., 117. 
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fermentation as a process rather than as the action of an entity. The second difference is 
Daquin’s insistence on referring to Talbor’s remedy and cinchona more broadly as a 
specific (spécifique) and sometimes specific febrifuge. This term is wholly absent from 
Blégny’s sections of the text. 
 After praising the new preparation of Talbor in restoring what had been a “drogue 
méprisable,”139 Daquin begins somewhat paradoxically by insisting that while the 
specific is most effective against intermittent fevers (quotidians, tertians, double tertians, 
quartans, double and triple quartans), continuous fevers can also be treated with it.140 
Febrile matter (la matière des fièvres) is spread through the whole mass of the blood, and 
it is important to first expel heterogeneous and impure matter with bloodletting and 
evacuations of the stomach, to clear the way for the specific to act. In spite of his 
traditional insistence upon a preliminary evacuation, the rest of Daquin’s explanation of 
fever “pathogenesis” and the therapeutic action of the specific is quite novel. The 
primitive cause (cause primitive) of a fever lies in irregular movements in the blood, but 
these would quickly be rectified by nature, if not for the fact that they are also maintained 
by a more permanent cause:  
In unsettling the whole animal economy, these irregular movements corrupt 
the leavens that serve the digestion, and in so doing render the chyle impure 
and ill-formed. We can regard this depraved chylification as the immediate 
and antecedent cause of fevers, such that a remedy cannot truly be a febrifuge 
                                                 
 139 Interestingly, Daquin here attributes the preparation, whether he came across it by invention or 
discovered it by chance (hazard),to Talbor’s audacity (hardiesse), a trait that would have passed as a 
“temerité punissable dans un autre qu’un Empiric.” Throughout, any praise Daquin has for Talbor is 
qualified by calculated jabs like this one. See also 94-95, on the failure of empirics like Talbor to determine 
if the fever of a given patient is a cause or merely an effect of another disease; and 97-96, on Talbor not 
always following his own recipe. 
 140 This represents a disagreement with Blégny’s opinions: he believes the remedy is effective 
against both intermittent and continuous fevers. 
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unless it entirely rectifies the bad disposition of the stomach and that of the 
leavens, and this is what the English febrifuge neatly does.141 
 
Corrupt digestive levains, through a process of “depraved chylification,” are what 
continuously renew and spread the fever, then, and the function of a true febrifuge is to 
rectify them.  
 Daquin uses the same vocabulary later in the treatise, after stressing the 
importance of infusing the wine with cinchona for a sufficient period of time, lest it not 
place all of its bitterness (amertume) and virtue in the wine. Talbor, he writes, did not 
always properly prepare h 
is own febrifuge, and he sometimes administered it at different points during a fever 
when it should, in fact, be used only after a fever access, lest it interfere with the body’s 
natural ability to heal itself: 
Properly speaking, this indisposition is a kind of crisis, which nature 
excites in order to remove raw, impure, or superfluous matter from the 
vessels. Consequently, this crisis should not be suppressed prematurely, 
lest the leavens remain in the hearths (foyers), subsisting with all their 
force, which gives rise to the inopportune relapses which were the first 
cause of the contempt in which cinchona was held, despite being a quite 
excellent febrifuge.142 
 
Cinchona needs to be used in conjunction with the body’s natural healing faculties, and 
should not interrupt them, lest some levains survive within the “hearths” or “kitchens” 
                                                 
 141 “…en déreglant tout l’œconomie naturelle, ils [les mouvements irréguliers] corrompent les 
levains qui servent à la digestion, et par ce moyen rendent le chyle impur et mal conformé; on peut 
regarder la chylification dépravé comme la cause immediate et antecedante des fièvres; de sorte qu’un 
remède ne peut estre veritablement fébrifuge, s’il ne rectifie tout ensemble la mauvaise disposition de 
l’estomach et celle des levains dont je viens de parler, et c’est proprement ce que fait le fébrifuge Anglois.” 
Blégny, Le Remède anglois, 83. Emphasis added. 
 142“…cette indisposition n’estant a proprement parler, qu’une maniere de crise que la nature 
excite pour deposer hors des vaisseaux, des matières cruës, impures, ou superfluës, laquelle par consequent 
ne peut estre supprimée prematurement, sans que les levains demeurent dans les foyers, et subsistent dans 
toute leur force, ce qui a donné lieu à ces recheutes importunes, qui ont esté les premieres causes du mépris 




(foyers) of digestion.143 This, according to Daquin, was the cause of the relapses which 
had earlier discredited the drug. As he later states, in cases where the drug is resisted by 
the ferments (synonymous with levains), purges may be necessary, but the dosage of the 
drug must then be redoubled afterward to compensate.144 Here again Daquin shows a 
more traditional predilection for evacuations, but the disease-causing ferments remain the 
target: purges can at best clear the way for cinchona’s specific action against them. 
 Daquin’s levains and their disordered digestion through which they spread the 
sharp febrile matter into the blood and throughout is strongly reminiscent of Van 
Helmont and Sylvius’ insistence on disordered digestion as the main factor in disease.  
For Sylvius, acidic pancreatic juice and alkaline bile were crucial to the process of 
digestion understood as a kind of fermentation: disease was usually acidic within this 
system and was the result of an incomplete neutralization during digestion that then 
spread that acidity to different parts of the body.145  
 The genesis of such ideas can also be found in Van Helmont, with important non-
corporeal features not present in the versions of Sylvius and later iatrochemists: as Walter 
Pagel notes, the acid is not simply a chemical substance, but a ferment that is capable of 
formally rearranging matter, “an agent capable of trans-forming one thing into another,” 
part of the interface between the immaterial formal realm of the archeus and the material 
world of the body.146 Although acid served the function of separating the useful from the 
harmful in food, an erroneous command from the archeus could produce dangerous 
                                                 
 143 Lopiccoli, “L’uso terapeutico della chinachina,” 76; Monginot, Traité de la guérison des 
fièvres par le quinquina, 28–29. This definition of foyers is from Lopiccoli; the term is also used by 
Monginot. 
 144 Blégny, Le Remède anglois, 101. 
 145 Ragland, “Experimenting with Chemical Bodies,” 152–153. 
 146 Pagel, Joan Baptista van Helmont, 131. 
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acidity in organs and other places where it should not be.147 Such commands were often 
the result of the arrival of a “foreign guest” or disease semen, which enters the body and 
irritates the archeus by implanting its morbific idea, then actualized in matter by the 
agency of the archeus.148 The acid was thus the material manifestation of an immaterial 
encounter between the archeus and an offending morbific idea. 
 The other semantic distinction of Daquin’s section, the description of cinchona as 
a “specific,” also has a lineage in earlier chymical medicine.149 There is little trace in 
Daquin, however, of either the Avicennan “tota substantia” definition of specifics or the 
Helmontian view that they “expunge the Idea or Image of a Disease.” 150 In Daquin’s 
usage, the concept is closer in spirit to the Paracelsian arcana, that is, therapeutic 
substances which have special virtues for curing specific afflictions for reasons that are 
hidden from human knowledge and instead discovered through experience (or sometimes 
through their “signatures,” shapes or qualities which suggest what illnesses they might 
respond to).151 
 The reference to levains, fermentation, and specifics in these descriptions suggests 
that the theoretical landscape for explaining a drug’s therapeutic action that existed by the 
time Talbor was marketing his remède anglois in the late 1670s was considerably 
different from that of the 1650s. Jarcho and Maehle have shown that in that debate, the 
                                                 
 147 Ibid., 138. Pagel explains: “This command, namely to form acid, normal or pathological, is 
given by an ‘imperious nod’ (nutus potestativus) and governmental ruling (actio regiminis). In this light, 
acid is the physical aspect or manifestation of the directive. As such it is not separable from, but immanent 
in, tissue and fibre. What is propagated is not acid, but the error. Disease through acid, then, was due to 
acid arising in not transported to, an organ” (138). 
 148 Ibid., esp. 141–154. 
149 See above, sect. 1. 
 150 Thomson, Ortho-Methodoz Iatro-Chymike, A6r. 
 151 See above, sect. 2, and Paracelsus, Essential Theoretical Writings, 88b, 194a, 195n1.Weeks 
defines arcanum as “an occult and eternal incorporeal entity embodying the exalted virtue of an object or 
herb. It can be extracted in certain forms.” He cites Martin Ruland, Lexicon Alchemiae (Franfurt: 1612; 
reprint: Hildesheim: Olms, 1964), which defines the term as follows: “Arcanum res est secreta, 
incorporabilis, atque immortalis, quae ab homine cognosci non potest, nisi per experientiam.” 
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main voices on both sides were fixated on the difficulties of reconciling cinchona within 
Galenic medicine, particularly on the drug’s lack of sensible evacuant properties and its 
classification as “hot.”152  
 The responses of François Monginot to these questions are instructive. Monginot, 
it will be recalled, was one of the main sources on which Blégny drew, citing him even in 
his 1680 Découverte, where he observes that Monginot’s views on cinchona are which he 
discusses in his own Académie des nouvelles découvertes. Writing in 1679 just as 
Talbor’s febrifuge was coming into vogue, Monginot could observe that the basic 
problem of fever relapses (the catalyst of the 1650s debate) could be solved by the 
changes in preparation and dosage that the remède anglois pointed to, which he suggests 
came not in spite of but perhaps because of its inventor’s hardiesse and lack of 
circumspection.153 Likewise, Monginot’s account of fevers used levains as its principal 
actors and described the pathological process as acidic fermentation using terms very 
similar to those of Blégny and Daquin.154 He was still compelled to acknowledge the 
earlier debate, paying due respect to Chiflet and Plempius, but observed that the problem 
that had unfairly hampered the drug lay not so much in the theoretical arguments of its 
proponents and detractors but in the lack of experimentation in preparation or dosage.155 
Still, in the final fifteen pages of his seventy-five-page treatise, Monginot felt compelled 
                                                 
 152 Maehle, Drugs on Trial, 225–230; Jarcho, Quinine’s Predecessor, chap. 3. 
 153 Monginot, Traité de la guérison des fièvres par le quinquina, 6. 
 154 Ibid., 19. “Il faut donc se representer que la fièvre est un boüilonnement ou une fermentation 
extraordinaire excite dans la masse du sang; Que cette fermentation contre nature altere ce sang, en trouble 
le mouvement, et pervertit l’économie de tout le corps; Que le principe ou la cause immediate de cette 
fermentation est un mauvais levain qui tient de l’aigre ou de l’acre et qui infecte et agite les humeurs de 
differente manière, d’où naist la difference des fièvres” 
 155 Ibid., 5. “Depuis et pendant près de vingt ans, le quinquina a eu ses approbateurs et ses 
ennemis, selon que chacun en a sçeu faire un bon ou un mauvais usage, sans qu’on ait changé beaucoup sa 
préparation, non plus qu’a la manière de le donner.” 
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to revisit the main objections of the 1650s debate, namely the lack of evacuations and 
cinchona’s problematic qualities. 
 How could cinchona end the fever without provoking any sensible evacuations? 
The actual febrile levain or ferment, he argues, was present in the body only in minute 
quantities, and thus was expelled insensibly through sweat or urine. The ferment was able 
to transform food into febrile matter, but once it was extinguished, this transformation 
could be reversed and corrected. Most people, he observed, will report that their fevers 
often end suddenly without any substantial evacuations.156 
 On the question of qualities, Monginot observes that all specifics against fever 
can be classed as hot, and points out that cooling remedies could interfere with the febrile 
process, which is itself an “instrument” to resolve and dissipate the cause of the fever; the 
heat should not be fought. He argues that the virtue of cinchona lies in its other secondary 
qualities, notably its bitterness (amertume), which is what allows it to “extinguish and 
resolve” unnatural fermentation. He also points out that any patient who has taken 
cinchona over a long period of time following a fever will observe that they felt no excess 
of heat while taking it.157 
 So long as the doses of cinchona are sufficiently strong and continue to be 
administered even after the end of the fever (to destroy any surviving ferments), then 
relapses will not occur. Any patients who believe they experience relapse have more 
likely developed a wholly new levain: “these returns are less likely to come from some 
                                                 
 156 Ibid., 59–60. 
 157 Ibid., 64–66. 
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levain hidden somewhere in the body, rather than those which are reborn through a new 
occasion.”158 
 Blégny and Daquin, writing in 1682 just a few years after Monginot, felt no need 
to reckon with these questions at all and believed that the new preparation and dosage of 
Talbor’s remède anglois had definitively solved the problem of relapse which had 
plagued the drug since the 1650s. The problematic Galenic qualities could be dismissed 
with the wave of a hand, and the febrile levain, acidic fermentation, and essential 
bitterness of cinchona could be taken as given. 
4. The persistence of the acid-alkali theory in Fagon’s account of cinchona, 1697 
 The final point to be made about this fermentationist account of fevers and the 
“specific” action of cinchona has to do with its staying power in the halls of high court 
medicine: these ideas were also expounded on by Daquin’s successor as first physician, 
Guy-Crescent Fagon, fifteen years later. They appear in a short, fifteen-page treatise, 
written in 1697 in response to the frequent fever relapses of Charles II of Spain, but not 
published until 1705 as “Nouvelles reflections nécessaires pour se servir utilement du 
kinkina,” following Les admirables qualitez du kinkina. Like Daquin, Fagon pursued an 
active career but published little in his life.159 As such, this treatise, like Daquin’s 
commentary in Le remède anglois, offers us a precious window on the views of 
                                                 
 158 “Ces retours viendroient bien moins de quelque levain qui seroit caché en quelque endroit, que 
de ceux qui renaîtroient par de nouvelles occasions,” Ibid., 70. 
 159 On Fagon’s publications, see Augustin-Marie-François-Jean Grozieux de Laguérenne, Guy-
Crescent Fagon, archiatre de Louis XIV, surintendant du Jardin royal des plantes (1638-1718), Thèse pour 
le doctorat en médecine, Paris (Paris: L. Arnette, 1930), 107–108.  
Fagon’s other noteworthy publication, a formal Latin quaestio later translated into French , was on 
another exotic, namely tobacco: see Guy-Crescent Fagon and Claude Berger, Quæstio medica ... An ex 
tabaci usu frequenti vitæ summa brevior? Praes. J.C. Fagon. (François Muguet: Paris, 1699); Guy-
Crescent Fagon and Claudius Berger, “Question agitée le 26 de Mars de l’année 1699 [...] Sçavoir si le 
fréquent usage du tabac abrege la vie,” in De la génération des vers dans le corps de l’homme, by Nicolas 
Andry de Bois-Regard (Paris: Laurent d’Houry, 1700), 347–86. 
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therapeutic action held by the two men whose medical opinions were most important in 
approving new remedies for royal privileges at this crucial early stage of the medical 
privilege regime. 
 Fagon opens by declaring that “there is no remedy more specific than cinchona” 
against fevers,160 and roundly rejects the view of cinchona’s action which supposed that it 
was only a temporary remedy bound to produce relapses of fever: according to this view, 
first articulated by Lémery (see above), cinchona traps the ferment in a coagulum but it 
eventually breaks loose. According to Fagon, the true effect of cinchona could be 
expressed in chymical terms virtually identical to those used by Blégny, Daquin, and 
Monginot before them:  
With its specific bitterness (amertume spécifique), it dulls (amortit) the 
sharpness of the fever’s leaven, in the first place through its mixing with the 
febrile leaven that it encounters along the way, with which it ferments, like 
crabs eyes with distilled vinegar, and through this effervescence it so destroys 
the sharpness of this leaven, softening it and rendering it unable to trouble or 
agitate the blood.161 
 
The “natural disposition of the stomach’s solvent” is thus restored, re-establishing the 
proper concoction of chyle.162 The active virtue of the cinchona is also distributed 
through the rest of the blood, where it finds other sharp (acidic) serous fluids that had 
                                                 
 160 In spite of his insistence on the specificity of cinchona here, Fagon would a few years later 
approve the Chevalier de Guiller’s poudre fébrifuge, an indigenous European alternative to cinchona. See 
below, chapter 5. 
 161 “Il amortit par son amertume spécifique l’aigreur du levain de la fièvre, ce qu’il fait en premier 
lieu par son mélange avec le levain fiévreux qu’il rencontre en son chemin, avec lequel il fermente, comme 
les yeux d’Ecrevice avec le vinaigre distillé, et par ce boüillonnement détruit tellement l’aigreur de ce 
levain, qu’il l’adoucit et n’est plus en état de troubler le sang ni de l’agitter,” Guy-Crescent Fagon, 
“Nouvelles reflections necesaires pour se servir utilement du kinkina,” in Les admirables qualitez du 
kinkina [...] avec de Nouvelles réflexions pour s’en servir, faites par Monsieur Fagon premier Médecin du 
Roi en 1697 (Paris: Martin et George Jouvenel, 1705), 167–169. 
 162 The passage above continues: “et en seconde lieu, il resserre par son amertume legerement 
astringente, les membranes de l’estomac et restablit la disposition naturelle de son dissolvant, et par ce 
moyen contribue à la coction parfaite du Chile, dont la douceur reparée tempere insensiblement le sang et 
toutes les humeurs, et rectifie petit à petit, tout ce qui pouroit renouveller le levain de la fièvre, ou en 
animer les restes ademy amortis.” 
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been spread by the febrile levain, and after effervescing (boüillonnant) with them, they 
are expelled through transpiration, thus preventing any renewal of the febrile or the 
“animation” of half-softened remains (les restes ademy amortis).  
 The central analogy Fagon employs is that of “crab’s eyes.” These are calcareous 
nodules that form on the stomachs of crayfish, which, when placed in an acid such as 
vinegar, have the effect of neutralizing it. This was a well-used image for acid-alkali 
reactions, and can be found in Van Helmont’s Febrium doctrina inaudita, which, 
although it does not address cinchona, likewise points to acid-alkali neutralization 
process beginning in the stomach as the solution to intermittent fevers.163 
 The language of bitterness countering fermentations also plays a role in Fagon’s 
entries in the royal Journal de santé, particularly his commentary on some of the 
treatments he had witnessed while his predecessor, Daquin, was still first physician. In 
one particular case where the king was suffering from fever, Daquin was unwilling to 
follow Fagon’s advice in increasing the quantity of cinchona and administering it more 
frequently and for longer periods. This led Fagon to use the intermediary channel of 
Madame de Maintenon to suggest the idea directly to the king. Here too we find the 
language of the cinchona’s “amortissement” (mortifying or dulling) of the sharp febrile 
levain, complete with a defense of the use of continued wine-infusions of cinchona. He 
also defended cinchona against the charge of overheating the king’s body through the 
corpuscular image of sharp points of the wine being blunted or absorbed by the cinchona, 
                                                 
 163 Joan Baptista Van Helmont, Ortus medicinae: Id est Initia physicae inaudita. Progressus 
medicinae novus, in morborum ultionem, ad vitam longam. (Amsterdam: Elzevir, 1648), 787. The crabs’ 
eyes reaction would be a well-used image for acid-alkali neutralization in eighteenth-century texts: see 
notably Chomel’s description in his entry on pearls in the Dictionnaire oeconomique; or later in the 




thus preventing its tartar from making an impression.164 Although as we have seen 
Daquin advised stronger, more frequent dosage over longer periods of time (especially as 
compared to the original “Schedula” recipe), Fagon seems to have found his predecessor 
insufficiently zealous with cinchona. It should be noted however that Fagon had in fact 
recently ousted Daquin as first physician, and his earliest entries in the Journal de santé 
can be read as self-serving “second opinion” commentaries on his predecessor’s “errors.” 
Despite their differences, both first physicians shared a basic conception of how the drug 
worked within the body, and it seems likely that this conception helped govern their 
response to petitions for exclusive-sales privileges. 
 Distant though such causal explanations may at first seem from straightforward 
therapeutics, misunderstanding the effects of cinchona could have dire consequences, 
according to Fagon. Many doctors would purge the patient after administering cinchona, 
presumably to evacuate the putrefying humors it had isolated, but as Fagon saw it, this 
could only have the effect of ejecting the cinchona itself. This would have the unintended 
consequence of delivering the febrile levain from its destroyer, leaving it free to re-
animate itself.165 Instead of administering purgatives, Fagon argued that the best way to 
deal with the relapse problem was to take cinchona more frequently, to ensure no leftover 
febrile levain remained to reignite the fever. Fagon did acknowledge that some critics 
might argue that cinchona was a hot drug and could have a detrimental effect on the 
patient if taken for such a long period. Against this view, and following the mainstream 
of opinion from Monginot onward, he argued in contrast that it was not hot or cold at all, 
but rather, that it acted through its bitter (amertume)—i.e. alkaline—and astringent 
                                                 
 164 Antoine Daquin, Guy-Crescent Fagon, and Antoine Vallot, Journal de la santé du roi Louis 
XIV de l’année 1647 à l’année 1711, ed. Joseph-Adrien Leroi (Paris: Durand, 1862), 211–213. 
 165 Fagon, “Nouvelles reflections,” 174. 
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(astriction) qualities, qualities which he attributes explicitly to the ancient authority of 
Hippocrates and Democritus.166 
 The basic agreement between Fagon and Daquin’s descriptions of cinchona’s 
therapeutic action illustrate an important continuity in pharmacological concepts between 
the two first physicians despite their other differences of opinion. Considering the critical 
role of the royal first physicians in the granting of pharmaceutical privileges, this 
commonality of opinion between Daquin and Fagon suggests that in France, privileged 
drugs were assessed with a “chymical criterion” of therapeutic action in mind. In the 
absence of sources specifying individual rationales for recommending privileges for this 
or that drug, it is of course impossible to say for certain, but the prominence of chymical 
ideas amongst two figures who held kingdom-wide regulatory powers almost certainly 
marks a unique phenomenon for this period, particularly in comparison to the Galenic 
criterion that generally held sway in the protomedicati of Spain and Italy. 
5. Medicinal specifics, acid-alkali pathology and the materialist reading of Van 
Helmont 
 At first glance it seems incongruent that the notion of a medicinal specific would 
not also entail a parallel concept, one which Walter Pagel called “the ontological 
conception of disease.” This concept, present as the morbific peregrinus exoticus in Van 
Helmont and as the disease semina he held in common with Paracelsian authors, would 
seem to be the logical counterpart of the concept of a medicinal “specific.” But instead, 
we find Daquin and later Fagon making use of specifics against diseases which appear to 
be defined physiologically as disordered ferments rather than ontologically, as ferments 
produced by the encounter of a peregrinus exoticus and a vital archeus, as in Van 
                                                 
 166 Ibid., 175–176. 
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Helmont. The quidditas, or as Van Helmont’s English translator John Chandler rendered 
it, “the essential thingliness of fevers” appears to drop out to some degree: instead the 
images of pathology and of therapeutic action given to us by Blégny and Daquin lead us 
into the then-popular “acid-alkali” or “neutralization” theory, which appears at first 
glance to be a basically physiological model, focused at returning bodily fluids to a state 
of internal balance not so different from humoral medicine. 
 This apparent disjuncture has prompted some scholars, such as Don G. Bates and 
Andrew Wear, to question whether the chymical conceptions of disease in this period 
were really all that revolutionary. Bates has described Willis’ fermentation theory as 
“new wine in old bottles,” deeming it to be “conservative” by comparison to the 
immaterial “formal ens” of Van Helmont, which departed much more substantively from 
Galenism and thus constitutes a “truly alternative worldview.”167 For Bates, the fever 
theories of Willis are representative of this period insofar as they were “transitional and 
derivative,” a characterization he asserts is also “certainly true” of Sylvius. Referring to 
Willis in particular, Bates observes that more work would be needed to confirm the 
hypothesis, but “it does seem likely to me that his work is a fairly conservative 
transformation (almost translation) of Galenic doctrine into a ‘modern’ corpuscularian 
materialism.”168 The vocabulary is modern, drawn from Harvey, Descartes, and 
Gassendi; but for Bates the implicit framework is still traditional Galenism.169 He 
supports this claim by arguing that Willisian fermentation resembles Galenic putrefaction 
(e.g. in heat production and breakdown of substance) more closely than it does 
                                                 
 167 Don G. Bates, “Thomas Willis and the Fevers Literature of the Seventeenth Century,” in 
Theories of Fever from Antiquity to the Enlightenment (Medical History Supplement No. 1) (London: 
Wellcome Institute for the History of Medicine, 1981), 52. 
 168 Ibid., 55. 
 169 Ibid., 51, 53. 
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Helmontian fermentation, which is more of an interface between the material world and 
the immaterial semina or formal ens that actively rearranges matter, so “Willis’s apparent 
use of Helmontian terms does not withstand examination.”170 
 Van Helmont himself probably would not have been pleased with the 
“materialization” of his ideas in physiology and pathology: indeed, Pagel has pointed out 
that Van Helmont had already condemned materialist tendencies in some of Paracelsus’ 
writings, and observed that the “materialist speculations” of Willis would have been 
“distinctly unacceptable” to Van Helmont.171 The uniqueness and sheer complexity of 
Van Helmont’s medical ideas make it difficult to assess his influence on later thinkers, 
but focusing on whether or not a given thinker adhered to all of his doctrines in all their 
complexity tends to obscure our appreciation of his considerable impact on late 
seventeenth-century medicine. As with any thinker, Van Helmont’s followers 
appropriated and transformed given ideas and omitted others as it suited them. As such I 
am inclined against using “pure” Helmontianism merely as a criterion for assessing how 
far Sylvius or figures like Blégny fell from the true path, and would argue that even if 
Van Helmont himself might have found their materialist reading “distinctly unpalatable,” 
they still constitute an important part of his legacy in the history of medicine. 
 In a similar vein, Evan Ragland has taken issue with Andrew Wear’s assessment 
that “Changes in physiological theories had little effect on medical practice, where the 
perceived need to evacuate the body of some malign substance, now often seen as 
                                                 
 170 Ibid., 54. 
 171 Pagel, Joan Baptista van Helmont, 83; Pagel, “Van Helmont’s Concept of Disease,” 438–439; 
Bates, “Thomas Willis,” 55. 
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chemical rather than humoral, still shaped therapeutic justifications.”172 A more detailed 
version of this argument appears in Knowledge and Practice in English Medicine, 1550-
1680 (2000), in which Wear argues that the Helmontian revolution “failed” in England 
not just because it lacked institutional support and because several of its proponents died 
in the 1665 plague, but also because patients revolted against it, preferring to stick to the 
language and practices of traditional Galenism. On the whole, however, Wear follows 
Bates in distinguishing between “pure” Helmontians and learned physicians who 
appropriated chymical ideas, more or less superficially, as a “modernised” vocabulary to 
clothe a still traditional medicine; and he likewise uses Willis as his prime example.173 
 Ragland has also criticized this view of what might be called “therapeutic 
immobility,” pointing out that viewing the body chymically not only opened the door to 
analogies between physiological phenomena and phenomena observed through in vitro 
chymical experimentation, but also that “the neutralization model of body chymistry 
emphasized therapy via chymical changes within the body, rather than purgation or 
evacuation. Surely this was an important new conceptualization of disease and drugs.”174 
The debate over fevers outlined in this chapter offers an excellent example of this point: 
particularly as deployed by Daquin and Monginot, the acid-alkali model allowed for 
healing to occur in the absence of any sensible evacuations, by extinguishing the tiny 
levain and ejecting it through transpiration and allowing the body to restore the febrile 
matter produced by its pathological process. The therapeutic action is only minimally 
evacuative; what remains rests on the idea of chymically transforming and “rectifying” 
                                                 
 172 Andrew Wear, “Early Modern Europe, 1500-1700,” in The Western Medical Tradition, 800 BC 
to AD 1800 (Cambridge: Cambridge University Press, 1995), 360. 
 173 Andrew Wear, Knowledge and Practice in English Medicine, 1550-1680 (Cambridge and New 
York: Cambridge University Press, 2000), 469–473. 
 174 Ragland, “Experimenting with Chemical Bodies,” 198. 
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corrupted febrile matter to once again become what it ought to have been. When 
practitioners like the Capuchin Aignan, or Monginot, Blégny, Daquin, and Fagon sought 
answers to the question of the effect of a drug, they moved away from the models of 
repletion and expulsion of traditional Galenism, and drew instead on novel chymical 
conceptions of what was happening inside the human body—conceptions which 
emphasized transformation. 
 Likewise, although the explicitly non-corporeal “ontology of disease” proposed 
by Van Helmont is largely absent from the accounts of fevers reviewed in this chapter, a 
certain material “thingliness” does seem to remain, particularly in Daquin, Monginot, and 
Fagon, who emphasize the material pathogenic agent—in the form of the levain or 
ferment—much more than the pathological process of fermentation or effervescence. As 
they describe it, fever engenders an acid/alkali imbalance, which often begins with an 
incomplete or disordered digestion, but the fever is not in itself reducible to this 
imbalance. Therapeutically speaking, one could not simply ingest any old alkali 
substance in whatever quantity until the overly acidic milieu of the stomach and the blood 
were neutralized.175 As Blégny and Daquin point out, other bitter substances may have 
some effect on fevers, but none are as “specific” or able to rectify the levain so 
effectively. We find in each of these authors an insistence on striking at a root cause, the 
levain, which, rather than being immaterial like the disease semina, is understood to be 
very small and intractable. This levain finds its counterpart in the “specific bitterness” of 
an alkali substance, cinchona. Unless it is stopped, this levain will continue its process of 
                                                 
 175 Although the digestive process is the main locus for fever pathogenesis in these accounts, in 
some cases, the levain even exists independently outside of the human body: Blégny for example refers at 
one point, dealing with malignant (not intermittent) fevers, to “sels arsenicaux répandus dans l’air que nous 
inspirons, ou cachez dans les alimens que nous avalons” (119). Are these arsenical salts descendants of the 
Helmontian causa occasionalis, or material versions of the disease semina? 
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fermentation, transmuting food and bodily matter into its acidic febrile matter: no amount 
of evacuation of such matter will correct this root cause, which the “specific” alkalinity 
of cinchona alone can rectify. Shorn of its links to the non-corporeal agents of Van 
Helmont, the febrile levain or ferment seems to persist almost as a materialist descendant 
of the disease semina of earlier iatrochemistry, capable of enacting material 
transmutation, and “extinguishable” only by the “specific” bitterness of cinchona. 
 The prominence of this acid-alkali theory in debates surrounding cinchona raises 
much broader questions about its role in medicine during this period more generally. 
Why did Sylvius and others decide to “materialize” Helmontian ideas at all? Looking 
beyond France to Germany and England, why was the acid-alkali theory so attractive to 
practitioners selling proprietary remedies, such as Otto Tachenius and his viperine salt, or 
John Colbatch and his vulnerary powder?176 We will need a full treatment of the acid-
alkali theory, from Van Helmont through to Sylvius, Tachenius, and the critique of 
Robert Boyle, in order to answer this question. Until that time, Ragland’s establishment 
of the origins of the system in a “materialist” reading of Van Helmont and his sketch of 
“Acids and Alkalies Effervescing across Europe” will have to suffice.177  
6. Conclusion 
 The stories of the Louvre Capucins and Robert Talbor are fundamental to the 
overall argument of this dissertation in three ways: first, the court patronage they were 
offered in France circa 1680 can be seen as a prototype of the medical privilege regime. 
Although they did not receive an exclusive sales privilege, the Capuchins received 
                                                 
 176 See above, this chapter, sect. 1; and ch. 4 sect. 3 on Colbatch. 
 177 Ragland’s account, which is part of his larger dissertation on the “long history” of experiments 
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support in the form of their pension and laboratory, which they used to produce their 
remedies for the court, the poor of Paris, and the French army, anticipating the much 
larger operation to be crafted a decade later by Helvétius. Talbor for his part enjoyed 
similar support, with the distinction that his was based upon a singular remedy, his 
cinchona-based remède anglois, the secret of which he disclosed to the king’s first 
physician under the condition that it only be published after his death. This model has 
obvious affinities with the later privilege regime, which also served the function (from 
the vendor’s perspective) of insuring and protecting a profitable medical secret. 
 Second, the chymical ideas and practices of the Louvre Capuchins, manifested 
particularly well in the Helmontian and “chymical-Hippocratic” ideas of Aignan, 
demonstrate the prominence of chymical medicine at court in this period. A reading of 
Talbor’s Pyretologia likewise reveals him to have been influenced by a reading of Van 
Helmont. The Capuchins, like Talbor, are often described in survey texts as effectively 
having come out of nowhere, or at best (in the case of Talbor) from the primeval muck of 
medical empiricism. A reading of their extant writings, however, immediately reveals 
that although learned physicians might have classed them as “empirics,” they were 
equipped with learning of their own, being conversant in contemporary chymical texts 
and practices. The prominence of such ideas is particularly surprising because both the 
Capuchins and Talbor arrived at court in the midst of the famous Affair of Poisons, which 
posed significant challenges to the public profile of chymistry by renewing its 
longstanding association with poisoning. As the previous chapter has shown, the Affair 
ultimately led to the legal regulation on the circulation of chymical substances and 
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requiring permits for chymical equipment. Iatrochemical ideas about pathology and 
therapy, however, appear to have persisted at court in spite of such restrictions.  
 Finally, the third point surrounds what I will call the “chymical criterion” for a 
medicinal specific, a shorthand for the new understanding of pathology and therapeutic 
action through reference to the then-popular acid-alkali theory, which appears first here 
in the case of cinchona but which will recur again throughout the rest of the dissertation. 
We have seen already that it appears in the writings of the two most prominent figures in 
according proprietary medical privileges, namely the royal first physicians Daquin and 
Fagon, and we shall see it again in chapter 4 through the language of “specifics” used by 
Helvétius to explain his remède spécifique against dysentery; and again in chapter 5, with 
the assessment provided by the naval physician Boizard concerning Ferdinand de 
Guiller’s tithymal-based febrifuge, an “indigenous” (that is, native to France) alternative 
to the “exotic” cinchona. It should of course be mentioned that not all proprietary 
remedies were touted as “specifics”; the acid-alkali theory was only employed by a 
handful of important vendors and court physicians, and it was always one potential 
“criterion” among many. The prominence of both of these ideas in the writings of Daquin 
and Fagon, the two key medical figures for the allotment of privileges in this period, 
nonetheless recommends them to our attention, as does their recurrence in these 
subsequent chapters.  
 The high profile of chymical ideas among court physicians reminds us that the 
late seventeenth century was a period where medical opinions were in a state of flux, a 
fact that was also appreciated by contemporaries. A fitting example of this appreciation 
occurs in the debate over the Louvre Capuchins in the Mercure galant, which opened this 
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chapter. An anonymous letter signed as “Hermocrate” from Montpellier, printed in 
response to the critics of the Louvre Capuchins, assessed the medical landscape in 1679: 
Truth is so hidden, and science so narrow, that there is no man who can 
dare boast that he knows something true and real. Reflect, if you please, 
on the different opinions of the time. Some are filled with Van Helmont 
and Willis, others with Descartes, or Tachenius. Following these modern 
authors, some hold to the party of the four humors, others to one alone, 
which breaks itself into several different parts; others hold to that of the 
acids and the alkalis. Each performs experiments, and each explains them 
according to his system, which is established on principles that differ one 
from the other.178 
 
The growing variety of intellectual options—described as rival doctrines or schools of 
medicine—was a source of disquiet, and even a cause for scepticism, as this passage 
suggests. This exciting (if potentially obfuscating) intellectual ferment forms a key 
backdrop to this dissertation, along with a panoply of social and economic features, such 
as the arrival of exotic new therapeutic substances into Europe, the growing medical 
needs of the fiscal-military state, and the breakdown of medieval corporatism exemplified 
by the privilege regime. Neither traditional Galenism, nor orthodox Helmontianism 
would rule the day, and the acid-alkali pathological model here described had a variety of 
different permutations with differing points of emphasis, all of which would not persist 
very far into the eighteenth century or succeed in displacing the four humours.  
Intellectually speaking, the assessment of given therapeutic substances in this period did 
not occur with reference to any single “criterion,” be it chymical or Galenic. The 
changing fortunes of the acid-alkali model were, like those of the alternative models, 
                                                 
 178 “La Verité est si cachée, et la Science si bornée, qu’il n’y a point d’Homme qui ose se vanter de 
sçavoir quelque chose de bon et de réel. Faites, s’il vous plaist, réflexion aux différentes opinions du temps. 
Les uns sont remplis de Vanhelmont ou de Villis, les autres de Descartes ou de Tachenius. Suivant ces 
Autheurs modernes, les uns tiennent le party des quatre humeurs, ou d’une seule, qui se brise en plusieurs 
petites parties différentes; et les autres tiennent celuy des Acides et des Alkalis. Chacun fait des 
expériences, et chacun les explique selon son Sistème qui est étably sur des principes differens les uns des 
autres,” Mercure galant (January 1679), 162-163. 
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subject to a dialectical play with the whole gamut of these social and economic factors, 
particularly the constant testing and retesting of new substances and preparations. While 
it is true that the “chymical criterion” certainly shaped the reception of cinchona and 
other drugs, the peculiarities of the drugs themselves also helped disseminate chymical 





The Contugi family and the true orviétan: 
The legitimacy, exclusivity, and transmission of a secret remedy, 1647-1741 
 
 For nearly a century, from 1647-1741, four successive generations of the Contugi 
family fought to extend and later preserve their exclusive privilege to sell the antidote 
known as orviétan. Touted primarily as a cure for all poisons, from the venom of vipers 
and rabid dogs, to human poisons like arsenic and pestilential diseases like plague and 
smallpox, orviétan came to be a sort of panacea for any number of lesser discomforts 
such as colic and digestion problems. The efforts of the family to preserve their exclusive 
legal privilege, first granted to the family patriarch, Christophe Contugi, in 1647, were 
also necessarily tied to their efforts to defend the hereditary medical secret of orviétan. 
Their repeated struggles illustrate how, even with the support of royal letters patent, the 
vendors of proprietary medicines in seventeenth century France were still engaged in a 
constant struggle with competitors, from the troupes of other medical charlatans to the 
apothecaries of the royal households and of the city of Paris. Such letters were perhaps 
the most powerful sources of authority available in the medical world of Ancien Régime 
France, but they were still not in themselves sufficient to wholly override the issues of 
legitimacy and exclusivity, which came up time and again in the recurrent legal battles 
that span the period of the family’s tenure of the privilege.  
 The persistence of these struggles led them to generate a surprisingly large corpus 
of print and manuscript sources, the richness of which was first recognized well over a 
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century ago by and Gustave Planchon (1892) and Claude Stéphen Le Paulmier (1893).1 
Le Paulmier’s L’Orviétan is the better known of the two works, tracing the genealogy 
and business fortunes of the Contugi family and providing a voluminous appendix of 
over fifty pièces justificatives, including letters patent, arrêts from various courts, and a 
panoply of notarized documents. In spite of its age, Le Paulmier’s account continues to 
serve as the basis for virtually all discussions of the Contugi family in the historiography, 
most recently the work of Brockliss and Jones.2 Planchon’s articles are less well-known, 
and focus on the legal conflicts between the Contugi family and Parisian apothecaries. 
Their accounts were written virtually at the same time—Le Paulmier notes that his book 
was already in press by the time he learned of Planchon’s articles—and while some 
overlap exists between them, each drew upon different archival sources and thus should 
be consulted in conjunction.3 
 The importation of Italian charlatanism into France has seen a more modern 
reappraisal through the work of Brockliss and Jones,4 but to the best of my knowledge 
this chapter marks the first archival inquiry into the Contugi family business in over a 
century. Charlatans have gained a much higher profile in the historiography of early 
modern medicine over the past twenty years, but none of this research has investigated 
French archives, focusing instead on the Italian epicenter of the charlatan phenomenon. 
                                                 
 1 Gustave Planchon, “Notes sur l’histoire de l’Orviétan,” Journal de Pharmacie et de Chimie 26, 
no. 3–7 (1892): no. 3, 97–103, no. 4, 145–52, no. 5, 193–98, no. 6, 241–50, no. 7, 289–98; Claude-Stéphen 
Le Paulmier, L’Orviétan. Histoire d’une famille de charlatans du Pont-Neuf aux XVIIe et XVIIIe siècles 
(Paris: Librairie illustrée, 1893). 
 2 Laurence Brockliss and Colin Jones, The Medical World of Early Modern France (Oxford: 
Clarendon Press, 1997), 239–241. 
 3 Planchon worked primarily with the sources held at the Paris École de pharmacie, now the BIUS 
Pharmacie, which are mainly copies of legal briefs (factums or mémoires) and arrêts that were kept in the 
archives of the communauté des épiciers-apothicaires; Le Paulmier’s book focused on sources at the 
Archives nationales and the notarial records of the Minutier central. 
 4 Brockliss and Jones, The Medical World of Early Modern France, 230–238.  
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David Gentilcore has published a foundational study of medical charlatanism in Italy 
(2006), examining the phenomenon from multiple angles, including its origins, typology, 
microhistorical studies of the careers individual charlatans, examinations of their materia 
medica, marketing strategies, and licensing, all supported by voluminous quantitative 
data, available online through the Italian Charlatans Database.5 Although references to 
orviétan are sprinkled throughout his text, Gentilcore leaves the drug in the background 
and mentions the Contugi family only once, citing Le Paulmier.6 The chapter on 
charlatans in his earlier Healers and Healing in Early Modern Italy (1998) gives much 
more attention to orviétan, but only two paragraphs are allotted to the Contugi family in 
France, likewise based on Le Paulmier.7 The only recent monograph on orviétan is 
Patrizia Catellani and Renzo Console’s L’Orvietano (2004), which provides an 
assessment of orviétan’s appearances in literature and theatre and, most importantly, an 
excellent analysis of the recipes for orviétan from printed pharmacopeias, upon which I 
will draw in section 4 of this chapter.8 For material on the Contugi family, however, 
Catellani and Console are likewise reliant on the older studies of Planchon and Le 
Paulmier. 
 Expanding on the archival corpus assembled by Planchon and Le Paulmier, this 
chapter will provide a reappraisal of the trials and tribulations of the Contugi family. In 
so doing it provides a French point of comparison to the Italian experience, showing how 
                                                 
 5 David Gentilcore, Medical Charlatanism in Early Modern Italy (Oxford: Oxford University 
Press, 2006); and “Italian Charlatans Database, 1550-1800,” Economic and Data Service, 
<http://www.esds.ac.uk/findingData/ 
snDescription.asp?sn=5800> (accessed February 5 2011). 
 6 Ibid., 248n67. 
 7 David Gentilcore, Healers and Healing in Early Modern Italy (Manchester: Manchester 
University Press, 1998), chaps. 4, esp. 98–99 on the Contugi family. 
 8 Patrizia Catellani and Renzo Console, L’Orvietano, Accademia Nazionale di Scienze Lettere e 
Arte di Modena, Collana di studi 25 (Pisa: ETS, 2004). 
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charlatanism played out in the absence of physician-dominated regulatory bodies like the 
Italian protomedicato tribunals in a context where charlatans could be legitimated by 
royal authority, which ran above that of the local urban corporations. With this goal in 
mind, I will provide a brief account of the origins of the Contugi orviétan privilege, 
followed by four detailed case studies documenting the efforts of the Contugi family to 
uphold their privilege to sell orviétan. The first case study focuses on Christophe 
Contugi’s efforts to secure the approval of the Paris Faculty of Medicine in 1648, less 
than a year after inheriting the secret of orviétan and gaining his royal letters patent. The 
second follows a sequence of legal battles at the Parlement of Toulouse and the royal 
Conseil privé in 1656, wherein Contugi attempted to enforce his kingdom-wide privilege 
in the Languedoc and faced off against a rival charlatan, Christophe Polony, who 
likewise claimed to be the sole inheritor of the secret of orviétan. The third surrounds the 
efforts of Christophe Contugi’s widow and son to keep the secret in the family (against 
the growing number of orviétan recipes appearing in pharmacopeias) and to preserve the 
exclusive privilege to sell orviétan in Paris against the alleged interloping of a royal 
apothecary, Antoine Boulogne, in the years 1683-1685. Finally, the fourth episode will 
chart the succession crises which typify the last two generations of the privilege’s tenure 
by the Contugi family, as well as the growing involvement of Paris Faculty doctors in the 
orviétan business. These developments culminated in 1741 with the actual sale of the 
privilege to a Faculty doctor, Charles Dionis, which marks a striking conclusion to its 
ninety-four year tenure by the Contugi family. 
 The questions that I follow through these cases are: How was orviétan legitimated 
both medically and legally? In the pluralistic legal environment of early modern France, 
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what options did a family like the Contugi’s have at their disposal to preserve their 
alleged monopoly over the name “orviétan” as well as the sign and mark under which 
they sold it? When conflicting privileges arose, how did civil magistrates settle disputes 
between rival vendors? How could medical secrets and medical privileges be “kept in the 
family” as inherited goods, transmitted from one generation to the next? How did such 
particularistic privileges coexist alongside (and often clash with) corporate privileges? 
And finally, when a medical secret was publicly revealed, could vendors continue to rely 
on their privileges and “brand recognition” to maintain their monopoly? 
 This chapter also reveals an astonishing story of privilege as an engine of familial 
social mobility and the attendant blurring of boundaries between supposed “fringe” and 
“élite” practitioners in the Parisian medical community. The Contugis started out in the 
seventeenth century as “charlatans” in the classic Italian sense of the term: they were 
costumed performers, marketing their antidote on stage to passers-by through an 
entertaining skit. By the eighteenth century, however, they were reputable bourgeois with 
their own boutique and a well-established, legally-protected niche in the urban medical 
economy. Even the first-generation family patriarch, Christophe, died a wealthy and 
respected bourgeois of Paris and sent his own younger sons to study and apprentice 
within the corporate medical community.9 Despite their fearsome reputation as defenders 
of orthodoxy in medicine, the doctors of the Paris Faculty also emerge from this narrative 
as sometime-allies of the charlatans, and in fact, in the case of Dionis, as their successors.  
1. Orviétan comes to France: The origins of the Contugi orviétan privilege 
 Tracking the origins of orviétan will take us back to the early decades of the 
seventeenth century, when the first signs of the importation of Italian-style medical 
                                                 
9 For details see below, sect. 5. 
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charlatanism began to appear in France; then, back to the Italian town of Orvieto, where 
it was allegedly invented at the end of the sixteenth century; and then, even further back, 
into the long-term history of theriac, one of its principle ingredients. Following a brief 
sketch of the history of theriac, this section will restrict itself to the origins of orviétan in 
Italy and account for how it came into the hands of the Contugi family in France. 
The history of orviétan adds an early modern episode to theriac’s millennial 
history. All published preparations of orviétan included quantities of theriac or its most 
conspicuous ingredient—viper flesh—and many later seventeenth-century 
pharmacopoeias explicitly related it to theriac.10 This ties orviétan into the mythology 
surrounding theriac as a poison antidote. Theriac was held to have been adapted by 
Andromachus from mithridatium, the ancient antidote attributed to King Mithridates VI 
of Pontus, who devised it to protect himself from being poisoned. We have already seen 
that theriac was the example par excellence of a poison antidote, a variety of remedy 
which stood apart from normal Galenic pharmacology, and whose action was explicable 
as a form of occult causation derived from the specific form the compound acquired 
through a process of fermentation.11 Orviétan has been linked to theriac by Gentilcore as 
well as Catellani and Console, but not to the larger history of medicinal specifics. As I 
have explained in Chapter 2, antidotes like theriac furnished explanatory categories to 
physicians who sought to explain drugs that seemed to work in ways unexplained by their 
manifest qualities. The 1966 monograph of Gilbert Watson remains the only long-term 
history the drug, but there have been signs of a revival of interest among historians of 
medicine in recent years: Christiane Nockels Fabbri has studied the use of theriac in 
                                                 
10 See below, sect. 4. 
11 See above, ch. 2, sect. 1. 
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against plague in the European Middle Ages, stressing the important amounts of opium in 
most medieval forms of theriac—a tendency which continued into the early modern 
period; and Carla Nappi has detailed the appropriation and transformation of theriac 
recipes in early modern China.12 
 The most extensive and judicious account of the origins of orviétan which I have 
been able to find is that provided by the fascinating physician and traveller Pierre-Martin 
de la Martinière (1634-1676) in his 1665 Traitté des compositions du mitridat, du 
thériaque, de l'orviétan, published as an addition to his extensive head-to-toe medical 
compendium, L’Empiric charitable.13 This source also contains one of the earliest printed 
recipes for orviétan. La Martinière was an author of popular medical works: throughout 
his voluminous writings, he reproached charlatans and alchemists as occasional 
fraudsters, all the while recognizing their often useful medical innovations and casting 
himself as a charitable discloser of medical secrets for the benefit of the common 
people.14 In his Traitté, after describing the composition of theriac and mithridatium, he 
                                                 
 12 Gilbert Watson, Theriac and Mithridatium: A Study in Therapeutics (London: Wellcome 
Historical Medical Library, 1966); Christiane Nockels Fabbri, “Treating Medieval Plague: The Wonderful 
Virtues of Theriac,” Early Science and Medicine 12, no. 3 (2007): 247–83; Carla Nappi, “Bolatu’s 
Pharmacy: Theriac in Early Modern China,” Early Science and Medicine 14, no. 6 (2009): 737–64. Theriac 
was also the subject of a 2010 conference in Paris whose proceedings are forthcoming: Françoise Michau 
and Véronique Boudon-Millot, eds. “Histoire, transmission et acculturation de la Thériaque, Actes du 
colloque de Paris (18 mars 2010),” forthcoming. 
 13 Pierre-Martin de La Martinière, Traitté des compositions du mitridat, du thériaque, de 
l’orviétan, et des confections d’alkermes et d’hyacinthe et autres compositions antidotoires. Partie de 
l’Empiric charitable. (Paris: chez l’autheur, 1665). 
 14 See Françoise Loux, Pierre-Martin de La Martinière: un médecin au XVIIe siècle (Paris: 
Imago, 1988). La Martinière lived a short but eventful life, outlined in Loux, 11-27, which is worth 
summarizing here. Orphaned by his father and estranged from his mother, La Martinière left Paris at the 
age of nine and apprenticed with a military surgeon. At the age of twelve, he set sail onboard a Portugese 
ship bound for the East Indies, but it was captured by corsairs. He was liberated by the knights of Malta at 
the age of sixteen after four years of slavery; he served hospital surgeon in Naples and Rome, and learned 
alchemy (in which he remained interested, if somewhat skeptically) with a knight of Malta in Milan and 
followed an alchemist from Turin to Germany. In 1653 he then served as a ship’s surgeon in the Baltic with 
a fur trading and exploratory expedition out of Coppenhagen; he returned to France in 1654 and lived near 
Rouen (where he may or may not have taken a medical degree) and became “Médecin chymique de la cour 
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launches into a critical investigation of the origins of orviétan, which he portrays as a 
latter-day successor of these two drugs.  
 Before providing what he takes to be the “true” account of orviétan’s origins, 
however, La Martinière first tells the story which is given by most of its vendors. This 
“fable,” as he qualifies it, traces the antidote back to a shepherd (sometimes named Lupi) 
who was tending his flock of sheep near Orvieto.15 His flock was troubled by poisonous 
snakes, especially while he was away at church, but one day he had the good fortune of 
observing how one of his sheep, after swelling up from a snakebite, ran to the edge of a 
pond of stagnant water and ate a certain plant. After this, the shepherd collected the plant 
and gave it to his sheep whenever they were bitten by snakes, and when the town of 
Orvieto was struck by plague, he used his herb on humans and “chased away the 
infection.”16 Word of his success travelled, and the shepherd found himself invited to 
Venice, where he likewise saved the city from the plague, after which they offered him 
“the treasure of Saint Mark” in exchange for his secret. He refused, saying that his secret 
was worth more than all the treasure in the world, and that he would rather use it 
charitably. He then travelled to Naples, which he likewise saved from the plague, but 
after spending some time there grew nostalgic for his old way of life and decided to 
return to his sheep, and so taught his secret to a physician in Rome. This physician, La 
Martinière tells us, is never named, but all the orviétan vendors claim some relation to 
him, a fact which, he points out sardonically, tends to discredit the whole legend:  
                                                                                                                                                 
royale” in 1664, availing himself of the privilege to practice in Paris, during which time he published most 
of his writings, including various travel narratives and works of medical popularisation. 
15 On this origin myth see also Gentilcore, Healers and Healing, 96–97. The myth draws on 
several established tropes, namely, learning from animals; and using the hermit shepherd as a critic of the 
established order. 
 16 La Martinière, Traitté des compositions du mitridat, du thériaque, de l’orviétan, 27. 
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One claims to be the grandson of this physician, another says the 
physician was his great-grandfather, another claims he was the grandfather 
of his father-in-law, and that in the lineage of this father-in-law, he was 
the only one to inherit the secret, getting it through marriage to his wife; 
and almost all of these operators say something similar, to such an extent 
that, to take them at their word, this Orviétanalized physician deflowered 
more women than Hercules to have so many bastards, for they all carry 
different names, and while they claim to be grandsons of this physician, 
not a single one claims, however, to be related to the shepherd, which 
demonstrates the story is a mere fable.17 
 
So much for the legend of orviétan. The real story, according to La Martinière, is the one 
he learned from several credible acquaintances while in Rome. This version begins in 
1560, at the time of Pope Paul IV,18 when there was a cardinal in Rome, a native of 
Piacenza (Plaisance) named Deodaté, “homme fort curieux et possesseur de quantité de 
beaux secrets,” who was saved from a serious illness by his apothecary Guerche Martin 
of Ferrara. The cardinal rewarded Guerche by disclosing to him the secret of one of his 
antidotes, which subsequently made him rich and famous. He called his composition 
“Anitan” which, according to La Martinière, means “Antidote du temps.” Guerche had 
two apprentice apothecaries in his boutique that were from Orvieto, one named Gregoire 
and the other Orassio Tavanty, who, after the death of Guerche, continued to sell their 
master’s remedy. This pair in turn hired an apprentice named Girolamo Ferranti 
(Hierosme Ferenty), who had two assistants, one named Desiderio Descombes, who was 
French, and the other Jean Vitrario, who was Italian. He taught his secret to both, and 
Descombes brought it to France in 1608, while Ferranti stayed in Rome, married his 
                                                 
 17 “L’un dit estre le petit fils de ce Medecin, l’autre dit que ce Medecin estoit son grand bysayeul, 
l’autre dit, que ce Medecin estoit le pere-grand de son beau-pere, et que sa lignée de cedit beau-père, il n’y 
a que luy seul qui a herité de ce Secret, l’ayant eu pour mariage de sa femme; et presque tous les 
Operateurs en disent de mesme, tellement qu’à les entendre, il faut que ce Medecin Orvietanalizé aye 
dépucelé plus de femelles que n’a jamais fait Hercule pour avoir tant de bâtards, car tous portent differns 
noms, et si toutesfois ils ne laissent de se dire, petits fils de ce mesme Medecin : car quant au Berger, nul ne 
se dit estre de sa parenté, ce qui fait connoistre que cette histoire n’est qu’une fable,” Ibid., 29–30. 
 18 Catalani and Console point out that Paul IV died in 1559, making this date anachronistic. 
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master’s servant girl and had a daughter by her named Claire. According to La 
Martinière, Claire was then married to Chrisophe Contugi, and the secret of the 
orviétan—which Ferenty had renamed in honour of the hometown of his masters—was 
given to him as dowry. Contugi and his wife then moved to France themselves, where he 
gained fame in the theater by portraying the character Spacamont and was later granted 
an exclusive privilege by the king to sell his orviétan throughout France.19 
 La Martinière’s account thus provides a convoluted chain of transmission by 
which the orviétan secret originates with a cardinal, is transmitted through successive 
generations of apothecaries in Rome, changes names from anitan to orviétan, and then 
branches into distinct traditions in the early seventeenth century, with Descombes 
bringing it to France while Ferranti remains in Italy—only to marry his daughter “Claire” 
off to Contugi, thus creating a second lineage of French orviétan charlatans. 
 The sixteenth-century origins and lineage of orviétan lies beyond the scope of this 
account, but all of the seventeenth century players La Martinière mentions—Ferranti, 
Descombes, Vitrario, and “Claire”—can be corroborated by other sources, although his 
account garbles some of their relations.20 Interestingly, as we shall see, the key to sorting 
out La Martinière’s confusion lies in the fact that the “Claire” he mentions—who is 
almost certainly Christophe Contugi’s wife Clarice (sometimes Clarisse), mentioned in 
numerous other documents—was twice widowed, and apparently transmitted the secret 
of orviétan to three consecutive husbands. 
                                                 
 19 La Martinière, Traitté des compositions du mitridat, du thériaque, de l’orviétan, 30–33; see also 
the account in Gentilcore, Healers and Healing, 98–99, which differs on some details, and makes Ferranti 
himself the first orviétan  charlatan, Hieronymo, on the Pont Neuf in 1610. 
 20 This is not the only story that turns up in garbled version in La Martinière: as we shall see in 
section 3, the account he provides of the battle between the “Narbonne” vs. “Toulouse” orviétan charlatans 
is certainly a confused retelling of the 1656 Contugi-Polony conflict in Toulouse. While Le Paulmier and 




 Although Le Paulmier was not aware of La Martinière’s account, he did 
nonetheless assemble details about these various players. Descombes, the French 
apothecary who La Martinière alleges apprenticed in Rome with Ferranti, is certainly the 
same Desiderio Descombes of Angoumois who was named “Operateur et distillateur 
ordinaire du Roi” and given the first letters patent to sell orviétan in Paris on 19 
December 1625.21 For the relation between Ferranti, Vitrario, and Clarice, the key source 
is a 1657 arrêt from the royal Conseil privé, the preamble of which establishes the 
lineage by which orviétan was transmitted down to Christophe Contugi: Contugi was 
“native of Rome, true Orviétan, husband of Clarice Vitraria, sole and unique inheritor of 
Jean Vitrario, physician, who married Clarice widow of Hierosme Fioranti, the first to be 
called l’Orviétan.” Following this account, Clarice was the wife of Hieronymo Ferranti, 
not his daughter, as La Martinière supposes; and she was twice widowed; her second 
marriage being to Jean Vitrario.22 Her third marriage to Chrisophe Contugi, likely at an 
advanced age, transmitted the orviétan secret to him. This much is also confirmed by Le 
Paulmier via the couple’s naturalisation letters, granted to “Christophe Contugi, dit 
l’Orvietan, et Clarisse Vitraria, romains de naissance” on October 21, 1646.23 The couple 
was already married at this point, and six months later, on April 9, 1647, Contugi secured 
                                                 
 21 On Descombes see Le Paulmier, L’Orviétan, 16–20. Descombes privileges were dispatched by 
the Grand Conseil, and have survived in its registers: see AN V5 1230, fol. 94-95 (19 December 1625); they 
are also reproduced in Le Paulmier, L’Orviétan 123-125. 
 22 For a reference to a chapbook advertising the medicines of one Giovanni Vitrario, “il 
Tramontano,” “surgeon and distiller in Rome in the Piazza Navon, at the sign of the phoenix,” see William 
Eamon, Science and the Secrets of Nature: Books of Secrets in Medieval and Early Modern Culture 
(Princeton, N.J.: Princeton University Press, 1994), 242. The corresponding note does not cite the work but 
the bibliography includes a work by Giovanni Vittario [sic], entitled Centuria seconda de’ secreti 
materiali, medicinal’, e curiosi (Viterbo, 1618). The same source is cited by Gentilcore, Medical 
Charlatanism 339. According to worldcat.org, the only two copies are at the BN and the Wisconsin-
Madison University Library. The work is apparently a sixteen page pamphlet. 
 23 Le Paulmier, L’Orviétan, 22. See the transcription on 128–129. 
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his first letters patent to sell orviétan.24 As we shall see, this episode also marks the 
beginning of the persistent trend: the secret and privilege of orviétan would often be 
transmitted to widows and the sisters of male heirs. 
 Privilege in hand, Christophe Contugi would go on to sell orviétan on the Pont 
Neuf and elsewhere for over thirty years and fight a number of legal battles to preserve 
his exclusive privilege. He died on the night of the July 9, 1681, in comfortable 
circumstance as an honourable bourgeois of Paris, if we are to take the word of the 
Faculty doctor Jean Bernier, usually implacably hostile in his writings to charlatans and 
empirics.25  But what about the fate of the orviétan widow, Clarice, who made the whole 
business possible and ensured the wealth of the Contugi family for another three 
generations after Christophe’s death? Her marriage with Contugi appears to have been 
childless, and Le Paulmier conjectures that she was still alive in 1658 but had certainly 
passed away by the September 9, 1659. On that date, Contugi married a young actress 
from his troupe, Roberte Richard, who played the role of Florinde in their theater skits.26 
The first of Christophe’s fourteen children with Roberte was born six months after they 
were married.27 Two decades later, she too would find herself widowed, but the privilege 
and secret of orviétan would pass to her eldest son, Louis Anne. 
  
                                                 
 24 I have not been able to locate a copy of the initial 1647 letters, although it seems likely that they 
would include the same provisions as the later renewed versions. If the letters were dispatched from the 
Secretary of State for the Royal House, (Series O1), then they are probably lost, as dispatch registers 
survive only from 1669 onward. 
 25 Le Paulmier, L’Orviétan, 48; Jean Bernier, Supplémens au livre des Essais de Medecine: Avec 
des Corrections, et des Observations necessaire pour lire cét Ouvrage avec utilité et plaisir. (Paris: Simon 
Langronne, 1691), 75. 
 26 Opposite Contugi’s Capitaine Spacamont, according to Bernier; Spacamont, as we shall see, is 
also the name used by Polony to deride Contugi. See below, sect. 3. 
 27 Le Paulmier, L’Orviétan, 43–44. 
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2. The Paris Faculty orviétan endorsement scandal, 1648 
 On November 27, 1648, in the midst of the Fronde, the charlatan Christophe 
Contugi visited Jean Piètre, the newly elected dean of the University of Paris Faculty of 
Medicine at his home. The charlatan, who was accompanied by a clerk or huissier (servus 
scribae), presented the dean with a small box of medicine and asked him to assess 
whether or not it was safe. Piètre, no doubt surprised by the visit, reports in the Faculty 
Commentaries that he told the two men that he would need time to examine the substance 
before passing judgement.28 
 The dean records that Contugi returned a few days later, on December 1, to learn 
what he had decided. By the authority of the king, Contugi explained, he sold a certain 
antidote called orviétan—“which is great in neither name nor utility,” the dean 
commented—and the medicine he had brought to the dean was a counterfeit of it, 
produced by his “ape,” Carmeline, another charlatan. Carmeline had been caught in this 
deception, and, being ignorant of the true composition of the antidote, he had prepared a 
false one which had led to many deaths. The dean responded, with perhaps a touch of 
sarcasm, by asking why Contugi had not come to seek the support of the faculty sooner if 
his own antidote was so salutary. Contugi eagerly and (in retrospect naively) replied that 
he had, in fact, come to former dean, Jacques Perreau, a few months earlier, seeking 
letters of recommendation for his remedy, but he had been rebuffed. And so, he admitted 
                                                 
 28 BIUS Médecine, Ms. 13, Commentaires de la Faculté de médecine de Paris, vol. 13 (1636-
1652), fol. ccclxxix (385) r° (November 27, 1648). NB: pages of this volume of the Commentaires are 
numbered twice, first in black ink in roman numerals, which older references always follow, but also in 
more recent pink Arabic numerals. Because secondary sources are divided in which numbering system they 
follow, I provide both here, i.e. fol. ccclxxix r° (black ink) = fol. 385 r° (pink ink). 
 The events recounted in this section are also described in lesser detail in Le Paulmier, L’Orviétan 
23-26, though he did not have access to the actual notarized attestation, which I was able to find thanks to 
Gerard Jubert’s work on Théophraste Renaudot, whose son Eusèbe happens to be one of its signatories: see 
Gérard Jubert, ed., Théophraste Renaudot (1586-1653) : Père des journalistes et médecin des pauvres 
(Paris: CHAN / Editions Champion, 2005), 537–539. 
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to the dean, that “on the advice of that great man, his good friend the Doctor de Gorris,29 
he contented himself with buying, at no great price, certain letters of recommendation 
from twelve doctors, illustrious men, and a certain broker of the whole business made 
300 livres for himself.”30 Here Piètre, reporting the conversation in the Commentaries, 
confesses that he was horrified (exhorruit) by this story, but dissimulated in order to learn 
which of the Faculty doctors had so disgraced themselves. Eager to impress the dean, 
Contugi produced all of his credentials, which he regularly carried on his person in order 
to convince sceptics, including his letters patent from the king and the recommendations 
from the twelve doctors, which were signed and sealed by public notaries. The dean 
shrewdly accepted all of these letters, dismissed Contugi, and told him again that he 
would carefully consider the matter. 
 On December 4, the dean exposed eleven doctors (the twelfth “doctor,” it turns 
out, was merely a licentiate) at a meeting of the Faculty, reading their letters of 
recommendation to the assembled regent doctors, declaring that they had violated the 
good faith given to them as doctors, not to mention their solemn oaths. The Faculty 
censor Quentin Thevenyn asked that they be allowed to publicly defend themselves, but 
the dean observed that their opinions were already clear in the notarized document, and 
so the eleven doctors were obliged to wait in a vestibule (vestibulum) while the 
                                                 
 29 On De Gorris see Laure Jestaz ed. Guy Patin, Les lettres de Guy Patin à Charles Spon, janvier 
1649 - février 1655 (Paris: Honoré Champion, 2006), 658n3. This Jean des Gorris (d. 1662) was the third 
Paris doctor of that name; he edited the Definitiones medicae of his grandfather, a former dean of the 
Faculty. The Discours de l’origine, des moeurs, fraudes, et impostures des ciarlatans is attributed to him 
by Barbier (see the reprint in the 1868 Oeuvres completes de Tabarin, vol. 2, 231-288), but this seems to 
me very unlikely given his role in the orviétan endorsement scandal; Quérard attributes this book to one 
Jean Duret. 
 30 “tunc iste, se conatum fuisse litteras commendatitias obtinere a Priore Decano M. Jacobo 
Perreau; quia non potuerit, consilio magni hominis D. Desgorris sibi amicissimi, contentum fuisse emere 
quasdam litteras commendatitias a duodecim doctoribus viris clarisimis non maximo pretio, unum aliquem 
totius negotii redemptorem trecentis libellis rem sibi confecisse,” Ibid., fol. ccclxxix (385) v°–ccclxxx 
(386) r° (1 December 1648). 
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assembled faculty decided their fate. As Piètre reports in the Commentaries, the regent 
doctors unanimously ruled that the eleven doctors were guilty of violating their oaths and 
would only be pardoned on the condition that they published a notarized recantation of 
their support for orviétan. The licentiate would be scolded and warned before the dean 
and the whole Faculty during his doctoral examinations.31 Piètre observes in the 
Commentaires that all of the accused recanted within a few days. On December 5, the 
day after the faculty meeting, a man sent by Contugi came to the dean’s home to recover 
his letters patent. As Piètre tells it, he chased the man away, and told him that royal letters 
meant nothing without the approval of the faculty.32 
 A second account of these events, peppered with commentary and invective, can 
be found in a letter written five years later (January 6, 1654) by none other than the 
famous Faculty doctor (and acerbic wit) Guy Patin, to his friend, the Lyonnais doctor 
André Falconet. Patin’s account is not entirely corroborated by that from the 
Commentaires and the actual documents: he dates the events to 1647, when in fact they 
happened in 1648, and his list of the accused is only partially accurate.33 These errors can 
probably be attributed to the vagaries of memory or partiality: Laure Jestaz, the editor of 
Patin’s letters, has observed that several of the names he adds were personal enemies. But 
what is really interesting is Patin’s estimation of the motives of Jean de Gorris, who in all 
versions appears as a friend of Contugi and the architect of the whole project: 
All his life De Gorris has been on the wrong side: the chymists, the 
charlatans, the gazetteer [Théophraste Renaudot], foreigners, folks with 
                                                 
 31 Ibid. fol. ccclxxx (386) v°–ccclxxxi (387) r° (4 December 1648). 
 32 Ibid. fol. ccclxxxi (387) r°–v° (5 December 1648). 
 33 Only eight of the names Patin provides are corroborated by the actual documents (Des Gorris, 
Des Fourgeais, Renaudot, Lesoubz, Chartier, Rainssant, and Mauvillain); instead of Allain, the two 
Guerins, and de Launay, whose names appear on the notarized recommendation and its recantation, he 
names four other doctors: Guenaut, Beaurains, Pijart, and Cledat. 
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secrets against gout, epilepsy, quartan fever; he was curious to know 
preparations of laudanum, antimony, and vitriol. A very unsuccessful 
practitioner, who killed a good many with his experiments, which saw his 
practice reduced [...] It isn’t his fault, it’s his custom. He is a man hungry 
for money and secrets. If a child, a monk, a woman, a charlatan tells him 
of some secret, he will adhere to them. He is a pathetic man, with less 
spirit than a beast, who does and tolerates even in his home many things 
which a man of spirit would never tolerate.34 
 
Knowing which other doctors were “hungry for cash,” de Gorris, already a friend of 
Contugi’s, undertook to have the recommendation signed. He and his fellow accused 
emerge from Piètre’s Commentaire entries and Patin’s letter as credulous fools, 
impoverished and desperate. We hear almost nothing of the voices of the accused in 
either source—indeed, the Commentaires show that they were not even given a hearing 
before their peers. But how might they have defended their actions? What motives did 
they have beyond credulity and venality? And what did their recommendation say in the 
first place? 
 The notarized recommendation itself has survived, and offers some answers to 
these questions, allowing for a more balanced understanding of the events of the fall of 
1648.35 Dated September 16, 1648, the recommendation begins with a lengthy preamble 
on the history of medicine, citing the example of wise men throughout the ages who have 
contributed new medicines that cure even the most desperate of illnesses, for instance the 
theriac of Andromachus, mithridatium, philonium, and the syrup of king Sabor. The letter 
                                                 
 34 “Le sieur de Gorris a toute sa vie esté du mauvais parti : des chymistes, des charlatans, du 
gazetteer, des estrangers, gens de secrets contre la goutte, l’epilepsie, la fievre quarte, et dans une curiosité 
de sçavoir des preparations du laudanum, de l’antimoine et du vitriol; très malheureux praticien, qui en a 
bien tué avec les experiences qu’il a voulu faire, à cause de quoy il s’est veu reduit sans pratique […]. Ce 
n’est point sa faute, ce n’est que sa coutume. C’est un homme affamé d’argent et de secrets. Si un enfant, 
un moine, une femme, un charlatan luy parlent de quelque secret, il leur adherera. C’est un pauvre homme, 
qui n’a tantost pas plus d’esprit qu’une beste, qui fait et qui souffre jusques en sa maison beaucoup de 
choses qu’un homme de cœur ne souffrira jamais,” Patin, Les lettres de Guy Patin à Charles Spon, 1164–
1166. 
35 AN MC LXXIII, 395 (September 16, 1648). Jubert, Théophraste Renaudot, 537–538.  
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goes on to place orviétan within this august company, and the signatories even provide a 
pharmacological evaluation of it. They note that it is a powder made of diverse 
ingredients (which are concealed, naturally) and that its occult virtue makes it an antidote 
to poisons, as experience has demonstrated time and again. But that it is also an opiate 
that is hot in the third degree (meaning that it was warming, following the Galenic 
classification), and thus useful against all sicknesses and distempers that arise from 
masses of cold, raw and pituitous humours, such as stomach colics, windy colic, 
paralysis, cold gouts, indigestion, and worms. These evaluations are all well in keeping 
with learned pharmacological categories, and the mention of occult causation harkens 
back to the Avicennan explanation of the action of antidotes.36 The recommenders also 
offer the following experiential justification for their endorsement: 
The experience over several years in this city of Paris bears faith and 
testimony to the above [attestation], and, for this reason, we the 
undersigned have judged it unreasonable to deprive the author of our 
approval and consent, he having shown us several proofs and 
experiments.37 
 
The curiosity about medical secrets and the appetite for novelty that Patin so faulted in de 
Gorris is implicitly defended in the letter by an appeal to the history of medical 
innovation. Likewise, the recommendation of orviétan itself is grounded in an appeal to 
the daily experience of its success for many years, as well as Contugi’s own 
demonstrations before the doctors.  
 The 1648 orviétan endorsement scandal reveals at the outset a number of salient 
points that will recur in the subsequent history of the antidote and its vendors. First, it 
                                                 
 36 See above, ch. 2, sect. 1.  
 37 “L’experience qui s’en est faicte en cette ville de Paris depuis plusieurs années faict foy et 
tesmoignage de ce que dessus. Et, pour ceste raison, nous ditz soubzsignez, n’avons pas jugé raisonnable de 
priver l’autheur de nostre aprobation et consentement, icelluy nous en ayant faict veoir plusieurs preuves et 
experiences,” AN MC LXXIII, 395 (September 16, 1648). 
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reveals that Christophe Contugi still saw the Paris Faculty of Medicine as an important 
source of legitimation even though he was in possession of royal letters patent. He did not 
need to have any recourse to the Faculty in order to get his letters patent in the first place, 
but a year and a half after securing them, we find him endeavouring to secure the support 
of the Faculty in defending his privilege against interlopers, first through its dean 
directly, then through the notarized recommendation from a dozen of its doctors.  
 Contugi was not unique among the Paris charlatans in seeking approval of the 
Faculty. The Commentaires show that over twenty-five years earlier, on February 1, 
1621, the earlier orviétan charlatan, Desiderio Descombes, was rebuffed by the dean at 
the time, Hardouin de Saint-Jacques, when he sought faculty approval for his orviétan. 
Indeed, it appears the Descombes also sought out individual regent-doctors to secure 
certificates from them: one of these, interestingly enough, was the future dean, Jean 
Piètre, then a young doctor who apparently witnessed Descombes’ demonstration but 
refused to provide a certificate. Descombes had better luck with the provost of the 
Châtelet, gaining the right to sell his orviétan in Paris that same year, and later gaining 
royal letters patent in 1625—apparently thanks to the support of the queen mother, Marie 
de Medici.38 
 Second, it shows that Contugi’s appeal to the Faculty occurred within the context 
of an existing legal battle with a rival vendor. Indeed, the text of the recommendation 
itself concludes with a denunciation of a counterfeiter, one François Narici, dit Maroquin, 
attesting only to the efficacy of Contugi’s orviétan. Likewise, the notarized recantation 
the doctors later signed was aimed at preventing the recommendation from being used in 
                                                 
 38 Le Paulmier, L’Orviétan, 17–19. It should be noted that Descombes appears to have sought 
Faculty support as part of his appeal to civil and royal authorities, rather than post facto, as Contugi did. 
For Descombes struggles to gain legitimacy, see BIUS Médecine, Ms. 11, Commentaires, fol. 256-360. 
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court by Contugi against yet another rival, Carmeline. Far from being litigants against the 
charlatans, as one might expect, the Faculty doctors were perceived by the Contugi 
family as potential allies in their legal battles against other charlatans. This too was far 
from unusual: as we shall see, each of the major legal battles fought by the Contugi 
family from 1648 to 1735 were against rival charlatans and apothecaries, never the Paris 
Faculty or its doctors.  
 Third, the episode suggests that any statement about the institutional attitude of 
the Faculty toward charlatans needs to be tempered by an account of the attitudes of 
individual regent doctors. Eleven Faculty doctors were willing (at least initially) to 
endorse a charlatan with an effective remedy. The charlatan for his part was still 
interested in courting the Faculty, even though he had already been legitimated by royal 
letters patent. As later episodes in the Contugi family saga demonstrate, the boundary 
lines between the Faculty and the charlatans were often quite blurry. Patin’s ridicule of 
Des Gorris’s poverty can be taken to mean that impoverished doctors were more 
susceptible to being bribed, but it also contains the implicit suggestion that some Faculty 
doctors were quite willing to consult “children, monks, women, and charlatans” in order 
to learn new medical secrets. 
3. The sign of the sun in the provinces: Competing orviétans, 1656-1657 
 In the spring of 1656, nearly a decade after his tangle with the Faculty, Christophe 
Contugi found himself being sued by three rival charlatans—Gilles Barry, François 
Fossa, and Chrisophe Polony—in courts at three different corners of France—the 
Parlements of Paris, Bordeaux, and Toulouse. Presented with such a challenge, Contugi 
availed himself of the rights of his royal privilege and drew recourse to the highest court 
163 
 
in France, the royal Conseil privé, where his letters were registered. The problem, as he 
presented it in his request, was a simple one: he could hardly stand before judges in three 
different places at once, nor was it realistic that he be expected to convey the original 
documents necessary for his defence to each of the courts. All three lawsuits surrounded 
the defense of his royally mandated exclusive privilege to sell orviétan, not just in Paris 
but throughout the kingdom of France—including both the right to the name of the drug 
itself and the right to sell it under the sign and mark of the Sun, “which the plaintiff has 
always used to establish the difference between his own antidote and that of others.”39 
Because each lawsuit dealt with the same question, Contugi requested that all three cases 
be brought together before the Conseil privé. In legal terms, the solution he sought was 
an évocation—the transferral of cases from inferior courts to a higher one—that would 
decide all three lawsuits in one fell swoop.40 On May 19, 1656, the Conseil privé, then 
presided over by the Chancellor of France, Pierre Séguier, recognized Contugi’s 1647 
letters patent as well as the arrêts he had already obtained in his favour at the three 
parlements 1655 and 1656 and accepted his request. The parties of all three cases were to 
                                                 
 39 “Qui a tousjours servy au supplicant pour establir la différence de son antidote d’avecq les 
autres,” AN V6 324, Conseil privé, Minutes d’arrêt, May 19, 1656. Cf. Le Paulmier, L’Orviétan, 130–132. 
 40 On the Conseil privé, see Bernard Barbiche, Les institutions de la monarchie française à 
l’époque moderne (XVIe - XVIIIe siècle) (Paris: Presses Universitaires de France, 2012), 289–290, 298–
299; and the more specialized study of Albert Hamscher, Conseil Privé and the Parlements in the Age of 
Louis XIV: A Study in French Absolutism (American Philosophical Society, 2007).  
 The Conseil privé was the judicial section of the royal Grand conseil, and served for all practical 
purposes as the court of last resort in France. Although it was theoretically an organ of the king’s 
prerogative to judge as the ultimate source of justice in the kingdom—his justice retenue, in the sense of it 
being the judicial power he retained rather than delegated to the courts. The Conseil privé rarely sat in the 
presence of the king personally and for practical purposes was a council of masters of requests overseen by 
the Chancellor of France. Most of the cases that came before it were civil suits between persons. The 
évocation of cases from inferior jurisdictions, which will play an important role in section 3 of this chapter, 
was one of its three major forms of action, alongside cassation (the nullification of arrêts from lower courts 




be summoned, and the pending lawsuits at the parlements would be suspended until the 
Conseil privé passed judgement.41 
 We know very little about how Contugi’s cases against Gilles Barry and François 
Fossa proceeded, but a surprising number of documents have survived surrounding his 
dispute with Christophe Polony, the rival charlatan from the Languedoc. We know, for 
instance, that the following month, on June 27, 1656, Contugi brought another complaint 
against Polony to the Conseil privé. There he established that following the May 19 
évocation, he had been careful to inform Polony and the Toulouse Parlement that the case 
had been reassigned to the Conseil privé. In spite of this, however, he tells the Conseil 
that Polony has not dropped his lawsuit in Toulouse and, in fact, that he secured one arrêt 
from the provincial Parlement on June 1, permitting him to sell his orviétan; and a second 
arrêt on June 10, returning to him his “tableau” (assumedly a backdrop or set-piece) and 
“the sign of the Sun,” which had apparently been seized by the court pending the trial’s 
outcome. These arrêts could not stand, Contugi argued, because they had been made in 
prejudice of the May 19 évocation of the case to the Conseil privé, and against his own 
royal letters patent, which gave him the right to sell orviétan throughout France under the 
mark of the Sun, to the exclusion of all others unless they had secured his permission. 
The court ordered that his request be appended to the subsequent proceedings, and that in 
the meantime the execution of two arrêts in favour of Polony be suspended pending the 
settlement of the case by the Conseil privé.42 
                                                 
 41 AN V6 324, Conseil privé, Minutes d’arrêt, May 19, 1656. Cf. Le Paulmier, L’Orviétan, 130-
132. 




 A third arrêt from over six months later demonstrates that in spite of this action 
Polony was still pursuing his case at the Parlement in Toulouse, this time in order to 
defend his own monopoly on orviétan and the sign of the Sun against two new 
interlopers, Boyer Saint-André and La Fortune. Contugi again requested that the arrêts of 
the Toulouse Parlement in favour of Polony be nullified; the Conseil judged that both 
parties in the case were to be heard, and that Polony was prohibited from taking any 
further legal action in Toulouse, under penalty of nullity, a sizable three thousand livre 
fine, as well as expenses and damages. The new arrêts he secured were suspended from 
execution, and Polony was summoned to appear before a commissaire in Montauban, 
who was to interrogate him and then report back to the Conseil.43 
 These three arrêts testify to a common phenomenon in pluralistic judicial 
contexts, what Lauren Benton has called “forum shopping,” wherein litigants jockey with 
one another to find the most advantageous forum for their dispute, pitting one tribunal 
against another.44 They also raise a number of questions: Why did Contugi want to move 
the case from Toulouse to the Conseil privé? Conversely, how was Polony so successful 
in securing the support of the Toulouse Parlement, and why did he fight so hard to keep 
the case within the jurisdiction of that court? And finally, what had Contugi been doing in 
the Languedoc in the first place? As we shall see, the Polony-Contugi debate provides a 
fascinating case study of the mechanisms of medical legitimation in action, raising 
questions about jurisdictional conflict, the extent of exclusive medical privileges, and the 
role of live poison trials in arbitrating disputes. It also provides a window into inter-
                                                 
 43 AN V6 338, Conseil privé, Minutes d’arrêt, January 12, 1657. Cf. Le Paulmier, L’Orviétan, 
135–137. 
 44 Lauren A. Benton, Law and Colonial Cultures Legal Regimes in World History, 1400-1900 
(Cambridge: Cambridge University Press, 2002), 106, 137. 
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charlatan disputes and raises the important but little-discussed question of branding in 
early proprietary remedies.45 
 Despite Christophe Contugi’s efforts, Polony continued to take legal action 
through the Toulouse Parlement well into 1657, and presented a request of his own to the 
Conseil privé only on May 12, 1657.46 It was at this time that he provided the Conseil 
with his credentials as well as his own version of the events in Toulouse, alongside his 
request that the case be returned to the jurisdiction of the Parlement there. This account is 
corroborated and much expanded by a printed account of the conflict: the provocatively 
titled Factum poétique pour Christophe Polony, vray Orvietan de Rome, contre Contugi 
Spacamont, Bateleur (an acrobat or juggler).47 This long text, written in verse, contains 
not only an account of the major events in the Contugi-Polony conflict at Toulouse, but 
also spoof versions of supporting “documents,” such as a parliamentary arrêt and a 
medical attestation, likewise presented in verse. Although it is obviously a satirical source 
written to provoke laughter, most of the facts it provides are corroborated (albeit in less 
detail) by Polony’s 12 May request to the Conseil privé. 
 As Polony describes it in his request, he inherited the secret of orviétan from his 
forefathers and first dispensed it in Rome. After many successful cures there, he was 
granted the approval of the University, the Hospital of Santo Spirito, and the first 
                                                 
 45 Branding and trademarking remain neglected topics in early modern medicine: for a recent 
discussion, see Alisha Rankin’s work on the terra sigilata: Alisha Rankin, “Empirics, Physicians, and 
Wonder Drugs in Early Modern Germany: The Case of the Panacea Amwaldina,” Early Science and 
Medicine 14, no. 6 (2009): 680–710; Alisha Rankin, “Authenticity, Alchemy, and ‘Earth’ in Early Modern 
Pharmacy” (History of Science Society Conference, Boston, 2013), unpublished conference paper; for a 
survey of French branding from this period, see the series of notices by Maurice Bouvet, “Sur l’historique 
du conditionnement de la spécialité pharmaceutique,” Revue des spécialités, 1928, 101–43, 213–23, 297–
315. 
 46 AN V6 345, Conseil privé, Minutes d’arrêt, May 12, 1657. 
 47 Factum poétique pour Christophe Polony, vray Orvietan de Rome. Contre Contugi Spacamont, 
Bateleur (s.l. [Toulouse?]: s.n., ca. 1656). This printed parody of a legal factum (a brief summarizing the 
main points of a lawsuit) contains a long poem of 470 lines, arranged in ten-verse stanzas following a 
rhyme pattern of ababccdede, and is followed by seven short epigrams, the last of which is in Occitan. 
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physician of the pope. Having heard of how welcoming the kingdom of France was to 
useful inventions in art and science, he resolved to go there, travelling through 
Languedoc in 1654. He alleges that he had many opportunities to prove the virtue of his 
antidote there, and that he was so successful that word of his cures reached the Estates of 
Languedoc, then meeting in Montpellier, and he was summoned to provide a trial of his 
antidote before the assembly. His trial was a success, and he was presented by the estates 
with a golden chain and medallion, having the figure of the king on one side, and the 
arms of the province on the other: “the said Estates dispatched an attestation following 
the most authentic forms, and beseeched him to stop in the said province to help fight the 
contagion that manifested itself in those places.”48 The Factum poetique provides an 
account of the trial by which he gained the medallion: 
Les trois Estats a Montpellier,  The Three Estates at Montpellier, 
Et les Docteurs en Medecine,  And the Doctors of Medicine 
Firent piler dans un mortier,   Had ground in a mortar, 
D’un Poison couleur Christalline, A cristal-coloured poison, 
Mon corps estoit tout enflammé My body all enflamed, 
De l’Arsenic et Sublimé,  By Arsenic and Sublimate, 
Qu’ils me firent prendre en un verre, That they had me take in a glass, 
Lors qu’ils crurent que j’estois mort, Once they believed I was dead, 
Parce que je tombé par terre,  Because I had fallen on the ground, 
Mon secret me guerit d’abort.49  My secret cured me thus. 
 
The Factum also adds that Polony had certificates from several lords, notably from 
“Monsieur le Prince de Conty.”50 Armand de Bourbon, Prince of Conti (1629-1666) was 
one of the leaders of the Fronde, and was then only recently back in the good graces of 
Louis XIV, having been delegated to open the Estates of Languedoc. Polony’s orviétan 
                                                 
 48 “…lesdits Estats luy auroient fait expédier une attestatoire en la plus authetique forme, et 
l’auroient prié de vouloir arrester dans ladite province pour la secourir contre la contagion quy se reveloit 
en divers lieux,” AN V6 345, Conseil privé, Minutes d’arrêt, May 12, 1657. 
 49 Factum poétique, 4. 
 50 Ibid., 5. 
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trial may have been part of the entertainment at Montpellier surrounding the Estates: 
Molière’s theater troupe was also present, and was also supported by Conti.51 
 With the support of the estates, Polony then began to visit the principal towns of 
the province in order to dispense his orviétan, but when he came to Toulouse, he 
encountered Christophe Contugi, “who claimed to be the true orviétan and sold his drugs 
under his name and mark,” all by virtue of an arrêt he had obtained there on January 8, 
1656, before Polony had arrived from Montpellier to defend his rights.52 The Factum 
poetique alleges that Contugi had already been there for six months, and sought to secure 
an arrêt approving his orviétan before leaving. At this time Contugi presented the 
Parlement with his royal letters patent and claims to have received the secret of orviétan 
as a dowry for marrying the daughter of its Roman inventor.53 
 According to the Factum, Polony was in Montpellier at the time of these events. 
When he learned of Contugi’s attempts to receive the endorsement of the Parlement, 
however, he made his way back to Toulouse without delay to sue him. Upon receiving 
the court summons, Contugi fled from Toulouse to Carcassonne, but was pursued there 
by Polony. Contugi initially planned to murder Polony when he arrived in Carcassonne, 
or so the Factum alleges, but in the end decided to return to Toulouse and fight him in the 
courts, expecting that he could wear Polony down by dragging the affair onward 
interminably: Contugi, the Factum tells us, was an expert “chicaneur” (pettifogger) in the 
                                                 
51 William Beik, Absolutism and Society in Seventeenth-Century France: State Power and 
Provincial Aristocracy in Languedoc (Cambridge: Cambridge University Press, 1985), 113, 321; Virginia 
Scott, Molière: A Theatrical Life (Cambridge: Cambridge University Press, 2000), 78; C. E. J. Caldicott, 
“Les séjours de Molière en Languedoc,” Revue d’Histoire littéraire de la France 87, no. 6 (1987): 994–
1014. 
 52 AN V6 345, Conseil privé, Minutes d’arrêt, May 12, 1657. 
 53 Factum poétique, 2. Note the confusion about the relationship between Contugi and Clarice: 
here, as in La Martinière, Clarice is described as the daughter, not the widow, of Vitrario, the supposed 
inventor of orviétan. 
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courts. But here again Polony got the better of him: he proposed that the dispute could be 
settled by a trial of their respective antidotes, and on March 14 1656 the Parlement called 
for such a trial to occur within a month, under the supervision of a commissioner 
delegated to the affair by the Parlement and in consultation with members of the local 
medical community (two doctors, as well as surgeons and apothecaries). Pending 
judgement, it would be Contugi—not Polony—that was permitted to continue selling 
orviétan.54 
 According to the Factum, Contugi was surprised by this gambit (which would 
allow him little latitude in stretching out the case) and found himself in a pinch, so he 
protested that it was unjust. Polony also protested, but for entirely different reasons: the 
arrêt ordered the subjects of the trial were to be “whatever animals were most suitable,” 
while Polony was so confident in his own orviétan that he would rather have his and 
Contugi’s own bodies serve as trial subjects. They could both drink the same poison and 
then ingest their respective antidotes—a high-stakes poison trial that Polony no doubt 
hoped would dispense with Contugi once and for all.55 
 As the Factum tells it, the test occurred before the town hall, where a crowd 
assembled “as if for a fair.” The doctor Laurens Ferrier served as commissioner for the 
Parlement, sitting at the head of a medical “consistoire” of three other doctors, named 
Purpan, Riordan, and Famus. Three pigs were brought: one for Contugi, one for Polony, 
and a third as a control to ensure the poison was effective. Contugi used a pair of scissors 
to cut his pigs ear in order that it be clearly distinguishable from the others, while Polony 
“avec beaucoup moins d’avarice,” simply tied a ribbon to the thigh of the pig he was 
                                                 
 54 Ibid., 7–8. 
 55 Ibid., 8. 
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assigned. The poison, apparently arsenic, was fed to each of the pigs, after which, the two 
marked pigs were made to swallow the respective antidotes of Contugi and Polony, 
mixed with water. The three were then brought to separate stalls, where they were to be 
kept overnight. In the meantime, Polony, ever the showman, made use of the assembled 
crowd for a trial of his own: 
Polony fit encore plus,   Polony did better: 
Quoy que c’est Arrest ne l’ordonne, Although the arrêt hadn’t ordered it, 
Pour rendre Contugi confus,   to vex Contugi 
Il fist l’essay sur sa personne,  he made a trial on his own person 
Et sans peur de la guerison,  and without fretting over recovery 
Il remplit son corps de poison,  he filled his own body with poison 
De la main d’un Apotiquaire,   from the hand of an apothecary 
Quand tout le monde le crut mort, when everyone thought him dead, 
Et mèmement son adversaire,  even his adversary, 
Son secret le guerit d’abort.  his secret immediately cured him. 
 
It is unclear if Polony ingested the same poison as was used on the pigs.  
 The next morning, only one pig was found alive, leaping in hunger: Polony’s. The 
versified “report” of the commissioner, Ferrier, made on the 6 May 1656, describes their 
reactions:  
Contugi fut le premier,    Contugi was the first, 
Qui se fourra dans ces chambrettes, to force his way into the stalls, 
Et dit qu’il ne pouvoit nier,  and said he could not deny, 
La funeste mort de sa beste,  the gruesome death of his beast; 
Et le manteau dessus le nés,  and with his coat above his nose, 
Qui luy couvroit la face,   covering his face, 
Grimassant comme les damnés, wincing like the damned, 
Pleuroit sa perte et sa disgrace  he cried of his loss and his disgrace. 
 
When Ferrier opens the door to Polony’s pig, hoverer, he reports: 
Je ne trouve donc qu’un pourceau, Thus I found but one pig, 
Avec un ruban à la cuisse,  with a ribbon on its thigh, 
Qui cherchoit du som et de l’eau, looking for some meal and water 
Qu’on luy donna sans avarice,  which we gave to it unbegrudgingly, 
Lors Polony sans regarder,  while Polony without regard [for cost] 
La fit soigneusement garder,   had it carefully looked after, 
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Puis qu’elle faisoit sa conqueste, because it had made his conquest, 
Car sortant de cette prison,  for upon leaving that prison, 
Elle faiosoit mille gambades,  she made a thousand gambols, 
et sembloit avec raison,   and seemed, with good cause, 
Se mocquer de ses camarades.56 to mock her comrades. 
 
The other doctors provided Polony with an attestation as well, and the Parlement 
pronounced an arrêt in his favour, allowing him to sell his orviétan.  
Cependant dans ce mesme jour, Nonetheless that same day, 
Contugi tout plein d’artifice,  Contugi full of trickery, 
Pour faire interdire la Cour,  In order to interdict the court 
Il court, a une autre Justice,  he ran to another judge, 
Ne pouvant gouster le sommeil, unable to get a wink of sleep, 
Sans un Arrest du grand Conseil, without an arrêt from the Grand conseil 
Contre cette Cour Souveraine,  against this sovereign court. 
Il eut avec illusion,   He gained it through deceptions, 
A force se soing et de peine,  by force of care and effort, 
Un Arrest d’interdiction.57  an arrêt d’interdiction. 
 
Contugi, meanwhile, retreated to a local cabaret, where he was accosted by the “menu 
peuple” of Toulouse, who accused him of selling them false orviétan and chased him to 
his lodgings, demanding refunds. Contugi closed the door behind him, and addressed the 
crowd from a window on high, swearing on his own name, that it was beyond his power 
to provide them with anything. He then fled by night, and his troupe left town. As the 
Factum tells it, when Polony learned of Contugi’s flight and his plan to contest the arrêt, 
he left Toulouse in pursuit, vowing to chase him out of France just as he had chased him 
out of the Languedoc. 
 Polony appears in fact to have continued pressing his advantage before the 
Toulouse Parlement for some time, but after the évocation and repeated arrêts, he could 
no longer ignore Contugi’s successful requests before the Conseil privé, and so made a 
request of his own before that court, including his version of events in Toulouse, leading 
                                                 
 56 Ibid., 13. 
 57 Ibid., 14–15. 
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to a new arrêt on May 12, 1657. His account corresponds fact for fact with that provided 
in the Factum poetique: in order to settle the dispute that had arisen between himself and 
Contugi over who held the true secret to orviétan, he proposed to the judges that he and 
Contugi put their remedies to the test, and the judges agreed. A poison trial was 
undertaken on pigs, and only Polony’s survived; faced with such a clear failure, Contugi 
sought to challenge the Toulouse judgement on his own turf at the royal Conseil privé. 
The arrêt specifies that Polony’s account was substantiated by the report of the medical 
commission in Toulouse, which was included among the documents provided to the 
court, along with the attestation of Polony’s orviétan provided by the Estates of 
Languedoc and his conspicuous medallion. Having reviewed this evidence, the Conseil 
privé ordered that the case be returned to the jurisdiction of the Parlement of Toulouse, 
and prohibited both Polony and Contugi from appealing the case before the Conseil privé 
again, under penalty of a 1,500 livre fine.58 
 This marks a sudden—but, as we shall see, not very long-lasting—change of 
events. Previously, Contugi had regained the upper hand by moving the lawsuits to his 
court of choice and appealing the Toulouse arrêts favorable to Polony. Polony had 
succeeded in shifting the legal battlefield back to Toulouse, but his victory would be 
short lived. Two weeks later, on May 23, 1657, Contugi made a new request at the 
Conseil re-establishing the question of his exclusive royal privilege to sell orviétan 
throughout the kingdom of France “under the sign of the Sun” as the central issue of the 
case. Surprisingly, the Conseil backtracked on its own decision, ordering the case to be 
returned to its jurisdiction.59  
                                                 
 58 Ibid. 
 59 AN V6 346, Conseil privé, Minutes d’arrêt, May 25 1657. 
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 How to explain this flip-flopping at the Conseil privé? The documents provide 
some hints. First, the pro-Polony arrêt appears to have been made without having 
consulted all of the previous arrêts and evidence presented during the case (letters patent, 
attestations, reports): it listed only the new documents brought by Polony as “seen.” 
Second, there is also a difference in the signatures below the arrêts: while three of the 
four previous arrêts had been signed by Seguier (the Chancellor) and Faviez, the case 
reporter (rapporteur) for the Conseil, the new one in Polony’s favour bears the signature 
of a different reporter, Amelot de Bisseuil. Third, the arrêt which overturned it and 
returned the case to the jurisdiction of the Conseil was signed once again by Seguier and 
Faviez, and refers to all of the aforementioned documents.60 I suspect that Polony’s 
request was assigned to De Bisseuil, and by either accident or design made it through the 
review of a bureaux and went before the Conseil itself without being recognized as 
related to the earlier case from the Contugi request, which was reported by Faviez. The 
oversight may have been only recognized when Contugi himself received word of the 
arrêt from a huissier, and then complained to Faviez. 
 What was the final outcome of the conflict between Contugi and Polony? A 
subsequent arrêt from eight months later (February 1, 1658) assigns the case to a 
                                                 
 60 On the procedure of the Conseil privé, see Hamscher, Conseil Privé and the Parlements, 80–
107. In its most basic outline, each case would be assigned to a master of requests who would serve as 
reporter for it; he would then be responsible for gathering pertinent documents, communicating with the 
contesting parties, and, most importantly, preparing a report for the entire council on the principal issue of 
the case with a recommended resolution. The assembled members of the council, made up of other masters 
of requests (all of whom were avocats) would express their opinions and vote on the outcome; ties were 
broken by the Chancellor himself.  
 The process became more complex during the reign of Louis XIV. While this track remained 
technically in place, it was supplemented by a series of between five and seven bureaux, each responsible 
for affairs pertaining to given subjects (police, commerce, Protestants, the church etc.) or certain types of 
action, such as cassation, which would review the reports in anticipation of council meetings. This allowed 
them to run their reports before colleagues before delivering them to the Conseil itself. The deliberations of 
the bureaux, if they generated any records, have not survived; we have only the final arrêts, signed by the 
reporting magistrate and the Chancellor.  
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commissionaire and summons both parties to report to him, but after that, the trail goes 
cold. Lacking an arrêt définitif, it seems likely that the dispute was settled out of court, to 
spare both parties the costs of litigation, a solution that was far from unheard of in this 
period.61 
 Whatever the outcome of the case at the Conseil privé, we know that Polony 
continued to ply his trade in the provinces. A decade after his run-in with Contugi, we 
find him in the town of Saintes, still calling himself “veritable orviétan de Rome” but 
now adding the qualification of “médecin occuliste de Sa Majesté.”62 There he apparently 
cured the blindness of one Jean Sauvignon. This feat was documented at Polony’s request 
by a notarial act, signed by a local lawyer, teacher, and clerk: the rationale being, “as 
much for the public interest as for his own reputation, it is important for [Polony] to take 
a notarized act of all cures and operations he has effected in the kingdom.”63  
 The Contugi-Polony conflict yields important insights about the different ways 
that charlatans legitimated themselves and about how “inter-charlatan” disputes were 
arbitrated. For Polony, legitimacy was derived from medical experience, ideally shown 
through first-hand demonstration, and then preserved through written testimony, 
including notarized acts and other legally binding documents. Polony was not alone in 
shrewdly collecting such attestations; in the absence of any centralized licensing regime, 
documenting successes was part of the standard modus operandi of charlatans in France 
and elsewhere in Europe, especially for itinerants who moved across different legal 
                                                 
61 See below, section 4: the 1685 Boulogne suit was also settled in this way, although in this case 
the notarized settlement survives. 
62 Charles Dangibeaud, “Un Orviétan à Saintes,” Recueil de la Commission des arts et monuments 
historiques de la Charente-Inférieure 15 (1901): 531–43. 
 63 “…tant pour l’intérest public que celuy de sa réputation et autres raisons, luy est important de 
prendre acte de notoriété de toute les cures et opérations qu’il a fait dans le royaume,” Ibid., 532. 
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jurisdictions. 64 In attempting to secure the legitimacy of the Faculty via notarized 
attestation in 1648, Contugi was engaged in much the same project. Indeed, the whole 
cause of the debate between him and Polony (following the account of the Factum 
poetique) was the former’s effort to secure some kind of legal recognition for his royal 
privilege in Toulouse. His goal in doing so was either to incorporate the Languedoc into a 
regular sales circuit of his own, or perhaps to franchise the sale of orviétan there to a 
subordinate or someone else. 
 Securing such attestations served several purposes. The first was judicial: they 
could be produced as documentary evidence before judges. The second was commercial 
and persuasive: various types of attestations, especially parchment letters and brevets 
with dangling wax seals, could be brandished as props on stage, to convince the sceptical 
passer-by of the official legitimacy of a charlatan and physically manifest a record of 
success. Charles Dangibeaud has cited the presence of sealed parchments in visual 
depictions of charlatans and operators from this period, notably on the table in the 
“Tooth-puller” of the Flemish painter Théodore Rombouts (see Appendix, Figure 11).65 
Numerous other examples could be added: for example, the famous 1660 engraving of a 
bespectacled, snake-handling charlatan by Francesco Curti after Giuseppe Maria Mitelli, 
which depicts a stack of parchments with dangling seals and medallions (see Appendix, 
Figure 12). Cure attestations could also be printed and distributed with handbills and 
broadsheets, as could the texts of royal brevets and letters patent. “Par permission du 
Roy” appears prominently on the backdrops of eighteenth-century engravings of 
                                                 
 64 On Bolognese fedi di guarigione and other forms of cure attestation across Europe, see Gianna 
Pomata, Contracting a Cure: Patients, Healers, and the Law in Early Modern Bologna (Baltimore: Johns 
Hopkins University Press, 1998), 50–51, 216–217n97; for their use in documenting miraculous cures, see 
Marc Bloch, The Royal Touch  (London: Routledge & Keagan Paul, 1973), 158–159. 
 65 Dangibeaud, “Un Orviétan à Saintes,” 533–534. 
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charlatans (see Appendix, Figures 13 and 14). We can imagine Polony carrying a number 
such attestations with him in his itinerant practice, brandishing them onstage when 
needed. Such attestations provided material support for his medical claims, whether they 
were notarized acts or letters from civil magistrates and princes like Conti, or his 
necklace and gold medallion from the Estates General—the effect of which was no doubt 
even more dramatic than that of the parchment. 
 Whatever the means by which it was documented and displayed, Polony’s 
legitimacy ultimately rested in effectively demonstrating his cures through live poison 
trials. When the court decided to use pigs, he responded by poisoning himself to 
demonstrate the effectiveness of his orviétan: at which moment, in effect, he literally 
embodied the experiential approach to medical legitimation. Contugi’s approach seems to 
have been more legalistic in nature, at least in Toulouse (if not before the twelve Paris 
Faculty doctors in 1648, for whom he apparently provided some kind of demonstration); 
he seems to have simply and straightforwardly sought to register his royal privileges 
before the Parlement there.  
In this case, however, a live poison trial was organized to arbitrate a dispute.  
How common were such practices? 66  Katherine Park describes poison competitions 
between pauliani snakehandlers in Italy, but these were unlicensed and disapproved of by 
physicians and civil authorities.67 Likewise, in his work on Italian charlatans, Gentilcore 
describes on-stage poisoning as a trope of snakehandlers, but also provides an interesting 
case study of a licensed charlatan named Lavinio Sclavo testing four poisons on himself 
                                                 
 66 The forthcoming work of Alisha Rankin, provisionally entitled “The Poison Trials: Antidotes 
and Experiment in Early Modern Europe,” promises to shed much light on this question. 
 67 Katharine Park, “Country Medicine in the City Marketplace: Snakehandlers as Itinerant 
Healers,” Renaissance Studies 15, no. 2 (2001): 104–20. 
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as an esperienza in the piazza before a crowd, that included one Giacomo Giacobelli, a 
former protophysician and member of the Roman College of Physicians. Sclavo secured 
a signed certificate of the successful test from Giacobelli, which brought the latter grief 
before protomedicato tribunal—not unlike what happened to De Gorris and the other 
Paris Faculty regent-doctors in 1648. Gentilcore also points out that the self-administered 
poison test had been described as a stock charlatan deception as early as 1544.68 
 Animal testing—sanctioned by civil and medical officials—appears to have been 
far more common in settling disputes. The use of animal testing is of course well attested 
in natural philosophic controversies, the most famous of which being the trials of 
snakestone involving Athanasius Kircher and Francesco Redi. Animal testing appeared in 
judicial settings as well.69 In 1649 the Bologna College of Physicians tested the orviétan 
of a charlatan named Francesco Nava by having two dogs bitten by a viper (the second 
dog serving as the control).70 In this case, however, only one drug was being tested and 
so the trial was not adversarial in the same way as Contugi and Polony’s.  
 The closest analogue I have found to the Polony-Contugi poison trial is from 
Brittany. In 1697 a live poison trial before the seneschal of Hennebont in Brittany was 
used to settle a dispute between a local druggist named Joseph Déru, called “Belle-
Fleur,” and the recently arrived charlatan, Paul Toscano, “medico chimico,” who sought 
to have Déru banned from selling orviétan. Indeed, the charlatan-chymist Toscano 
bragged of having won similar lawsuits against rival orviétan vendors in the past in 
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Genoble and Toulouse. The seneschal assembled a panel composed of the town physician 
and two surgeons, to which two local apothecaries were later added (following their 
complaint). Two stray dogs are selected for the trial, to which Toscano objected, arguing 
that the test should be on pigs, “being the animal which has the most similarity to the 
human body,” and that the earlier trials to which he was party used pigs. The dogs were 
used, in spite of Toscano’s objections, and his dog died, but he accused Déru of switching 
his own dog for a healthy one with the same colour of fur. Unfortunately, as in the 
Contugi-Polony case, the final sentence is not known.71 
 Some features of the Contugi-Polony’s litigation can thus be found among other 
cases in France and Italy, but the distinguishing element of their conflict is the overlap of 
competing forms of official legitimation. France was still a kingdom with a plurality of 
jurisdictions in 1656. The central monarchy had survived the Fronde and was reasserting 
its control, although Louis XIV was still a few years away from personal rule (1661), and 
the effective, centralizing state associated with Jean-Baptiste Colbert was still in the 
future. Legal pluralism had important consequences in the medical world: amidst the 
diversity of local jurisdictions, it made sense from the perspective of the itinerant 
charlatan to keep constant records of effective cures, successful trials, and permissions 
granted by civil authorities. All of these documents could be presented before a local 
tribunal in case of a conflict with a rival charlatan or a local medical corporation. By 
travelling to the south to sell his orviétan, Contugi was subverting provincial charlatans 
like Polony. He tied his own legitimacy to the expanding central monarchy, rather than 
relying on local authorities or attestations. In so doing, however, he encountered 
                                                 
 71 Edouard Guéguen, “L’essai de l’orviétan : une démonstration de toxicologie dans un prétoire en 
1697,” Revue d’histoire de la pharmacie 51, no. 178 (1963): 168–72. 
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resistance at the Toulouse Parlement, and again appealed to royal authority, aiming to 
move the conflict to the more favourable playing field of the Conseil privé, where his 
privileges were registered. 
The Contugi-Polony conflict stands as a testament to the complexity of 
overlapping jurisdictions, conflicting privileges, public drug trials, and the need to 
constantly preserve and carry records to demonstrate legitimacy. All of these factors must 
have been features of daily life for the charlatans of seventeenth-century France. This 
conflict also demonstrates that although an appeal to royal authority was a powerful asset, 
it was still far from absolute.  
4. From secret to brand: The Contugi privilege vs. pharmacopoeia orviétan, 1682 
 A few decades after their tangles in the provinces, the Contugi family would face 
new problems closer to home. In the fall of 1682 a new apothecary’s boutique opened 
opposite that of the Contugi’s on the rue Dauphine facing the Pont Neuf. Roberte 
Richard, the widow of Christophe Contugi, reported that the new boutique’s attendant, 
one Jean Regnault, was replicating their display and containers (montre et boëttes) and 
selling his own drug under the name of orviétan. Her son, Louis-Anne, was the legal 
holder of the orviétan privilege but happened to be out of town, and so Roberte, unable to 
tolerate such a flagrant violation of her family’s privileges, brought her grievance to the 
Châtelet—making the request under her own name—and on the December 18, 1682, the 
Commissioner Adrien Baudelot effected a seizure of all merchandise in the offending 
shop. Before long, however, Roberte found herself the defendant in a countersuit: the 
plaintiff was the royal apothecary Anthoine Boulogne, then living in Versailles, who 
made it known that the boutique opposite that of the Contugi’s belonged to him and that 
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Regnault was simply his store clerk (garçon de boutique), selling the orviétan on his 
behalf. The Contugi-Boulogne conflict would drag on for over two years, and would raise 
the pivotal question of whether the Contugis could continue to hold an exclusive 
privilege to sell orviétan when the secret of its recipe had been “divulged” in multiple 
pharmacopeias.72 
 Boulogne initially brought his case to the Prévôté de l’Hôtel du roi, where his 
own privileges were registered. This raised a jurisdictional conflict between the Prévôté 
de l’Hôtel du roi—which held jurisdiction over the servants of the royal house and the 
privileged artisans following the court, including royal apothecaries like Boulogne—and 
the Parc civil of the Châtelet—the court of first instance for the city of Paris, where 
Roberte had reported the initial infraction.73 Boulogne requested a règlement de juges 
from the Conseil privé to decide which court should hear the case.74 During this time, 
Contugi appears to have secured new letters patent on July 16, 1683 and registered them 
at the Châtelet. These jurisdictional conflicts tied up the case for over a year, but on 
March 27, 1684 an arrêt from the Conseil privé ordered the case to be placed the case 
under its jurisdiction and ordered both parties to present their arguments within a week.75 
 In response, Boulogne had a Requeste servant de Factum printed in order to lay 
out his case. He argued that the 1647 privileges that Roberte Richard invoked in the 
initial seizure were made out personally to Christophe Contugi and were non-hereditary, 
                                                 
 72 These details are from the notarized act that ultimately resolved the dispute: see BIUS 
Pharmacie, Reg. 31, “Transaction faite entre le Sieur et veuve Contugi et les apothiquaires privilégiés sur 
l’instance à l’occasion de la saisie faite à le Sieur Boulogne” (August 14, 1685),  fol. 272-275. For a 
summary see Planchon, “Notes sur l’histoire de l’Orviétan” 245-250. 
 73 See Michel Antoine et al., Guide des recherches dans les fonds judiciaires de l’Ancien Régime 
(Paris: Imprimerie nationale, 1958), 11–12 on the Prévôté de l’Hôtel, 163–178 on the Châtelet. 
 74 On the procedures of the Conseil privé see above, this chapter, n. 37 and n. 58. 
 75 Requeste servant de Factum pour Antoine Boulogne Ayde-Apoticaire du Corps du Roy, 
Défendeur. Contre Roberte Richard, veuve Contugi, dit l’Orvietan, et son fils, Demandeurs et Défendeurs. 
(Paris: s.n., 1684), 1–3. 
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since they mentioned nothing about his widow or heirs, and thus were extinguished upon 
his death. Likewise, he argued that these letters had not given Christophe, much less his 
widow, the right to run a boutique in Paris, but rather had allotted him only the right to 
sell it itinerantly (une faculté ambulante). Consequently, the initial seizure was without 
legal foundation. As such, Boulogne requested that their boutique be closed and that they 
be fined 3,000 livres for damages against him, pointing to the undue force of the seizure, 
alleging that the Contugi widow “closed his boutique down, broke everything that was 
found within it, and damaged and seized his sign,” not to mention “the loss of all the 
orviétan removed by the Contugis, the production of which had cost a considerable 
sum.”76 He also argued that the letters patent that Louis-Anne Contugi had secured in the 
intervening period were invalid because he has not provided the requisite demonstration 
before civil magistrates, and furthermore, that he registered them at the Châtelet in 
prejudice of their ongoing case before the Conseil privé.77 
 Most of these points were aimed at invalidating the initial seizure of goods 
ordered by Roberte Richard, but the response to the fifth question—as to whether the 
Contugis could in any case prohibit apothecaries from selling orviétan—strikes at the 
heart of the issue of pharmaceutical secrecy and the prerogatives of apothecaries. 
Boulogne argued that orviétan is not a medical secret at all, but a publicly-known 
antidote described in various pharmacopeias. As examples, he first cites Schroeder’s 
Pharmacopoeia medico-chymica, “the Roman pharmacopeias for more than four 
centuries,” the pharmacopeiae of Brussels, Antwerp, Lyon, Augsburg, Venice, Naples, as 
                                                 
 76 Ibid., 5. 
 77 I have not been able to find a copy of the 1683 letters patent. The condition is not present, 
however, in the reconfirmed privileges Contugi secured in 1685: see AN O1 30, fol. 397 (27 December 
1686). It is possible that Boulogne is drawing this stipulation from the 1647 privileges, and deliberately 
conflating them with the 1683 privileges in order to add another argument to his case. 
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well as the recent and royally-sponsored pharmacopeia of Moyse Charas.78 As Boulogne 
would have it, physicians daily prescribed orviétan using any one of these various 
formulae. Boulogne granted that these recipes may not be the same as that used by the 
Contugis, but this difference was not due to their recipe being a hereditary medical secret, 
but rather to the fact that the Contugis used discounted, nearly-expired ingredients (this, 
he alleges, had been argued by several authors, who had exposed them). Quality, then, is 
what distinguishes the orviétan of the apothecaries from the orviétan of the Contugis, and 
this quality is rooted in the skill of the practitioner: Boulogne asked rhetorically, 
Who could convince themselves that a woman without experience, and her 
son, without having any tincture of medicine or pharmacy, would know 
how to make mixtures, preparations, coctions, and settle everything that 
goes into the composition of a remedy which apothecaries only attempt 
after having undertaken much work, long study, repeated public 
examinations, and the production of a masterpiece—in sum, after having 
provided evidence of their capacity to be admitted [to the guild] and be 
granted the faculty to exercise this art?79 
 
Boulogne thus argues that the orviétan produced with all the assurances of the corporate 
world is quite simply better than anything Contugi and his mother Roberte could ever 
hope to produce. Boulogne clinches his case with a volley of arguments against the 
notion that orviétan was a hereditary family secret: Not only was orviétan in the 
pharmacopeias, but it had also been produced publicly, even in Paris, in a demonstration 
organized by Henry Rouvière, the syndic of the apothecaries of the royal households, 
Boulogne’s own corporation, before the Lieutenant General of Police and the Paris 
Faculty. Likewise, he argued that “this remedy cannot be too public at a moment when so 
                                                 
 78 On the presence of orviétan recipes in these pharmacopoeias, see below. 
 79 “Qui peut se persuader qu’une femme sans expérience, et sons fils sans avoir aucune teinture de 
médecine ny de Pharmacie sçache et puisse faire les mélanges, les préparations, les coctions, et régler tout 
ce qui entre en la composition d’un remède que les Apoticaires n’entreprennent qu’après de grands travaux, 
de longues études, des expériences publiques et réitérées, la confection de leur chef d’œuvre, et avoir donné 
des preuves certaines de leur capacité pour pouvoir estre admis, et avoir la liberté d’exercer cet Art,” 
Requeste servant de Factum pour Antoine Boulogne, 9. 
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many have been accused of poisonings,” clearly referring to the recently concluded 
Affair of Poisons.80 If orviétan were the special preserve of the Contugis, it would 
“dismember” pharmacy and alienate apothecaries from their proper function; as such, it 
would run contrary to the order of arts and crafts which the king intended for his subjects. 
 Boulogne’s argument rests upon two foundations: the necessary superiority of the 
training and consequently skills of corporate apothecaries, and the assertion that orviétan 
is not itself a hereditary medical secret at all. The second claim has an important basis. 
By 1685, orviétan had indeed been included in several pharmacopeias. The most recent 
of these, the Pharmacopée royale of Moyse Charas, criticised those charlatans who 
claimed to own the true secret of orviétan in much the same terms as Boulogne.81 But the 
question still remains: Did Charas or any of the other pharmacopeias have the familial 
recipe of the Contugi family for the “one true orviétan”?  
 It is virtually impossible to say. Patrizia Catellani and Renzo Console have 
demonstrated that recipes of orviétan were extremely variable, and astutely point out that 
this variability was in fact a product of the conditions of competition and medical secrecy 
under which orviétan was originally disseminated. Secrecy served to encourage a 
multiplication of recipes, as different charlatans, apothecaries, and physicians sought to 
replicate, imitate, counterfeit, or publicize the secret. Under these conditions, the number 
                                                 
 80 “…ce remede ne peut estre trop public dans un temps où tant de gens ont esté accusez de 
poison,” Ibid. 
 81 “Les bons effets que l’Orviétan bien préparé a pû produire autrefois, ont donné occasion à 
divers affronteurs d’employer toute sorte de moyens pour faire croire qu’eux ou leurs devanciers en 
estoient les seuls inventeurs, et qu’il n’y avoit qu’eux qui en eussent la vraye recepte; En sorte que 
plusieurs de ces trompeurs ont couru les Provinces et les Royaumes, et que sous l’apparence frauduleuse de 
quelque bon succez, en pantalonnant et se joüant du peuple crédule dans les Places publiques, ils ont attrapé 
son argent, et amassé des sommes considerables du debit extraordinaire qu’ils ont fait d’un Orvietan 
supposé,” Moyse Charas, Pharmacopée royale galénique et chymique (Paris, 1676), 323–324. 
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of ingredients expanded and recipes became exceedingly complex.82 Throughout the later 
sixteenth and early seventeenth centuries, orviétan does not appear in printed 
pharmacopeias: at least initially, members of the corporate medical community seem to 
have sought to keep their distance from the orviétan charlatans.83 According to Catellani 
and Console, recipes for it begin to appear in printed pharmacopeias beginning with 
Johann Schröder’s Pharmacopoeia medico-chymica in 1655, which is likewise the first 
that Boulogne cites in his Requeste.84 Indeed, by the time Boulogne wrote, recipes for 
orviétan were readily available in the pharmacopeias of Schröder (1655), Prévost (1666), 
Kratzman (1667), Herford (1667), Hoffmann (1675), and Charas (1676); the official 
pharmacopeia of Rome (1668) and Lyon (1676); as well as in La Martinière’s 1665 
treatise on theriac, mithridatium, and orviétan.85 It seems plausible that orviétan made its 
entry into the pharmacopoeias at precisely the moment where they began to include 
chymical remedies, as the titles of Schröder and Charas suggest. 
 In other areas, Boulogne’s claims are more dubious. Orviétan was not included in 
the Roman pharmacopeia until 1668, which is a far cry from the “four centuries” that 
Boulogne alleges. But this hyperbole can perhaps be explained by another of his claims, 
namely that of the public demonstrations and preparations of orviétan he mentions having 
been recently undertaken by Rouvière, the royal apothecaries’ syndic. This almost 
certainly refers to Rouvière’s public preparation of theriac, described in the 1685 Journal 
                                                 
 82 Catellani and Console, L’Orvietano, 59. 
 83 Ibid., 61. 
84 Johann Schröder, Pharmacopoeia medico-chymica sive Thesaurus pharmacologicus, 4th ed. 
(Ulm, 1655), 184. 
 85 Catellani and Console, L’Orvietano, 61–79. Of these, Boulogne only cites Schröder, Charas, 
and the pharmacopeia of Lyon and Rome. 
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des Sçavans.86 Beforehand, Rouvière secured all of the ingredients in the Galenic recipe 
for the theriac of Andromachus in large quantities, including opolbalsam and xylobalsam, 
and on the day of his demonstration, he presented the Paris Faculty, apothecaries, and the 
interested public with the spectacle of fifty-eight dozen live vipers, pronounced a speech, 
and then cooked the vipers with only two spoons of water in a massive bain-marie. He 
then kneaded the resultant juices with the other ingredients into trochiques (bread 
lozenges), which preserved the volatile salts to which theriac’s virtues as an antidote were 
credited.87 The royal apothecaries’ preparation followed an earlier public preparation of 
theriac, organized the previous year (1684) by the urban apothecaries Matthieu-François 
Geoffroy, Antoine Josson, and Simon Boulduc.88 
 The reference to Rouviere’s public theriac demonstration thus allows us to 
understand some of Boulogne’s more puzzling statements, namely his claim that the 
secret of orviétan has been included in pharmacopeias for centuries: he seems to be 
saying that orviétan is largely indistinguishable from theriac. To what extent can orviétan 
be seen as a species of theriac? No recipe for the Contugi family orviétan appears to have 
survived, at least that I know of, but the question can be answered by looking at the 
variety of other orviétan recipes that have survived. Catellani and Console have 
examined thirty-five different recipes and determined that the number of ingredients 
varies between nine and fifty-seven, with an average of twenty-six. They provide useful 
comparative tables showing which ingredients appear in which recipes, and also offer a 
                                                 
 86 “Préparation célèbre de la Thériaque nouvellement faite à Paris par M. de Rouvière,” Journal 
des Sçavants 13.13 (16 April, 1685): 228–231. The demonstration appears to have happened the previous 
March, around the same time as the arrêt that led Boulogne to produce his Factum.  
87 Ibid. 
88 Olivier Lafont, Échevins et apothicaires sous Louis XIV : la vie de Matthieu-François Geoffroy, 
bourgeois de Paris (Paris: Pharmathèmes, 2008), 47–52. 
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statistical approach to the data: acknowledging the hypothetical nature of the exercise, 
they selected the twenty-six most frequent ingredients to construct a kind of “ideal-type” 
of the orviétan.89 Of these, the three most frequent are angelica root, honey foam, and 
“aged” theriac.90 So, it can safely be said that most pharmacopoeia recipes of orviétan 
contained prepared theriac, and many of those that did not contained either mithridatium 
or some theriac ingredients, most notably viper flesh.91 Therefore, even if orviétan cannot 
be reduced to theriac, as it might contain dozens of other ingredients, it seems clear that 
the two drugs were closely related. Indeed, it may not be a coincidence that the renewed 
interest in theriac, most dramatically illustrated by public preparations like the one 
described in the Journal des Sçavans, matched up quite closely with the appearance of 
orviétan in the pharmacopeia. 
 With this in mind, what was the outcome of the lawsuit between Boulogne and 
Contugi? Both parties eventually decided to settle out of court, signing a notarized 
cessation of hostilities on 14 August 1685.92 Interestingly, Rouvière, the royal apothecary 
who led the theriac demonstration, appears as a party in the contract in his capacity as 
                                                 
89 Catellani and Console, L’Orvietano, 119–134. 
90 Most orviétan recipes I have seen are careful to specify the use of “old” (vetere, vielle) in the 
sense of “aged” or well-fermented theriac (not “old” in the sense of “expired”). In his 1698 Pharmacopée 
universelle, Lémery explains the virtues of old theriac in the following terms: “La thériaque vieille est 
préférable à la récente quand il s’agit de résister au venin, parce qu’ayant fermenté ses parties se sont 
subtilisées, exaltées et rendues capables de dissoudre et de raréfier les congélations qui se dont faites dans 
le sang et dans les autres humeurs soit par les morsures ou piqueures des animaux venimeux, soit par les 
autres poisons coagulans, soit par l'air infecté, soit par la trop grande quantité d'acide qui se rencontre dans 
les corps,” Nicolas Lémery, Pharmacopée universelle (Paris: Laurent d’Houry, 1698), 601–602. 
91 Catellani and Console follow Planchon in dividing orviétan into two general categories: the 
various forms of “Italian orviétan,” which contain theriac; and the supposed orviétanum praestantius 
(“more-potent orviétan”) of Lémery and the eighteenth century Paris Codex, which is more of an opiate or 
analgesic than an antidote: see Catellani and Console, L’Orvietano, 58–60. 
 92 BIUS Pharmacie, Reg. 31, “Transaction faite entre le Sieur et veuve Contugi et les apothiquaires 




syndic for the corporation of the apothecaries of the royal households, of which Boulogne 
was a member.  
 According to the contract, the parties recognized the expensive legal fees that 
continued litigation at the Grand conseil would entail and resolved that, in order to 
“foster peace and friendship between them,” they followed the “good counsel” of their 
friends and agreed to return their affairs as close as possible to the status quo that existed 
before Roberte’s initial seizure.93 The pending lawsuit at the Grand conseil was dropped, 
and the following specifications were made concerning the sale of orviétan: 
Louis Anne de Contugi remains free to compose, sell, and retail his 
orviétan as before, while the apothecaries of the Royal Houses will not be 
allowed to sell their orviétan (whose composition is taught in the 
pharmacopoeias) from the houses on the edge of the Pont Neuf, or to 
counterfeit the display, tickets, containers, marks or signs of said Contugi, 
son, nor to post signs with the name of Orviétan outside of their boutiques, 
as he does, nor in the roads, crossroads, and public squares of Paris, under 
penalty of all expenses, damages, and interest falling on the offender.94 
 
The settlement thus prohibits Boulogne and any other royal apothecaries from selling 
orviétan out of any boutique on the Pont Neuf or from replicating any of the material 
aspects of the Contugi orviétan brand, including their displays, handbills (billets de 
distribution), containers, and signage. The contract does not, however, prohibit them 
from otherwise making or selling “their orviétan,” carefully distinguished from that of 
the Contugi’s as the orviétan that is included in the pharmacopeias recipes.  
                                                 
 93 BIUS Pharmacie, Reg. 31, 274r°-v°. 
 94 “…demeurant libre au Sieur Louis Anne de Contugi fils de composer, vendre, et débiter son 
orviétan comme auparavant, sans que les apotiquaires des Maisons Royales puissent vendre et débiter leurs 
orviétan dont les compositions sont enseignez par les autheurs des pharmacopées aux maisons qui sont au 
bout du Pont Neuf, prendre ny contrefaire le montre, les billets de distribution, les boëtes, la marque ny 
l’enseigne dudit Sieur Contugi fils, ny afficher comme luy au dehors leur boutique, ny dans les Rues, 
Carrefours et places publiques de Paris le nom d’orviétan a peine de toutes dépens, dommages, et intérêts 
contre les contrevenans,” BIUS Pharmacie, Reg. 31, 274v°. 
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 Implicit within the agreement is a recognition on the part of the Contugis that the 
genie was out of the bottle, as far as their medical secret was concerned, but they might 
still retain their cachet in advertising, branding, and sales location. So long as their rivals 
did not interfere with these features, then apothecary production and sale of what might 
be called “pharmacopeia-orviétan” could be tolerated. The settlement thus reinforced a 
trend already apparent in the Polony debate; that is, it stressed the Contugi orviétan as a 
brand rather than a medical secret.  
What was the Contugi brand in concrete terms? Answering this question will take 
us from legal debates and notarized settlements and into print advertising and material 
culture. These images corroborate one of the main points of the Polony case, namely, the 
centrality of the sign of the Sun. It appears prominently at the top of the Contugi 
broadsheet advertising poster as a sun with a human face, surrounded by the motto, “ut 
sol solus ut sal salus” (see Fig. 4).95 The sign is surrounded by coats of arms, including 
those of the Pope and of France and Navarre. The rest of the border is made up of snakes, 
mushrooms, frogs, fish, spiders, scorpions, snails, and rabid dogs, all sources of poisons 
to which orviétan served as an antidote. These images may also have been present on the 
larger displays (tableaux and montes) that are mentioned.  
 The sun is without a doubt the most important of these images, and appears 
prominently on the small lead containers (boites) that orviétan was apparently sold in 
(see Fig. 1 for an intact example). Even in the twenty-first century, these containers 
continue to be unearthed by French hobbyists with trowels and metal detectors. Their lids 
often had the figure of the sun with a face (see Appendix 3, Figures 3-5 and 8-10) and a 
                                                 
 95 Roughly, “Sole as the sun, salutary as the salt,” perhaps referring to the volatile salt to which 




few words, such as the name of the variety of orviétan or a motto.96 The prominence of 
the sign of the sun—with its obvious links to the authority of Louis XIV—on both the 
broadsheet and the container lids, helps illustrate just what was at stake in the court 
debates between the Contugis and rivals like Polony and Boulogne. If we take the 
Contugis at their word, “the sign of the sun” was an inalienable mark, inseparable from 
their family and the hereditary secret to the true orviétan, even if it was used fraudulently 
by other charlatans.  
 After the debate with Boulogne, the conflicts surrounding the Contugi orviétan 
privilege seem to die down for a few decades. The parties appear to have lived in peace 
after the contract. In the following year, Louis-Anne Contugi would have his royal 
privileges confirmed and secure a passport to travel and sell orviétan throughout France. 
The December 27 1686 letters patent even specify that he holds the privilege jointly with 
his mother, perhaps in response to the difficulties that had arisen when Roberte acted 
legally to defend her son’s privileges in his absence.97 Antoine Boulogne would go on to 
be royal first apothecary in 1704.98 Matters were settled with the royal apothecaries, and 
in the eighteenth century it would be the urban apothecaries guild that would duel with 
the Contugi family in the courts.  
  
                                                 
96 A veritable subculture of treasure hunters, numismatists and antiquarians maintain online 
forums where they display and help one another identify their discoveries; on their forums I have found 
images of several orviétan containers. Those in Figs. 2-3 may not have been Contugi-brand orviétan, and 
are marked “Orvietan de Rome.” The container in Figs. 6-8, however, is almost certainly a Contugi 
container as it bears the “ut sol solus ut sal salus” motto found on the broadsheet. 
 97 For the letters see AN O1 30, fol. 397 (27 December 1686); and the passport see AN V5 1246, 
fol. 209, February 6, 1686, registered at Conseil privé January 20, 1687. Le Paulmier, L’Orviétan 147–150. 
 98 Maurice Bouvet, “Les apothicaires royaux,” Bulletin de la sociétié de l’histoire de la pharmacie 
5, no. 58 (1928): 62. 
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5. Charles Dionis and the fate of the Contugi orviétan privilege, 1700-1741 
 
 Two developments characterize the passage of the Contugi orviétan monopoly 
into the eighteenth century: the first was a series of problems with ensuring the 
privilege’s succession down the Contugi family line; the second, closely related, was the 
growing involvement of Paris Faculty doctors with the family business. These 
developments culminated in the privilege’s departure from Contugi hands in 1740, when 
it was purchased by a Paris Faculty Doctor, Charles Dionis (1710-1776). 
 The second-generation privilege holder in the Contugi line, Louis-Anne, died in 
1696, and his widow Marie-Jeanne continued the business until her own death in 1699, at 
which time it passed into the hands of their two oldest children Jean-Louis and Marie-
Geneviève.99 Their new brevet of July 12, 1700 confirmed Jean-Louis as the successor of 
the privilege, but he was only fifteen years old, so his older sister, who was “instructed in 
the composition of orviétan,” was appointed to “work conjointly” with her brother until 
his twenty-fifth year. The brevet also specified that the first physician Fagon would 
appoint “a capable man to inspect the composition.”100  
 The same succession problems recurred in the fourth and final generation of the 
Contugi family’s tenure of the privilege. Jean-Louis died in 1719, having acquired the 
title of esquire and valet garderobe of the Duke of Orléans, then Regent. Through his 
connections with the Regent, Jean-Louis ensured that the orviétan privilege would pass 
on to his son Florent, then only ten years old. In the meantime, the business was directed 
                                                 
 99 Le Paulmier, L’Orviétan, 66–68. Marie-Geneviève apparently had a rambunctious lifestyle, 
frequenting cabarets and cafés: in 1700, shortly after being granted the joint privilege with her brother, 
several relatives made an attempt to have her committed to a convent. She appealed directly to the first 
physician Fagon and Phélypeaux, Secretary of State for the Royal House; on which see Le Paulmier, 
L’Orviétan 70–2. 
 100 AN O1 44, fol. 297v-198r, Item 1006,  “Brevet portant que Geneviève Contugi travaillera 
conjointement avec son frère a la composition de l’orviétan jusques au temps qu’il ait 25 ans.” Also 
transcribed in Ibid., Pièce XXVII, 178–179. 
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by his widow, Marguerite du Chesnoy, until her death in 1727.101 During Florent 
Contugi’s tenure of the privilege, this inspector was none other than the Paris Faculty 
doctor Nicolas Andry de Boisregard (1658-1742). Andry was quite far from being a 
marginal figure: he was in fact a former Dean of the Faculty (1724-1725) and famous 
author of De la génération des vers dans le corps de l’homme (1700) and L’orthopédie 
(1741), and a contributor to the Journal des sçavans. 102 As Le Paulmier has pointed out, 
Andry was also Charles Dionis’s father-in-law: as orviétan inspector he was in the 
perfect position to recognize the profitability of the drug—he himself received 400 livres 
annually from it for his inspections—and likely had a hand in recommending its purchase 
to his son-in-law after the death of Florent Contugi.103 
 Andry was the official orviétan inspector in 1729, when a trio of local 
apothecaries had the Lieutenant General of Police effect a search of Florent Contugi’s 
home and boutique, still on the Quai des Augustins, as a reprisal against an earlier search 
and seizure Contugi had effected against them for selling orviétan near his boutique.104 
The pretext for this reprisal—which forms but one episode in the long war between the 
Contugis and local apothecaries—was provided by the 1728 arrêts which aimed to 
reform the privilege system.105 The apothecaries had reported Contugi to the Lieutenant 
                                                 
 101 Ibid., 75–80. 
 102 Nicolas Andry de Boisregard, De la génération des vers dans le corps de l’homme (Paris: 
Laurent d’Houry, 1700); and L’orthopédie (Paris: veuve Alix, 1741). On Andry's career, see Brockliss and 
Jones, The Medical World of Early Modern France, 449–450 (mainly on his work L’orthopédie), and 
especially Jacques-Albert Hazon, Notice des hommes les plus célèbres de la Faculté de médecine en 
l’Université de Paris (Paris: Benoît Morin, 1778), 192–195, which remains the best source of biographical 
details on Andry. Hazon notes that the daughter married to Dionis was Andry’s only child. 
 103 “Nicolas Andry, inspecteur préposé à la composition de l’orviétan, et beau père de Charles 
Dionis, avait inspiré ce marché avantageux pour sa fille. On y voit, en effet, que la vente de ce remède 
produisait encore de beaux bénéfices,” Le Paulmier, L’Orviétan, 96. 
 104 The best account of the conflict between Florent Contugi and the apothecaries’ guild is 
Planchon, “Notes sur l’histoire de l’Orviétan,” 293–298. See also Le Paulmier, L’Orviétan, 86-88. 
 105 See above, ch. 1. 
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General of Police for failing to deliver his brevet to be re-examined under the new 
privilege regime. The Parisian apothecaries’ guild had likely been on the lookout for such 
an opportunity. Their guild was attentive to any potential violations of their own 
corporate privileges and, consequently, exceedingly diligent in inquiring with the 
Châtelet and other courts to secure copies of any new privileges, acts, and judgments 
pertaining to potential interlopers, including the Contugis.106 The apothecaries 
accompanied the bailiff (huissier) who had been delegated to effect the seizure, and 
surprised Florent Contugi in his chambers, still in his nightgown (chemise). Contugi, who 
was by then twenty years old, immediately sent for Andry and his legal guardian 
(curateur), the Paris bourgeois François Perrin. Andry claimed that he did not know of 
the 1728 arrêts, and argued that the failure to present the privilege for re-examination 
was “not due to any lack of respect or submission.” He, the guardian, and the young 
charge refused to open a cabinet which contained the drug’s ingredients for the bailiff to 
inspect, on the grounds that opening it would disclose the drug’s secret. Consequently, 
the cabinet and the boutique were sealed, but nothing was seized.107 Contugi successfully 
appealed the apothecaries’ sealing of his boutique the following week at the Grand 
conseil, but the back-and-forth of lawsuits with the apothecaries would go on for years, 
                                                 
 106 See above: although the Boulogne episode (see above, this ch., section 4) occurred with 
privileged royal apothecaries, the judgements and privileges surrounding it were diligently copied into the 
registers of the Paris apothecaries guild, held at the BIUS Pharmacie. For the long series of suits and 
countersuits of which this episode forms a part, see BIUS Pharmacie, Boîte BA, Affaires Contugi (procès 
de l’orviétan), 1726-1736.  
 107 “Lesdits Andry, Perrin, et Contugi n’ont voulu représenter les clefs ni faire ouverture de ladite 
porte pour ne pas communiqué et faire voir les drogues qui entrent dans la composition dudit orviétan,” 
BIUS Pharmacie, BA 17, “Procès verbal de transport et saisie faite à la requête des maîtres et gardes 
apothicaires en la boutique de Contugi et apposition des scellés sur la porte de son magasin,” August 6, 




ultimately ending with them gaining the right to inspect the Contugi orviétan boutique in 
1736.108 
 Andry was party to this episode, and would thus have been able to inform his son-
in-law Dionis of both the profitability of the privilege as well as its attendant pitfalls 
before Dionis purchased it in 1741. He was afforded the opportunity to acquire it by yet 
another succession crisis: Florent Contugi died in 1740 without leaving behind a wife or 
any children of his own (he never married). The privilege passed to his sisters, 
Margueritte-Françoise and Anne. The latter was married to a lawyer, Louis Sagot, but 
neither of the two sisters seems to have been willing or able to run the business, and so 
they decided to sell the privilege to Dionis in exchange for an annual pension of 1,000 
livres.109  
 The fact that the last holders of the Contugi orviétan privilege were women bears 
some emphasis here. As we have seen, women played important roles in the orviétan 
dynasty: how did these features among privileged vendors like the Contugis compare 
with practitioners in the corporate medical world? Medical dynasticism appears to have 
been a feature shared across the corporative/non-corporative divide. Multigenerational 
businesses were especially common among apothecaries.110 But the role of women 
                                                 
 108 BIUS Pharmacie, Reg. 9, Arrêts des conseils du Roy (1614-1777), 63-67; for the conclusion 
see esp. no. 67, “Lettres patentes maintenant F. Contugi dans son monopole, avec autorisation aux 
apothicaires de procéder chez lui aux visites et autorisation de débiter de l’orviétan,” December 31, 1736. 
 109 MC ET XV 353, “Désistement de privilège de Margueritte-Françoise Contugi et Anne Contugi 
à Charles Dionis,” September 5, 1741, 2 fols.; and AN O1 85, p. 333-337, “Lettres patentes de privilège 
exclusif pour la composition de l'orviétan en faveur du Sieur Dionis,” September 29, 1741. Technically, the 
Contugi sisters “desisted” from the privilege, which Dionis then proceeded to renew with the Secretary of 
State in his name. It should also be noted that in addition to the 1,000 livre pension payable to the sisters,  
another 1,000 was also due to the six children of their aunt, Marie-Geneviève Contugi (veuve Marchand), 
who had previously held the privilege jointly with their father Jean-Louis until his majority (see above). 
This provision may be the legacy of an earlier agreement between Jean-Louis and Marie-Geneviève. 
 110 Christian Warolin, “Le cadre de vie professionnel et familial des apothicaires de Paris au XVIIe 
siècle” (Thèse de doctorat en Histoire, Université Paris IV-Sorbonne, 1994), 225–278; Christian Warolin, 
“La dynastie des Boulduc, apothicaires à Paris aux XVIIe et XVIIIe siècles,” Revue d’histoire de la 
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appears to have been considerably more important among the secret remedies vendors. In 
stark contrast with the important role of women in bearing, transmitting, and selling 
secrets and privileges in the Contugi monopoly, the rights of women in the medical 
guilds were being curtailed in the sixteenth and seventeenth centuries. While in the 
fifteenth century widows were permitted to continue running their husband’s shops so 
long as they hired a journeyman, guild statutes were gradually modified across France to 
oblige the widows to actually marry the journeyman, rather than merely employ him.111 
Among the secret remedies vendors, by contrast, a widow like that of General La Motte 
could run her late husband’s business for decades.112 Likewise, as we have seen, mothers 
and sisters like Roberte and Geneviève Contugi played active roles in the family business 
on both formal and informal levels: their names were in fact listed alongside those of the 
male orviétan heirs in the family privileges.113 
 In short succession, the Contugi sisters sold all of their equipment and related 
facilities to Dionis as well, notably the house and boutique on the Quai des Augustins, for 
                                                                                                                                                 
pharmacie 89, no. 331 (2001): 333–54; Françoise Lehoux, Le Cadre de vie des médecins parisiens aux 
XVIe et XVIIe siècles (Paris: Picard, 1976). 
 111 Brockliss and Jones, The Medical World of Early Modern France, 190, 263; Susan Broomhall, 
Women’s Medical Work in Early Modern France (Manchester: Manchester University Press, 2004), 24–31; 
Jean Flahaut, “L’exercice de la pharmacie par les veuves d’apothicaires du XVe au XVIIIe siècles. lère 
partie: aspects réglementaires,” Revue d’histoire de la pharmacie 90, no. 335 (2002): 367–78. 
112 On La Motte’s widow see above, ch. 1, sect. 5. 
 113 This phenomenon does not appear to be unique to France: the cases of the Grimaldi electuary 
in Bologna and the Colochi plague remedy in Venice likewise suggest that women played important roles 
in transmitting medical secrets in multi-generational familial monopolies. On the Grimaldi electuary, see 
David Gentilcore, Medical Charlatanism in Early Modern Italy (Oxford: Oxford University Press, 2006), 
66–78; and Gianna Pomata, “Practicing between Earth and Heaven: Women Healers in Seventeenth-
Century Bologna,” Dynamis 19 (1999): 119–43. On the Colochi plague remedy, see Jane Stevens 
Crawshaw, “Families, Medical Secrets and Public Health in Early Modern Venice,” Renaissance Studies 
28, no. 4 (2014): 597–618. See also Brockliss and Jones, The Medical World of Ealry Modern France, 
627–628, for similar cases. It should also be mentioned that the famous English proprietary remedy, 
Daffy’s elixir, was entrusted to Anthony Daffy’s widow to be passed on to his daughters as a source of 
income, although this was later contested by his widow’s new husband: see Haycock and Wallis, Quackery 
and Commerce 7. For more on Daffy’s elixir see below, ch. 5.  
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the sum of 8,000 livres.114 There can be little doubt that the medical secret orviétan was 
communicated to Dionis, either by the Contugi family or perhaps even by Andry, who 
appears to have been privy to it as official inspector. This medical secret is not, however, 
mentioned in the notarized contracts, and it seems not to have been assigned any 
monetary value. 
 How can we explain the interest of a Paris Faculty doctor in acquiring the 
privilege to what Brockliss and Jones have called “that most quintessentially 
charlatanesque of remedies”?115 Was he “hungry for cash” to use Guy Patin’s phrase, as 
De Gorris supposedly had been in 1648? This is certainly possible, but as his own 
privilege notes, Dionis was descended from a line of famous courtly practitioners: he was 
grandson of Louis XIV’s surgeon, Pierre Dionis, and son of the Dauphine’s physician, 
François Dionis.116 Brockliss and Jones have pointed out that the Paris Faculty became 
“complicit” with “Quack Street” in the late eighteenth century, as its doctors embraced 
the financial rewards of medical entrepreneurialism, but as this chapter has shown, the 
Faculty’s complicity extends much further back, through Andry and all the way to the 
mid-seventeenth century endorsement by Jean De Gorris and the twelve doctors.117  
 For the first twenty years of his tenure of the privilege, Dionis appears to have 
operated much as the Contugis had, focusing primarily on the Parisian market. This 
changed drastically beginning in 1762: from then until the end of his life in 1776, Dionis 
granted short-term contracts, typically three-years in duration, to a broad range of 
medical practitioners to sell orviétan on his behalf “en son nom et comme son 
                                                 
 114 Ibid., “Vente et constitution à Charles Dionis,” September 29, 1741, 2 fols. 
 115 Brockliss and Jones, The Medical World of Early Modern France, 638. 
 116 AN O1 85, p. 333-337, “Lettres patentes en faveur du Sieur Dionis”; Le Paulmier, L’Orviétan, 
97. 
117 Brockliss and Jones, The Medical World of Early Modern France, chaps. 10, esp. 636–637. 
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commissionaire,” and registered with the Prévôté de l’Hôtel du Roi.118 Whereas Adrien 
Helvétius harnessed the power of the state’s fiscal infrastructure to distribute his remedies 
to the French provinces,119 Dionis devised a putting-out system, wherein he served as the 
central producer and the legal privilege-holder but contracted the actual distribution and 
sale of the drug to a vast network of sub-contractors. This finally actualized the kingdom-
wide potential inherent in the original 1648 privilege:  where Christophe Contugi 
personally went on tour to sell his antidote in the provinces, a century later Dionis simply 
contracted an army of vendors to do it for him.  
Dionis was not without his critics, of course, and his operation may have harmed 
the Paris Faculty’s credibility. When it protested the establishment of the Commission 
royale in the 1770s, the advocates of this new regulatory body could point to the 
Faculty’s long history of support for charlatans: they ridiculed the Faculty’s gall for 
wanting to be involved in the new regulatory regime, described Dionis’ letters patent as 
“a shameful and abusive privilege to flood the whole kingdom with charlatans,” and 
alleged that “it is from the bosom of the Faculty herself that these colonies of acrobats 
receive their missions.”120 Despite such protests, the Faculty never challenged Dionis’ 
privilege as it had De Gorris’ endorsement of the same drug a century earlier, and the 
                                                 
 118 For a breakdown, see above, ch. 1, sect. 3, and Pierre Baron, “La vente de l’orviétan en France 
à la fin du XVIIIe siècle,” St. Honoré les Bains, 6-8 June 1997, Actes de la Société française d’histoire de 
l’art dentaire, accessed May 10, 2014, http://www.biusante.parisdescartes.fr/sfhad/vol2/debut.htm. See 
also the useful graph in Brockliss and Jones, The Medical World of Early Modern France, 640–642; and 
the list of commissionnaires in Le Paulmier, L’Orviétan, Pièce LII, 233–246. 
 119 See below, ch. 4, esp. sect. 5. 
120 “Pourquoi la Faculté n’autoriseroit-elle pas les Empiriques, puisqu’elle souffre qu’un de ses 
members ait le privilège honteux et abusif d’inonder tout le Royaume de Charlatans? C’est du sein même 
de la Fauclté que les colonies de Bâteleurs reçoivent leur mission,” Observations sur la requête présentée 
au roi par la Faculté de médecine de Paris, contre l’établissement de la Commission royale de médecine. 
(Louvain: Vanderbeck Junior, 1773), 18. 
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story of the Contugi orviétan privilege ends, ironically, in the august hands of a Paris 
Faculty Doctor. 
6. Conclusions 
Throughout the century-long period covered by these case studies, secrecy, 
branding, and legitimacy played changing roles in the maintenance of the Contugi family 
monopoly. The medical secret of orviétan, acquired through Christophe Contugi’s 
marriage to Clarice, formed the historic root of the family business, but as time went on, 
branding—in the form of the “sign of the sun”—came to take on a greater importance as 
the family’s claims to the medical secret of orviétan became more and more tenuous in 
the face of rival orviétan charlatans and later the published officinal recipes used by 
competing royal and urban apothecaries. The Contugi orviétan passed from being a full-
fledged medical secret to being a medical brand, competing against other recipes and 
counterfeits. In some ways, the transition was inevitable: success breeds competition and 
imitation. The resolution of the 1685 conflict with the royal apothecaries demonstrates in 
high relief that by the second generation of the monopoly, Louis-Anne and his mother 
Roberte had realized that their litigation should focus on protecting their brand from 
imitators and ensuring the exclusivity of their privileged point-of-sale on the Pont Neuf. 
Further case studies of pharmaceutical monopolies in this period may be able to establish 
if the passage from the preservation of medical secrecy to an emphasis on protecting 
branding is related to larger processes of medical commercialization. 
 Approaches to legitimation also show interesting developments which are 
peculiar to the French context. In the absence of a protomedicato licensing charlatans, the 
Contugis appealed to royal authority for the right to sell orviétan. Although there can be 
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little doubt that a royal privilege was the best single source of protection and legitimation 
for a non-corporative pharmaceutical vendor in this periods, they were not without their 
limitations. A privilege gave vendors a foot to stand on, legally speaking, but litigation 
was still necessary to enforce their rights against interlopers. In this respect, they were 
like any Ancien Régime corporation: their privileges existed on royal parchment, but in 
practice they had to be upheld in the courts. 
This form of legitimation-from-above clashed with existing practices of 
charlatans like Polony, who carefully documented their successes with notarized cure 
attestations and kept collections of approvals from a variety of local and provincial 
jurisdictions, critical to itinerant vendors who travelled regularly from place to place in 
search of new markets. Securing a royal privilege presented the theoretical advantage of 
transcending the judicial pluralism of a large and diverse kingdom, but in practice 
Christophe Contugi still encountered resistance from local charlatans and judicial 
authorities when he tried to actualize the kingdom-wide potential of his letters patent. 
Indeed, the Contugi-Polony conflict in particular can be read as a manifestation of the 
larger forces of centralization in absolutist France. Christophe Contugi, enjoying the 
support of royal privileges to distribute his orviétan throughout the kingdom, went on 
tour to register these privileges at the provincial level in order to extend his operation 
from the center in Paris to the periphery. His privileges afforded him this right, so long as 
he guarantee the efficacy of his orviétan before local magistrates. Logistically, the 
privileges also afforded him the option of delegating the distribution to subordinates, a 
potential which Dionis would later actualize. Polony, on the other hand, depended upon 
the local authorities in the Languedoc for legitimacy: he initially enjoyed the support of 
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the provincial Estates General and of the recently rehabilitated Frondeur, Conti, who had 
taken up residence in the Languedoc. In the light of these difficulties, the family appears 
to have become entrenched in Paris—itself a sufficiently lucrative market—and it was 
not until the 1760s that Dionis was able to extend a centralized operation across France. 
Indeed, the role of the Paris Faculty within the story of orviétan is one of its most 
surprising features. Rather than adversaries, Faculty doctors were allies in several of the 
family’s struggles. Charlatans and apothecaries, not Faculty doctors, were the main rivals 
of the Contugis both in the marketplace and the courts. Indeed, Christophe Contugi 
looked toward Faculty physicians as potential allies and legitimators; Faculty doctors 
themselves, from De Gorris to Andry and culminating with Dionis, saw something to 
gain from collaborating with vendors of proprietary remedies like the Contugis. 
 The century-long story of the Contugi orviétan provides an excellent illustration 
of the difficulties inherent in maintaining a multi-generational familial medical monopoly 
in Ancien Régime France. Privileges provided a basis of legitimacy, but had to be 
assiduously defended. Medical secrets were subject to being revealed, drugs and their 
brands could be counterfeited, and ensuring the transmission of legal rights and property 
through the rocks and shoals of generational succession presented the same problems to 
familial medical-monopolists as it did to the rest of society. The Contugi family also 
provides a useful background for the two following case studies. The Helvétius and 
Guiller-Lajutais families would also base their fortunes on a royal privilege granting them 
a pharmaceutical monopoly throughout the kingdom of France. But both would go a step 
further than the Contugis: they saw that, besides being a legitimator, the state could also 




The Helvétius family and the transformations of ipecacuanha: 
The royal court, the army, and state-sponsored charity, 1688-1805 
 
 On August 23, 1688, Adrien Helvétius (1662-1727) was granted a fifteen-year 
monopoly privilege for the sale of his Remède spécifique contre le cours de ventre, le flux 
de sang, et la dysentérie (“Specific remedy against bowel runs, bloody flux, and 
dysentery”). Helvétius received this privilege following a series of patient trials he 
undertook the year before at the Paris Hôtel-Dieu, under the supervision of two royally-
appointed commissioners. Initially, the hospital’s staff and administration were not 
willing to grant Helvétius access to their patients: it took not one but two letters from no 
less than the Marquis de Seignelay—Secretary of State for the Navy and for the Royal 
Household and son of the famous Jean-Baptiste Colbert—to enforce their compliance.1  
The first of these was written to the governing council (bureau) of the hospital, while the 
second was addressed personally to one of this council’s most prominent members, 
Nicolas Potier de Novion, Premier président of the Paris Parlement. In this letter, 
Seignelay expressed his hope that following successful trial results—which seemed likely 
given Helvétius’ reputation—the remedy might provide a great relief to poor patients 
suffering from bloody flux and dysentery in the hospitals, as well as the sailors of Louis 
XIV’s ever-growing navy. Helvétius had apparently informed Seignelay that he had not 
yet been allowed access to the hospital, and the letter concludes with the following 
warning: “His Majesty orders me to write to you that he desires that you assist [the 
                                                 
1 AN O1 31 fol. 136v, Seignelay to the Administrators of the Hôpital général and the Hôtel-Dieu 
[in duplicate] (July 15, 1687); and fol. 142r, Seignelay to Potier de Novion, (July 19, 1687). 
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king’s] good intentions in these matters, and that if you have any difficulties in doing so 
that you take the trouble to let me know about them so that I might inform him.”2 
 Faced with this implicit threat, the hospital complied.3 Like other hospitals, the 
Hôtel-Dieu was primarily a charitable religious institution, and had good reason to 
suspect an ambitious physician like Helvétius, interested as he was in testing drugs on 
patients. Three months later, its records show that a confrontation occurred after 
Helvétius attempted to remove a patient from the hospital who was on point of death and 
had been given his last rites. Helvétius boasted that he could save the man and that he 
would have him fed and cared for in a private room, but the nuns and the spiritual 
director of the hospital refused to permit it out of fear that the man would die while being 
transported.4 The governing council for its part supported them in their refusal, but 
Helvétius once again went over their heads and appealed to Seignelay, who penned 
another letter, this time ordering the hospital to permit four patients—Estienne Ruisseau, 
Abel Noir, Charles Reguier, and Estienne Canon—to be removed and put under 
Helvétius’ personal care.5 It is unknown if one of these men was the dying man who had 
been served last rites, but the tests of Helvétius’ remedy were deemed successful by the  
royal commissioners, and Helvétius was granted his exclusive sales privilege. This 
privilege marks the beginning of a sixty year relationship that Adrien Helvétius and his 
son would cultivate with the French state, supplying their patented dysentery specific and 
                                                 
2 “Sa Majesté m’ordonne de vous escrire qu’elle désire que vous secondiez en cela sa bonne 
intention, et qu’en cas que vous y trouviez quelques difficultés vous preniez la peine de me les faire scavoir 
pour luy en rendre comte,” Ibid., fol. 142r. 
3 AAPHP, Registres des délibérations du Bureau de l’Hôtel-Dieu, liasse 1438, no. 6436, fol. 129r 
(August 1, 1687). 
 4 Ibid., fol. 172v (November 17, 1687). 
 5 AN O1 31 fol. 235r, Seignelay to Administrators of the Hôtel-Dieu (November 17, 1687). 
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eventually a whole line of other pharmaceuticals to the army and state-sponsored poor 
relief projects. 
Helvétius’ letters patent granted him the right to “establish at his home and 
elsewhere whatever furnaces and laboratories that he sees fit,” a provision which allowed 
him to produce large volumes not only of his remède spécifique, but also of “any other 
remedies that he is obliged to make for the healing of the sick and for the utility of the 
public.”6 These rights, coupled with his record of success in private practice among 
Parisian élites, ultimately furnished him with the necessary connections at court to 
present his remedy as a solution to the population-scale medical problems faced by the 
central administration of the French fiscal-military state. By 1690, Helvétius was 
supplying his drug to the French army in Alsace, and by 1706, he had expanded beyond 
his dysentery specific to produce an entire line of pre-packaged drugs. These were 
distributed with printed instruction sheets in standardized “medicine chests” (boëtes de 
remèdes), which travelled out to the provinces through the fiscal infrastructure of the 
French state—the intendants and their subdelegates—and were then distributed through 
the local charitable infrastructure of parish priests, village surgeons, and Daughters of 
Charity.7 
                                                 
 6 “La faculté d’avoir chez luy et ailleurs tells fourneaux et laboratoires qu’il croira luy estre 
nécessaires tant pour la composition de son Spécifique, que pour tous les autres remèdes qu’il est obligé de 
faire pour la guérison des malades, et pour l’utilité du public,” Lettres patentes du Roy portant pouvoir au 
Sieur Helvétius Docteur en Medecine, de débiter seul ses remedes contre le Cours de ventre, le Flux de 
sang, et la Dyenterie, dans toute l’étenduë du Royaume (Paris: Jean-Baptiste Coignard, 1688), 3r–v. 
 7 The Daughters of Charity (Filles de la Charité), were an uncloistered women’s religious order 
founded by Saint Vincent de Paul and Saint Louise de Marillac in 1633 and took annual (rather than 
perpetual) vows to serve the poor. They were largest female religious community in France by the 
eighteenth century and were particularly prominent in hospitals. See Colin Jones, “Vincent de Paul, Louise 
de Marillac and the Revival of Nursing in Seventeenth Century France,” in The Charitable Imperative: 
Hospitals and Nursing in Ancien Régime and Revolutionary France (London: Routledge, 1989), 89–121; 
Matthieu Bréjon de Lavergnée, Histoire des filles de la Charité, XVIIe-XVIIIe siècle : la rue pour cloître 
(Paris: Fayard, 2011). 
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Despite the fact that their careers contain elements of considerable interest to 
historians of medicine, the military, and the state, Adrien Helvétius and his son and 
successor Jean-Claude Adrien (1685-1755) remain little-known. The literature on them is 
dwarfed in both depth and volume by that surrounding their famous descendant, Claude-
Adrien Helvétius (1715-1771), the financier-turned-Enlightenment philosophe whose 
1758 work De l’esprit, was met with public outcry for its supposed atheist materialism.8 
When he is mentioned at all in surveys of the history of medicine, Adrien Helvétius 
receives a paragraph or two, where he is typically presented as the “popularizer” of 
ipecacuanha, the South American root which formed the principal ingredient of his drug. 
In this respect his case is usually compared to that of Robert Talbor and cinchona.9 
Beyond acknowledgements of this “popularizing” role, the details of their medical 
careers remain almost completely unexplored.10 Adrien and his son have, as of yet, been 
the subject of only a single monograph, that of Louis Lafond, La dynastie des Helvétius, 
published in 1926.11 Lafond uncovered a number of important sources, most notably 
Helvétius’ 1708 mémoire to the Controller General Desmaretz, where he petitioned to 
have a new office created, that of “Distributor General of Remedies”; his main goal, 
however, was not to contextualize Helvétius within the history of medicine but rather to 
set down biographical details of the family lineage leading up to the famous philosophe 
Helvétius and to reproduce, in extenso, important primary sources surrounding the family 
                                                 
8 David W. Smith, Helvétius: A Study in Persecution (Oxford: Clarendon Press, 1965); David W. 
Smith et al., eds., Correspondance Générale d’Helvétius, 5 vols. (Oxford: Voltaire Foundation, 1981). 
 9 See for example François Lebrun, Se soigner autrefois : Médecins, saints, et sorciers aux 17e et 
18e siècles (Paris: Temps actuels, 1983), 75–76, 171–173; Paul Delaunay, La vie médicale aux XVIe, 
XVIIe, et XVIIIe siècles (Paris: Editions Hippocrate, 1935), 188, 220, 316.  
 10 The best and most accurate summary currently available is that of Brockliss and Jones, The 
Medical World of Early Modern France, 233, 622–623, 730–731. Most of their information is drawn from 
the sole monograph by Lafond. 
 11 Louis Lafond, La dynastie des Helvétius. Les remèdes du Roi. (Paris: Occitania, 1926). 
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lineage. As such, this chapter represents the first new account of Adrien Helvétius’ career 
in ninety years, drawing upon previously undiscovered archival sources to contextualize 
his unique relationship as a medical supplier to the French fiscal-military state. 
Helvetius also falls between the cracks of the broader history of medicine in this 
period. Although a prominent court practitioner, serving notably as a personal physician 
to the future Regent, he was never a member of the Académie royale des sciences, which 
stands as one of the main loci of historiography for this period. Likewise, recent accounts 
of the Louis XIV’s personal health and “royal medical household” tend to privilege the 
king’s first physicians and first surgeons, giving scant mention to figures like Helvétius, 
whose courtly orbits were slightly more distant from the Sun King and his successors.12 
Helvétius also comes too early to be included in histories of Enlightenment “proto-public 
health”: although there is a sound basis for including him in such narratives, they tend to 
focus on the latter half of the eighteenth century, exploring the large-scale quantitative 
inquiries of organizations like the Société royale de médecine.13 Intellectual historians of 
medicine would likewise find little material to dig into with Helvétius, as he left no major 
theoretical or empirical corpus in print. Although a collection of his and his son’s 
manuscript consilia survives, most of his publications were all either short pamphlets on 
practical therapeutic questions and the “Mémoires instructifs” which accompanied his 
                                                 
 12 Alexandre Lunel, La maison médicale du roi, XVIe-XVIIIe siècles. Le pouvoir royal et les 
professions de santé (Seyssel: Champ Vallon, 2008); Stanis Perez, La santé de Louis XIV: une biohistoire 
du Roi-Soleil (Seyssel: Champ Vallon, 2007). 
 13 Andrea A. Rusnock, Vital Accounts: Quantifying Health and Population in Eighteenth-Century 
England and France (Cambridge: Cambridge University Press, 2002), esp. ch. 4; Jean-Pierre Peter, “Une 
enquête de la Société royale de médecine : malades et maladies à la fin du XVIIIe siècle,” Annales. 
Histoire, Sciences Sociales 22, no. 4 (1967): 711–51; Caroline C. Hannaway, “The Société Royale de 
Médecine and Epidemics in the Ancien Régime,” Bulletin of the History of Medicine 46, no. 3 (1972): 257–
73; Caroline Hannaway, “Medicine, Public Welfare and the State in Eighteenth Century France: The 
Société Royale de Médecine of Paris (1776-1793)” (Dissertation, Johns Hopkins University, 1977). 
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packaged drugs.14 His only book-length publication was the Traité des maladies les plus 
fréquentes et des remèdes specifiques pour le guérir, first published in 1703, and 
subsequently reissued in dozens of editions throughout the eighteenth century. The Traité 
des maladies is a field-guide to medical diagnosis and treatment, classing diseases in 
simple clinical terms and explaining how to treat them with his proprietary remedies. A 
copy of the Traité des maladies accompanied the single-sheet “Mémoires instructifs” in 
each chest he sent out to the provinces and army hospitals.15 Finally, although historians 
of the French state under Louis XIV would be the most likely to encounter the 
considerable archival record of Helvétius’ shipments to the French provinces, most have 
not as of yet turned their attention to the medical dimensions of the fiscal-military state 
that I outline here, and in which Helvétius played a critical role. 
Although Helvétius is remembered primarily as the “popularizer” of the use of 
ipecacuanha against dysentery in Europe, his remède spécifique was much more than the 
South American root which forms its main ingredient. In this chapter, I argue that 
Helvétius’ mature remède spécifique of circa 1710 was in fact the product of a series of 
profound material, intellectual, and organizational transformations. I describe each of 
these in the following sections of this chapter: (1) the first transformation I describe is 
                                                 
 14 On Helvétius’ consilia, see Joël Coste, Les écrits de la souffrance : la consultation médicale en 
France (1550-1825) (Ceyzérieu: Champ Vallon, 2014), 35–36, 58, 169–172, 176. See BIUS Ms 2075, 
“Consultations de médecine,” XVIIIe siècle, 718 p. (see esp. pp. 1–88 for Jean-Adrien Helvétius); and 
BIUS Ms 5017, “Mélanges,” XVIIe siècle, 125 fols. (see esp. fol. 21–80 for Helvétius’ consilia). Some of 
these consilia are transcribed in Coste, Les écrits de la souffrance, 219–227. 
15 With the possible exception a short three-page pamphlet on administering cinchona to the poor 
published in 1686 and often attributed to him, Helvétius has no signed publications before his 1688 
Méthode. The Méthode was the instructions which accompanied the first version of his drug and were 
printed in the same pamphlet as his letters patent. His only book-length publication is the 1703 Traité des 
maladies les plus fréquentes, subsequently reissued in dozens of editions. The remainder of his publications 
are short “Mémoires instructifs” for the various drugs included in his physic chests which closely match 
those of the Traité (a copy of which was included in each chest), and a host of short practical pamphlets on 
curing different conditions: these include his 1691 Lettre sur la nature et la guerison du cancer, the 1694 
Methode pour guerir toute sorte de fievres, sans rien faire prendre par la bouche, the 1697 Traité des 
pertes de sang, the 1710 Methode pour traiter la Verole, and the 1721 Remedes contre la peste. 
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that of Helvétius’ himself: over two decades, he went from being a reputedly 
unscrupulous upstart to respected court physician. (2) This is followed by intellectual and 
material changes that transformed ipecacuanha root from a dangerously violent emetic to 
a medicinal specific against dysentery. (3) The third is a question of scale, which 
transformed the remède spécifique from a drug targeted to individuals into one which 
could be mobilized to treat entire populations in the French army hospitals of Alsace in 
1690. (4) This was followed by the transformation of its accompanying usage instructions 
from what we might call a printed “simulation” of medical judgement into a simple, easy-
to-use set of instructions that could be comprehended without any prior medical training. 
(5) Finally, the last section of this chapter will explore the compound result of all of these 
transformations by showing how they converged around 1706 to produce one of the 
world’s first state-sponsored mass-distribution systems for medicines. 
1. From the “beardless Asclepius” to the respectable “Médecin Hollandois” 
By the time Helvetius first got his hands on ipecacuanha root in the early 1680s, it 
had already been known for over forty years in Europe as an exotic emetic, remarkable 
primarily for the sheer violence of its action. By the end of the decade, however, it would 
be newly recognized as a medicinal specific against fluxes and dysentery. Who was 
Adrien Helvétius and how did he first come across the Brazilian root which would bring 
him—and later his son—such wealth, fame, and opportunity? 
The answer depended on who was asked. To the Paris Faculty doctor Jean 
Bernier, he was “the Beardless Asclepius,” a young charlatan—only 26 when he received 
his royal privilege—who had gained a reputation and a clientele that were far beyond his 
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years and learning.16 Bernier underlined his reputation for experimenting “on worthless 
souls” (in vili anima).17 To the celebrated memoirist Saint-Simon, by contrast, Helvétius 
was “a big Dutchman” (un gros Hollandois), as well as “a good and honest man” 
recognized for his charity—all this despite the fact that he was “the horror of Fagon” and 
was held in disdain by all the physicians because was allegedly an empiric without a 
degree (an unfounded rumor, as we shall see).18 Indeed, opinions on Helvétius appear to 
have changed as he rose in Parisian society, even among individual authors: the social 
commentator Bonaventure d’Argonne, for instance, presented Helvétius’ rise to fame in 
an almost picaresque mode in his 1699 Mélanges d’histoire et de litterature, but in a later 
1713 edition, he retracted these statements and instead described Helvétius as having 
been a reputable physician from the start.19  
The positive and negative accounts of Helvétius’ rise to fame are likely two sides 
of the same coin. Their divergences can in part be reconciled by a look at the supply and 
demand of Helvétius’ drug. On the demand side, we find patients who felt they were 
                                                 
 16 Jean Bernier, Essais de medecine, où il est traité de l’histoire de medecine et des medecins 
(Paris: Simon Langronne, 1689), 473–476. 
 17 The phrase, quite appropriate in this case (as well as the one recounted above) is taken by 
Bernier from Gilles Ménage, Menagiana, ou Bons mots, rencontres agreables, pensées judicieuses, et 
observations curieuses (Amsterdam: Adrian Braakman, 1693), 322: “Deux Médecins fesoient consultation 
dans la chambre de Muret. A prés avoir long temps discouru de choses et d’autres en Latin; ne croyant pas 
que le malade l’entendist, la conversation tomba enfin sur quelque nouveau remède dont on n’avoit pas 
encore fait d’épreuve. L’un dit à l’autre, Faciamus periculum in anima vili. Alors Muret se levant sur ses 
genoux, dit : Vilem animam appellas pro qua Christus non dedignatus est mori?” We know Bernier was a 
reader of Ménage from his Anti-Menagiana: où l’on cherche ces bons mots, cette morale, ces pensées 
judicieuses et tout ce que l’affiche du Menagiana nous a promis (Paris: d’Houry, Langronne et Osmond, 
1693), see 52 for his critique of this specific epigram, which he deems to not be out of character for the 
humanist Marc-Antoine Muret (1526-1585), but which he found appropriate enough to characterize 
Helvétius' treatment of the servant boy of a prominent cleric. The anecdote recurs in Johnsoniana: Or, 
Supplement to Boswell (London: John Murray, 1836), 229, although neither Ménage nor Muret is named; 
and the phrase is used by Thomas de Quincey in Confessions of an English Opium Eater and Other 
Writings, ed. Robert Morrison (Oxford: Oxford University Press, 2013), 231. 
 18 Arthur Michel de Boislisle, ed., Mémoires de Saint-Simon (Paris: Hachette, 1879), 8:92–94. 
19 Bonaventure d’Argonne, Mélanges d’histoire et de littérature recueillis par M. De Vigneul 
Marville, vol. 1 (Rotterdam: Elie Yvans, 1700), 38–41; Bonaventure d’Argonne, Mélanges d’histoire et de 
littérature recueillis par M. De Vigneul Marville. Nouvelle édition, revûë, corrigée, et augmentée, vol. 1 
(Paris: Claude Prudhomme, 1713), 49–54.  
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cured and amply praised and rewarded Helvétius, facilitating his rise to courtly medical 
practice and ultimately helping him attain lucrative government contracts. The health of 
these patients, as well as Helvétius’ continued success, depended on maintaining a steady 
supply of the exotic plant that formed the indispensible basis for his drug: ipecacuanha. 
With this in mind, it is hardly surprising that from the supply side, Helvétius came over 
time to be reviled by the merchants and apothecaries who provided him with ipecacuanha 
and who, upon witnessing his ever growing rewards, could not help but feel that they had 
been swindled. Their negative accounts were told and retold with gusto by Paris Faculty 
doctors like Bernier, who resented Helvétius’ success and suspected that his wonder drug 
was not a lasting cure to dysentery, much as cinchona offered only fleeting relief from 
intermittent fevers.  
These disparate accounts of Helvétius’ rise to fame agree on at least two points. 
The first is that Helvétius was a foreigner, naturalized French but Dutch by birth.20 The 
second is that he built his fame on ipecacuanha. Although it is not the goal of this section 
to provide a full biography of Adrien Helvétius, it is nonetheless useful to begin with a 
few details on his origins and family.21 
There is also a chronological dimension to Helvétius’ reputation, which stands out 
particularly in the radically different accounts provided by Bonaventure d’Argonne. The 
rumours of unscrupulous business practices that surrounded Helvétius in the 1680s 
                                                 
 20 For the family genealogy see David W. Smith, ed., Correspondance générale d’Helvétius, 5 
vols. (Oxford: Voltaire Foundation, 1981-1998), 5:115–118; for biographical details on Johann Friedrich, 
see R. Krul, “Jean-Frédéric Helvétius et sa famille,” Janus 1 (1896): 564–71; R. Krul, “Haagsche en 
Amisfoortse Krukkendans. Bijdrage tot het leven van Johann Friedrich Schweitzer (Helvetius),” Haagsch 
Jaarboekje, no. 5 (1893): 4–32. It should be mentioned that the Helvetius family was not of Swiss descent, 
as his name might seem to suggest: the Latin name Helvetius dates from a sixteenth-century German 
ancestor who travelled to Switzerland and returned a Reformed preacher, and was thereafter known as “der 
Schweitzer.” 




receded over time as he becomes better and better connected at court, so that by the time 
we reach the accounts of Saint-Simon in 1701 and d’Argonne in 1713, he emerges as an 
honest and wholly respectable physician, noted for his charity to the poor and his success 
at court. 
It is this first transformation—that of Helvétius and his reputation—that forms the 
basis of this section, and which sets the stage for the subsequent transformations of his 
drug, its instructions, and most importantly, the breadth of patients for whom it was 
intended. Paradoxical though it may seem, in order to supply his drugs to the bottom of 
the social hierarchy, Helvétius first needed to make his way to the very top: before he 
could send bulk shipments of his drug to soldiers and peasants, before he could even have 
it tested on patients in the Parisian hospitals, he first had to gain a reputation for success 
among an élite clientele.  
 Adrien Helvétius was the son of a famous alchemist, Johann Friedrich Helvetius 
(c. 1629-1709), known throughout Europe for his controversial eyewitness-account of 
transmutation, the Vitulus aureus, or “Golden Calf” (1667). Although born in Germany 
(Köthen, Anhalt) Johann Friedrich had studied medicine at Harderwijk and moved to 
Amsterdam and then The Hague to practice, eventually serving as physician to the Dutch 
Estates General.22 His son Adrien was also a physician: against rumors that he was an 
empiric, Adrien always signed as “A. Helvetius D.E.M” (Docteur en Médecine). Several 
sources claim that Adrien was first schooled in medicine and “Operations Chimiques” by 
his father and that he subsequently studied medicine at the renowned University of 
                                                 
22 Krul, “Jean-Frédéric Helvétius et sa famille,” 569; d’Argonne, Mélanges (1713), 1:49. There is 
no evidence that he was ever physician to William III. 
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Leiden, but his name is nowhere to be found in the Leiden matriculation registers.23 He 
may of course have studied there informally, but in all legal documents, he designates the 
University of Reims as his alma mater, and the university’s registers confirm he received 
the doctorate April 30, 1680, at the relatively young age of eighteen.24 As Brockliss and 
Jones have noted, Reims was one of the less prestigious provincial medical faculties, and 
had a reputation for venality, often granting degrees to students who had undertaken most 
of their studies elsewhere.25 Although Adrien was baptized protestant at the Reformed 
Kloosterkerk in The Hague, he professed the Catholic faith by the time he was 
naturalized French in 1684.26 He maintained ties with his father at The Hague until the 
end of his life in 1709, a fact which enabled him to serve as a middle-man and diplomatic 
feeler on behalf of France during the War of the Spanish Succession (1701-1714).27 
 The second point on which all sources agree is that Helvétius was responsible for 
popularizing the use of ipecacuanha against dysentery. The earliest accounts, however, 
suggest that he acquired his supply of the root through less than scrupulous means, 
                                                 
 23 Willem Nikilaas Du Rieu, Album studiosorum Academiae Lugduno Batavae MDLXXV-
MDCCCLXXV (The Hague: Martin Nijhoff, 1875). Adrien’s older brother, Johannes Balthasar, is listed for 
1673 and 1675: see col. 581, 601. He graduated in 1678 and practiced in Amsterdam. Schweitzer, Sweitzer, 
and Zwetser (a spelling Johann Friedrich sometimes used) yielded no results for Adrien, however. 
 24 Adrian Engelhardus Helvetius is listed as having received his doctorate in medicine from the 
University of Reims on April 30, 1680: see BM Reims, Bibliothèque Carnegie, ms.1085, Catalogus 
secundum litterarum ordinem digestus omnium eorum qui laurea apollinari coronati fuerunt in Academia 
Remensi, a natalibus Facultatis medicae, a die scilicet 21a anni 1550 ad diem destructionis Universitatum et 
Facultatum, 1794, labore Ludovici Hieronimi Raussin [Louis-Jérôme Raussin], professoris in dicta 
Facultate, ad usum proprium, p. 61. 
On his degree, granted when Helvétius was scarcely 20 years old with no mention of a thesis title, 
see Lafond, Dynastie 21; Brockliss and Jones, Medical World 305. 
25 Brockliss and Jones, The Medical World of Early Modern France, 487, 493–494. 
 26 AN O1 28, fol. 76, Lettres de naturalité pour Helvétius, médecin natif de La Haye en Hollande 
(March 1684). 
 27 Louis de Rouvroy Saint-Simon, Mémoires (1707-1710) Additions au Journal de Dangeau, ed. 
Yves Coirault, vol. 3 (Paris: Gallimard, 1984), 393–394; Claude Frédéric Lévy, Capitalistes et pouvoir au 
siècle des lumières. (Paris: Mouton, 1969), 263–268. A substantial manuscript collection of Helvétiu’ 
reports, dealing almost exclusively with peace and trade negotiations, has survived from this period: see 
BnF NAF 2041, “Recueil des lettres et mémoires du sr Helvétius sur les négociations qui se sont faites 
entre la France et la Hollande, avant la paix d’Utrecht, 1704–1711,” 494 leaves. 
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although they differ on exactly who it was that he swindled. The most repeated story of 
Helvétius’ rise to fame and fortune is Bonaventure d’Argonne’s 1699 “picaresque” 
version. In this account, which d’Argonne later retracted, Helvétius first came to France, 
“a country where new remedies can easily engender new diseases,” in order to enrich 
himself by selling his father’s medicinal “powders.” He had no luck doing so at first, and 
was soon pressed by necessity to return to Holland. His father equipped him with ever 
more proven powders and sent him back to France. His big break finally came while he 
served as an assistant to an established Parisian doctor named d’Aforti to heal an old 
druggist (who goes unnamed). The old druggist was saved through the ministrations of 
d’Aforti, and offered him five or six pounds of “Brazil root” (ipecacuanha), “as if it was a 
very precious thing.” The doctor refused, preferring payment in gold, and so the root 
went to his assistant instead: Helvétius subsequently made a fortune on it, much to the 
consternation of Aforti, whose jealousy explains the subsequent disdain in which 
Helvétius was held by learned physicians.28 
Although it continued to be cited in later accounts of Helvétius’ career—most 
notably that of Louis Lafond, easily the most complete to date—this story was 
completely retracted by d’Argonne a decade later in the 1713 edition of the Mélanges. In 
this revision, D’Argonne even confesses to having “traded in false memoirs” on the 
introduction of ipecacuanha in France: “the story is indeed worth telling,” he observes, 
“but this must be done in citing the facts, not in substituting them with fables.”29  
The new version of Helvétius rise to fame provides little information about his 
ipecacuanha supply, providing instead a litany of ever more important patients he cured, 
                                                 
28 Argonne, Mélanges  (1700), 1:39–40. 
29 Argonne, Mélanges (1713), 1:49. 
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establishing how he came to the attention of the French court. The first of these was his 
successful cure of M. de la Chabane, Councillor to the Parlement of Bordeaux, “who had 
been abandoned by four of the most famous doctors of the Paris Faculty.”30 Other 
successful cases followed: Helvétius treated M. Turet of the Saint-Sulplice Seminary, M. 
Tronçon, the Superior of the same seminary, and M. Jacques-Charles de Brisacier, 
Superior of the Missions Etrangères Seminary. These cures of prominent ecclesiastics 
marked the “beginning” of Helvétius’ reputation, according to d’Argonne, and as we 
shall see in Chapter 6, laid the foundation for his relationship with the MEP (Société des 
Missions Etrangères de Paris), which imported Helvétius’ drugs for use in their 
Southeast Asian missions.31 
Despite such important successes, d’Argonne asserts that it was his work at the 
bedside of the Duchess of Chaulnes that truly established his fame in Paris.32 The 
duchess rewarded him with a gift of one thousand écus, a pension, and secured for him 
the protection of Colbert.33 This success may have more to do with his father’s patronage 
links than his own record in curing prominent ecclesiastics: d’Argonne asserts that 
Helvétius was introduced to the bedside of the Duchesse de Chaulne through the 
intervention of Godefroi, Comte d’Estrades, who had kept Johann Friendrich Helvétius as 
a physician during his time as ambassador in Holland, and that he had honoured Adrien 
with “friendship and confidence” out of gratitude to his father.34 
                                                 
 30 Ibid., 1:50. 
 31 See below, ch. 6, sect. 2. 
 32 Elisabeth de le Féron, the wife of the Governor of Brittany, Charles d’Albert d’Ailly, who 
protected the Louvre Capuchins. See above, ch. 3. 
33 Assumedly the elder Colbert, Jean-Baptiste, not his son Seignelay, who is called by that title 
later in the Mélanges. This would place these events before Colbert’s death in 1683. 
 34 d’Argonne, Mélanges (1713), 1:51. 
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Helvétius’ biggest break came when Monseigneur the Grand Dauphin, the eldest 
son and heir of Louis XIV, was attacked by dysentery. Daquin, the royal first physician, 
asked if the drug could be used “with certitude,” and Helvétius offered to have it tested in 
the hospitals. At the same time, the King’s Jesuit confessor, Père Lachaise, requested a 
supply of the drug to send with Père Bèze, a member of the Jesuit party that accompanied 
the 1687 French embassy to Siam.35 Its effects were deemed to be so remarkable that 
Lachaise spoke of it to Louis XIV personally, who then ordered Seignelay to have it 
tested in the hospitals. It is the convergence of Helvétius’ reputation among these courtly 
and ecclesiastic élites, facilitated by his own practice but also by his father’s reputation, 
that likely explains how he came to the attention of the highest levels of French society, 
namely Lachaise and Louis XIV himself. The friction mentioned above between 
Helvétius and the Hôtel-Dieu staff is unsurprisingly omitted.36  
The profound differences between d’Argonne’s 1699 and 1713 accounts testify to 
the important change in Helvétius reputation that had occurred in the interim. In 1699, 
there was still enough rumour and scepticism surrounding Helvétius that d’Argonne 
could describe him as a kind of medical picaro, clever but sometimes unscrupulous, sent 
by his alchemist father to make his own fortunes in a foreign land. By the time of the 
revised account, written with the benefit of hindsight, he was cast as a respectable 
physician from day one, and his success was explained through reference to his practice 
among a steadily rising clientele in Paris.  
                                                 
 35 Once again, see below, ch. 6, sect. 2. 
36 Argonne, Mélanges (1713), 49–53. D’Argonne also states that Helvétius confessed to Daquin 
that his remedy was ipecac, and though Daquin didn’t know of its usefulness in cases of dysentery, he 




Other early references likewise suggest that Helvétius had a reputation as a 
crooked businessman. Nicolas Lémery, for example, observes in the entry on 
ipecacuanha in his 1698 Traité des drogues simples that Helvétius bought a supply of the 
root from an apothecary named Craquenel. This apothecary had tried it on some patients 
(assumedly as an emetic) but found it problematic: not knowing its value, he kept the root 
in an attic. Lémery likewise confessed that he himself had received a sample of the root 
from a physician named Gras, who had travelled back from the Americas with it in 1672, 
and had presented it to the academy of the Abbé Bourdelot. Lémery even observed that 
he once had the opportunity to secure a large supply of it, but was uninterested in doing 
so: “as I had no experience of it at that time, I did not want to buy it, and have regretted it 
since.”37 Helvétius, however, bought it and made very successful use of it, “making a 
great secret of this remedy, until the king had the goodness to make it public.” 38 Lémery 
does not directly underline any injustice in this, but others, such as Bernier, did: “How 
could that root not be charmed for the Merchant Physician [Helvétius], having sold at 
twelve écus what had not cost him even half an écu, after having seized a monopoly to 
the prejudice of the good faith which ought to reign among merchants?”39 Bernier also 
describes two occasions on which Helvétius brought lawsuits against fellow Parisian 
physicians who had procured ipecac, in order to protect his exclusive privileges. In the 
first case, a physician bought a few pounds of ipecac from an abbot at a fair price only to 
find himself faced with unreasonable terms from Helvétius. The affair was then brought 
                                                 
 37 “Comme alors je n’en avois veu aucune experience, je ne voulus point l’acheter, de quoy je me 
suis repenti depuis,” Nicolas Lémery, Traité universel des drogues simples (Paris: L. d’Houry, 1698), 388. 
38 Ibid. 
39 “Comment cette racine ne seroit-elle pas maudite pour le Medecin Marchand, ayant vendu 
douze écus ce qui ne lui coûtoit pas un demi, après s’en estre emparé par un monopole, et au préjudice de la 
bonne-foy, qui doit regner entre les Marchands?” Jean Bernier, Supplémens au livre des essais de médecine 
(Paris: Simon Langronne, 1691), 86. 
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before justice, and the unnamed physician would have been ruined had he not been 
counselled to settle with Helvétius. In the second case reported by Bernier, a merchant 
brought a hundred pounds of ipecac to Paris and found himself faced with a criminal 
lawsuit—plotted and conducted by a bailiff (huissier) that was an accomplice of 
Helvétius—which landed him in prison. Like the physician, the merchant was advised by 
“un certain particulier” to accommodate Helvétius, which he did in order to secure 
release.40 
This last rumor is corroborated by a sequence of legal disputes between Helvétius 
and Jean-Augustin Garnier, a hatter by trade who had business connections in Cadiz 
which he used to import ipecacuanha to France on Helvétius’ behalf. In 1689, shortly 
after Helvétius’ was granted his letters patent, Garnier sued Helvétius in the Parc civil of 
the Châtelet, on the grounds that Helvétius had coerced him into accepting a low rate of 
compensation for the sixty pounds of ipecacuanha he had already supplied, as well as for 
an additional twenty-five pounds he was contracted to supply. 41 The Châtelet case was 
settled in Helvétius’ favour by default, a decision which Garnier subsequently appealed at 
the Paris Parlement.42 In his testimony, Garnier argued that Helvétius took advantage of 
him while he was imprisoned for unrelated debts. The shipment of ipecacuanha arrived 
while he was in prison, and Helvétius visited him and offered to pay both his bail and his 
debts, on the condition that Garnier grant him immediate access to the ipecacuanha, 
which was being held. Garnier confessed that he had foolishly taken Helvétius to be an 
                                                 
40 Ibid. Bernier was careful to never mention Helvétius by name in his account, calling him instead 
“the Beardless Asclepius,” but the references to ipecacuanha make his identity quite clear. 
 41 AN Y 638, Châtelet, Parc civil (Tuesday September 6, 1689). 
 42 Most of what follows draws from the detailed testimony of the case recorded in Nicolas Nupied, 
ed., Journal des principales audiences du Parlement, 1685-1701. Tirez de Memoires de M. François Jamet 
de la Guessière, vol. 5 (Paris: François Le Breton, 1707), 421–422. 
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honest man, and thus never asked to have this agreement in writing. Released on bail, 
Garnier granted Helvétius access to the ipecacunha, but once he had it in hand, Helvétius 
refused to loan Garnier the money to pay his debts, or to pay the agreed upon sum for the 
root. Worse yet, as Garnier tells it, he was then arrested by a huissier and an armed posse 
of other officers of the law, who brought him to “a low and very dark room,” and told 
him to sign a new contract with Helvétius, accepting a lower rate of compensation: if he 
refused, he was made to understand that he would be thrown into the Bastille, under a 
trumped up charge of counterfeiting the king’s coin.43 
Garnier argued that this contract was invalid because it was extorted under duress 
(par crainte et violence), and that he was the one who had in fact introduced Helvétius to 
ipecacuanha in the first place, providing him with his earliest samples of the drug as well 
as vital information on its use from his contacts in Cadiz.44 Helvétius for his part argued 
that Garnier’s lurid tale of greed and coercion was pure fantasy, that the notary’s minutes 
contained no evidence that any earlier contract had been rescinded, and that Garnier had 
even provided him with a receipt after he paid the agreed sum. Helvétius further argued 
that he had known about the plant long before he had ever contracted Garnier to supply it: 
as evidence he produced patient cure attestations which demonstrated he had been curing 
cases of dysentery as early as 1684, and pointed out that the plant was described in print 
over twenty years earlier by an unnamed Dutch physician.45 Despite Helvétius’ insistence 
on these points, rumors based on Garnier’s testimony would float around for years to 
                                                 
 43 Ibid. 
44 According to Garnier, the threat met the legal definition of extortion because it was “sufficient 
to frighten even a steadfast man” (ut posset cadere in constantem virum): he was made to believe he was 
about to be thrown in the Bastille, and violence was manifest, as he had been removed by archers and put in 
a prison. An obligation made in vinculis (in chains) was null and void. 
 45 See below, notes 44 and 45. Nupied, Journal des principales audiences du Parlement, 5:422. 
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come: the anonymous reviewer of Helvétius’ Traité des remèdes in the 1704 Mémoires 
de Trévoux observed, “It is surprising that there are still those who would steal the glory 
of this discovery from Helvétius, to give it to a merchant-hatter, named Garnier,” who, 
“pushed on by the enemies of this Author [Helvétius], dared to claim that the public owe 
the discovery of this specific to him.” Mémoires de Trévoux review claimed that Garnier 
was later condemned at the Châtelet and Parlement, and reduced to confessing his slander 
against Helvétius.46 
The Parlement’s final ruling favoured Helvétius: Garnier’s appeal was dismissed 
and he was ordered to content himself with the agreed rate of reimbursement from 
Helvétius for the sixty pounds of the root that had already been delivered.47 As a token 
compromise, however, the Parlement ruled that Garnier should not be obliged to supply 
the final twenty-five pounds of the root.  Garnier reported that Louvois, the War Minister, 
had recently ordered him not to sell the root to anyone but the army, and on top of this, it 
was very unlikely he would be able to get any from Cadiz given the state of war then 
between France and Spain, which held the two sources of the root—Brazil and Peru—
within its dominion.48 This conflict, the War of the League of Augsburg or Nine Years 
War (1688-1697), would later play a considerable role in Helvétius’ fortunes. 
The common theme in the accounts of d’Argonne, Bernier, Lémery, and Garnier 
is that the other actors—including physicians, apothecaries, and merchants—did not 
appreciate the potential value of ipecacuanha root, while Helvétius did, and went on to 
                                                 
46 “Il est surprenant qu’il se trouve encore des personnes qui luy veulent enlever la gloire de ce 
découverte, pour la donner à un Marchand Chapelier, nommé Grenier (sic) […] cet homme, poussé par les 
ennemis de cet Auteur [Helvétius], osa divulger que le public luy devoit la découverte de ce spécifique, 
imposture qui ne se soutint pas long tems, car ayant été mis en cause, il ut condamné au Châtelet, et au 
Parlement par Jugements extraordinaires, et fut réduit à avouer pour excuser sa calomnie, qu'il ne l'avoit 
publié qu'apres avoirété suborné.” Mémoires de Trévoux (April 1704), 561. 
 47 AN X1A 6481, Paris Parlement, Grand chambre, Plaidoiries, fol. 115r-v (May 30, 1690). 
 48 Nupied, Journal des principales audiences du Parlement, 5:422. 
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make a fortune using it. These other actors not unreasonably felt as though they had been 
swindled, selling their ipecacuanha too cheaply due to the information asymmetry 
between them as suppliers and Helvétius as a buyer. These accounts also demonstrate that 
ipecacuanha was available in France by the time Helvétius arrived on the scene, but no 
one was yet aware of its virtues against dysentery. 
2. From emetic to specific: Transforming ipecacuanha into the remède spécifique  
In keeping with the usual secrecy that served as a bulwark for privileged medical 
monopolies, ipecacuanha root is named neither in Helvétius’ printed letters patent nor in 
his initial instructions on how to administer the drug, the 1688 Méthode. Despite this, it 
seems likely that the secret was out before long: Garnier and other suppliers were quick 
to draw the link between Helvétius purchasing ipecacuanha from them and his 
subsequent successes in curing dysentery, and their public disputes with Helvétius likely 
helped spread the word. Here it should be remembered that knowing the identity of a 
botanical simple is not coterminous with a full knowledge of the drug of which it forms 
the critical component: this must also include the method of processing and 
compounding, instructions for administration and dosage, and pharmacological reasoning 
about its effect within the patient’s body. Consequently, this section explores the material 
and intellectual dimensions of how Helvétius transformed ipecacuanha from an emetic 
into a medicinal specific against dysentery. 
The first step in this transformation must have been Helvétius’ suspicion that the 
plant had a discernible effect on patients suffering from dysentery. Helvétius nowhere 
provides an account of a “eureka” moment, but if we take him at his word in his 
testimony to the Parlement, it seems that he was already aware of it by 1684. What was 
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known about the root in Europe at that time? How did Helvétius first become aware of it, 
and why did it stick out to him, amongst the panoply of other plant substances, both 
indigenous and exotic, that were available in Paris at the end of the seventeenth century? 
How did he go from seeing it as an emetic to seeing it as a specific? 
Here at least we can rely on Helvétius’ own statements: in his 1688 testimony 
before the Parlement, he says he first learned of ipecacuanha from the work of a “Dutch 
physician” who had published a description of it more than twenty years earlier. In his 
1703 Traité des maladies, he goes even further, naming the author as “L’illustre Pison, 
Médecin d’Amsterdam,” namely Willem Piso (1611-1678).49 The work in question, De 
medicina Brasiliensi, printed alongside the natural historic work of his colleague Georg 
Marggraf as part of the Historia naturalis Brasiliae (1648), was produced following the 
two men’s participation in Governor Johann Maurits’ exploration and colonization of 
Dutch Brazil (Recife) under the auspices of the Dutch West India Company.50 The book 
includes the first printed description and illustration of ipecacuanha, although there is 
evidence that it was known to Europeans at an earlier date. The first European to 
document its properties was probably Manoel Tristão, a lay brother serving as an 
apothecary at the Jesuit college in Bahia, Brazil, down that coast from Recife. Tristão 
documented it in a manuscript recipe collection some time before 1625, which made its 
                                                 
49 Adrien Helvetius, Traité des maladies les plus fréquentes et des remèdes spécifiques pour les 
guérir, avec la méthode de s’en servir pour l’utilité du public et le soulagement des pauvres (Paris: Laurent 
d’Houry and Pierre-Augustin Le Mercier, 1703), 263–264. 
50 Willem Piso and Georg Marggraf, Historia naturalis Brasiliae. De medicina Brasiliensi libri 
quatuor. Historiae rerum naturalivm Brasiliae libri octo., ed. Johannes de Laet (Leiden and Amsterdam: 
Franciscus Hackius and Ludovicus Elzevirius, 1648); Willem Piso, História natural do Brasil ilustrada, 
trans. Alexandre Correia (São Paulo: Companhia Editora Nacional, 1948).  
On Piso see Amy Buono, “Interpretative Ingredients: Formulating Art and Natural History in 
Early Modern Brazil,” Journal of Art Historiography, no. 11 (2014): 1. 
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way into the hands of Samuel Purchas,51 and as Piso himself acknowledges, its virtues let 
it to be “preserved religiously by the Brazilians, who were the first to reveal its virtues to 
us.”52 
Piso describes ipecacuanha root primarily through reference to its purgative 
faculty, which evacuates “by above and below,” but also adds that it acts against venom 
or poison (venenum), and that it is the “easiest remedy to find” in Brazil for many 
diseases arising from “long obstructions,” including fluxes of the bowels (fluxus 
ventris).53 He also distinguishes between the two species of ipecacuanha, the brown and 
the white, which differ in their grades and faculties, as well as in where they grow. 
Although he does refer to bowel flux, Piso does not use the term dysentery (dyssenteria) 
or refer to specifically “bloody” (sanguineus) flux in his entry. The description tends 
toward natural history and practical therapeutics, providing little in the way of 
pharmacological reasoning, with the exception of the second-to-last passage, which 
observes: “Indeed, besides the bowel flux, it cures other diseases, opposes venoms, and it 
expels poison immediately through vomit, either by occult or by manifest qualities.”54 
The very suggestion of an occult quality may have captured Helvétius’ attention. As we 
have seen in Chapter 2, occult qualities and substances which act tota substantia provided 
a critical antecedent for subsequent iatrochemical theories of how medicinal specifics 
could serve as counter-ferments which could act radically against the disordered process 
of fermentation which produced a given disease. Piso’s point that the root also acts 
                                                 
51 Samuel Purchas, Hakluytus posthumus, or Purchas his pilgrimes (Glasgow: Maclehose 1905-
1907 orig. 1625), 16:417, 478. Further details in Leite 1938-50, 8:133-134, 9:167. For all of this see Jarcho, 
Quinine’s Predecessor 306 n. 2. 
 52 “Quamobrem religiose à Brasiliensibus reservatur, qui illius virtutes primi nobis revelarunt,” 
Piso and Marggraf, Historia naturalis Brasiliae, 102. 
53 Ibid., 101–102, Cap. LXV, De ipecacuanha, eiusque facultatibus. 
54 “Praeterquam enim quod fluxibus ventris, aliisque morbis medeatur, venenis adversatur, 
virusque, tum occulta qualitate, tum manifesta, per vomitum statim expellit,” Ibid., 102.  
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“against poisons” likewise recalls the action of antidotes, which offered a foundation for 
an alternative pharmacology that moved away from traditional conceptions of expulsion 
and repletion common in Galenic therapies.  
In the Traité des maladies, Helvétius even disagrees with some of Piso’s 
assertions, most notably pointing out that it does not appear to be effective against poison 
“in these countries” (Europe), “although some allege that it serves as one in the Indies,” 
and instead proposes that “it specifically cures” (elle guerit spécifiquement) bowel fluxes 
including dysentery, alongside its more well-known faculty of provoking vomiting.55 A 
conceptual shift is discernible in these corrections: from Helvétius’ perspective, Piso had 
seen faculties in ipecacuanha which defied traditional pharmacological reasoning on 
manifest qualities, and instead seemed occult or antidote-like. Lacking the notion of a 
medicinal specific, Piso was either confused about the root’s action, or was referring to 
effects which were unique to the climate or poisons of the tropical Brazilian climate. 
In both the references to occult qualities and antidote-like action, Helvétius may 
have seen in ipecacuanha a close analogue to current discussions surrounding medicinal 
specifics like cinchona, which had been popularized in Paris by Robert Talbor just a few 
years earlier. Indeed, signs of such a reading are apparent in a passage of the 1688 
Méthode, notably in his use of cinchona as an exemplar in defense of his view that he had 
found in ipecacuanha another medicinal specific:  
I confess that it is difficult enough to understand how a remedy can act 
with equal success on patients of diverse temperaments, in different states, 
attacked by a disease that has different types and which does not always 
come from the same cause. But if no one presently disputes the virtue of 
Cinchona, and if this remedy has been received as universal by all 
physicians, then it should not seem so extraordinary that another specific 
should be encountered, and that, matching the other in scope, this one 
                                                 
55 Helvetius, Traité des maladies (1703 ed.), 264. 
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should be just as sovereign in all species of bowel flux, as that foreign 
bark is for all the intermittent fevers.56 
 
He also added that this new specific had an advantage over cinchona, namely, that it 
cured without relapses. In sum, the conceptual shifts in chymical medicine that had 
occurred in the decades since Piso had published his work, as well as the popularisation 
of cinchona in the 1680s, both converged to offer Helvétius a new pharmacological 
category in which to place ipecacuanha, namely, that of the medicinal specific. 
In addition to reframing the root in pharmacological terms, Helvétius also had to 
contend in a material sense with its recognized emetic faculties. As he observes in his 
Traité, upon realizing its use as a specific against dysentery, “I applied myself 
particularly to determining the proper dosage, to correcting the violent effects of the 
vomiting, and to making this root more purgative through a preparation whose use is at 
once gentle and easy.”57 
As with most secret remedies, no recipe for the remède spécifique survives, and 
Helvétius’ own writings offer only a few hints as to how he transformed raw ipecacuanha 
root into a drug against dysentery. Despite these limitations, it is still possible to offer 
informed speculation on how Helvétius produced his remedy by looking at the work of 
one of his contemporaries, the apothecary Simon Boulduc (1652-1729), member of the 
                                                 
 56 “J’avoüe aussi qu’il est assez difficile de comprendre comment un même remede peut agir avec 
un succès égal, sur des malades de divers temperaments, en diferens états, attaquez par une maladie qui a 
differentes especes et qui ne vient pas toûjours de mesmes causes. Mais si personne ne dispute 
presentement de la vertu du Quinquina, et si ce remede est reçu comme universel par tous les Medecins, il 
ne doit par paroîre si extraordinaire qu’il se rencontre un autre Specifique, qui égalant celui-là en son 
étenduë, soit aussi souverain dans toutes les especes de Flux de ventre, que cette écorce étrangères l’est 
pour toutes les fièvres intermittentes,” Helvétius, Méthode (1688) 17-18. Emphasis added. 
57 “Je me suis particulièrement appliqué à en régler la juste Dose, à corriger les effets violents du 
Vomissement, et à rendre cette Racine plus purgative, par une préparation dont l’usage est doux et facile,” 
Helvetius, Traité des maladies (1703 ed.), 264. 
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Académie royale des sciences.58 Boulduc undertook a series of chemical analyses of the 
two varieties of ipecacunaha, publishing his results in a series of short articles in the 1700 
and 1701 Mémoires de l’Académie royale des sciences.59 These analyses were the 
continuation of a larger Académie project of analysing plants, initiated in 1668 when they 
were placed under the direction of Samuel Cottereau Duclos. The broad goals of this 
project extended from the natural philosophic—determining the constituents of plants to 
find support for divergent matter theories—to the practical, in the sense of improving 
pharmaceutical preparations.60 
In oblique terms, without naming any parties, Boulduc explains that although the 
plant has been known reasonably well in Europe for decades, its reception has been 
hampered by “negligence and incredulity,” in the form of various “doubters” who prefer 
to use a narrow set of tried-and-true remedies, and by the “timidity” of practitioners who 
have been scared away by the root’s apparent violence as an emetic. Thankfully, these 
factors have not succeeded in stopping practitioners who were “more entrepreneurial” 
(plus entreprenans) from recovering ipecacuanha and other plants from oblivion, clearing 
the way for current usage of the plant and all the advantages it offered to the public. For 
Boulduc, the case of Helvétius shows that “A reasonable boldness, joined with a 
                                                 
58 On Boulduc’s origins and career, see David J. Sturdy, Science and Social Status: The Members 
of the Academie Des Sciences 1666-1750 (Woodbridge, Suffolk: Boydell Press, 1995), 244–248. 
 59 Simon Boulduc, “Analyse de l’ypecacuanha,” Mémoires de l’Académie royale des sciences, 
January 8, 1700, 1–5; “Observations sur les effets de l’ypecacuanha,” Mémoires de l’Académie royale des 
sciences, November 12, 1701, 192–94. Thanks to Lawrence M. Principe for bringing these sources to my 
attention. 
 60 Alice Stroup, A Company of Scientists: Botany, Patronage, and Community at the Seventeenth-




mediocre knowledge, is more useful for discovery than profound science accompanied by 
too much slowness and timidity.”61 
Boulduc’s main interest is in identifying “what principle, or what part of the mixt” 
is associated with its specific virtue against flux and dysentery. Like Piso, Boulduc 
begins by distinguishing the different types of ipecacuanha: namely the grey and the 
brown. He believes the brown is better and more certain against dysentery, but notes that 
the grey is favoured in usage because its emetic effects are less violent. He employs two 
methods of analysis: ordinary distillation and solvent extraction.62 Distillation provided 
him with “peu de lumières” on the plant, offering little insight into mixed matter as it is 
normally, instead only presenting it in a destroyed form. Boulduc argues that he could 
have omitted it altogether and been just as well off in his analysis. This is a manifestation 
of a larger phenomenon in this period, namely, the decline of analysis by fire, and the 
growing preference among chymists for solvent extraction.63  
A double-solvent extraction yielded much more interesting results: the first 
solvent Boulduc used was spirit of wine, in order to extract the sulphurous or resinous 
parts; the second was distilled rainwater, to extract the salt, Boulduc being “very 
persuaded that the virtue of this root does not reside in the resin alone, but again in its 
saline parts, which the spirit of wine could not bite into, and for which water alone is the 
                                                 
61 “Une raisonable hardiesse jointe à une connoissance mediocre, est plus utile pour les 
découvertes qu’une science profonde accompagnée de trop de lenteur et de timidité,” Boulduc, “Analyse de 
l’ypecacuanha,” 3. 
62 Ibid. Boulduc adds also that there is also a “white ipecacuanha,” but that this is not really 
another variety of ipecacuanha, having very little effect, and which is used for pregnant women and small 
children 
63 Fredric L. Holmes, “Analysis by Fire and Solvent Extractions: The Metamorphosis of a 
Tradition,” Isis 62 (1971): 129–48. 
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proper solvent.”64 Boulduc applied his two stage solvent extraction to both the brown and 
the grey ipecacunaha, evaporating the solvent after each stage and weighing the extract. 
In both cases, he found that the grey yielded more of the extract, and left less solid 
residue. 
But which of these extracts was associated with the anti-dysenteric virtue of the 
root? The published version of the Mémoires includes no description of his patient trials, 
instead only furnishing his conclusions; the corresponding notice in the Histoire de 
l’Académie royale des sciences, specifies concerning the extracts that “M. Boulduc tested 
them on several patients with all necessary precautions, and faithfully reports the 
results.”65 But if we turn to the manuscript procès-verbaux, we learn a great deal more: 
there Boulduc describes eight patients, including two male and six female. With the 
exception of a single 25-year-old woman, all of his trial subjects are all either younger 
than 15 or older than 60, and all suffered from flux or dysentery.66 Boulduc was not able 
to apply a uniform method in each case, but he carefully details the specific 
circumstances of each patient, the course of treatment over time, and the effects it had on 
the patient’s condition. In most cases, his tests were geared at delineating the different 
effects of the first extraction and the second extraction. In one case, he gave a 60-year-old 
woman the second extract, which improved her condition, and then tried the first extract, 
witnessed her condition deteriorate, and returned again to the second extract, which cured 
                                                 
64 “J’ay crû devoir me servir de cette double extraction, l’une faire par l’esprit de vin, l’autre par 
l’eau, très persuade que la vertu de cette racine ne residoit pas dans sa resine seule, mais encore dans ses 
parties salines, sur lesquelles l’esprit de vin n’avoit pû mordre, et dont l’eau seulle est le propre dissolvant,” 
Boulduc, “Analyse de l’ypecacuanha,” 4. 
65 “M. Boulduc les a éprouvez sur différentes malades avec les precautions necessaires, et il en 
rapporte fidellement l’histoire,” “Analise de L’ipecacuanha,” Histoire de l’Académie Royale Des Sciences. 
Année 1700, 1703, 46–48. 
66 Archives de l’Académie des Sciences, Procès-verbaux, vol. 19 (January 9, 1700), fol. 4r-6r for 
the patient trials. These are, in the order of Bouduc’s presentation: a 60 year old woman; three girls, aged 
15, 10, and 5; an 80 year old man; a 70 year old woman; a 63 year old abbé; and a 25 year old woman. 
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her completely. In the case of three young girls, aged 5, 10, and 15, he was able to apply 
a more uniform method: he tried the first extract, which worked on the oldest girl, but 
failed to cure the youngest; he then tried the second extract, and found them all entirely 
cured.67 
In his final article on ipecacuanha, Boulduc explicitly eschewed any definitive 
theoretical conclusions about the nature of the active virtues in ipecacuanha. Instead, he 
argued that the task of searching for principles was useful precisely because of the 
conjectural knowledge it produces, which is sufficient to guide the hand of practice:  
What I am so bold as to promise is that in performing the analysis and in 
searching for the virtues of this root—named Ipecacuanha, so vaunted for 
dysentery—I have found the means to make this otherwise fierce remedy 
into a gentle and manageable one, by blunting or rather removing the 
emetic force which accounts for all of tis violence.68 
 
Without making a causal argument about principles and virtues, Boulduc argued that his 
analysis had led him to a method of preparing ipecacuanha which moderated its emetic 
effects, and in so doing bolstered its “specific” action against dysentery. 
For Boulduc as for Helvétius, the problem with ipecacuanha was twofold: either 
its emetic action comes too quickly, physically hampering “the distribution” of the 
substance in the digestive tract; or, the violence of this emetic action—and the 
apprehension of it—forces the practitioner to diminish the dosage to the point where it 
would have little effect, hence also the bad reactions of patients “who tremble at the mere 
mention of ipecacuanha.” On all of this, Boulduc observes that “I reflected on the 
problem and realized that, if one could slow or even wholly suppress its excessive power, 
                                                 
67 Ibid. 
68 “Ce que j’ose d’autant plus me prometre qu’en faisant l’Analyse et la recherche des vertus de 
cette racine tant vantée pour la dysentérie, nommé Ypecacuanha, j’ay trouvé le moyen de rendre doux et 
traitable ce medicament d’ailleurs si farouche, en emoussant ou plûtôt en supprimant la force émetique qui 
en fait toute la violence,” Boulduc, “Observations sur les effets de l’ypecacuanha,” 192. 
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by divesting it of its resinous parts, and leaving only the saline parts behind, then we 
could use it without apprehending any ill effects.”69 The double solvent extraction 
provided the means. The first (alcohol) extract of the root produced even more violent 
emetic effects, while the second (water) extract was free of the resinous part and 
contained only the “saline” part, which provokes urination and purges very moderately 
without nausea, “and finally, produces the specific effect of which this root is gifted, 
which is to cure dysentery, an effect I have observed not once, but several times, and 
always happily.”70   
Lacking an actual recipe from Helvétius prevents us from drawing any definitive 
conclusions about his preparation for the remède spécifique. Nonetheless, the evidence 
from Boulduc’s analysis a decade later is suggestive of at least one possible way in which 
Helvétius may have achieved the basic material transformation of ipecacuanha from 
emetic to specific. From Helvétius’ own statements, we can safely say that it was from 
reading Piso that he first learned of ipecacuanha, and the suggestion of an occult quality 
may have served to motivate him to obtain a supply. But the raw plant alone did not 
wholly constitute the medical secret of his drug: it was already available in Paris, and 
known even to prominent medical figures like Lémery. 
It was also this preparation, or the “correction” to use Helvétius’ own term, which 
he described having busied himself to achieve in the Traité, and which manifests the 
crucial information asymmetry between him and his ipecacuanha suppliers. They thought 
                                                 
 69 “Je fis réflexion et je crûs, que, si l’on pouvoit ralentir ou même supprimer entierement sa trop 
grande force, en le dépoüillant de ses parties resineuses, et ne luy laissant que ses parties salines, on 
pourroit s’en server sans an apprehender aucune mauvaise suite,” Ibid., 193. 
70 “Le second au contraire dépoüillé de ses parties résineuses, et ne contenant que les parties 
salines, poussa par les urines considérablement, purgea modérément avec peu ou point de nausées, et 
produisit l’effet spécifique dont cette racine est doüé, qui est de guérir la dysenterie; c’est ce que je n’ay pas 
éprouvé une seule fois, mais plusieurs fois et toujours heureusement,” Boulduc, “Observations sur les effets 
de l’ypecacuanha,” 193. 
228 
 
they were selling him a dangerously violent emetic, and initially, were likely pleased to 
be rid of it; whereas Helvétius knew the emetic faculty could be corrected, and that the 
plant had another, “specific” virtue which was far more valuable.  
3. From court to camp: Helvétius as a military-medical entrepreneur 
The transformation of Helvétius’ reputation and the transformation of 
ipecacuanha—from an emetic to a specific, in both intellectual and material terms—
together provide the foundation for Helvétius’ subsequent endeavours. Indeed, the 
reciprocal relation between Helvétius’ reputation at court for curing dysentery and his 
continued supply of “corrected” ipecacuanha provided the direct foundation for the next 
transformation of his remède spécifique, namely, the move into military-medical 
contracting and bulk supplying. 
We have already seen that the highest echelons of the French state, particularly 
the Marquis de Seignelay, were instrumental in securing the hospital trials that led to 
Helvétius’ 1688 privilege. We have also seen that military applications, particularly in the 
navy, were underlined in Seignelay’s own orders to the Parisian hospitals. Finally, we 
also know that by the time of the Parlement’s sentence on the case between Helvétius and 
Garnier, on May 30, 1690, the Marquis de Louvois, France’s War Secretary, had ordered 
Garnier not to sell ipeacacuanha to anyone but the army.  
The Secretary of State for the Royal Household had been careful to include a 
proviso in Helvétius’ 1688 letters patent which would exempt the navy and army from his 
monopoly and the fixed price of 3 louis d’or that had been placed on the drug.71 The 
correspondence of the War Secretary shows that by October 1688, he was soliciting 
                                                 
 71 AN O1 32, 224r-225r, Permission au Sr Helvetius medecin de ebiter son remede pour les 
dissenteries (August 24, 1688); and Lettres patentes du Roy portant pouvoir au Sieur Helvétius (Paris: 
Jean-Baptiste Coignard, 1688). 
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prices and volumes from Helvétius for supplying it in bulk to the French army.72 Despite 
these negotiations, there is no evidence that Helvétius supplied it until two years later: 
while the potential military applications of the remède spécifique had been part of the 
equation since day one, it was not until the drug was needed to combat a mounting 
epidemic of dysentery in the French garrisons of the Alsatian borderland in 1690 that 
Helvétius appears to have actually supplied it. 
Evidence from French consular correspondence suggests that senior government 
ministers were making inquiries into securing a stable supply of ipecacuanha around the 
time Helvétius was granted his monopoly.73 In 1687, the French consul in Cadiz, Pierre 
Catalan, was already closely involved in facilitating the shipment of large volumes of 
cinchona to French ports.74 By November 24, 1687—just a week after Seignelay 
intervened in Helvétius’ favour during his conflict with the Hôtel-Dieu staff— Louis 
Phélypeaux, Comte de Pontchartrain, then Intendant of Finances (later Controller-
General) requested information on ipecacuanha and a samples from Catalan in Cadiz. 
The consul reported that the plant was vulgarly known as bejuquillo and sometimes radix 
aury in the Indies, because it grew in rocky areas near gold mines, one of which was 150 
leagues from Cartagena (modern Colombia). It was used there against flux and fevers, 
following a preparation in which it was crushed in a mortar, passed through a tammy 
cloth, and then placed in a terrine and heated over a fire to reduce its force, after which it 
                                                 
 72 SHD A1 811, fol. 6, Louvois to Helvétius (October 18, 1688). 
73 Samir Boumediene, “L’acclimatation portuaire des savoirs sur le lointain : Les drogues 
exotiques à Séville, Cadix et Livourne (XVIe-XVIIe siècles),” in Les savoirs-mondes : mobilités et 
circulation des savoirs depuis le Moyen Age, ed. Liliane Hilaire-Peréz and Pilar González Bernaldo 
(Rennes: Presses Universitaires de Rennes, 2015), 141–143. I am indebted to Samir Boumediene for the 
suggestion of looking at the French consulary corresponcence from Cadiz. 
74 Catalan’s letters indicates that, following an order from Pontchartrain, he supplied over 610 
pounds of good quality cinchona for France, shipped via Le Havre: AN AE B1 213, Catalan to 
Pontchartrain, fol. 85r (December 8, 1687), and fol. 86v (December 22, 1687). 
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was taken with lukewarm water followed by wine. Interestingly, Catalan reported that the 
goal of this preparation was in fact to provoke vomiting: “They [his informants] say that 
the cure is certain once the bejuquillo provokes vomiting.”75 Helvétius, by contrast, 
worked explicitly against the emetic property, identifying it as detrimental to the plant’s 
specific action against dysentery. 
Catalan was able to find a small supply (une petite caisse) and sent it to Le Havre 
along with a sample of cinchona and a Latin mémoire from a “famous physician,” which 
seems not to have survived.76 Securing a larger supply for France proved to be far more 
difficult, as a letter from March 1688 reveals: 
I am taking measures to bring 300 pounds of Bejuquillo or radix aury 
from Peru. This root is not so abundant here as you believe, I have been 
assured that the galleons only bring back between 50 and 100 pounds on 
each voyage. Nonetheless I will write you at the first opportunity and will 
do my best to collect, if at all possible, the 300 pounds, or at least as much 
as can be found.77 
 
Following Catalan’s assessment of how much each galleon fleet carried, the annual 
supply of ipecacuanha to Cadiz—and likely to Europe as a whole—may have been very 
small indeed. The difficulties of securing a supply in France would only get worse when 
Spain entered the War of the League of Augsburg against France, as we have already 
seen from the judgement of the Paris Parlement, which rescinded the remainder of 
                                                 
75 “L’on dit que la guérison du flux de sang est sure quand le bejuquillo a fait vomir,” AN AE B1 
213. Catalan to Pontchartrain (November 24, 1687), fol. 82v-82r.  
76 AN AE B1 213. Catalan to Pontchartrain (December 8, 1687), fol.  85v: “J’ay fait une exacte 
recherche de la racine Beguquillo, elle est extrêmement rare, pourtant j’en ay trouvé heureusement une 
livre, assuré véritable, je vous l’envoiré Monseigneur par le premier navire avec une recepte du plus 
fameux médecin d’icy de l’usage qu’on en fait.” This was sent on December 22, along with 610 poudns of 
cinchona to Le Havre: see fol. 87r (December 22, 1687), which also mentions the Latin mémoire from the 
“famous physician.” 
77 “Je prene mes mesures pour faire venir du Perou 300 livres de Bejuquillo ou radix aury. Cette 
racine n’est pas sy abondante que vous croyés puis que on m’a assuré que les galions n’en apportent pas 
chaque voyage plus de 50 à 100 livres. Cependant j’escriray par la première occasion et feray en sorte 
qu’on ramasse, s’il est possible, les 300 livres ou du moins tout ce qui s’y trouvera,” AN AE B1 213, 
Catalan to Pontchartrain (March 15, 1688), fol. 106r-v 
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Garnier’s ipecacuanha contract with Helvétius in 1688, and also reports that Louvois had 
instructed Garnier not to sell the root to anyone but the French army. 
Scarcely a month after Helvétius was granted his fifteen-year privilege, France 
found itself at war with most of Europe. Like so many others, this war was intended to be 
short and swift: Louis XIV invaded the Rhineland on September 25, 1688, with the 
primary goal of securing a more defensible frontier in Alsace, the most strategically 
vulnerable of France’s provinces. France made swift gains, but a growing contingent of 
other European powers began to rally their forces to prevent further French expansion. As 
the French realized their planned short war was becoming a long, protracted conflict, the 
French army hunkered down in its fortresses along the Rhine, and the highest levels of 
the French military, including Louvois himself, began advocating a deliberate policy of 
destruction to prevent any army from approaching the border. The results of this plan are 
now known as the 1689 Ravage of the Palatinate, during which an extensive belt along 
the Rhine, including fortifications as well as villages and farms, were razed to secure the 
French defensive position.78 Despite these measures, in the year following the Ravage of 
the Palatinate, the French army along the Rhine found itself besieged by two very 
different enemies: namely, dysentery on the one hand, and on the other an ad hoc medical 
supply system which the senior bureaucrats of the War Office saw as inherently corrupt 
and ineffective. 
Historians over the past two decades have pointed out that France, like most early 
modern states, had not yet nationalized many functions which supported the waging of 
                                                 
78 John A. Lynn, “A Brutal Necessity? The Devastation of the Palatinate, 1688-1689,” in Civilians 
in the Path of War, ed. Clifford J Rogers and Mark Grimsley (Lincoln: University of Nebraska Press, 
2002), 79–111; Jean-Philippe Cénat, “Le ravage du Palatinat : politique de destruction, stratégie de cabinet 
et propagande au début de la guerre de la Ligue d’Augsbourg,” Revue historique 633 (2005): 97–132. 
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war, and instead relied on ad hoc contracting with private entrepreneurs to meet various 
fiscal, organizational, and supply needs. Tax collection was farmed out to raise revenue; 
entrepreneurs provided military manpower, transportation, fortifications, and 
ammunition; and mercenaries continued to form an important contingent in early modern 
armies.79 Health care, particularly the supply and daily needs of army hospitals, were also 
met through private contracting, but in comparison with these other kinds of supply and 
service, medical entrepreneurs have as of yet received little scholarly attention, especially 
in France.80  
From the 1660s onwards, French army hospitals were dependent upon 
entrepreneurs who received contracts on an annual basis and were supposed to be closely 
monitored by commissaires des guerres. These functionaries were charged with 
regimental management, the review of troops, logistics, and regularly reporting on all of 
these matters to the Secretary of State for War.81 This system presented numerous 
practical problems for the commissaires, who always had to be on the lookout for 
corruption and fraud on the part of hospital entrepreneurs (usually called “malversations” 
                                                 
79 For an excellent survey of this literature, see Jeff Fynn-Paul, Marjolein ’t Hart, and Griet 
Vermeesch, “Entrepreneurs, Military Supply, and State Formation in the Late Medieval and Early Modern 
Periods: New Directions,” in War, Entrepreneurs, and the State in Europe and the Mediterranean, 1300-
1800, ed. Jeff Fynn-Paul (Leiden: Brill, 2014), 1–12. 
80 There has been no comprehensive study of the role of army hospital entrepreneurs under Louis 
XIV: for brief surveys, see Monique Lucenet, Médecine, chirurgie et armée en France au siècle des 
lumières (Clichy-la-Garenne: Édition I&D, 2006), 36–51; Guy Rowlands, The Dynastic State and the Army 
under Louis XIV: Royal Service and Private Interest, 1661-1701 (Cambridge: Cambridge University Press, 
2002), 97–98; John A. Lynn, Giant of the Grand Siècle: The French Army, 1610-1715 (Cambridge: 
Cambridge University Press, 1997), 420–426; Léon Mention, L’Armée de l’ancien régime, de Louis XIV à 
la Révolution (Paris: Société française d’étidions de l’art, 1909), 274–278; Louis André, Michel le Tellier et 
l’organisation de l’armée monarchique (Paris: Félix Alcan, 1906), 475–487. The English navy in this 
period has been better served: on the origins of private contractor hospitals, see Matthew Neufeld and 
Blaine Wickham, “The State, the People and the Care of Sick and Injured Sailors in Late Stuart England,” 
Social History of Medicine 28, no. 1 (2015): 45–63. 
81 Rowlands, The Dynastic State and the Army, 97–98; Lynn, Giant of the Grand Siècle, 88–92. 
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and “fripponnerie”).82 Although the daily activities of the hospital entrepreneurs 
generated the most voluminous records, the commissaires des guerres also negotiated 
with smaller military-medical suppliers, most notably apothecaries, who supplied 
medications and dispensed them to hospitalized soldiers. 
Some commissaires des guerres took an active interest in rendering the care of 
sick and wounded more efficient. Writing to Louvois, Denis Baudouin, the commissaire 
de guerre stationed at Landau, “took great care to enter into the details of the hospital” 
and was preparing a règlement intended to make the Landau hospital more efficient and 
serve as a model for others. He pointed to a number of problems: the ditches taking the 
runoff from hospital latrines needed to be properly engineered and kept from plugging 
up, lest they “infect” the hospitals; the courtyards of the hospitals should be paved; 
convalescent homes should be established in nearby villages to clear hospital beds and 
remove soldiers that were recovering from those that were still sick. By far the longest 
portion of the letter, however, dealt closely with the problem of supplying medicines to 
hospital patients: 
We have contracted an apothecary to furnish the necessary remedies at six 
deniers per day per patient. I have observed that this variety of 
entrepreneur-apothecaries are all miserable sorts who do not have the 
means to make any provision, and if they have any, it’s always the scraps 
from the boutiques, and they dispense as few medicines as they can, and 
always in the wrong dosages.83  
                                                 
82 Lucenet, Médecine, chirurgie et armée en France, 36–51. The most of important form of fraud 
on the part of the entrepreneurs was charging the standard daily patient care rate for patients who were, in 
fact, not in the hospital, a practice which could only be controlled through diligent record keeping and 
auditing, comparing the hospital registers with those of the commissaires des guerres and almoners, and 
heavy fines for fraud. Other forms of cost-cutting, skimping, and even theft on the part of entrepreneurs 
were also common, notably the provision of substandard food or dirty linens, but perhaps the most notable 
cases on the Alsatian border in the 1690s surrounded the arms, equipment, and uniforms of soldiers who 
died in hospital being confiscated by the entrepreneurs who hoped to re-sold back to the regiment. See for 
example SHD A1 1000, fols. 283, 301. 
83 “L’on a traité à six deniers par journée de malades avec un apotiquaire pour fournir les remedes 




Baudouin proposed an alternative method which would ensure the quantity, quality, and 
correct dosage of the remedies used in the hospitals and would allow for greater 
accountability from the apothecaries: 
For a large hospital in an advanced position, where armies often send 
more wounded than can be received, it would be better to buy a good 
supply of remedies at His Majesty’s expense, which could then be put in 
the hands of an apothecary who would be paid to compound and distribute 
them. The sick would be better treated and there would be no danger of 
shortfalls: the only abuse to fear would be that the apothecary would sell 
them. But we could prevent this by obliging all of the physicians to 
specify in French instead of Latin the dosage of the remedies in their 
prescriptions, which will be entered in the apothecary’s registers; and it 
would suffice to hold said apothecary to account each week for the 
consumption of said remedies. It seems to me that this would cost His 
Majesty nothing extra.84 
 
By March, just a few months later, it seems that Baudouin’s suggestions were being 
implemented. The first drug to be supplied in this way was cinchona: Louvois informed 
the commissaires that the crown had purchased a large quantity of cinchona, which was 
to be requested as needed by each hospital from a central supply under the control of the 
War Office.85 By May, Louvois was interested in testing another drug for similar use: he 
sent six chests (boëtes) of “remède pour la dissenterie” with an attached “mémoire pour 
en servir” to Baudoin at Landau and to his counterpart at Philipsburg, the commissaire 
                                                                                                                                                 
moyen de faire aucune provision, ou s’ils en ont, c’est peu et toujours le rebut des boutiques, donnant le 
moins qu’ils peuvent de remedes, et toujours mal dozés,” SHD A1 966, fol. 188, Baudouin to Louvois 
(January 11, 1690).  
84 “Il servit mieux pour un grand hopital dans une place de guerre avancé ou les armées apportent 
souvent plus de malades qu’on ne peut recevoir, d’achepter aux despens de Sa Majesté une bonne provision 
de remedes pour estre ensuite remise entre les mains d’un apotiquaire qui seroit payé pour les composer et 
distribuer; les malades ne seroient mieux soulagés, on ne seroit pas en danger d’en manquer, il n’y auroit 
qu’un abus à craindre qui seroit que l’apotiquaire n’en vendra. Mais on pourra le prevenir en obligant les 
medecins de bien specifier en francois et non [en Latin] la doze des remedes dans leurs ordonnances qui 
seroient mise sur le registre de l’apotiquaire, et su—aire compter ledit apotiquaire toutes les semaines de la 
consommation desdits remedes; il me parait qu’il n’en couteroit pas plus à Sa Majesté,” Ibid. 
85 SHD A1 915, fol. 163, 166 (form letter), Louvois to Baudouin in Landau and Fontemorte in 
Philipsburg (March 24, 1690). 
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Fontemorte.86 By July 1, Baudouin was reporting back on the efficacy of the drug: 
soldiers whose dysentery was just beginning were promptly cured by the drug, while he 
estimated that the drug was not at all effective in cases of “old dysenteries,” which 
accounted for most of the casualties at the Landau hospital.87 Fontemorte provided a 
similarly positive review, noted the drug’s inefficacy on old cases, and requested more of 
the drug, having already used up the initial supply: 
The remedy it pleased you to send us for dysentery has turned out to be so 
good that we have consumed almost all of it. I humbly beseech you 
Monseigneur to order more of it to be sent here, because we have hardly 
any other diseases. We have observed that the remedy must be used at the 
beginning [of the disease], and that it has no effect once the sickness sets 
in.88 
 
The situation began to worsen in the following weeks. De la Grange, the Strasbourg 
intendant, inspected the fortifications and hospital at Landau on August 5, and observed 
that although the hospital was clean and well maintained, there were over 1,600 patients 
there, and no more could be added. “Many have the bloody flux, if the remedy you send 
M. Baudouin commissaire succeeds, it will need to be sent to the other hospitals.”89 The 
prose reports and tabulated états of admissions, discharges, and deaths at the Alsatian 
hospitals are not broken down by disease, but all reported that dysentery was the main 
cause: on August 14, De la Grange observed “Most of the sick at the hospitals of Landau 
                                                 
86 SHD A1 918, fol. 320bis, Louvois to Baudouin and Fontmorte (May 13, 1690) 
87 SHD A1 991, fol. 83, Baudouin to Louvois (July 1, 1690). 
88 “Le remède qu’il vous a plu d’envoyer icy pour la dissenterie se trouve si bon, qu’il est presque 
tout consommé, je vous supplie très humblement Monseigneur de vouloir bien ordonner que l’on nous en 
envoye encore, puisque nous avons presque pas d’autre maladies. On a observé qu’il faut servir dudit 
remède dans le commencement, et qu’il est sans aucun effet, lorsque le mal est entrée,” SHD A1 991, fol. 
111, Fontemorte to Louvois (July 19, 1690). 
89 “Il y en a beaucoup qui ont le flux de sang, si le remède que vous avez envoyé a M Baudoin 
commissaire réussi, il en faudra pour tout les autres hospitaux,” SHD A1 1000, fol. 162, De la Grange to 
Louvois (August 5, 1690). 
236 
 
and Haguenau are sick from bowel runs and bloody flux. There are also many cases at 
Strasbourg.”  
By the middle of August, it appears that all of the hospitals of Alsace were 
dealing with a full-blown epidemic of dysentery.90 Aware of the gravity of the situation, 
Louvois ordered De la Grange to collect data from all seven hospitals and report back to 
him with a full état, which the latter did on September 2. De la Grange estimated that 
over 5,000 soldiers were presently in hospitals, and confessed that the record keeping 
methods and time-spans used by the commissaires at each site differed, a problem which 
he promised would not occur again in the future. But as far as he was able to determine, 
in the past two months, 9,030 soldiers had been admitted to the hospitals, 4,402 had been 
discharged, and 1,054 had died. Of these deaths, nearly half, 428, had occurred at 
Landau, where the epidemic was most deadly, all within the month of August. The 
Landau figures also show the relatively small part that wounds played among 
hospitalized soldiers: of the 947 patients in the hospital on the day the survey was taken, 
only 94 suffered from wounds. Deaths from the epidemic peaked at the end of August but 
continued into September: at Landau, Baudouin reported that in the first two weeks of 
that month, 182 were admitted, 117 convalescents were discharged, and 141 died. After 
visiting the Landau hospital, Fontemorte reported that there was such a stench in the 
hospital that he could hardly stand it: “it comes from the mattresses, on which the 
dysenterics are laid two by two, making it impossible to change them.”91 Despite this 
grim portrait, the situation in fact improved markedly in the month of October: at the end 
                                                 
90 The intendant De la Grange  reported, “La plus part es malades qui son tans les hospitaux de 
Landau et d’Haguenau le sont de cours de ventre, et de flux de sang. Il y en a aussy beaucoup à 
Strasbourg,” SHD A1 1000 fol. 174, De la Grange to Louvois (August 14, 1690). 
91 “Elle provient des matelas sur lesquels les dissenteriques sont couches deux à deux, comme il 
n’est pas possible des les changer,” SHD A1 991, fol. 211, Fontemorte to Louvois (October 3, 1691). 
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of the month, Baudouin reported that the rates of dysentery had declined, and the 
remaining casualties were due primarily to intermittent fevers.92 
 As the epidemic abated, the shipments of dysentery remedy entered an explicitly 
experimental phase, possibly due to a lack of the earlier permutation of the drug. 
Baudouin’s correspondence, as well as Fontemorte’s, suggests that the Bureau de guerre 
began sending them different varieties of the remedy, and that the two commissaires 
reported back on the effects of these variants: Baudouin’s September 14 report, for 
instance, suggests that he had been sent three distinct varieties of the drug: a black 
powder, a white powder, and a third compounded remedy “wrapped in paper.” Based on 
Baudouin’s observations, only the last variety—the packaging of which matches that 
used by Helvétius—was effective, although he had been sent a much larger quantity of 
the other, ineffective powders.93 A large shipment of this variant was sent to De la 
Grange in October, along with a letter explaining how to administer it which was copied 
and forwarded with the shipments to Strasbourg, Sélestat, and Brisach, with instructions 
to report back on its effects.94 This letter has not survived, but an addendum from 
Louvois does: 
Concerning the dysentery remedy which I sent to you, I would add to what 
I have already written that the man who gave it to me told me that all the 
                                                 
92 SHD A1 991, fol. 303, Baudouin to Louvois (December 7, 1690). Baudouin reported that at 
Landau in the month of October, 383 were admitted to the hospital, 509 convalescents were discharged, 78 
died, and 416 remained in the hospital. 
93 “Le dernier remede que vous en avez envoyé Monseigneur pour la dissenterie en a gueri 
entierement un soldat auquel on a fai prendre trois fois de ce remede; Je vous suply de en envoyer encore, 
ayant epuisé ce que vous m’en avés envoyé. Je observerai Monseigneur que ce n’est pas de la poudre noire 
ny blanche dont vous en avés envoyé plus de boëtes; mais c’est le remede qui est envelopé dans du papier 
et qui est comme du papier brulé (?),” SHD A1 991, fol. 193, Baudouin to Louvois (September 14, 1690). 
94 SHD A1 1000, fol. 258, De la Grange to Louvois (October 10, 1690). “J’ai receu  les lettres que 
vous m’avez fait l’honneur de m’escrire les 23 25 27 du mois passé, et premier de celuy-cy, avec les deux 
boettes de poudres que vous m’avez adressés pour guérir la disanterie, je les ay fait distribuer dans les 
hospitaux de Strasbourg, Schelstat, et Brisack, et j’ay envoyé a Mrs. les commissaires la copie de la lettre 
qui contient la manière de s’en servir, afin qu’après avoir observé l’effet de ce remède, ils m’en envoye un 
mémoire pour que je puisse vous en rendre compte.” 
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powders must be put into a mortar with a bit of white wine to dissolve 
them, and after this they should be infused, following the earlier 
instructions. In cases where the patient is not cured in the first three days 
that he takes the remedy, continue to give it to him for another three, 
which adds up to six days in sequence, being careful to ensure that he 
unclenches his teeth, otherwise he will only swallow the wine, and the 
powders will remain in his mouth, and he will spit them out, which will 
prevent the remedy from having its effect.95 
 
Evidence that such a report was made survived from the correspondence of at least one 
commissaire, Fontemorte, who reported that the “remedy for dysentery, which is half 
black powder, half grey” was not at all effective at Philipsburg. He enclosed the report of 
the hospitals’ physician with his letter, but this has unfortunately not survived.96 There is 
evidence that another shipment of “une poudre pour la dissenterie” was made on 
November 5, but because the page containing the letter which accompanied it is missing 
from the dispatch register, it is impossible to tell which variant was sent.97 
 From these hints, we can suppose that Helvétius was experimenting with different 
versions of the drug, perhaps due to the difficulty of supplying his original 1688 version 
in such large quantities. The descriptions of two distinct powders to be mixed together 
on-site may refer to brown and grey (or even white) ipecacuanha: Helvétius may have 
                                                 
95 “J’adjousteray à ce que je vous ay escrit sur le remede que je vous ay envoyé pour guérir de la 
dissenterie, que celuy qui me l’a donné m’a dit qu’il falloit mettre toutes les poudres dans un mortier avec 
un peu de vin blanc pour les bien dissoudre, et après les faire infuser, suivant que je vous l'ay marqué, 
qu’en cas que le malade ne guérisse pas, pendant les trois jours qu’il prendre ce remede, il faudra continuer 
a luy en donner encore trois autres jours, qui sera six jours de suite, observant de luy bien faire desserrer les 
dents, parce qu’il n’avalleroit que le vin, et les poudres restant dans sa bouche, les cracheroit ce qui 
empescheroit le remede de faire son effect, il faut aussy que le malade boive fort peu, et que ce ne soit que 
de la tisanne,” SHD A1 999, fol. 240, Louvois to De la Grange (October 17, 1690). 
96 “Je joinds icy les observations et le raisonnement du médecin de l’hospital sur l’épreuve qu’il a 
fait du remede pour la dissenterie, qui est moytié poudre noire, et moytié poudre grise, lequel il n’approuve 
point du tout, il en desduit les raisons, et je scay qu’il n’a produit aucun bon effect, le flux de sang qu’il 
arreste dès le deuxième ou troisième jour revenant plus grand qu’il ne l’avoit esté,” SHD A1 999, fol. 249, 
Fontmorte to Louvois (November 5, 1690). 
97 The table for SHD A1 999, lists the following item “5 novembre. Le même [Louvois] envoye 
une poudre pour la dissenterie,” but these pages of the volume have been cut out of the binding (four stubs 
remain). The conservator, Bertrand Fonck, suggests these pages were cut out illicitly by an autograph 
vendor or some other interested party. 
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tried to compensate for a shortfall in his supply of brown ipecacuanha by mixing it with 
the grey or white varieties. Likewise, Louvois’ letter suggests that the version sent in 
October was intended to be compounded locally: this may be due to difficulties in 
keeping the ready-compounded powder dry during transport from Paris to Alsace. 
Baudouin’s letter is telling in this regard: he condemns the “black” and “white” varieties, 
which he had been sent the largest volumes of, preferring instead the remedy that was 
“wrapped in paper,” which likely corresponds to Helvétius’ original packaged drug. 
Finally, a third possibility should be acknowledged, namely that some of these shipments 
may not have come from Helvétius at all: they could have come from a competitor, or 
may be the result of the army itself attempting to buy raw ipecacuanha in bulk and have it 
compounded on-site by the entrepreneur-apothecaries, following a recipe which 
Helvétius or another physician had provided. 
 Whatever the case, it seems clear that this first experience of military supplying 
triggered a critical shift in Helvétius’ career. He went from producing a drug destined for 
the consumption of small numbers of élites, to one which was targeted at military 
populations in campaign hospital settings at a considerable distance from Paris. How 
widely was it applied in other military settings in the coming decades? Although more 
research is needed to fully flesh out how many campaigns made use of it, we know that it 
was widely used in Savoy and the Piedmont during the War of the Spanish Succession 
(1701-1714), and Helvétius includes a reference letter from Louis Joseph, Duke of 
Vendôme, Marshal of France, France’s highest general, which testified to its successful 
use in that conflict, as well as those of individual hospital physicians from Oulx, 
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Briançon, and Fenestrelle.98 Beyond this long-term medical supply relationship, 
Helvétius would even go on to become official inspector of military hospitals in Flanders 
from 1707 onward. 
Helvétius was not wholly unique in this period as a medical entrepreneur turned 
military contractor. We have already seen that the Louvre Capuchins supplied their 
proprietary remedies to the court at Versailles as well as the French army in 1679.99 In 
the early eighteenth century, Helvétius’ example was followed by other vendors of 
proprietary remedies who marketed their drugs to the French military: these include 
Antoine du Muth de la Motte, who received a royal privilege for his golden elixir and 
allowed it to be produced following his recipe for the disabled soldiers of the Hôtel des 
Invalides;100 and that of Ferdinand de Guiller’s poudre fébrifuge, which serves as the 
basis of the next chapter. Indeed, senior officials like Pontchartrain as well as local 
intendants were constantly on the lookout for potentially useful medical secrets that could 
help solve military health problems.101 
Finally, although the military-contracting experiences of Helvétius and these later 
vendors went reasonably well, at least one contemporary case, that of Pierre-Jean Le 
Mère (c. 1652-1726), known as “Le Médecin soldat,” shows that in addition to being 
lucrative, supplying the military with medicines could also be quite dangerous. Le Mère 
had served as a surgeon in the French army, and learned the secret of a febrifuge from a 
Turk while travelling in the east. He used it to cure Sébastien Le Prestre, Marquis de 
                                                 
98 AN G7 716, “Placet à Monseigneur Desmaretz,” fols. 14r-15v: reference letters from Michelet, 
physician of the Oulx hospital (October 11, 1707); fol. 14v Trava, of the Briançon hospital (no date); fol. 
15r from Cassarel, Fenestrelle hospital (October 6, 1707); and fol. 15v, from Vendôme (March 14, 1706). 
99 See above, ch. 2, sect. 1. 
100 Maurice Bouvet, “La spécialité pharmaceutique au XVIIIe siècle : Les gouttes du général de la 
Motte,” Revue moderne de pharmacie 12, no. 1 (1922): 7–15. 
101 See below, ch. 5, sect. 1. 
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Vauban, who had been abandoned by the Paris Faculty doctors. As a reward, Le Mère 
was made naval physician to the port of Brest and proposed to test his drugs there and 
then to supply them to the navy. In 1691, however, he claims that he was asked to vacate 
his position by Louvois, who intended to give it to someone else, and offered to pay him 
a minor pension for his trouble. When he refused Louvois’ repeated offers, he promptly 
found himself arrested under lettre de cachet under a series of charges, most notably that 
of conspiring to poison the sailors of the navy with medicines containing corrosive 
sublimate and arsenic. He spent the next thirty years of his life in the dungeons of 
Vincennes and the Bastille, being finally released in 1726 at the age of 74 following the 
repeated petitions of his relatives.102  
As a medical contractor, Helvétius also had close analogues across the channel in 
England. These include John Colbatch (d. 1729), whose connections to army officers 
enabled him to try his proprietary Vulnerary Powder and Tincture of the Sulphur of 
Venus, intended, respectively, to stop bleeding and help heal wounds, on English 
soldiers.103 In the English navy, William Cockburn (1669-1739) provides a similar case. 
His success, like that of Helvétius, was based on a dysentery cure applied to military 
populations: after testing his electuary against dysentery shipboard in 1696, he went on to 
supply it to the navy for forty years.104 Citing these two examples in particular, Harold J. 
Cook has suggested that after the so-called Glorious Revolution, “the new military 
establishment reinforced the growing cachet of empirical, practical, ‘clinical’ medicine, 
                                                 
102 I encountered Le Mère’s case in the rich prisoner records of the Bastille at the Bibliothèque de 
l’Arsenal, ms. 10493. The only historical account of his tragic life is that of Roger Goulard, “Les aventures 
de Pierre-Jean Le Mère « Médecin soldat »  au XVIIe siècle,” Bulletin de la Société française de l’histoire 
de la médecine 14, no. 7–8 (1920). I plan to revisit this case in a later publication. 
103 Harold J. Cook, “Sir John Colbatch and Augustan Medicine: Experimentalism, Character and 
Entrepreneurialism,” Annals of Science 47, no. 5 (1990): 475–505. 
104 Charles Creighton and Anita Guerrini, “Cockburn, William (1669–1739),” Oxford Dictionary 
of National Biography, 2008, http://www.oxforddnb.com/view/article/5777. 
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undermining the ideas of medical judgement held dear by the learned physicians,” and 
that it was “oriented to a mass clientele, based upon the power of practitioner over 
patient, directed toward quick and simple cures, and rooted in a belief in specific disease 
entities rather than unique physiological imbalances.”105 This description fits Helvétius’ 
case as well, but despite these analogues in France and England, there is at least one 
aspect of his career which appears to be singular: Helvétius’ adaptation of his drug to a 
“mass clientele” was taken one step further. He began supplying his drugs not just to 
soldiers, but to peasants as well, as part of a royally-funded program of medical charity.  
Although Helvétius’ 1690 experiments no doubt played a role in re-shaping the 
medical compound of the remède spécifique into a population-scale drug which could be 
delivered to populations beyond the army, this new application had to be accompanied by 
a critical transformation in the instructions which accompanied his medicines. In the 
military case, Helvétius could transmit his instructions to the War Office, which could 
send them down to the intendants and commissaries des guerres, where he could rely on 
the existing medical infrastructure of the army hospitals. Supplying his drugs to the rural 
poor of the French provinces, where they would be dispensed and administered by a far 
more irregular set of actors with variable literacy skills and medical training—from local 
barber-surgeons, to parish priests, and Daughters of Charity—required a revolution in 
printed medical instructions, to which we will now turn. 
4. The de-individualization of administration instructions  
Although Helvétius nowhere provides an account of how his therapeutic views 
evolved over time, evidence of how he adapted the drug for delivery en-masse to 
                                                 
105 Harold J. Cook, “Practical Medicine and the British Armed Forces after the ‘Glorious 
Revolution,’” Medical History 34, no. 1 (1990): 2, 3. 
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populations can be found by tracking the evolution of the printed instructions he provided 
on how to take the drug. This section looks at the initial 1688 Méthode that accompanied 
the first version of the drug, and compares its instructions to his 1703 Traité de maladies 
and to the single-sheet “Mémoires instructifs” which accompanied his chests to the 
provinces. 
Helvétius’s 1688 Methode projected a complex, two-month treatment based on a 
battery of different labelled packets of powder taken in conjunction with a precise 
regimen of food and drink, with numerous contingency instructions for special cases and 
complications. In the morning and evening of days 1-3 of the treatment, the patient must 
take the powder of a packet labelled A, mix it in half a glass of wine, and then take some 
soup two hours later; the contents of this packet are intended to soften corrosive humours 
that are excoriating the patient’s intestines. The patient then continues to take A-packets 
in the same way on all “unmarked” days; the marked days, spread across the following 
two months, each provide special instructions. On days 4, 9, 13 and 15, for instance, the 
patient takes one of the doses marked B, B2, B3, and B4, diluted in half a glass of wine: 
these, Helvetius writes, are meant to expel the viscous and silty bile from the stomach 
which is preventing food from being digested and souring their chyle, leading to the 
disastrous complications that often accompany the flux and dysentery. On day 7, and 
afterward on every fifteenth day of the treatment, they must purge using the medicine 
marked C with an infusion for which he provides a recipe. Patients are to follow this 
regimen carefully, even after they feel they have recovered, lest they relapse. This 
regimen is to be modified in special conditions, based primarily on age and temperament, 
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as well as pregnancy.106 Helvétius also acknowledges the emetic properties which 
continued to persist in the remedy despite his preparation, but stresses the need to avoid 
vomiting as much as possible when taking them. In the later pages of the Methode he 
provides further advice on regimen and recipes for an infusion, and enema, and an oil to 
respond to certain complications that accompany dysentery (notably hemorrhoids), and in 
the former cases even offers a simplified recipe to be used in places where the preferred 
ingredients are not available.107 
Helvétius concludes his Methode with a few pages of apologetics, aimed 
primarily at fellow physicians who might be sceptical of so-called specifics like his. He 
confesses that he himself was surprised at the common effectiveness of his remedy in 
patients with radically different temperaments, but counsels any who doubt it to try it, 
and is confident that they will be forced to acknowledge its effectiveness. He notes that 
he will charge no special fee for those who come to him early for his medicine, but that 
he will charge extraordinary fees to those who wait too long to call on him. The poor, 
however, will always be treated gratis, not only for dysentery but for fevers, dropsy, and 
the falling sickness. Finally, he warns the reader to suffer no imitations: the king is the 
only one who knows his secret, and that all others are counterfeiters whose remedies will 
not produce the effects they promise. On the back cover, he even includes the text of a 
certificate from Daquin approving his remedy.108 
By 1690, however, the secret was out (probably thanks to his trial with Garnier) 
and all of Helvétius’ subsequent instructions accompanying the medicine chests sent out 
to the provinces and all of his other publications refer to ipecacuanha as the key 
                                                 
 106 I hope to explore these and other details in an article focusing on Helvétius’ instruction sheets. 
107 Methode de Mr. Helvétius, 1-17. 
108 Methode de Mr. Helvétius,17-20. 
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ingredient of his “Poudre Spécifique contre la Dysenterie.” Indeed, the treatment regimen 
is also vastly simplified in the 1703 Traité des maladies les plus fréquentes as well as the 
mass-audience instructions derived from it that later accompanied his medicine crates to 
the army and the provinces. Gone is the two month regimen and all mention of packets 
labeled A, B, or C. Instead, we find only single packets of powdered root of ipecacuanha 
being diluted in wine or broth, which the patient is counseled to take early in the 
morning. If the patient still experiences pains and evacuations the next day, he or she 
should take another dose; if not, then he or she can wait a day or two before taking a 
second dose. A third and even fourth dose are recommended if the dysentery persists, and 
in the days in between, the patient should take another of his drugs, the “Poudre 
corrective,” to fortify the stomach and aid digestion, but again only if the dysentery is 
persistent. If it goes into remission he or she should take a dose of yet another drug, the 
tincture of coral (later called anodyne coral). After these instructions, Helvétius provides 
special instructions for cases where dysentery is accompanied by fever and a short 
recovery regime. He even counsels patients to write to him and describe their condition if 
his remedy fails, and promises to write back. Indeed, beyond mixing the powder with 
wine or broth, the only counsel that carries over from the earlier Methode is the 
exhortation for the patient to avoid vomiting as much as possible and the special 
instructions for age, temperament, and pregnancy.109  
The pamphlets that Helvétius would enclose with his medicine crates are even 
more concise. In them, he distinguishes two different uses of ipecacuanha: the first is to 
provoke vomiting; the second, specific to dysentery, is to melt and divide thick humours 
trapped in the intestines. This requires much lower doses than if it is being used as an 
                                                 
109 Helvétius, Traité des maladies les plus fréquentes 266-270. 
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emetic (each dose contains only about a half grain of ipecacuanha). Here the ipecacuanha 
is mixed with anodyne coral in a base of flatbread (pain à chanter) to form a pill, 
swallowed with a small glass of wine or bouillon. A dosage scheme based on age 
follows: one pill for children 2-6, two for 6-12, three for 12-24, and especially robust 
patients can take four to six pills at once. In this case, the ipecac must be kept there for as 
long as possible and so vomiting must be avoided: “We must always exhort the patient to 
resist vomiting for as long as possible, so that the remedy will stay in the stomach for as 
long as possible.”110 To this end, Helvétius recommends having the patient drink warm 
water after swallowing the drug.  
 How can we explain this transformation? To begin, the initial 1688 instructions 
still make use of the basic concepts of learned medicine: allowances for different 
constitutions, regimens, and control over the non-naturals. They have admittedly made an 
important departure from individualized therapy by prescribing a basic, uniform 
treatment regime for the majority of patients, but at several points they read more like an 
attempt to simulate learned medical judgement by anticipating certain types of 
complications, and providing solutions to them. Most fundamentally, however, the 1688 
instructions presuppose a high degree of control over the patient’s non-naturals for a 
protracted period of time. In this way, they still bear the hallmarks of the conditions in 
which Helvétius had been practicing up until then, namely the treatment of bourgeois and 
aristocratic patients. The 1703 instructions presuppose just the opposite. In the dedicatory 
epistle to the collected version of the 1703 instructions, Helvétius observes that the past 
few years had afforded him experience in devising remedies for patients who were 
                                                 
110 “Usage de L’Hypecacuanha Préparé, appellé Poudre Spécifique contre la Dysenterie,” 2. 
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precluded from more “ordinary relief” by the “tumult of warfare.”111 He even observes 
that he personally still uses “ordinary” forms of medicine when possible, such as 
bloodletting and enemas, because these can sometimes halt disease at its origin by 
regulating a patient’s non-naturals. But in cases where it becomes entrenched and 
obstinate, specific remedies are the only true recourse.112 
 Perhaps the most important question about this transformation is whether it marks 
an overall simplification of the treatment regime or simply a distinction of two different 
approaches to administering the poudre spécifique: would aristocratic patients, for 
instance, still be receiving a treatment that looked more like the 1688 one, while soldiers, 
sailors, and the rural poor were given the “rough and ready” treatment of the 1705 
instructions? The question is difficult to answer, but I should note that there are no 
reprints of the more extensive instructions, nor are their points taken up again in the 
editions of the Traité des maladies from 1703 onward. In cases where Helvétius was 
personally managing a treatment, the “rough and ready” instructions would almost 
certainly have been modified. Other physicians who used his drugs likely personalized 
their treatment as well. But for a practitioner who was serious about treating entire 
populations, the 1688 instructions were a dead end: they could not really replace the 
judgement of a physician, and given the unlikelihood of being able to control regimen 
and administer ancillary therapies in the context of dispensation in military hospitals and 
among the rural poor, the better option was to dispense with individualizing elements 
entirely.  
                                                 
 111 Adrien Helvétius, Mémoires instructifs sur l’usage des différents remèdes spécifiques pour les 
armées du Roy et les malades de la campagne (Paris: Pierre Le Mercier, 1705), aiiij r. 
 112 Ibid., [B2] r. 
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 The transition from complex, particularized instructions, to simple, generalizable 
instructions marks the culmination of a series of transformations that began with the 
pharmacological re-conceptualization of ipecacuanha from an emetic to a medicinal 
specific, and Helvétius’ efforts to devise a “corrective” preparation of the root itself. 
5. Distribution, charity, and the fiscal state 
In September of 1709 Helvétius submitted an extensive proposal to the new 
Controller-General of Finances, Nicholas Desmaretz (1648-1721). He proposed the 
creation of a new office, that of Distributor General of Remedies for the Relief of the 
Poor (Distributeur général des Remèdes pour le soulagement des pauvres), which he was 
prepared to purchase, as well as a host of cost-saving reforms to the existing practices of 
distributing his remedies annually to the rural poor of the French provinces. The main 
goal of these reforms and the attendant office was to save “an infinite number of persons 
in the parishes of the countryside,” who are annually killed by “contagious diseases” 
(maladies contagiueses) for lack of any help or remedies.113  
 Helvétius’ proposal was one of hundreds that were submitted to the office of the 
Controller-General, who actively solicited propositions for reform from both inside or 
outside of the government. Most projects sought either to respond to abuses in the 
existing financial system or proposed methods for securing new sources of revenue for 
                                                 
 113 AN G7 716, Propositions et projets de réformes adressés au contrôleur général par des officiers 
royaux ou des particuliers, Ocotber-December 1709, “Le Sieur Helvétius, Proposition de création d’un 
office de Distributeur général des remèdes.” This box includes a placet, three separate mémoires, and three 
letters from Helvétius, two of which are dated: 2 and 29 September 1709. The opening words of one of the 
mémoires neatly summarizes the basic goal of improving the distribution of remedies: “Une funeste 
expérience apprend que les Maladies contagieuses emportent tous les ans dans les paroisses de la 
Campagne une infinité de personnes, faute de Remèdes, et de secours. Ceux que les Sieurs intendants 
demandent, arrivent souvent trop tard, et la grande quantité que l’on en envoye toutes les années, coute au 
roy considérablement. Pour prévenir la perte de tant de Peuples, on propose de faire trouver toujours dans 
toute l’étendue du Royaume des Remèdes spécifiques contre les différentes espèces de maladies. Ils seront 




the state coffers. Desmaretz delegated the task of examining the proposals to his long-
time assistant, Jean-François Charmolüe de la Garde, who would then produce an abstract 
or report summarizing its main points. Those that passed this initial reading and met with 
Desmaretz’s personal approval might see their authors invited for a personal audience. 
The proposal might be amended in consultation with other officials, and then it would be 
accepted or rejected in the Royal Council of Finance. If accepted it would be reworked 
into a royal edict or decree.114 
The medical nature of Helvétius’ proposal may at first seem anomalous within 
such a corpus, but three factors establish why it would be of interest to the office of the 
Controller-General. First, as we shall see, Helvétius had cultivated an extensive 
relationship with Desmaretz’s predecessor Michel Chamillart and the provincial 
intendants who answered to him, and his distribution system was closely tied to the state 
tax infrastructure. Second, as Gary McCollim has noted, one of the most prominent 
methods of expanding revenue that was advised in the proposals was to create and sell 
new venal offices, privileges, or rights, a class of proposal within which Helvétius’s 
falls.115 Perhaps most importantly, Helvétius’ remedies represented a relatively cheap 
way of improving mortality in the provinces, both in the light of the economic costs of 
epidemics in rural areas as well as persistent anxieties that France was declining in 
population, as we shall see. 
Helvétius’ proposal, as well as De la Garde’s report, provides invaluable 
information about the extent of Helvétius’ operations between 1706 and 1709, as well as 
                                                 
 114 Gary B. McCollim, Louis XIV’s Assault on Privilege: Nicolas Desmaretz and the Tax on 
Wealth (Rochester, NY: University of Rochester Press, 2012), 128–159. 
 115 Ibid., 136–137. On the phenomenon of venality of offices more broadly, see William Doyle, 
Venality: The Sale of Offices in Eighteenth-Century France (Oxford: Clarendon, 1996). 
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his ideas about how an expanded version of it could be financed and delivered. Within 
the scheme he proposes, each village in a given generalité (the territory administered by 
an intendant) would receive fifteen livres worth of medicine at the price of five sous per 
dose, the customary rate paid by the king.116 With this modest investment, he argues, the 
Intendants will be able to greatly reduce the large numbers of deaths that occur in rural 
parishes for lack of available medical care, especially with the most common rural 
ailments, such as dysentery, sustained and intermittent fevers, colic, asthenia (langueur), 
all of which can be cured through prompt evacuations, and can be prevented from 
recurring through taking stomach-fortifying cordials.117  
The proposal also shows that, by this point, Helvétius had expanded from his 
dysentery specific to include a veritable therapeutic armamentarium of twelve medicines, 
dispatched to the provinces in chests.118 These were accompanied by clearly-written 
“Mémoires instructifs” for those who will distribute them, on their use, dosage, and 
storage, and by a copy of his own Traité des maladies les plus fréquentes, which provides 
a short introduction to medicine, including the rudiments of pulse taking and uroscopy, 
instructions for the delivery of the different medications included in each chest, and 
recipes intended to feed convalescents on 2 sols each per day.119 Where possible, 
Helvétius intends for local surgeons to be charged with distribution, but in cases where 
none are available Helvétius envisions lay distributors that will be able to “diagnose by 
the numbers” through the use of his Traité: 
                                                 
116 AN G7 716, “Placet à Monseigneur Desmaretz,” fol. 2v. 
117 Ibid., 9r. 
118 These are: l’or potable; l’elixir de la vie; quintessence d’absinthe; poudre de corail anodine; 
poudre specifique (contre dysenterie); poudre febrifuge purgative; poudre vomitive; poudre tempérente; 
poudre sudorifique; pillules purgatives; baume diuretique; and pilules d’alun. 
119 Ibid., 6r-8r. 
251 
 
Though these measures we can save a very considerable number of men 
for the King each year: for the diseases of country people mostly come 
from an abundance of raw and bilious humors, caused by an excess of 
work, and by bad food. As such it is normally only necessary to have a 
remedy that can release the poor sick when they feel stricken. They will 
simply have to look in the table of my Traité to find the disease which 
they believe afflicts them, and they will straight away find a Specific 
Remedy which is precisely suitable to their illness, along with the conduct 
and the regimen that they should follow to make good use of it.120 
 
The notion of the medical specific is here crucial: once a diagnosis has been established, 
they will know which one to use in each particular case, and can then refer to the 
Mémoires instructifs: 
I have had short mémoires printed in which the virtue and usage of each 
Specific Remedy is briefly described, to the last detail. My goal was to 
avoid confusion and to facilitate the method of using these remedies even 
to the least experienced.121 
 
But how will the remedies and instructions reach the rural parishes and the newly minted 
medics in the first place? Helvétius ingeniously proposes that the medicines will reach 
the rural poor by travelling down the one connection that connects them all to the crown: 
the tax system. He observes that this system, which is already operating in several 
intendancies, could be extended throughout the kingdoms by royal edict. The medicine 
chests would be sent out to each intendant, who would then provide them to the receivers 
of the taille (the direct land tax) in each bourg. The receivers would in turn provide the 
medicines to seigneurs, syndics, parish priests, and surgeons, who would be charged with 
                                                 
120 “Par ces établissements on peut sauver tous les ans un nombre très considérable d’hommes au 
Roy; Car les Maladies des Gens de la Campagne ne viennent la plus part que d’une abondance d’humeurs 
crües et bilieuses causées par un excez de travail, et par la mauvaise nourriture. Il ne s’agit pour l’ordinaire 
que d’avoir un Remède présent pour dégager ces pauvres malades dans le tems qu’ils se sentent frapper. On 
n’aura qu’a chercher alors a la table de mon Traité, la maladie dont on les croira attaquez, et on trouvera sur 
le champ un Remède spécifique qui conviendra précisément a leur mal, avec la conduite, et le régime qu’ils 
doivent observer pour en servir utilement,” Ibid., 8v. 
121 “J’ay fait imprimer de petits Mémoires dans lesquels la vertu, et l’usage de chaque Remède 
spécifique est décrit en abrégé, et avec la dernière exactitude. Mon but a été d’éviter par la confusion, et de 
faciliter aux gens mesme les moins experimentez la manière d’employer les Remèdes prescrits,” Ibid., 9r. 
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them. These distributors would actually pay the receivers of the taille an advance for the 
medicines: this advance would travel back up the tax system through the Receivers 
General of each généralité and ultimately to Helvétius, to support the costs of 
production.122 The distributors would then be able to recover their advance and fund the 
charitable dispensation of the remedies through the sale of a portion of them to those 
wealthier patients who were able to pay. Medicine would thus flow down to the rural 
poor through the same channels by which non-noble landowners were taxed. 
 The notion of the rural poor being provided with low-cost medicines by the state 
through its tax infrastructure strongly implies that the main goal of the state is to keep 
them healthy enough to pay their taxes and serve as soldiers. It also shrewdly insures 
Helvétius from any defaults by obliging the distributors to pay the Receivers General in 
advance. From the royal perspective, it would also have the advantage of costing nothing: 
the normal charitable distribution of Helvétius’s remedies in fact cost the crown tens of 
thousands of livres, as we shall see. As far as I have been able to ascertain, these cost-
saving measures was never actually enacted, and the Controllers-General simply paid 
Helvétius in installments for the drugs, rather than downloading the costs onto the 
distributors.  
 Helvétius’ argument also points to the limited sources of medical care available in 
rural areas, where barber-surgeons were often the most common medical practitioners. 
He argues that his system will save the sick in areas that are not served by a surgeon from 
having to call one in from a neighbouring town, which, he observes, often costs 30 sols 
just to get them to travel out, another 20 sols for a medicine, 6 for bloodletting, and 10 
                                                 
 122 Ibid., 9v-10r. For a succinct description of the activities of the taille receivers and the Receivers 
General, see McCollim, Louis XIV’s Assault on Privilege, 27–29. 
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sols for an enema. In such cases the poor often die for lack of care, while his system will 
ensure that they receive prompt aid. 
 Sensitive to the interests involved, Helvétius also recognizes that this could upset 
rural surgeons by depriving them of business. In response, he argues that this objection is 
not strong enough to overcome the general utility of his project, and he has even made 
provision for means by which the surgeons themselves could profit by his system rather 
than loosing anything by it. A fixed cost of 5 sols per dose will enable surgeons to sell the 
medicines for higher rates to those who can afford them, which will in turn underwrite 
the costs of distributing them charitably to the poor. Further, the medicines will in fact 
attract more patients to the surgeons. Even when distributing the drugs charitably, the 
surgeons could still be permitted to charge patients for the visit or for ancillary 
procedures like bloodletting. As such, the distribution of his remedies will make them a 
small profit in the short term and possibly improve their reputation in the long term, 
especially if they use his remedies to treat the rich, who, he observes, can prove to be 
very generous in their gratifications when cured, something he virtually guarantees his 
medicines will be able to effect.123 
 In villages without surgeons, the parish priests will be able to announce in their 
sermons that the local syndics are furnished with his remedies by the Receivers General, 
and in cases where funds are lacking to pay the advance, the priests can hold a charitable 
fundraiser (queste) for the poor in the parish. He writes that even if each parishioner can 
only spare a single sol each month, it would be enough to recover the costs in most 
cases.124 In his report on the proposition, De la Garde adds yet another funding scheme to 
                                                 
123 Ibid., 10v-11r. 
124 Ibid., 11r. 
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those Helvétius proposes: alms could be collected from the various tax farms to supply 
the advance.125 If the cost were indeed recovered by the distributors (as Helvétius 
assumes they could be), the surplus could be used by the Intendants to found new 
establishments for the Daughters of Charity to extend their teaching and nursing activities 
wherever they see fit, and that the nuns could then serve as distributors for Helvétius’ 
remedies. 
To what extent had this system been implemented in the years running up to 
1709? An assessment of the scale that Helvétius’ distribution system had already attained 
is available from the report on Helvétius’ petition that De la Garde prepared for 
Desmaretz. According to the “Etat des remèdes que le sieur Helvétius a fournis à 
Messieurs les Intendants des Provinces depuis quatre ans,” written in a different hand and 
appended to de la Garde’s report, the figures for 1706-1709 were, respectively, 60,000, 
48,000, 59,000, and 47,000 prises (packaged doses), for a total of 214,000 prises over 
four years. This means that Helvétius was providing an average of over 53,000 prises of 
his various remedies annually in the first four years of his operation, a figure which by 
1721 had doubled to reach 100,000 prises.126 As the report specifies, his remedies had 
been sent to nineteen généralités, with nine remaining that had not yet received any 
shipments, most of which are in the Midi. The report observes that this is more likely due 
to simple ignorance of the fact that the king provides this charity, rather than a lack of 
need in those provinces.127 
                                                 
125 “Le moyen naturel de faire fournir ces remedes qu’il en coutat rien au Roy seroit d’en prendre 
le fond par forme d’aumones sur tous les traittez, fermes et sous-fermes, baux et marches que les gens 
d’affaire font avec le Roy,” AN G7 716, “Mémoire” (de la Garde), 1v. It is not entirely clear if de la Garde 
means for this to happen alongside the means suggested by Helvétius, or as an alternative to them. 
 126 See below, AN E 2027, fol. 219-220; AN E 2032, fol. 204-205. 
127 AN G7 716, “Etat des remèdes que le sieur Helvétius a fournis à Messieurs les Intendants des 
Provinces depuis quatre ans,” appended to the “Mémoire (de la Garde).” The provinces listed as not yet 
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If Helvétius was already providing the remedies to the provinces on an ad hoc 
basis, what reason was there to give him an office? From the perspective of the crown, 
the most basic reason was to gain the funds from selling it to him: De la Garde’s report 
assigns a price of 50,000 livres for the office.128 Helvétius also provided two reasons. The 
first was to streamline the service by securing a stable funding scheme and annual 
delivery rate, which would cut back on the delays in the existing system, whereby (as De 
la Garde emphasizes) intendants often request remedies from the Controller-General too 
late, especially during epidemics, leaving Helvétius to provide them after the peak of 
when they were needed.129 The second, already suggested above, was to extend the 
service to the remaining provinces, which he speculated were not currently being served 
mainly because their intendants were not aware of the possibility. From Helvétius’ own 
perspective, the proposal may also have helped ensure that the distribution of his 
remedies would continue under Desmaretz, who had taken over the office of Controller 
General from Chamillart a year earlier.  
How was the petition received? As far as can be told from the surviving items in 
the Controller-General’s records, the proposal was deemed admissible by De la Garde, 
but it seems to have been delayed nearly a month before reaching Desmaretz, during 
which time Helvétius wrote two letters reminding the Controller-General of it and 
requested an audience. It is not clear whether or not Helvétius was granted his audience, 
but we know his petition was ultimately denied: a note on the report, dated October 8, 
1709 and written in Desmaretz’ hand, reads “the king does not want to establish this 
                                                                                                                                                 
having received Helvétius’ remedies are: Châlons-en-Champagne, Lyon, Riom, Allençon, Caen, Grenoble, 
Aix, Languedoc, and Perpignan. 
128 AN G7 716, “Mémoire” (de la Garde), 2v. 
129 AN G7 716, “Mémoire” (de la Garde), 1r. 
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office.”130 Although the practice would not crystallize into an office and be extended 
across the whole kingdom, the proposal likely had the effect of providing Desmaretz with 
an idea of his operations, crucial from Helvétius’ perspective for extending an existing 
practice under Chamillart into the new ministry of Desmaretz and later ensuring that it 
would pass on to his own son. 
 The rejection of Helvétius’ 1709 proposal did not mark an end to his role as state 
medical contractor. The intendants continued to request and receive medicines. A 
surviving “Etat de ce qui est dû au Sieur Helvétius” for his services from July 1710, 
shows that in the first five months of that year he had already supplied 26,620 prises of 
his drugs to the provincial intendants. 131  The total bill of 6,767 livres also vastly exceeds 
his 1,000 livre pension as a physician to the Duc d’Orléans in this period.132 Unique 
among surviving documents, this état provides a breakdown of the different “menus 
frais” associated with the chests he sent to the intendants, for example, the printing of the 
“mémoires instructifs” and the Traité, the packaging (embellage) of the medicines, 
various containers (pots, fioles), a scale and set of weights for measuring the medicines, 
and finally the price of the “caisse” which contained all of these items. This list of small 
expenses, usually added up to about 16 livres per chest.133 No figures are provided for the 
costs of the plant simples and other ingredients of the medicines themselves, 
                                                 
 130 “8 Oct. 1709. Le roy ne veut point etablir cette charge,” Mémoir, Le Sr. Helvetius médecin de 
Monsieur le duc d’Orleans, 6 fols. Note on 1r, top left. 
 131 Pennsylvania Historical Society (PHS), Simon Gratz Autograph Collection, case 12, box 20, 
folder 67, “Etat de ce qui est dû au Sieur Helvétius Médecin pour 26,620 prises de ses Remèdes spécifiques 
qu’il a fourni à messieurs les Intendans des Provinces par les ordres de Monseigneur Desmaretz, depuis le 
dernier Mémoire qu’il a eü l’honneur de presenter à Sa Grandeur, au mois de Juillet 1710.”  
 The chance survival of this document in the collection of a nineteenth-century Philadelphian 
autograph collector, signed by Helvétius, is the only bill I have found from Helvétius for his services. All 
other payment data comes from the authorisations dispatched by the royal council to the Controllers 
General, and do not include any information beyond the total figures. With thanks to David W. Smith for 
referring me to this source. 
 132 L’état de la France, 2 vols. (Paris, 1712), 2:131. 
 133 PHS, Gratz collection, case 12, box 20, folder 67, “Etat de ce qui est dû au Sieur Helvétius.”  
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unfortunately, but this mundane list of items serves as a hint of the proto-industrial scale 
of production that must have been necessary to annually supply dozens of these chests, 
containing hundreds of packaged doses, to the provincial intendants.134 Based on the 
earlier relations with ipecacuanha suppliers in the 1680s, it seems very likely that the 
production of these chests required complex commercial connections to secure exotic 
simples, which may have been facilitated by Helvétius’ state connections as well as the 
service of French consuls in cities like Cadiz. They probably required the employment of 
a labor force to collect the locally available simples that went into the production of the 
dozens of other drugs that were included in each chest.135 We can also infer that 
Helvétius operated a “laboratoire” with a chymical furnace, as provided for by his letters 
patent. He very likely required the services of laboratory assistants for the various tasks 
of distillation, extraction, and compounding, not to mention the final packaging of large 
volumes of substances into individual doses. Lacking archival documentation which 
could shed light on these issues, however, they must remain inferences for the time being. 
 What we can say for certain is that by the 1720s, “Helvétius père et fils,” as they 
appear in the arrêts of the King’s Council, were being paid over 30,000 livres for 
standard annual orders of 100,000 packaged prises of their remedies.136 The arrêts show 
that supplemental shipments were also ordered, likely in response to unexpected demand 
                                                 
 134 Unfortunately, so far as I am aware there is no study which explores proto-industry in relation 
to the production of medicine. For a survey of the phenomenon more broadly, see Sheilagh C. Ogilvie and 
Markus Cerman, European Proto-Industrialization: An Introductory Handbook (Cambridge: Cambridge 
University Press, 1996). 
 135 See below, ch. 5, on the labor force employed by Guerin and Lajutais to produce the poudre 
fébrifuge. 
 136 AN E 2027, fol. 219-220 (March 29, 1721); AN E 2032, fol. 204-205 (June 5, 1722). Both 
arrêts authorise the Ferme général to pay “Helvétius père et fils” a total of 30,000 livres, broken into 
instalments, for the delivery of 100,000 prises of their remedies, “avec les imprimez d’instructions pour 
l’usage desd remèdes, boetes, fioles, potes, ballances, caisses , et embellages.” The payments in this period 
were made via Charles Cordier, chargé de la Regie des Fermes Generales. 
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or epidemics.137 The shipments destined to the provinces were received by Jean-Jacques 
Jacquin, commis at the Paris Customs Office (Bureau de douannes de Paris), who 
organized their transportation. 
What did the shipments he sent to the intendants contain in this period? By 1722, 
each chest was standardized to include seven distinct drugs in various quantities for a 
grand total of 353 prises per chest, and a much smaller quantity of seven vials of 
perishable substances (vials of different cordials, a boulle medicamenteuse, a few ounces 
of theriac, etc.). Twelve such chests were sent to each intendant for distribution, 
accompanied by a larger thirteenth chest with bulk quantities (rather than separate doses) 
of some of the drugs (cinchona and theriac, for example) and associated cordials and 
balms. Alongside the drugs, each chest also contained the “mémoires instructifs,” copper 
weights and a set of scales for weighing the drugs. The text of the inventory specifies that 
these chests are delivered independently from those sent with the armies and “are to be 
distributed by the intendants to their subdelegates, and by the subdelegates to the women 
religious, surgeons, or other intelligent persons in the cities, towns, and villages of their 
departments.” 138 The inventory concludes by requesting that the intendants monitor the 
usage of the chests in order to determine if certain drugs are used up faster than others in 
given regions and to write to him via the Controller-General to request more; and to send 
him a relation of the nature of any epidemics that strike the region so that he may send 
appropriate drugs and provide the necessary counsel. This last provision appears to have 
been put into effect during the Great Plague of Marseille in 1720: the records of the 
                                                 
 137 See for example AN E 2032, fol. 110r-v (April 25, 1722), a 2,000 livre payment to Helvétius 
for 4,000 prises sent to Caen and 4,000 to Provence. 




Controller General show that extraordinary shipments of Helvétius’ remedies were 
dispatched to Provence as part of royal relief efforts.139 
 One remarkable feature of this distribution system is that it generated numerous 
archival records which allow the shipments to be tracked with regularity in the French 
departmental archives from the late 1720s onward.140 Brittany and the Auvergne offer 
instructive examples. In both cases, we can then follow the annual delivery of thirteen 
chests, and it is usually even possible to see exactly what villages they were sent to. 
Receipts and “états de distribution” from the local subdelegates are generally available 
and for some years even the letters of surgeons, priests, nuns and other “charitable 
persons” who actually delivered the drugs into to the hands of patients have survived. 
The importance of the Daughters of Charity for the drugs distribution is particularly 
apparent in the surviving documentation. Their letters often thank the intendant, the king, 
and Helvétius for the remedies, report on their good effect in bringing relief to the local 
poor, and in some cases, inform the intendants of any delays or irregularities in the 
annual delivery of the drugs from the subdelegates.141 Following Helvétius’ express 
advice, some distributors would also write back to the intendant with reports on which 
                                                 
 139 AN G7 1729 no. 44; G7 1730 no. 262; G7 1731 no. 20; no. 185. 
140 My own survey draws on the intendancy fonds (series C) of the Ille-et-Villaine and Puy-de-
Dôme departmental archives. The survey I present here barely scratches the surface of these voluminous 
fonds, and I intend to return to them in a subsequent publication. Although records of the distribution of 
Helvétius drugs appear to be a standard features of intendancy fonds, no study of the overall phenomenon 
exists, although a smattering of dissertations and articles, usually focusing on local charitable care, have 
made use of these fonds in the Languedoc and Brittany: see Simone Mirr, “Médecine des pauvres dans les 
campagnes du Languedoc au XVIIIe siècle” (Thèse de doctorat en Médecine, Université Montpellier 1, 
1992); René Fresneau, “Les boëtes d’Helvetius dans les épidémies en Bretagne, au XVIIIe siècle” (Thèse 
de Médecine, Université de Paris, 1946); Christine Nougaret, “La lutte contre les épidémies dans le diocèse 
de Rennes au XVIIIe siècle,” Bibliothèque de l’école des chartes 140, no. 2 (1982): 215–33; Lafond, La 
dynastie des Helvétius, 148–199; Jean Hossard, “Les « remèdes du Roi » et l’organisation sanitaire rurale 
au XVIIIe siècle,” Revue d’histoire de la pharmacie 63, no. 226 (1975): 465–72. 
 141 See for example AD Ille-et-Villaine C 1330 (1731), Mother Superior of the Daughters of 
Charity of Plouën to De La Tour, May 16, 1731; (1732), M. Duchon, Daughter of Charity at Vannes, to De 
La Tour, 26 May 1732; (1735) Sister Therèse, Daughter of Charity at Saint-Méen, to Pontcarré de Viarmes,  
21 May 1735. 
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remedies were in highest demand, allowing each new shipment to adapt to the demand in 
the previous year. 
The shipments can be tracked in particularly minute detail in the généralité of 
Rennes from 1729 onward, as can the numerous problems that arose in their distribution. 
In 1733, for instance, the Controller-General Philipert Orry requested manifests from the 
intendants of where they were sending the remedies and who was entrusted with their 
distribution. Orry learned from these manifests that the intendant in Rennes, De La Tour, 
was disobeying the king’s wishes by distributing most of his annual shipment in the city 
of Rennes and other towns (Vannes, Saint-Brieuc, Quimper and Dol), where the poor had 
recourse to the established hospitals, rather than sending the drugs out to the countryside 
as he had been ordered to do.142 A similar problem occurred in 1735, in the généralité of 
Clermont, where the intendant was likewise redirecting the remedies to the urban 
hospitals.143 
 In addition to being improperly directed, the system could also be wholly 
overwhelmed. In the fall of 1741, for example, after the normal shipments of remedies 
had already been distributed, Brittany was struck by an epidemic of dysentery. The 
intendant requested additional shipments of Helvétius’ remedies, but the Controller 
General refused to allocate the funds, advising the intendant to raise them charitably from 
the local nobility and ecclesiastic landholders in each parish that had been struck. A 
circular letter was printed to explain the situation. Some parishes succeeded in raising the 
funds, and Helvétius sent them additional shipments of his drugs.144 Helvétius also 
                                                 
 142 AD Ille-et-Villaine C 1330, Orry to De La Tour (Rennes), September 30 and October 26, 1733. 
143 AD Puy-de-Dôme, 1C 1382 (1735). 
 144 AD Ille-et-Villaine C 1331, Orry to Pontcarré de Viarmes (Rennes), October 30 and November 
7, 1741; printed circular, “A Rennes, 4 Novembre 1741.” 
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received reports from local medical officials and provided advice to the intendants. In 
some cases his letters were printed as short pamphlets and circulated to the distributors in 
areas struck by the epidemic as supplemental instructions on how to manage the 
epidemic. In one notable case, Helvétius distinguished between different forms of 
dysentery and also tied the disease to the quality of local water, advising peasants to boil 
their drinking water with nails or some other rusty iron in order to purify it.145 
The patients who received these drugs are usually referred to in general terms—
“pauvres de la campagnes,” “paysans,” “dysenteriques”—but on occasion the distribution 
of the remedies can even be followed down to the individual patient. The subdelegate 
Aulterroche, based in the town of Issoire in the généralité of Clermont, sent with small 
scraps of paper (including a playing card in once case) on which the allotments of 
individual doses are written, sometimes mentioning the name or occupation of the 
patient.146 
Some intendants also received remedies for charitable distribution from other 
sources. In addition to the chests of Helvétius’ remedies, the intendants of Clermont also 
received the pastilles and onguent divin of the médecin du roi Jean-Baptiste Chomel 
(1639-1720) and later his son Pierre-Jean-Baptiste (1671-1740).147 The distribution of 
these remedies was managed through the episcopal infrastructure by the archbishop, 
                                                 
 145 Nouvelle consultation de M. Helvetius sur deux especes de Dyssenteries, l’une appellée Séche, 
et l’autre suivie de Pourpre. à Versailles ce 24 septembre 1741 (1741). Copy in AD Ille-et-Villaine C 
1331. 
146 AD Puy-de-Dôme, 1C 1383 (1738). 
 147 Although he pays only incidental attention to the distribution of these remedies, the best 
description of the Chomel family is David Sturdy, “Pierre-Jean-Baptiste Chomel (1671–1740): A Case 
Study in Problems Relating to the Social Status of Scientists in the Early Modern Period,” The British 
Journal for the History of Science 19, no. 3 (1986): 301–22. BnF ms. fr. 6801, Dépenses pour les 
Établissements charitables, arrêtées de la main du Roi et des ministres (1714-1791), fol. 324-346, contains 
a series of mémoires on Chomel remedies operation, dating from the 1730s.  
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rather than trickling down through the local subdelegates.148 The intendants in Rennes, by 
contrast, seem not to have received Chomel’s remedies, or else they were distributed 
directly to the archbishop there and have left no trace in the intendancy fonds. 
Adrien Helvétius died on February 20, 1727.149 By the end of his career, he had 
no doubt amassed a fortune, not to mention numerous honours at Versailles. He had been 
appointed physician to the Duke of Orleans, the future Regent, in 1701. On January 7, 
1708, the year before submitting his proposal to Desmaretz, he was appointed Inspector 
general of the French military hospitals in Flanders. From 1705 onward, he also served in 
a variety of diplomatic roles, most notably as a peace “feeler” in the Netherlands under 
the pretext of visiting his father, and in Madrid under the cover of providing medical 
services to the queen of Spain in 1714. In January of 1724, he was ennobled.150 His son, 
Jean-Claude Adrien Helvétius (b. 1685), studied at the Paris Faculty, graduating in 1708, 
and became a médecin ordinaire to Louis XIV and Louis XV, and later first physician to 
the queen, Marie Leszczyńska, in 1728. He had apparently been assisting his father with 
production of the remedies for the provinces, and after his father’s death in 1727 he took 
exclusive charge of the operation until his own death.151 
Following the distribution of Helvétius’ remedies to the provinces through the 
eighteenth century would of course be a project in itself, but it suffices to say here that 
the practice continued with some regularity beyond even the death of Jean-Claude Adrien 
Helvétius on July 17, 1755. His son, Claude-Adrien, did not continue the three-generation 
                                                 
148 AD Puy-de-Dôme, 1C 1381, esp. folders for 1733 and 1734, the latter of which includes a letter 
from Chomel himself to the intendant, and a prospectus of his remedies. The folders for 1735-1738 also 
include numerous printed instructions for Chomel’s remedies: 1C 1382 
 149 For his acte de décès see Lafond, La dynastie des Helvétius, 65. 
 150 Ibid., 52–65. 
 151 Ibid., 153. 
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family tradition in medicine but became a Fermier—a royal tax farmer—likely an office 
opened to him by his family’s court connections: the Fermiers, after all, were those who 
annually paid Adrien and Claude Adrien Helvétius for their annual shipments. He retired 
from this position at the age of 33 to practice philosophy.   
The “Remèdes du Roi” operation, as it came to be called, passed briefly into the 
hands of Jean de Diest, a regent doctor of the Paris Faculty, and then in 1762 to Joseph-
Marie-François de Lassone, then first physician to the queen. According to Brockliss and 
Jones, “the service had become a cottage industry for the Lassone family,” and Lassone 
worked with his son and Claude-Melchior Cornette to develop new remedies, and that 
“by the 1780s, the Lassone enterprise was in the enviable position of being both 
monopoly producers and supplier of the drugs in a sizeable, but cosily protected, market.” 
In what stands as the only instance I have found where the operational costs and profits of 
the whole enterprise were estimated, Lasonne was accused in the 1760s of spending 
18,000 livres on production annually and charging the government 55,000 livres for the 
drugs, which tallies up to a 68% profit margin.152 Lassone’s own son took over at his 
death in 1788, on the eve of the revolution, and oversaw the distribution of a final 
shipment of the remedies on April 12, 1790.153 The system appears to have been 
interrupted by the Revolution, but was re-established under the Empire in 1805.154 
We have already seen that Helvétius’ role as a military contractor was not wholly 
unique in this period. It is also worth posing the question here of how unique Helvétius’ 
                                                 
 152 Brockliss and Jones provide a good account of the operation once it was in Lassone’s hands: 
see Brockliss and Jones, The Medical World of Early Modern France, 731–734. 
 153 Ibid.; Lafond, La dynastie des Helvétius, 186–189. 
 154 AN F8 2, dossier VI, Police sanitaire, Distribution de médicaments an XIII-1815, 
Rétablissement de la fourniture annuelle des boîtes de médicaments pour les épidémies, an XIII. Lafond, 
La dynastie des Helvétius 145-146. 
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medicine chests and his distribution system were in the decades around 1700, both in 
France and abroad. The German context provides a near-contemporary analogue in the 
form of the “physic chests” produced by the philanthropic Francke Foundations 
(Franckesche Stiftungen) of Halle.155 The Foundations financed an orphanage and other 
activities through the sale of proprietary drugs, which they distributed in Germany and 
Russia and also shipped through an extensive network of German Pietist clients in 
Britain’s North American colonies, as well as to their own missions in India. Although it 
did not supply the state or the military, the Francke pharmaceuticals are perhaps the most 
comparable operation to that of Helvétius, and both emerged at virtually the same time.  
Helvétius’ chests and those of the Francke Foundations can be compared on five 
points. First, the success of both rested on a privilege. In 1698 Francke Foundations 
received its privilege from the Elector of Brandenburg which exempted it from the 
corporate privileges of the urban apothecaries.156 In a manifestation of the distinct 
differences with centralizing “absolutist” France—where a single royal privilege could 
suffice—the fragmented political conditions of the Holy Roman Empire obliged the 
Foundations to secure multiple monopoly privileges for their drugs in a number of 
jurisdictions beyond Halle.157 Second, although the organizational framework differed 
greatly, both Helvétius’ distribution of remedies to the French provinces and the 
networks of the Foundations were driven by a charitable imperative. Third, the 
Foundations possessed a similarly global breadth to Helvétius’ operation: as we shall see 
                                                 
155 Renate Wilson, Pious Traders in Medicine: A German Pharmaceutical Network in Eighteenth-
Century North America (University Park, Pa.: Pennsylvania State University Press, 2000). 
156 Ibid., 67–68. Wilson points out that the provision for pharmaceuticals was part of the overall 
privilege for Francke Foudnations. It was intended to enable the orphanage to produce its own medicines 
without needing to have recourse to the town apothecaries “at night and in the winter,” but was leveraged 
into an overall source of funding for the whole Foundations, ultimately providing between one-third and 
half of their total income in the eighteenth century.  
157 Ibid., 78. 
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in Chapter 6, Helvétius’ operation extended to Southeast Asia, and the Francke 
Foundations extended to Russia, India, and America. The fourth and most conspicuous 
similarity is in the material format of their deliveries: both the Francke and Helvétius 
operations diversified their production into a full range of proprietary drugs in the 1710s, 
assortments of which were packaged in “physic chests” which included single-sheet 
instructions alongside the publication of an overall guide to health and sickness grounded 
in the use of their proprietary drugs. Finally, it should also be mentioned that although the 
Francke Foundations do not appear to have had close links with the military, they did 
receive an order from Frederick William I, King of Prussia, in 1734 to provide their 
“physic chests” for an army of 10,000 men, and most of their sales went through 
wholesale and retail networks, rather than being sold to the state for military or poor 
relief efforts, or to “corporate consumers” of the kind detailed in Chapter 6.158 As such, 
although the Francke “physic chests” bear numerous similarities to those of Helvétius, 
they also highlight the distinctly French character of Helvétius’ operation, which was 
centralized and closely tied to the fiscal-military state. 
It should also be mentioned that the distribution of Helvétius’ remedies also had 
at least one precedent in France. As early as 1672, Gabriel Calloet de Querbrat (or 
Caloet-Kerbrat), an avocat at the Bretagne Parlement who was connected with the dévot 
Compagnie du Saint-Sacrement, had advocated that inexpensive remedies should be 
distributed charitably, at royal expense, to the poor peasants through the episcopal 
                                                 
158Wilson provides detailed information on the net profits of the Francke pharmaceuticals over the 
course of the eighteenth century, but nothing that would enable a comparison to either Helvétius and 
Lajutais, as my information includes only sales by unit and by revenue, but not profits, which in both cases 
would require information on production costs, which is unfortunately absent. Wilson is undoubtedly 
correct, however, that their net profits, which varied between 20,000 and 35,000 Reichstahlers per anum, 
must have put them in the highest tier of European pharmaceutical production in this period. Ibid., 90. 
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infrastructure as well as to soldiers and sailors.159 This plan would be realized in part by 
Chomel, whose pastilles and onguent divin—commonly called “les remèdes des 
pauvres”—were distributed through the same infrastructure as Helvétius’ chests into the 
1730s. 
6. Conclusion 
This chapter has followed Adrien Helvétius as he transformed ipecacuanha 
through courtly practice, military-medical contracting, and finally to the state-sponsored 
charitable distribution of his remedies to the French provinces, a practice which outlasted 
the Ancien Régime itself. While the utility of his drugs to the military was already 
apparent during his 1687 hospital trials, the precise rationale behind the state’s massive 
investment in supplying his drugs to the provinces is less clear. We can read it as a 
development of Helvétius’ private acts of charity, noted by Saint-Simon and others, 
which included the regular consultation hours and the distribution of his drugs gratis to 
those who could not afford to pay for them.160 But charity on this scale had important 
costs: Helvétius’ crowning achievement was to find someone or something he could bill 
for such costs, namely, the state itself. This raises the final question: why was the state, in 
the form of the Controller-General and ultimately Louis XIV himself, willing to pay 
                                                 
 159 Gabriel Calloet-Kerbrat, Pour etablir dans touttes les paroisses du Royaume, sans qu’il en 
couste rien à personne: L’accord des procez et des querelles, et la distribution des remedes pour les 
Pauvres gens de la Campagne (S.l.: s.n., 1672); Jean-Luc Bruzulier, “Saint Yves, Modèle Pour Les Dévots 
Bretons Du XVIIe Siècle? : L’exemple de Gabriel Calloët Kerbrat, Avocat Général Des Pauvres,” in Saint 
Yves et Les Bretons : Culte, Images, Mémoire (1303-2003), ed. Jean-Christophe Cassard and Georges 
Provost (Rennes: Presses universitaires de Rennes, 2015), 241–53; Jean-Pierre Gutton, “Aux origines d’un 
ministère de l’Assistance et de la Santé dans la France de l’Ancien Régime,” in Histoire du droit social: 
mélanges en hommage à Jean Imbert, ed. Jean-Louis Harouel (Paris: Presses universitaires de France, 
1989), 287–93; Lafond, La dynastie des Helvétius, 125.  
 160 “Il y avait pourtant longtemps qu’Helvétius était à Paris, guérissant beaucoup de gens buttés ou 
abandonnés des médecins, et surtout les pauvres qu’il traitait avec grande charité; il en recevait tous les 
jours chez lui à heure fixe tant qui voulait venir, à qui il fournissait les remèdes, et souvent la nourriture, ” 
Louis de Rouvroy Saint-Simon, Mémoires (1691-1701) Additions au Journal de Dangeau, ed. Yves 
Coirault, vol. 1 (Paris: Gallimard, 1983), 823. 
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thousands of livres per year to the distribution of remedies to the poor of the French 
provinces? 
 In the annual letters to the provincial intendants, Helvétius’ drugs are framed as 
an exercise of charity by a benevolent monarch interested in the welfare of his subjects. 
But in the final decades of Louis XIV’s reign, this spirit of noblesse oblige may also have 
taken on a special intensity through growing fears that the kingdom of France was slowly 
being depopulated. Although historical demographers now know that France had the 
largest population in Europe, and that its population was in fact growing in this period, 
many contemporary observers, including such prominent figures as the Archbishop 
François Fénelon, the Marquis de Vauban, and Pierre Le Pesant de Boisguilbert, 
highlighted the problem of depopulation and pointed to the suffering of the peasantry 
during epidemics, dearth, famine, and war, observed the desertion of rural villages, and 
fields going uncultivated.161  Some, such as Vauban and Boisguilbert, even blamed the 
inequalities of the tax system for the destruction of the French peasantry, and advocated 
for its reform, in precisely the same years as Helvétius’ remedies began to be distributed. 
Referring explicitly to the “Gens de la Campagne,” Helvétius himself points out in his 
1709 proposal that his remedies “can save a considerable number of men for the King 
each year,” and it is conceivable that the annual distribution of hundreds of thousands of 
drugs through the infrastructure of the very tax system which had come under such 
scrutiny may, in fact, have been a measure intended to remedy the perceived problem of 
depopulation.  
                                                 
 161 See Carol Blum, Strength in Numbers Population, Reproduction, and Power in Eighteenth-
Century France (Baltimore: Johns Hopkins University Press, 2002), esp. 4–10; Jean-Claude Perrot, “Les 
économistes, Les Philosophes et La Population,” in Histoire de La Population Française, ed. Jacques 
Dupâquier, vol. 2 (Paris: P.U.F, 1988), 499–551; Joseph J. Spengler, French Predecessors of Malthus; a 
Study in Eighteenth-Century Wage and Population Theory, (Durham, N.C.: Duke University Press, 1942). 
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 What we can say for certain is that, over the course of two decades, Adrien 
Helvétius had transformed ipecacuanha root from an emetic into a proprietary specific 
and had adapted it for mass distribution. By the end of the first decade of the eighteenth 
century, he had carved out a completely unique niche for himself in the European 
medical marketplace by supplying his drugs en masse to the largest possible clientele—
the soldiers and peasants of Louis XIV’s France—at the expense of the largest possible 





The Lost Secret of the Chevalier de Guiller’s poudre fébrifuge: 
Recovering Privileges and Securing Military Supply Contracts, 1713-1808 
 
In July of 1768 an anonymous physician from Avignon made an inquiry in the 
Mercure de France concerning a “marvelous remedy” he had read about in an old 
pamphlet. The remedy in question was called the poudre fébrifuge, invented by one 
Chevalier de Guiller in the time of Louis XIV. The author writes that such a remedy 
would be of great interest to him, living as he does in a country ravaged by fevers, and 
asks the readers of the Mercure to respond if perchance they know anything about this 
drug and whether or not its secret had been lost after the death of its last holder, Pierre 
Brodin de la Jutais, two or three years earlier: “If to the contrary someone has inherited it, 
we implore them to announce it to the public.”1  
A few months later, he received a reply. In the pages of the September 1768 
Mercure, the Marquis de Chambray offered some guesses about the medical secret of the 
drug and reported an interesting story he had heard about how Guiller had discovered it—
a story told to him by M. Daubenton, Commissaire général and earlier the premier 
commis (clerk or administrator) for the navy office.2 It seems that Guiller was French by 
                                                 
 1 “Si au contraire quelqu’un en a hérité, on le prie d’en faire part au public,” “Lettre de M.***. 
Docteur en médecine à Avignon, de la société royale des Sciences de Montpellier, à l'auteur de du Mercure 
de rance, sur la poudre fébrifuge,” Mercure de France (juillet 1768), 165-166. 
 2 Almost certainly the agronomer Louis Marquis de Chambray, see André J. Bourde, Agronomie et 
agronomes en France au XVIIIe siècle (Paris: SEVPEN, 1967), 2:719; the former commis is either 
François-Ambroise Daubenton (1663-1741) or his son Jean-Baptiste (1690-1774); on both see Anne Mézin, 





descent but entered the employ of the Venetians and became a cavalry commander.3 
While serving in Dalmatia under the General Delfin,4 he was sent to inspect a prisoner 
camp where he encountered an old Arab physician. The Arab had attempted to defect 
from the Ottomans to the Venetian army, but had instead been imprisoned by the 
Venetians as a spy. The Arab begged Guiller to speak to the General on his behalf. 
Guiller did, and secured the Arab’s release. A few days later, Guiller was visited in his 
tent by the Arab physician, who, “as a mark of his gratitude, offered him the secret of a 
powder febrifuge, which he claimed to be infallible.” Guiller accepted the gift, used it, 
recognized its efficacy, and “the love he had retained for his homeland inspired him to 
share it with France.”5 
 De Chambray’s account then details how the patriotic Guiller presented this 
poudre fébrifuge to Guillaume Le Blond (d. 1718), the French consul in Venice, who in 
turn informed the powerful Jérôme Phélypeaux de Pontchartrain (1674-1747), Louis 
XIV’s Secretary of State for the Navy and the Royal Household. Le Blond sent a sample 
of Guiller’s drug, and it was given to Guy-Crescent Fagon, the royal first physician. After 
a trial (épreuve) of the drug—the details of which are not specified—Fagon reported that 
the drug cured several (plusieurs) patients, but failed in the case of several others. The 
crown already had a more “certain” febrifuge in cinchona, and therefore would not 
                                                 
 3 Louis Marquis de Chambray, “Lettre sur la poudre fébrifuge de M. de la Jutais,” Mercure de 
France (September 1768), 186-191. 
 4Probably Daniele Delfìn (1656-1729), who led Venetian forces against the Ottomans in the 
Morean War (1684-1699) and the Ottoman-Venetian War (1714–18). See Treccani.it: Enciclopedia, 
http://www.treccani.it/enciclopedia/dolfin-daniele-detto-girolamo/ (accessed July 17, 2015). 




purchase Guiller’s secret, although he was to be commended for his “zeal” in the service 
of the king.6  
The story could have ended there, but three years later Guiller was travelling in 
France on other business and came in person to the office of M. Daubenton, Chambray’s 
source for the story, who was then an administrator in the navy office. Guiller asked that 
his febrifuge be tested again, fearing that the previous sample had spoiled en route or had 
not been properly administered. A second trial was organized by Pontchartrain and 
Fagon; this time around, it was found to be “infallible,” having cured hospital patients 
suffering from all species of fevers.7 
 I have not been able to confirm every detail of the tale recounted by the Marquis 
de Chambray (which, it should be noted, was based on second-hand testimony at over 
fifty years remove from the events described), particularly the story of the Arab physician 
in Dalmatia. But we can be quite sure that in 1712, Ferdinand de Guiller was invited from 
Venice to the court of Louis XIV on the recommendation of the consul Le Blond in 
connection to the poudre fébrifuge.8 The crown offered to buy the remedy, but Guiller 
told Fagon that he did not intend to profit from it; he simply hoped to have the 
satisfaction of being useful to his homeland. When the king was informed of the quality 
of the drug and of Guiller’s lack of interest in personal gain (désintéressement), Guiller 
                                                 
 6 Ibid., 188. 
 7 Chambray, “Lettre sur la poudre fébrifuge de M. de la Jutais.” 
8 See AN AE BI 1163, Le Blond to Pontchartrain, April 30, 1712, fol. 269: “J’espère que Votre 
Grandeur aura reçeu la lettre du S. de Guiller, que j’ai eu l’honneur de luy envoyer le 16 de ce mois, en la 
suppliant de m’en addresser la reponce.” Ibid., September 3, 1712, fol. 251: “J’ai oublié samedy passé 
d’envoyer la lettre dud. Ferdinand de Guiller, qu’il m’a laissé avant son départ pour se rendre auprès de 
Votre Excellence, et pouvoir effectuer ce qu’il s’est engagé. Il est party avec son epouse prenant la route de 
Gennes.” Unfortunately the attached letters in both cases have not survived. Le Blond is mentioned in the 
Mercure as well as the mémoire produced by Lajutais daughters in their later attempts to renew the 




found himself amply rewarded: he was knighted in the royal hospitaller order of Saint 
Lazarus and granted a generous annual pension of 1,200 livres for his services. Alongside 
these honours, Guiller also received a royal brevet granting him exclusive sales for his 
poudre fébrifuge throughout France on September 30, 1713, which specifically 
underlined the drug’s potential utility to the French army.9 
 This chapter traces the surprising fortunes of the Chevalier de Guiller’s poudre 
fébrifuge through the eighteenth century. While my focus will be on the period from 1713 
to 1737, the privilege and the medical secret of the poudre fébrifuge passed through the 
hands of three generations and was examined by three successive licensing regimes 
before the end of the century. Guiller himself secured the original privilege in 1713, but 
left no heir and took the medical secret of the drug with him to his grave in 1730. His 
death produced an exceptional series of events that opens a window onto the ways in 
which trade secrecy, medical privilege, and military contracts operated in this period. 
This chapter draws on a corpus of documents surrounding this drug, including account 
ledgers, correspondence, and military-medical reports, most of which were preserved as 
evidence in a vicious legal battle between the two medical entrepreneurs, Pierre Brodin 
de Lajutais and Étienne Guérin, who collaborated together to recover the medical secret 
and its accompanying privilege in the 1730s.  
                                                 
 9 For the original parchment brevet, see AN V7 246 (6), dossier 3, item 2, “Brevet en parchemin du 
privilège accordé par le Roi audit Sieur Guiller pour la fabrication et vente de la Poudre Febrifuge,” signed 
by Louis and Phelypeaux, September 30, 1713. This is so far one of only a handful of brevets I have found 
(most survive only as copies in the dispatch registers of the Secretary of State for the Royal Household). 
 In 1749 Lajutais or his daughters appear to have secured a copy of Guiller’s original request for 
the brevet and the support letters of Fagon and Boudin from the dispatch registers of the secretary of state, 
held in the naval archives, which they later provided a copy of in their 1775 petition for the renewal of their 
privilege. The copy, which is certified authentic by Maurepas, Secretary of the Navy, also included an 
annotation in pencil in the hand of Pontchartrain, which reads: “Decision du Roy: Bon. Pension de 1,200 




 The first section of the chapter will treat Guiller’s original drug, its assessment by 
the first physician, Guy-Crescent Fagon, and the mixed results of a series of naval 
hospital trials undertaken in 1714. Particularly, it will extrapolate from the only surviving 
medical report of these trials to contextualize the poudre fébrifuge within the debates 
surrounding fevers and medicinal specifics in this period. The second section explores 
how Guerin and Lajutais managed to “rediscover” the secret and recover the privilege for 
the poudre, eventually exploiting it for their own gain as entrepreneurs-fournisseurs to 
army hospitals during the War of the Polish Succession (1733-1738). Here I draw 
primarily on evidence deposed during their later lawsuit, judged by a commission of the 
royal Conseil privé. This evidence includes their ledgers as well as the regular 
correspondence that was necessitated by their collaboration: Lajutais resided in Arles, 
where he was a tobacco manufactory controller, while Guerin was based in Paris but 
regularly shuttled between Versailles and the other abodes of the court to advance his and 
Lajutais’ mutual projects. As much as the lawsuit itself, the simple fact of their 
partnership generated documentation of negotiations which otherwise would have gone 
unrecorded, most notably the various dealings at court necessary to secure privileges and 
contracts. Their ledgers also allow a glimpse into the mechanisms of remedy production 
and distribution, and allow for a comparison of the relative share of sales between 
consumer retail and government wholesale in the secret remedy trade. The third section 
of the chapter treats the two parts of the medical secret that formed the basis of the 
privilege, namely, the identity of the elusive plante fébrifuge and the recipe for its 




sketches the various legal debacles that followed it, and traces the legacy of the poudre 
fébrifuge to Lajutais’ daughters, who resurrected the privilege once again in 1775. 
 The range and variety of the sources surrounding the poudre fébrifuge makes it an 
unusually rich case study. Add to this the fact that the story of the poudre fébrifuge is 
virtually unknown to modern scholarship, having received only a short notice by Maurice 
Bouvet in 1924 and passing mention in the more recent work of Alexandre Lunel.10 Most 
importantly, Guiller’s poudre fébrifuge confirms several features apparent in the case-
studies of orviétan and Helvétius’ remède spécifique. On the one hand, it provides further 
evidence for the link between medicinal specifics and the needs of the emergent fiscal-
military state, which I have described in chapter 4. On the other, it provides an interesting 
contrast to the way medical secrecy and medical dynasticism played out in the case of the 
Helvétius and Contugy families by showing what can happen when the transmission of a 
secret is broken. As we shall see, such a situation could effectively prompt a new 
generation of would-be privileged vendors to reverse engineer a drug whose secret had 
been lost.  
1. In the shadow of cinchona: The criterion for testing Guiller’s poudre fébrifuge, 
1713 
 
 The Chevalier de Guiller’s poudre fébrifuge is unique among the drugs discussed 
in this dissertation insofar as a detailed medical report on its efficacy has survived. In 
most cases, documentation exists which suggests tests were undertaken prior to the 
granting of a privilege, whether these be a small number of personally supervised trials 
                                                 
 10 Maurice Bouvet, “Les facultés d’approvisionnement données par Louis XIV à un fabricant de 
remède secret,” Courrier médical (May 18, 1924); Maurice Bouvet, “Histoire sommaire du remède secret,” 
Revue d’histoire de la pharmacie 45, no. 153–54 (1957): 60; Alexandre Lunel, La maison médicale du roi, 




under the aegis of the fist physician, or larger trials on hospital patients, like those 
undertaken by Helvétius for his dysentery specific. The poudre fébrifuge provides the 
only case I have found in which an official medical report by an “independent” third 
party (that is, someone other than the vendor and the royal first physician) has survived. 
This report includes a detailed account of the trial cases and a theoretical evaluation of 
the internal effects of the drug. My goal in this section is to contextualize this report in 
contemporary debates about fevers, which have been treated in chapter 2, and to show 
how cinchona served as a “model” medicinal specific with which the poudre fébrifuge 
was unfavourably compared. 
 Several months before he was granted his full brevet, on June 20, 1713, Guiller 
was given royal permission to collect an unnamed “racine fébrifuge” wherever it might 
grow, including the forests of communes and nobles. The brevet further enjoined the 
officers of the royal waters and forests to cooperate with him in this endeavour.11 By this 
point, we can assume that Guiller was being shepherded through the testing process 
necessary to secure a brevet by the first physician Fagon. The opening of the brevet also 
makes clear that it was granted upon the recommendation of Fagon and Jean Boudin, a 
royal physician in ordinary and former dean of the Paris Faculty, “after having 
undertaken experiments on a large number (un grand nombre) of patients who were all 
cured.”12 As a consequence of their report, “His Majesty ordered Sieur Guiller to prepare 
                                                 
 11 AN V7 246 (6), dossier 3, item 1, “Brevet pour la cueillette du racine fébrifuge,” June 20, 1713, 
signed by Louis and Phélypaux with seal. These “medicinal foraging rights” were likewise reaffirmed when 
he received his full brevet: “Permet Sa Majesté aud. Sr. Guiller de faire la recherche de lad. racine febrifuge 
dans toute ses forests dans celles des communautez ou des particuliers et generalement dans tous les 
endroits ou il en decouvrira, et d’en prendre quantité dont il aura besoin, sans qu’il puisse estre empesché, 
attendu qu’il sagit bien, et de l’avantage public,” AN V7 246 (6), dossier 3, item 2, “Brevet du Sieur Guiller 
pour la Poudre Febrifuge,” September 30, 1713. 




a sufficient quantity both for his army hospitals and to be sold at a reasonable price to all 
those who need it to be cured.”13At the outset, then, supplying the army is explicitly 
underlined as an objective. The expressed rationale for granting the brevet is to reward 
the inventor and provide assistance to royal subjects (following the conventional rhetoric 
employed in these sources). The brevet fixes the price of the drug at 10 sols per dose, and 
also specifies that Guiller could establish offices (bureaux) in other cities for its 
distribution—in effect granting franchises or concessions to subsidiary vendors. 
 The certificates from the first physician provide some insight into the process by 
which Guiller was rewarded with these privileges. Fagon reports that he and Boudin used 
Guiller’s powder on a number of patients suffering from various types of intermittent 
fevers (tertians, double tertians, and quartans) and that it cured all of them, “even some 
who had not been cured by cinchona,” a point which, as we shall see, was of crucial 
importance: the comparison to cinchona would come to be a persistent refrain 
surrounding the poudre fébrifuge in 1713 as in 1733. 14 Fagon also states that he knew of 
the plant that Guiller used (without mentioning its name) but that it had never been used 
before because of some drawbacks: it purged too quickly and caused “accidents.” None 
of these drawbacks exist with Guiller’s powder thanks to his innovative preparation.  
Fagon’s attestation thus tells us very little about the exact circumstances of the 
trials. Instead, it focuses on the character of the vendor and the expediency of the drug for 
military purposes. Fagon distinguishes Guiller from the common crop of charlatans by 
                                                 
 13 “Sa Majesté auroit ordonné aud. Sr. Guiller d’en faire preparer une quantité suffisante tant pour 
les hopitaux de ses armées, que pour estre distribué a un prix modique a tous ceux qui en auront besoin 
pour leur guerison,” Ibid. 
 14 AN V7 246 (6), dossier 3, item 16. Guerin would likewise later state that “deux ou trois prises de 
ce remedes guerissent plus seurement et sans crainte de retourt les fievres les plus opignatres que ne 




emphasizing the sincérité and honnêteté with which he disclosed his secret.15 
Consequently, the poudre fébrifuge was validated not only through the patient trials, but 
also by the first physician’s personal assessment of the character of its inventor. Fagon 
also points out that the poudre’s key ingredient, a plant which he does not name, 
naturally, can be found plentifully throughout the French countryside and can be prepared 
quite easily:  
Consequently [the poudre febrifuge] can be employed at very little 
expense in all of the hospitals of the king’s armies, and without a doubt, it 
will spare His Majesty from great expenses, and save an infinite number 
of soldiers by healing them. They will suffer neither from the infection of 
hospital air nor from the swindling [friponnerie] of the entrepreneurs.16  
 
To judge from Fagon’s assessment, the most important advantages of the drug were the 
soldiers it would keep in the field and the money it would save the crown. Beyond this, 
Fagon compares it to a proven febrifuge, cinchona bark; and attests to the good character 
of its vendor. The details of the trials remain in the background, being guaranteed by the 
personal credit of the royal first physician as an expert witness.17 
 Interestingly, the initiative for organizing large-scale hospital trials of the poudre 
fébrifuge came not from the army, as Fagon’s letter might lead one to expect, but from 
the navy: specifically, Jérôme Phélypeaux de Pontchartrain (1674-1747), who held the 
dual post of Secretary of State for the Royal Household and the Navy in the later years of 
                                                 
15 “Le Sieur Ferdinand de Guillers nous a declaré fort honestement la preparation et avec une 
syncerité fort differente de la manière avec laquelle les charlatans s’expliquent sur leurs secrets,” AN V7 
246 (6), dossier 3, item 3, Fagon certificate (Janvier 30, 1713), 1v°. 
 16 AN V7 246 (6), dossier 3, item 3, 1v°-2r°. 
 17 The role of the first physician as an authoritative witness is comparable to the “gentlemanly 
truthfulness” described in Steven Shapin, A Social History of Truth: Civility and Science in Seventeenth-
Century England (Chicago: University of Chicago Press, 1994), chap. 3. It also bears an analogy to the 
nonmaterial forms of credit which Clare Haru Crowston has recently described as a crucial category of 
analysis for understanding power and patronage under the Ancien Régime: see Crowston, Credit, Fashion, 




the reign of Louis XIV.18 Alongside his many other responsibilities, Pontchartrain kept 
an eye open for new drugs that might be of use to the French navy. Throughout the 
opening decade of the eighteenth century, his correspondence shows that he regularly 
received petitions from vendors hoping to furnish their remedies to the navy. 
Pontchartrain’s subordinates, notably the port intendants, provided him with reports and 
samples of new remedies that they encountered. He solicited samples of given drugs for 
testing and sometimes sought the expert medical advice of Fagon on these questions.19  
 It was in fact Fagon who first brought the poudre fébrifuge to his attention. On 
May 16, 1714, Pontchartrain wrote to the first physician concerning a proposal he had 
received from a certain Sieur Gerauldy, “concerning a remedy which he has invented 
which he claims cures all varieties of fevers and even serves as a counter-poison,” asking 
for his expert opinion on this remedy.20 Fagon, however, had a remedy of his own in the 
“development pipeline”—Guiller’s poudre fébrifuge—and advised Pontchartrain not to 
bother with Gerauldy’s, as Guiller’s was “of a superior quality.” This prompted 
Pontchartrain to request that Fagon send a sample to Beauharnois, Intendant of the Navy 
at Rochefort, where Gerauldy had likely proposed his remedy. A few weeks later, 
                                                 
 18 On the patronage network of the Phélypeaux and on the career of Jérôme, see Sara E. Chapman, 
Private Ambition and Political Alliances: The Phélypeaux de Pontchartrain Family and Louis XIV’s 
Government, 1650-1715 (Rochester, NY: University of Rochester Press, 2004). 
 19 Among those mentioned in the naval correspondence (AN MARINE series B2 and B3) during 
Pontchartrain’s term are: a “remede du Sieur Pimont” which Pontchartrain sought for testing; an unguent 
for curing ulcers; a “poudre des Chartreux,” the use of which is unspecified; “tablettes pour le rhume” 
based on oyster shells; a new hernia remedy; and the root simarouba, used for curing dysentery (perhaps a 
competitor to Helvétius’ ipecac). 
 20 AN MARINE B2 238, fol. 128, Pontchartrain to Fagon (May 16, 1714). Gerauldy appears to have 
produced remedies for several conditions: assuming it is the same Gerauldy, my table of privilege-holders 
shoes that he received a brevet for his “essences et opiates pour les dents” in 1700, and another for his 




Pontchartrain received a sample large enough to supply the hospitals of the four Ponant21 
naval arsenals: Rochefort and Brest, each being sent 200 prises, and Lorient and Le 
Havre with 100 prises each, along with printed instructions on how and when the prises 
should be taken. Pontchartrain prepared a form letter to the senior officials at each port 
(Intendants or ordonnateurs), asking them to distribute the drugs to the sick of the naval 
hospitals and then to report back on their efficacy.22 
 Alongside these efforts, Guiller appears to have been personally investigating 
bulk purchasers for his drug in this period. The next fall (presumably while waiting to 
hear back concerning the effects of all the trial samples) Guiller received a letter from 
Boudin, confirming that he had spoken to Pontchartrain on Guiller’s behalf and that the 
drug would be distributed throughout naval hospitals: “I found him very well disposed 
toward the poudre, and he told me that he would send it wherever he could.”23 Boudin 
cautioned however that much of this would depend upon the diligence of Pontchartrain’s 
commis, advising Guiller to follow the matter closely. On top of this he suggested Guiller 
contact two Jesuits to see if the missions in India might be interested in purchasing a 
shipment, suggesting that even at this early stage Helvétius was not alone in seeking bulk 
purchasers other than the state.24 
                                                 
 21 I specify Ponant (Atlantic) ports because no samples for testing appear to have been sent to any 
of the Levant (Mediterranean) ports, for reasons I have not yet been able to determine. Some hints in the 
Levant fonds however suggest that they may have drawn more of their drugs from local vendors in 
Montpellier and Marseille. 
 22 AN MARINE B2 238, fol. 270-271. 
 23 “Je l’ay trouvé très disposé en faveur de la poudre, il m’a dit qu’il en envoyoit partout ou il 
pourroit,”AN V7 246 (6), dossier 3, item 6, Letter from Boudin to Guiller (November 30, 1714. 
 24 Ibid. On proprietary drugs supplied to missionaries, see below, ch. 6, sect. 2. On medicine and 
the Jesuits in India, see Ines G Županov, Missionary Tropics: The Catholic Frontier in India, 16th-17th 




 Three of the port officials acknowledged receipt and passed the samples along to 
the medical staffs for trials at their respective hospitals.25 Unfortunately, a detailed report 
has survived from only one: Charles de Clairambault, ordonnateur at Port Louis, the 
naval base south of Lorient. He forwarded the accounts of the trials undertaken by his 
surgeon-major, Pierre Labat, and the port physician, Guillaume Boizard (d. 1715).26 
Labat used the powder on a man suffering from a double-tertian; the patient recovered 
after a single dose, but the fever was already in remission when the dose was 
administered, and Labat felt that any purgative would have cured him at that point. The 
surgeon-major advised Clairambault that they should wait until the habitual fall and 
winter fevers arrived in earnest for a more conclusive trial of the drug.27  
 Sure enough, in the middle of the winter of 1714-15, the sailors at Port Louis 
came down with fevers, as did several non-military patients. The effects of the poudre 
fébrifuge, however, were disappointing. The surgeon-major Labat tried it on “twenty or 
thirty” patients in the hospital; the port physician, Boizard, wrote that he administered 
multiple doses to five different patients, some male others female, all outside of the 
hospital. Labat reported that it produced good effects on one man, aged of thirty years, 
who had suffered from a quartan fever for eight months: after only two doses he was 
cured. In the other cases, however, the effect of the drug had been terrible, producing 
such violent purges that the patients strongly protested. All this in spite of the fact that he 
had followed the printed instructions to the letter. In some patients the poudre seemed to 
                                                 
 25 AN MARINE B3 222, fol. 214, Clairambault (Lorient), June 27, 1714; and MARINE B3 220, fol. 
286, Champigny (Le Havre), June 27, 1714. 
 26 AN MARINE B3 230, fol. 53r°-54r°, “Mémoire des médecin et chirurgien major de l’hopital de la 
marine du Port Louis” (January 31 and February 1, 1715). On Labat and Boizard, see Henri François 
Buffet, Vie et société au Port-Louis: des origines à Napoléon III (Rennes: Bahon-Rault, 1972), 371, 375. 




have no effect at all; in others, it provoked vomiting; but in neither case was the fever 
cured. Labat concluded, “This alleged febrifuge has two important disadvantages: 
namely, the violence and the uncertainty of its effects.”28  
 The terse assessment of the surgeon confirmed that of the physician. In Boizard’s 
report, the defining features of the poudre are excessive and violent evacuations, patient 
protest, and only mixed efficacy against the fever. Boizard observes that after he gave 
one dose to a woman suffering from a quotidian fever, “The young woman vomited and 
purged abundantly almost forty times, and the fever left her, but she protested that if 
presented with the same circumstances she would have preferred to keep the fever than 
lose it at that price.” The other patients included a man suffering from a tertian fever who 
likewise experienced evacuations from above and below but was not cured; a poor man 
of whom he lost track; a man suffering from a tertian, to whom he gave three doses, the 
final of which provoked painful colic but did not cure the fever; and finally a woman 
who, after a single dose, flatly refused to take any more. But the most interesting part of 
his report is the theoretical explanation Boizard offers for the failure of the drug: “I 
conclude that this remedy cannot be a febrifuge neither by its nature nor by the virtue of 
its substance, but only by the violent evacuations which eject the febrile leaven that 
occupies the primary [digestive] and even the most internal channels.”29 The so-called 
poudre fébrifuge was not by its nature a true febrifuge, as far as Boizard was concerned: 
                                                 
 28 AN MARINE B3 230, fol. 53v°. 
 29 “Je conclus que ce Remede ne peut estre febrifuge de sa nature ni par la vertu de sa substance, 
mais seulement par la violence de son evacuation par laquelle il peut faire sortir les levains fievreux qui 
occupait les premieres voyës et meme les plus interieures,” AN MARINE B3 230, fol. 53v, Mémoire des 




it was only so accidentally, insofar as it was a powerful purgative that could evacuate the 
“febrile leaven” from the digestive tract. 
 I have already discussed the notion of “febrile leaven” as it emerged from the 
“materialist” reading of Helmontianism present in the acid-alkali theory of pathology.30 
We have seen that this view of disease was particularly widespread in fever theory after 
the dissemination of Talbor’s Remède Anglois, and that it was shared by the first 
physician, Fagon, who used it to explain the “specific” action of cinchona.31 What is 
remarkable in this case is that the “chymical criterion” for understanding medicinal 
specifics appears to have been espoused by both Fagon—who approved the poudre 
febrifuge—and by the port physician Boizard—who categorically rejected it.32  
 When Boizard assessed the effect of the poudre fébrifuge, he observed that it was 
merely a powerful purgative, a type of drug long criticized by Helmontians and other 
chymical physicians. When purgatives work at all, they do so accidentally by ejecting 
everything in the stomach and intestines. A truly specific febrifuge would strike in a more 
targeted way at the root cause of the disease, namely the febrile leaven, or to use 
Boizard’s terms, “by radically extirpating its leaven” (par l’extirpation radicale de son 
levain).33 Boizard argued that using a violent purgative to get the job done was to cure as 
the empirics did when they used plants like hellebore: that is, through brute force and by 
                                                 
30 See above, ch. 2, sects. 2 and  5. 
31 See above, ch. 2, sect. 4; and Guy-Crescent Fagon, “Nouvelles reflections necesaires pour se 
servir utilement du kinkina,” in Les admirables qualitez du kinkina [...] avec de Nouvelles réflexions pour 
s’en servir, faites par Monsieur Fagon premier Médecin du Roi en 1697 (Paris: Martin et George Jouvenel, 
1705). Fagon declared in 1697 that “there is no remedy more specific against fevers than cinchona,” 
although a few years later he would approve the poudre fébrifuge as more effective. 
32 On the “chymical criterion,” see above, ch. 2, esp. sect. 5. 




risking the destruction of part of the patient’s body.34 And even then, such methods, like 
the purges brought on by the poudre fébrifuge, were uncertain, and may leave the fever 
still firmly seated, thus only adding to the patient’s misery. 
 Boizard has unfortunately not left behind any publications that might give us a 
better idea of his background and training, but the language of his report strongly 
suggests that he was a chymical physician, as do other details about the medical staffing 
at Port-Louis. Boizard died only a few months after making his report, in July of 1715, 
and the ordonnateur Clairambault needed to find a replacement. He proposed one Avril 
Lescot as the new hospital physician:  
His method of work is particular, for he trusts no one but himself, being 
physician, surgeon, and apothecary at the same time, compounding his own 
remedies and administering them himself. There seems to be less charlatanry 
in his practice than in that of other physicians, and as he claims that his 
remedies have a greater virtue than those of others, there is every likelihood 
that he would cost the King less because his patients would be better cured, 
for it is commonly known that physicians and lawyers drag out sickness and 
lawsuits when they know they will be well paid.35 
 
Clairambault met with resistance from Pontchartrain on this question. In his next letter, 
Clairambault observed that “Those who claim that Sieur Lescot was recommended to me 
by a writer who dabbles in chymistry are quite ill-informed.” He then adds, “As regards 
the chymical remedies that he himself compounds, and his assurances that similar 
remedies cannot be acquired from the apothecaries, I believe, Monseigneur, that this can 
                                                 
34 Ibid. 
 35 “Sa manière de travailler est particuliere car il ne se fie à personne qu’à luy seul etant medecin 
chirurgien et apotiquaire faisant ses Remedes et les apliquant luy même et il paroist en cela moins de 
charlatanerie dans sa conduitte que dans celle des autres medecins. Et comme il pretend que ses Remedes 
ont plus de vertu que les autres il y a aparence qu’il en coutera moins au Roy puisque ses malades seront 
plûtôt gueris, car on dit ordinairement que les medecins et les procureurs font souvent durer les maladies et 
les procez quand ils savent qu’ils seront bien payés,”AN MARINE B3 230, fol. 382r°, Clairambault (Lorient) 




only be advantageous to the sick, for he has worked for thirty years testing these remedies 
and must therefore have perfect knowledge of their force and virtue.”36  
 Pontchartrain ultimately refused to allow Lescot to be appointed as hospital 
physician, on the grounds that the holder of the post should be a medical licentiate, and 
that it was improper for a physician to make and administer his own drugs. Mixing 
pharmacy and medicine together would give him too much power over patients, 
Pontchartrain argued, and he may be tempted to test new drugs on patients. This 
particular concern is especially ironic, given the fact that Pontchartrain had recently 
ordered a large-scale test of poudre fébrifuge, a drug devised by a practitioner who had 
no more formal medical credentials than Lescot, and had received references from 
another port intendant, Beauharnois, concerning a febrifuge tested at Rochefort. The 
implication would seem to be that there were minimal requirements for formal medical 
training at the naval hospitals, and that anyone wanting to test remedies and sell them to 
the navy was expected to go through the proper channels at Versailles and personally 
seek the approval of Fagon and Pontchartrain.37 
 In 1704 Lescot had in fact been condemned in Rennes and Brest as a charlatan. 
But the way in which Clairambault defends his candidacy is telling: he wanted a 
practitioner that broke down the traditional boundaries; one with a reputation for famous 
cures; and one who could produce and administer chymical remedies. The fact that 
                                                 
 36 “Ceux qui disent Monseigneur que le Sr Lescot m’est recommandé par un écrivain qui se mesle 
de Chimie sont bien mal-informés. A l’egard des Remedes de Chimie qu’il compose luy même et qu’il 
assure qu’il ne s’en trouve pas de pareils chez les apotiquaires, je crois Monseigneur que cela ne peut estre 
qu’avantageux aux malades car puis qu’il y a trente ans qu’il travaille et qu’il a éprouvé ces remedes, il en 
doit connoitre parfaitement la force et la vertu,” Ibid., fols. 395-397r°, August 5, 1715. 
 37 On Lescot see Louis Nicolle and Édouard Guéguen, “Comment le charlatan Lescot ne fut pas 
nommé médecin de l’hôpital de la Marine royale au Port-Louis,” Revue d’histoire de la pharmacie 57, no. 
201 (1969): 335–37. These minimal requirements were likely the result of the 1707 Edict of Marly, which 




Clairambault wanted a figure like Lescot to succeed Boizard as hospital physician 
strongly suggests that the latter was not a conventional Galenic physician. These details, 
coupled with Boizard’s assessment of the drug, may place him among a new school of 
practitioners seeking medicinal substances which would work against specific diseases in 
large populations. As Harold J. Cook has suggested, this kind of practitioner found a 
special niche in the growing militaries of Western Europe.38  
Like Helvétius’ justification of his dysentery specific, Boizard’s assessment of the 
poudre fébrifuge demonstrates that cinchona had emerged as an obligatory point of 
reference for anyone wishing to tout or assess a substance as a medical specific. 
Daubenton’s story of the first trial ends with the drug being found wanting in comparison 
to the proven effectiveness of cinchona. Fagon’s certificate following the second trial 
insists that the poudre fébrifuge succeeded on patients where even cinchona had failed. In 
the report of the third trial at Port Louis the physician Boizard explains the failure of the 
drug in the language of the acid-alkali theory, then closely associated with explaining the 
therapeutic action of cinchona. Seventeenth-century Europeans had of course shown 
great interest in American plants like cinchona, but Fagon’s endorsement of the poudre 
fébrifuge exemplifies another trend: a broader interest in finding cheaper indigenous 
European alternatives to exotic plants, which could be expensive or otherwise difficult to 
obtain.39  
                                                 
 38 Harold J. Cook, “Practical Medicine and the British Armed Forces after the ‘Glorious 
Revolution,’” Medical History 34, no. 1 (1990): 1–26. 
 39 Kapil Raj has pointed to this tendency in Antoine de Jussieu (1686-1758), member of the 
Academy of Sciences and professor of botany at the Jardin du Roi: see Relocating Modern Science: 
Circulation and the Construction of Knowledge in South Asia and Europe, 1650-1900 (Houndmills: 
Palgrave Macmillan, 2007), esp. 55–56; for earlier examples, see Alix Cooper, Inventing the Indigenous: 





 The exchanges surrounding Guiller’s poudre fébrifuge circa 1713-1714 also 
exemplify the same convergence of entrepreneurial, medical, and military interests as 
Helvétius’ dysentery specific. The trials of both drugs were spurred on by the medical 
needs of the growing armies and navies of the period, and like other logistical problems, 
these needs were met by private military contractors. In the final decades of Louis XIV’s 
reign, the highest levels of the fiscal-military state—personified here by Pontchartrain, 
and in the case of Helvétius by Seignelay—had taken an interest in prospecting and 
testing drugs for use in the field, particularly those responding to the perennial health 
problems of crowded military hospitals, namely dysentery and fevers. 
These population-scale needs seem, at first glance, to be at odds with the 
relatively small scale of drug testing. Like Helvétius’ dysentery specific, Guiller’s poudre 
fébrifuge was initially tested on relatively small groups, and generated little in the way of 
systematic records. In the case of the poudre fébrifuge, we have no details at all 
surrounding the first trial, beyond the fact that it was supervised by Fagon who deemed 
the drug ineffective. Guiller attributed this result to the drug’s spoilage en route during its 
transport from Venice. He was careful to transport it himself the next time around, and 
was personally present during the trial. With Fagon’s second trial in 1713 we hear only of 
the drug’s success on “several” patients, including some cases where even cinchona had 
not been effective. Finally, with the large military hospital trials arranged by 
Pontchartrain in 1714, hundreds of prises were sent for testing. We know that in the case 
of the surgeon Labat, the drug was given to “twenty or thirty” patients, but the single 
instance where it was deemed successful is the only one described at any length. In the 




whom he administered it. Two of these patients were women (far from the population 
Pontchartrain and Fagon envisioned for the trial), and more space is devoted to his 
pharmacological commentary than to the details of the patient case histories.  
Despite the criticisms of Boizard at Port Louis, it should be noted that theirs was 
only one of four ports where the drug was sent for testing. At least one physician, the 
famous Jean Cochon-Dupuy (1674-1757), correspondent of the Académie royale des 
sciences and port physician at Rochefort, endorsed the drug following his own trials, 
though his report has, unfortunately, not survived for comparison. We do however know 
that the Rochefort intendant requested a new shipment.40 In all of these cases, the expert 
judgment of the practitioner was the paramount criterion, independent of the exact 
number of patients on whom the drug was tested, which could range from “several” to 
“twenty or thirty.”  
 Whatever the results from the other port trials, perhaps the most interesting thing 
to note about this stage in the saga of Guiller’s poudre fébrifuge is that the drug was 
granted a royal privilege which explicitly underlined military applications, even before 
extensive military hospital trials were undertaken. The successful trials undertaken 
personally by the royal first physician at a civilian hospital provided the basis for granting 
a privilege that was explicitly earmarked for military purposes.  
2. Lajutais and Guerin’s scheme to recover Guiller’s privilege, 1732-1733 
 Guiller retired to the town of Mondragon in Provence, comfortably pensioned, 
knighted, and privileged with a monopoly for the sale of his drug throughout the 
kingdom. The extent to which he profited by his privilege is unclear: in contrast to the 
                                                 




case of Helvétius, I have not been able to find receipts for bulk purchases by the navy or 
army, nor is there any evidence that he set up bureaux for its sale throughout France.41 
On July 1, 1729, he did, however, collect an attestation from the provincial intendant’s 
subdelegate and the town consul of Mondragon, who testified not only to the efficacy of 
the poudre fébrifuge but also to the importance of its charitable distribution to the local 
poor.42 This attestation was intended to support the renewal of Guiller’s privilege when 
the new 1728 commission requested all existing brevets be submitted for reexamination. 
Before he was able to forward it on to the commission, Guiller died in Mondragon on 
August 18, 1729, followed six months later by his wife, Marie-Victoire.43 
  A little less than two years after Guiller’s death, two men initiated a partnership 
to renew his privilege for the poudre fébrifuge and market it themselves. These two men, 
Pierre Brodin de Lajutais and Etienne Guerin, had worked together as administrators at 
the snuff manufactory in Mondragon. The sale of tobacco in France in this period was a 
legal monopoly, which had recently passed from the hands of the East Indies Company to 
the Fermiers généraux, the private firm which collected taxes and duties on behalf of the 
French crown.44 Lajutais and Guerin were members of a class of bureaucrats who 
                                                 
 41 Guerin in fact suggests that Guiller did not work very hard to commercialize the poudre 
febrifuge, concluding that he was not sufficiently motivated: his generous royal pension was more than 
sufficient for his needs and he lacked an heir: “Je connois bien aujourd’huy la negligence aujourd’huy la 
negligence de Mr Le Chevalier de Guiller, la pension que le Roy lui avoit accordé, et se voyant sans enfans, 
ces raisons l’excusent de n’avoir pas mieux tiré party d’un pareil remede,” AN V7 246 (6), dossier 1 item 5, 
Guerin to Lajutais (August 7, 1732). 
42 AN V7 246 (6), dossier 1, no. 30, Attestation from Durand and Augier, July 1, 1729. 
 43 AD Vaucluse GG 112, Mondragon, Baptêmes, mariages, sépultures, fol. 552v°, 714v°. 
 44 On the tobacco monopoly, see the classic work of Jacob M. Price, France and the Chesapeake; 
a History of the French Tobacco Monopoly, 1674-1791, and of Its Relationship to the British and American 
Tobacco Trades (Ann Arbor: University of Michigan Press, 1973); Michael Kwass, “Court Capitalism, 
Illicit Markets, and Political Legitimacy in Eighteenth-Century France: The Salt and Tobacco Monopolies,” 
in Questioning Credible Commitment: Perspectives on the Rise of Financial Capitalism, ed. D’Maris 




benefited from the farming out of government functions by the early modern state, which 
some scholars have called “court capitalism.”45 The fact that both men were involved 
with the tobacco monopoly bears emphasis here. Their place in the world of court 
capitalism, however minor, likely provided them with the incentive and connections that 
led them to see the poudre fébrifuge as an exploitable asset. Together they would use it to 
secure a “farmed-out” operation of their own as medical contractors to the French army. 
Guerin had also served with his father as an entrepreneur (contractor) in charge of 
erecting fortifications, and therefore had some experience in military contracting.46 
Likewise, the familiarity of both men with the processing and grinding of tobacco may 
also have come in handy in the extensive plant processing operation needed to meet bulk 
pharmaceutical orders. 
When the Mondragon manufactory was closed in 1731, the older and higher-
ranking Lajutais was transferred to another manufactory in Arles, while Guerin was 
obliged to make his way up to Versailles to solicit a new posting from the Fermiers 
généraux.47 Lajutais had evidently forged close personal ties to Guiller just before he 
                                                 
 45 The term was first coined by George V. Taylor and expanded more recently by Gail Bossenga, 
“Markets, the Patrimonial State, and the Origins of the French Revolution,” 1650-1850: Ideas, Aesthetics, 
and Inquiries in the Early Modern Era 11 (2005): 443–510; George V. Taylor, “Types of Capitalism in 
Eighteenth-Century France,” The English Historical Review 79, no. 312 (1964): 478–97. 
 46 AN V7 246, (6), dossier 3, Item 12, Guerin to Fontanieu, Intendant of Dauphiné, October 10, 
1733. 
 47 The reason for the closure of the Mondragon snuff works is unclear. Along with Paris, it was 
one of only two sites where snuff was ground (the more common form of tobacco being in rolls): see Price, 
France and the Chesapeake, 42, 116. The closure may be tied to the passage of the tobacco monopoly from 
the East Indies Company to the Fermiers, but there are also other possibilities: Mondragon was in the 
Principauté d’Orange, which has the peculiar distinction of being a French enclave within the papal enclave 
of the Comtat Venaissin. The closure could be tied to economic conflicts in 1730s between France and the 
papacy, with France requesting that the Comtat close down tobacco plantations and extradite French 
contrabandiers. Mondragon’s proximity to tobacco plantations in the Comtat may have allowed it to serve 
as a cover for tobacco smuggling between the papal enclave and France. See René Moulinas, “Problèmes 
d’une enclave dans la France d’Ancien Régime : culture, commerce et contrebande du tabac dans le Comtat 





died: he had married Guiller’s stepdaughter, claimed to have been taken under his wing, 
and claimed to possess his “livre bleue,” possibly a book of medical secrets. Lajutais 
would later leverage his close relationship with Guiller to evidence his legitimacy as 
inheritor of the poudre fébrifuge. This claim provided the initial impetus for his 
partnership with Guerin, who, for his part, served as Lajutais’ agent on the ground at 
Versailles, making all the necessary inquiries to renew the privilege and, equally 
important, to recover the medical secret it protected, which Guiller had taken with him to 
the grave. 
 Guerin was apparently much younger than Lajutais and better suited to the social 
world of Versailles. His skills in navigating both the world of the royal court and the 
central government bureaucracy would prove crucial for his and Lajutais’ plans. From 
June 1732 to November 1733, he lived in Paris and frequently commuted to the court at 
Versailles, pursuing his own interests with the fermiers and following leads on the poudre 
fébrifuge. He also regularly corresponded with Lajutais, who was based in the Provençal 
town of Arles, to keep him apprised of his progress. Guerin’s side of this correspondence 
has survived, and describes his actions in great detail. After having little success in 
securing a new position for himself from the fermiers, on June 21, 1732, Guerin eagerly 
accepted Lajutais’ proposal to collaborate on recovering both the privilege and the 
medical secret of the poudre fébrifuge. 
                                                                                                                                                 
épisode de la mainmise de la France sur le Comtat Venaissin : la guerre économique franco-comtadine 
1730-1734,” in Actes du 77e congrès national des sociétés savantes, Grenoble, 1952 (Paris: Imprimerie 
nationale, 1952), 349–60. Finally, there may also have been problems with the leaf from local plantations: 
according to Price, it was found to be “vile and unsaleable” around 1700. The subfarmers at Mondragon 
were forced to buy it due to the active influence of local cultivators with the intendant of Provence. See 




Lajutais quite sensibly suggested that Guiller begin his investigations at the Jardin 
du Roi. In addition to being the foremost site of botanical knowledge in the kingdom, the 
Jardin was, according to Lajutais, the location where Guiller had held a public 
demonstrations of the drug in the final year of Louis XIV’s reign.48 Guerin explained that 
he had already visited the Jardin twice, but was unable to find anyone who could answer 
his question and so suggested that Lajutais send him one of Guiller’s printed mémoires on 
the drug’s virtues to assist him in his inquiry. As if to whet Lajutais’ appetite, Guerin also 
added that he had had the pleasure of meeting the royal first physician, François 
Chicoyneau (1672-1752), during a recent fête at Versailles, and that the latter had offered 
his protection.49 
 By July 12, Lajutais had mailed Guerin copies of Fagon’s attestation and Guiller’s 
1713 brevet. Guerin wrote back immediately telling him that he would need originals, not 
copies, if he was to pursue the matter any further.50 These finally arrived on August 2,51 
by which point Guerin’s visits to the Jardin du Roi had also yielded fruit: the plante 
fébrifuge, he believed, was a species of tithymal (titimale; modern spurge, the euphorbia 
genus), specifically tithimalus amigdaloïdes, so called for its almond taste (more on the 
plant in the following section).52 With the identity of the plant apparently recovered, and 
with the original 1713 brevet and attestation in hand, Guerin managed to secure an 
audience with the first physician Chicoyneau, confident that the whole matter could be 
settled then and there. 
                                                 
 48 AN V7 246 (6), dossier 1, item 28, Memoire Pour le Sieur Guerin Contre le sieur Brodin de 
Lajtuais. 
 49 AN V7 246 (6), dossier 1, item 1, Guerin to Lajutais (June 21, 1732). 
 50 Ibid., item 2, Guerin to Lajutais (July 12, 1732). 
 51 Ibid., item 3, Guerin to Lajutais (August 2, 1732). 
 52 Modern euphorbia genus, or spurge in English. Throughout I use the now archaic tithymal, 




He was mistaken. Chicoyneau carefully examined the documents and found them 
satisfactory, but explained that they were not in themselves sufficient to renew the 
privilege. Samples of the drug would still need to be examined by the new secret 
remedies commission, formed in 1731 by his immediate predecessor as first physician, 
Pierre Chirac (1650-1732).53 Guerin was taken aback, and reports that he directly quoted 
the portion of Fagon’s attestation that distinguished Guiller’s moral character, from that 
of “common charlatans”: 
I had the honor of representing to him that Monsieur Fagon had not at all 
treated Monsieur de Guiller in this way, and that he had contented himself 
“with what Sieur Ferdinand de Guiller had quite honestly declared, with a 
sincerity very different from the way that charlatans explain their secrets,” 
and that by my account you were ready to do the same.54 
 
Guerin was implying that just as Guiller had been an honnête homme with an honest 
remedy, so too were he and Lajutais. Why was an examination by a full commission 
necessary when in the past the simple judgement of the first physician had sufficed?  
 But Chicoyneau was firm on this point. The days when the personal authority of 
the first physician had sufficed to approve a drug had passed, and the matter would need 
to go before the commission. The first physician explained that they would also need to 
personally communicate the preparation of the drug to him, and Guerin reports with some 
surprise that Chicoyneau had already inferred that tithymal was the main ingredient of the 
drug. This alone was no medical secret: the key to the drug’s success, he observed, was in 
the preparation.  
                                                 
53 See above, ch. 1. 
 54 “J’ay eû l’honneur de lui représenter que Mr Fagon n’en avoit point usé ainsy avec Mr de 
Guiller, mais qu’il s’estoit contente que le Sr Ferdinand de Guiller avoit déclaré fort honnêtement, et avec 
une sincérité fort différente de la manière avec laquelle les charlatans s’expliquent sur leurs secrets, et que 
vous estiés en estat de le faire de mesme sur ma représentation,” AN V7 246, (6), dossier 1, piece 4, Guerin 




Guerin reported all of this to Lajutais and implored him to send the secret of the 
preparation to him in a letter sealed with Guiller’s own mark, which he would then 
personally and “very religiously” forward on to Chicoyneau, ensuring that no one else 
would see it. Guerin even wrote a draft cover letter for Lajutais to recopy in his own 
hand, explaining their project and beseeching that Chicoyneau honour them with the 
same favour that Fagon did Guiller. 
 The progress of the enterprise slowed to a crawl in the following months. Lajutais 
had inherited the recipe for how to prepare the plante fébrifuge but was leery about 
sending the secret through the mail, worrying that he might be swindled. Requests for a 
sealed letter detailing the preparation became a persistent refrain in Guerin’s letters. As 
the months wore on, he would underline again and again, in an increasingly frustrated 
tone, “It is necessary for you to send me the tithymal recipe as the chevalier de Guiller 
relates it in his blue book, if all my efforts here are to succeed.”55 To add further urgency, 
Guerin claimed that a meeting of the secret remedies commission was imminent, and that 
the commission did not meet very frequently, so they might miss their chance to get the 
drug approved. 
 Guerin did his best to assuage Lajutais’ concerns. He instructed him on how to 
securely send a letter through the French postal system and explained why it was best to 
use him personally as an intermediary rather than to the first physician directly: 
                                                 
 55 “Il estoit necessaire pour faire reussir toutes mes opperations de m’envoyer la preparation du 
tithimalle de la manière que le chevalier de Guiller le raporte dans son livre bleu,” AN V7 246, (6), dossier 
1, piece 8, Guerin to Lajutais (November 3, 1732). The book of secrets is also mentioned during a later 
interrogation session with Lajutais, in which the commissionnaire Le Roux (drawing, it should be noted, on 
questions furnished by Guerin himself), asks him “s’il n’est pas vray que le sieur de la Jutais a dit au Sr 
Guerin qu’il avoit lui le livre des secrets du S. Guiller mais que ce livre n’apprenoit point le nom de la 
plante febrifuge et que cela le mortiffioit beaucoup.” In order to discredit Guerin’s claims, Lajutais of 





Chicoyneau was so busy constantly attending to the king that he might leave the recipe 
unattended in his study, and the curious fellow phycians whom he often received in his 
chambers might discover it in his absence, and learn the secret.56 The safest way to 
prevent the letter from being intercepted or neglected by the busy first physician (and 
thus left open to prying eyes) was to have Guerin deliver it personally to Chicoyneau, or 
so Guerin claimed. Lajutais was also afraid that the first physician himself might steal his 
secret and profit by it, a concern which Guerin dismissed as pure folly: “When 
Chicoyneau asks you for this preparation, I assure you it is not out of some desire he has 
to know it, but rather because it is wise and prudent for the king’s first physician to grant 
a permission only after having been informed of how the remedy is compounded.”57  
 By December 30, Lajutais was still unconvinced, so Guerin reported to him that a 
pair of vendors, Rivot Mancini and one Giambacorta, opérateur, attached to the house of 
Her Supreme Highness the Archduchess,58 had just made a trial before Chicoyneau of a 
secret remedy called the “baume ou huile de filosophe,” and had come to court to obtain 
                                                 
56 “Mr Chicoyneau qui est continüellement auprès du Roi qu’à peine peut-on lui parler, negligeroit 
pas peut-estre votre preparation et de repondre à vostre lettre. Nombre de medecins qui sont 
continuellement soit dans sa chambre ou à son cabinet pourroient malgré eux s’en instruire,” AN V7 246 
(6), dossier 1, piece 7, Guerin to Lajutais (October 5, 1732). To reinforce his point about papers at court 
never being entirely private, Guerin tells Lajutais a tale of court intrigue from the time of the Cardinal de 
Richelieu. The Cardinal had been meeting with a good friend in his cabinet (office), and left him alone 
there for a few minutes while he greeted an important female visitor who had come to his door; upon 
returning, the cardinal realized that he had left some of his papers out and open to prying eyes. Although he 
could of course not be sure that his friend had read any of them, he nonetheless called the captain of the 
guard and had the man arrested and sent him to the Bastille, ordering the guard to ensure he spoke to no 
one. Two years later, when he was finally released from his imprisonment, the friend returned to the 
Cardinal and asked him why he had been so suddenly and harshly imprisoned. The latter replied, that, 
considering the circumstances, “il auroit mieux voulu pour lors qu’il eut esté son ennemi que son ami.” 
Thus it is the world of les grands, or so Guerin, passing himself as a seasoned courtier, tells his provincial 
friend Lajutais. 
 57 “Quand il [Chicoyneau] vous demande cette preparation, ce n’est pas je vous assure par l’envie 
qu’il a de la scavoir, mais par ce qu’il est de sage et de regle que quand le premier medecin du Roi accorde 
quelqu’un permission il faut qu’il soit informé de la maniere que les remedes sont composés,” AN V7 246, 
(6), dossier 1, piece 7, Guerin to Lajutais (October 5, 1732). 





their privilege. The pair had paid fifty louis d’or to an unnamed person—with whom 
Guerin assures Lajutais he is acquainted—in order to expedite the issue of the brevet. The 
implication was that if Lajutais were more cooperative, Guerin could secure the same 
deal for him.59 Still Lajutais would not budge. Trade secrecy, it would seem, was a 
double edged sword. Guiller’s death before transmitting the identity of the plante 
fébrifuge to his posterity had already posed a challenge to renewing the privilege, and 
now Lajutais’ fears that the secret of its preparation would be stolen out from under him 
was, from Guerin’s perspective, on the verge of ruining their whole enterprise.  
The project of recovering the privilege for the poudre fébrifuge might have ended 
there, but instead an unexpected turn of events gave it new life: just as Guerin’s hopes for 
a new position form the fermiers were once again dashed,60 Chicoyneau opened a new 
session of the secret remedies commission and, even more importantly, France began to 
mobilize for war.61 This was the military buildup following the death of the Polish king, 
Augustus II, in which the French, under the leadership of the Cardinal Fleury, were 
preparing to intervene against the Austrian Habsburgs in order to support their candidate 
for the Polish succession, Stanislaw Leszczyński, and to check Habsburg power in central 
Europe. A few months later, this would eventually lead to the War of Polish Succession, 
when Louis XV declared war on Austria and Saxony on October 10, 1733.62 
                                                 
 59 AN V7 246, (6), dossier 1, piece 10, Guerin to Lajutais (December 30, 1732). 
 60 Guerin was apparently embarrassed before the Controller General of Finances when he applied 
for an unspecified position in Dunkerque: Lajutais had given him insider information suggesting that the 
current occupant of the position, the elderly Mr Gassin, was on point of death, but Gassin unexpectedly 
recovered,  and  Guerin’s eagerness to replace him seems not to have been appreciated. 
 61 AN V7 246 (6), dossier 1, piece 15, Guerin to Lajutais (July 25, 1733). 
 62 Thérèse Charmasson, Anne-Marie Lelorrain, and Martine Sonnet, Chronologie de l’histoire de 
France (Paris: Presses universitaires de France, 1994), 412; John L. Sutton, The King’s Honor and the 




 Guerin and Lajutais initially had no greater ambitions than to retail the poudre 
fébrifuge through a network of franchise vendors. Now their project to renew the 
privilege became intimately tied to securing a medical supply contract with the army. 
From this point on (August 5, 1733) Guerin’s letters are supplemented by a series of 
expense claims he later presented to Lajutais and which allow his movements to be 
followed in astonishing detail. From August 1733 to August 1734 alone, he made no less 
than forty-five trips to Versailles, six to the royal palace at Marly, and had spent fifty-five 
days renting a room in Fontainebleau. Beyond his meetings with Chicoyneau, these visits 
were dotted with numerous other items, including expensive dinners he hosted for 
“persons whom he had to ingratiate with for the success of their plans,”63 the tobacco and 
other “gifts” he provided to various administrators in the Bureau de guerre, gratuities for 
a potential investor, the costs of securing a copy of Guiller’s earlier brevet from the 
dispatch registry of the Secretary of State for the Royal Household, and payments to the 
écrivains who produced the neatly-written petitions (placets and mémoires) to supply the 
poudre to the army. In total, Guerin records having spent over 631 livres on these items 
alone.64 
 Here it should be acknowledged that Guerin’s ledgers were deposited as evidence 
in his favour during his lawsuit against Lajutais, and he may have exaggerated his 
expenses in order to secure more money from his former business partner. They 
nonetheless provide an index of the precariousness of soliciting privileges and contracts 
                                                 
 63 “…personnes qu’il faloit affectioner pour la reussite des vües du rendant [Guerin] et de son 
associé [Lajutais],” AN V7 246 (6), Compte de recette et dépense que rend le S. Guerin au S. de Lajutais 
son associé a compter depuis le 5 aoust 1733 jusqu’à cejourdhuy, 11r°. Guerin priced his return trips to 
Versailles at 6 livres 10 sols per trip. 




at court. Guerin constantly needed to remain at court to counter the malicious rumours of 
the project’s adversaries. He also had to ensure that the commis were forwarding his 
mémoires and placets on for consideration by the proper officials. Later, he had to wait 
for days to be personally summoned by Dangervilliers, Secretary of War, and remain on-
hand to receive the order for a shipment of the poudre that would come down from the 
Bureau de guerre.65 
 In spite of these challenges, Guerin’s reports back to Lajutais show that matters 
seemed well in hand by the fall of 1733. On September 11, Guerin informed Lajutais that 
he had just spent two hours with Chicoyneau in the latter’s office and that the secret 
remedies commission was going to discuss their proposal the following Tuesday. Further, 
he had prepared a mémoire for Cardinal Fleury—then de facto prime minister of 
France—on the potential utility of the poudre fébriuge in the army, which Chicoyneau 
had read over before hand and approved. At this stage, the first physician emerges as a 
full collaborator in Guerin and Lajutais’ enterprise: in his letters Guerin even mentions 
having dinner with him, and being acquainted with his wife. Chicoyneau also drew 
benefits from his clients: in one letter Guerin asks Lajutais to select six pounds of the 
very best Spanish tobacco from the Arles manufactory, to be sent as a gift for the first 
physician. Gift-giving also extended to important government bureaucrats: Guerin also 
asks for an additional pound or two of tobacco for his friend Chaila, a commis in the 
                                                 
 65 For example: “Fait dépense de la somme de quarante cinq livres pour quarante cinq jours le 
loyer de chambre à Fontainebleau afin d’estre à portée de recevoir les ordres du ministre, entretenir la 
bonne idée qu’il avoit donné de la poudre et combattre les opinions des personnes qui tachoient de la 
decrier ainsy qu’il peut se justifier,” AN V7 246 (6), “Compte de recette et dépense que rend le S. Guerin au 




Bureau de guerre.66 Lajutais’ privileged position in Arles made gifts of tobacco, which 
was heavily taxed in this period, the ideal grease for the wheels of power in Versailles. 
 A few days later, on September 19, after yet another delay—Chicoyneau had been 
detained in Versailles to treat the Spanish ambassador—Guerin reported that the poudre 
fébrifuge had at last been brought before the commission, where it was met with vigorous 
opposition: 
Yesterday, my dear sir, I obliged Monsieur the king’s first physician to come 
to Paris concerning our business. You could hardly imagine how much all the 
physicians, surgeons, and apothecaries opposed it, once he presented it to the 
assembly. Some claimed that as the royal privilege had expired, you could not 
be accorded another; others said that the King had bought the secret from 
Monsieur de Guiller. In the end they were all opposed and only Monsieur the 
first physician stands fast for us. I am here [in Versailles] on his heels to 
obtain what we seek, and I am vehemently rebutting all of these devils of 
physicians, surgeons, and apothecaries, and am proving to the court that what 
they advance is false and inappropriate. They claim they know how to 
prepare the poudre fébrifuge; I have challenged them in the presence of the 
royal first physician. I will not leave the court until this affair is settled, one 
way or another.67 
 
Chicoyneau stood by their project, and his personal support was sufficient for them to 
move ahead. Despite the opposition of “powerful adversaries” on the commission, Guerin 
reported that they had begun trials of the drug on October 11, 1733. As in the case of 
Guiller in 1713, the trials were performed on an indefinite number of hospital patients 
and were directly supervised by the first physician, in this case at the Charité hospital in 
                                                 
 66 AN V7 246, (6), dossier 2, piece B, Guerin to Lajutais (11 September 1733). 
 67 “J’ai obligé hier, mon cher Monsieur, Mr le premier medecin du Roi de se rendre à Paris au 
sujet de nostre affaire. Vous ne scauries encore, lors qu’il la préposa a l’assemblée, combien tous les 
medecins chirurgiens apothicaires se sont opposés, les uns dit [sic] qu’attendu que le privilege du Roi etant 
expiré, il n’y avoit pas lieu de vous en accorder un autre; les autres disent que le Roi a payé ce secret a Mr 
de Guiller. Enfin ils s’y sont tout opposés et il y a que Mr le premier medecin qui tient encore bon pour 
nous. Je suis icy a ses trousses pour obtenir ce que nous desiront et je repond vivement a tous ces Diables 
de medecins chirurgiens et apoticaires et je prouve à la cour qu’ils avencent faux et mal apropos, [ils] disent 
qu’ils scavent la manière de preparer la poudre de febrifuge; je leur en ai faict defi en presence de Mr le 
premier medecin du Roi je ne quitte point la cour que je n’aye fini d’une manière ou d’autre cette affaire,” 




Avon, near Fontainebleau.68 If the trials were successful, he was convinced that 
Chicoyneau’s favourable report to the king would secure them the privilege—although he 
also asked Lajutais to immediately mail him the not inconsiderable sum of five or six 
louis d’or, as he was running out of money and would need to make “certain 
indispensable liberalities” toward those who had helped him so far, namely Chaila, 
administrator at the Bureau de Guerre. Tellingly, he also added, “La guerre est tout de 
bon à present,” implying once again that these developments were closely tied to the 
mobilisation then occurring.69 
 Chicoyneau’s personal attestations to the drug’s effectiveness overcame the 
resistance of their “powerful adversaries” in the commission. The royal brevet—which 
was granted in Lajutais’ name alone—was signed by Louis XV at a meeting of the 
Council of State on November 17, 1733.70 Guerin and Lajutais had finally secured the 
privilege, but soon learned they had lost their bid for the military contract. The lack of 
surviving correspondence after this point prevents us from knowing exactly what 
happened, but it seems that they first aimed to supply their drugs to the Army of Italy 
through a third party named Jean Giraud, the contractor (entrepreneur) charged with 
running the campaign hospitals.71 Giraud’s bid lost, and the hospital contract went 
instead to one d’Articulle (or Darthicule), based in Turin, who planned to supply his own 
medications.72 Guerin and Lajutais requested that the king order the entrepreneur to use 
their medications, which, they claimed, could more surely cure a fever in three doses than 
                                                 
 68 No records survive in AD Seine-et-Marne, series H. 
 69 AN V7 246, (6), dossier 1, piece 18, Guerin to Lajutais (October 11, 1733). 
 70 AN O1 77, fol. 287-289. 
71 AN V7 246, (6), dossier 3, item 13, Draft proposal to Cardinal Fleury (s.d.). 




cinchona could in fifty.73 They then made their own attempt to underbid d’Articulle, 
proposing to undertake the whole hospital contract themselves.74 This attempt was 
rebuffed by the War Secretary, but this would prove to be but a temporary setback. 
Although they had lost the chance to supply the poudre fébrifuge to the army of Italy, 
Guerin would spend most of 1734 on a second round of contract bidding, chasing the 
court from chateau to chateau and bribing administrators in order to supply the drug to 
the military hospitals of Alsace. He was ultimately successful, and he and Lajutais were 
amply rewarded for all their efforts in 1735, as we shall see below. 
 The dramatic progress Guerin made with both Chicoyneau and the Bureau de 
guerre was no doubt tied to the immediate military needs to which the poudre fébrifuge 
responded during the mobilization for the War of the Polish Succession. But a crucial 
question remains: how had Guerin overcome Lajtutais’ previous reluctance to send him 
the recipe for the drug? The surviving letters are mute on this question, but the answer, at 
least as Guerin would later claim, is that he in fact had not: Guerin simply invented a new 
preparation of his own, and submitted it to the commission and to Chicoyneau for 
bedside trials. As Guerin tells it, Lajutais’ name was the one on the brevet because of his 
link to Guiller, but his secrecy concerning the preparation had forced Guerin to devise a 
preparation of his own. This begs the question: was this poudre fébrifuge still the same 
drug as the one that Guiller had devised in 1713? How was it prepared? And more 
fundamentally, was Guerin in fact correct in his identification of tithymalus amigdaloides 
                                                 
73 Ibid., item 16, Mémoire (s.d.). 
74 Ibid., item 14, untitled draft proposal beginning “Il y a actuellement a la cour plusieurs 




as Guiller’s elusive plante fébrifuge? It is to these questions that I will turn in the 
following section. 
3. Re-discovering the plante fébrifuge and the secret of its preparation 
 A little over thirty years after Guerin and Lajutais’ efforts, Gabriel François Venel 
(1735-1775), professor of materia medica at Montpellier, described tithymal-based 
remedies in his 1765 article on “Titimale ou Tithymale” in the Encyclopédie: 
Pharmacologists have made a great many species of tithymal in the list of 
remedies. All of these species possess the same medicinal properties. 
Principally their seeds and roots have been employed for internal uses. 
The seeds, which are swallowed whole, and the roots, which are dried and 
made into a powder, are very violent purgatives, which physicians hardly 
prescribe anymore […] The powder of tithymal root is nothing but a 
charlatan’s remedy, and the seeds are a remedy used by peasants, and they 
succeed only among the most vigorous [of patients].75 
 
As far as Venel was concerned, all species of tithymal had the same basic properties, 
most importantly a caustic milky latex (suc laiteux). Pharmacologically speaking they 
were nothing but violent purgatives, as is implied by “spurge,” the modern English name 
of the genus. His condemnation of the medicinal use of plants in the tithymal family 
bears a more-than-passing resemblance to that of Boizard regarding Guiller’s poudre 
fébrifuge fifty years earlier: a violent purgative, appropriate only for the strongest of 
patients, and associated to charlatans. Venel makes no mention its possible use as a 
febrifuge in his article. 
                                                 
 75 “Les pharmacologistes ont fait encore beaucoup d’especes de titimales dans la liste des remedes; 
toutes ces especes possedent les mêmes propriétés médicinales. On a principalement employé leurs 
semences et leur racine pour l'usage intérieur. Les semences avalées entieres et les racines séchées et mises 
en poudre sont des purgatifs très-violens que les médecins n’ordonnent presque plus […]. La poudre de 
racine de titimale n’est plus qu’un remede de charlatan, et les semences un remede de paysan, qui ne réussit 




 Understandings of tithymal were very different earlier in the century. Even thirty 
years earlier, the supposed interchangeability of all species of tithymal was not yet an 
accepted fact, and the applicability of at least one species to cure fevers is acknowledged 
in the materia medica treatises of two prominent Academicians and professors at the 
Jardin du Roi, namely Joseph Pitton de Tournefort (1656-1708), professor of botany, and 
the apothecary Étienne-François Geoffroy (1672-1731), professor of chymistry. Indeed, 
the initial crux of the problem of the poudre fébrifuge for Guerin and Lajutais was that 
there were so many different species of tithymal and they were not sure they had the right 
one. When Guerin informed him of the name of the plant, tithymalus amigdaloïdes and 
mailed him a sample of it, Lajutais heartily thanked him and added “I had always 
believed that it was tithymal, but I could never figure out what species it was, as there are 
many varieties.”76 Indeed, Tournefort had enumerated sixty-three species of tithymal in 
his 1700 Institutiones rei herbariae.77 But already in October of 1732, it seems that 
Lajutais began to worry that they had the wrong one: he prepared tithymalus 
amigdaloïdes following Guiller’s recipe but found it to be different from the powder 
Guerin had succeeded in producing in Paris in both its color (he does not specify which 
colour it is or should be) and its effect (he reported that when he chewed on it his throat 
became inflamed). He became worried that Guerin was providing Chicoyneau with a 
powder different from that of Guiller’s and that by telling Chicoyneau that it was the 
same, Guerin might leave the first physician with the impression that he was a cheat (un 
                                                 
76 “J’avois toujours bien crû que c’étoit un titimale, mais je n’avois jamais pu sçavoir de quelle 
espece il etoit, car il y a de plusieurs sortes,” Lajutais to Guerin (August 11, 1732), quoted in AN V7 246, 
(6), dossier 1, item 28, Mémoire pour le sieur Guerin, 2. 
 77 Joseph Pitton de Tournefort, Institutiones rei herbariæ, ed. Antoine de Jussieu, 3rd ed. (Paris: 




fourbe).78 For his part Guerin pointed out that Fagon’s original attestation had suggested 
the plant needed to be harvested at a specific time of the year (summer): perhaps Lajutais 
had harvested it in the wrong season, or Guerin had the wrong preparation.79 Worse still, 
it was possible that Guerin had incorrectly identified the plant. In any case, the question 
was moot because as we have seen Lajutais was completely unwilling to send Guerin the 
recipe from Guiller’s book of secrets. 
 We have already seen that in spite of his partner’s distrust, Guerin continued to 
pursue their common enterprise, finally securing the royal privilege in Lajutais’ name on 
November 17, 1733. When they came to blows before the commissioners of the Conseil 
privé a few years later, however, Guerin revealed that Lajutais refused to send him the 
secret of the preparation (clearly demonstrated by the letters he had deposited as 
evidence), which had forced him to devise one of his own. Guerin argued that he was the 
one who had “rediscovered” the identity of the plante fébrifuge and had invented the 
preparation that secured the privilege, and so Lajutais’ brevet should be revoked, and the 
monopoly over the poudre fébrifuge granted to him. 
 Lajutais for his part maintained that Guerin was not the true “restaurateur du 
secret” because he had not identified the correct plant: it was tithymalus linifolium, not 
tithymalus amigdaloïdes!80 Likewise, he persistently denied ever being ignorant of this 
secret. In his account of events, he knew exactly which species was the plante fébrifuge 
from the beginning, and its preparation was transmitted to him personally by the 
Chevalier de Guiller. All of the evidence in his correspondence with Guerin that might 
                                                 
78 Lajutais to Guerin, October 17, 1732, quoted in AN V7 246, (6), dossier 1, item 28, Mémoire 
pour le sieur Guerin, 2. 
 79 AN V7 246, (6), dossier 1, piece 8, Guerin to Lajutais (November 3, 1732). 




suggest otherwise was simply part of a clever ruse on his part to mislead his subordinate 
and prevent him from stealing a secret that was rightfully his. He was merely curious to 
see if anyone in Paris knew the secret of the poudre fébrifuge: Guerin’s mission to 
recover the secret on his behalf was nothing more than a fool’s errand devised by Lajutais 
to keep his subordinate in the dark. 
 In his Mémoire Guerin concedes some of these points, but with important 
qualifiers. He argues that although they ended up using tithymalus linifolium, his 
conclusion that the operative plant was a species of tithymal was nonetheless crucial at 
the beginning of their investigation. Furthermore, the tithymalus amigdaloïdes he had 
first identified was just as effective as tithymalus linifolium for making the poudre 
fébrifuge: the latter’s great virtue was simply that it was easier to find when foraging. 
And finally, he was also the one who discovered tithymalus linifolium anyway, and had a 
certificate to prove it (more on this later).81 
 Here it should be underlined that all of these claims were made in the course of a 
heated legal battle over whether or not Guerin and Lajutais were legal associés with equal 
rights to the not inconsiderable profits that were coming out of the sale of the drug. 
Leaving behind this maze of lies and recriminations for the moment, it is useful to draw 
recourse to the herbals and botanical works of Tournefort and Geoffroy, which, when 
placed alongside the evidence from Guerin and Lajutais, provide instructive hints about 
the true identity of the plant, its probable method of preparation as a febrifuge, and even 
the locations where it was being harvested. 
                                                 




 The only species of tithymal for which Tournefort provides a medical preparation 
in his Histoire des plantes qui naissent aux environs de Paris (1698) is what he calls 
tithymalus cyparissias, which he describes as growing outside of Paris in the Bois de 
Boulogne. 
The tithymal of which we speak is a good hydrogogue; it is proper to correct 
it through maceration in vinegar, or in a solution of cream of tartar: for as 
soon as this root is swallowed, it leaves a considerable bitterness and the 
impression of fire, which is felt not only in the throat, but all the way down 
the esophagus, and sometimes even in the stomach. This purgative is proper 
for hydropics, cachectics, and for those who have intermittent fevers: it can 
be used in all diseases where there is need to remove nasty leavens which 
resist ordinary purgatives.82 
 
Tournefort’s account of tithymalus cyparissias is taken up by Geoffroy in his entry on 
esula major (which he identifies with Tournefort’s tithymalus cyparissias), in his Traité 
de la matière médicale, where a few other details are added.83 Geoffroy closely follows 
Tournefort on its violence as a purgative and likewise admits its use as a febrifuge for 
intermittent fevers. He also adds several other details concerning how to soften or temper 
its purgative effects through maceration and how to prepare it as a powder. He explains 
that “the method by which the bark of the Esula root it corrected in our boutiques” is to 
macerate the plant’s fresh bark or rind (écorce) in either vinegar, verjus, quince, lemon, 
or barberry (an evergreen shrub berry) for twenty-four hours, after which it is to be dried 
and given as a powder. He observes that it evacuates serosity (water buildups in tissues 
                                                 
 82 “Le Tithymal dont nous parlons est un bon hydragogue, on a raison de le corriger par la 
maceration dans le vinaigre, ou dans la solution de crème de tartre : car pour peu que l’on avalle de cette 
racine, elle laisse une acreté considerable et une impression de feu, qui se fait sentir non-seulement dans la 
gorge, mais tout le long de l’œsophage, et quelquefois mesme dans la ventricule […] Ce purgatif est propre 
pour les hydropiques, pour les caketiques, et pour ceux qui ont la fièvre intermittente : on peu s’en servir 
dans toutes les maladies où il faut emporter les méchans levains qui resistent aux purgatifs ordinaires,” 
Joseph Pitton de Tournefort, Histoire des plantes qui naissent aux environs de Paris avec leur usage dans 
la medecine (Paris: De l’Imprimerie royale, 1698), 153. Emphasis added. 
 83 Etienne-François Geoffroy, Traité de la matiere medicale: ou, De l’histoire des vertus, du choix 




beneath the skin), and can thus be useful against dropsy. Like Tournefort, Geoffroy also 
cites its potential utility against quartans and other intermittent fevers, but only when 
“more temperate” remedies have failed. He adds that it should never be given alone in 
such cases, but rather with other remedies to help moderate its effect. Anticipating 
Venel’s later remarks, he also adds that the seeds of tithymal are good purgatives for 
peasants, who have strong viscera.84 
 It is difficult to say whether or not Guerin or Lajutais consulted Tournefort: it may 
have figured among the seven “books or tomes on medicine” which Lajutais lent to 
Guerin and wanted returned after their relationship soured. These are in fact the only 
books mentioned in their ledgers.85 The remarks of Guerin in various places make it clear 
that the rind of the tithymal was their main interest, but the lists of equipment and 
supplies that appear in his and Lajutais’ ledgers leave it unclear whether or not they were 
macerating the rind in verjus or some other liquid.86  
                                                 
 84 Ibid. 
85 V7 246 (6) Cotte 3e 1739, “Journal en forme de compte,” p. 7. 
 86 The tools and materials on Lajutais expense ledger are: “deux cents livres pour achapt de sucre, 
pots de fayence, fourneau, ustancilles de verre et autres drogues pour l’arcanne (the name of a second drug 
which they sought to sell to the army); trente cinq livres pour achapt de papier, ficelle, boistes, grandes et 
petites pour envelopper et paqueter la poudre febrifuge a la maison du Sr Blanc; soixante livres pour six 
milliers d'imprimes contenant les vertus et usage de la poudre febrifuge; trente une livres pour avoir fait 
placer l’enseigne à costé de la boutique du Sr Blanc (18 livres of which went to the sign’s painter); douze 
livres pour la façon de deux timbres de bois servant a faire la marque au haut des imprimes; seize livres 
pour avoir achepté une livre de laine a broder; soixante livres pour une garniture de feu consistant en deux 
landiers, une pelle, et pinsettes le tout d'argent aché (?); douze livres pour un serrure, soixante et dix livres 
pour l'achapt de bois de charbon pour l'usage de la chambre chez le Sr Blanc; vingt-cinq livres pour achapt 
de chandelles pendant le cours de l'année chez le Sr Blanc,” AN V7 246 (6), cotte 3e, “Journal en forme de 
compte que rend le Sr Lajutais au Sr Guerin cy devant son agent, ainsi ordonné par jugement de Mgrs les 
Commissaires généraux du Conseil,” 3-5. 
 The “emballages, drogues, et ustancilles” Guerin purchased for their enterprise are: cloth, rope for 
shipping; “un arrosoire de fer blanc” (watering can?); a supply of over twenty-two pounds of cinchona for a 
project that was never realized; half a ream of paper; “deux grandes machines de bois doubles de fer blanc 
et quatre roulettes de cuivre”; a copper basin “devenue inutile à la Société,” AN V7 246 (6), dossier 2, 




The ledgers also do not include labour costs, as these were likely paid by Lajutais 
and thus did not figure into Guerin’s claims. A few hints do survive in the 
correspondence as to where and how the roots were collected and processed. We know 
that Guerin and Lajutais had foraged for tithymal in the Bois de Boulogne, where 
Tournefort had encountered various species of tithymal in his herborisations decades 
earlier.87 At one point in his brief against Lajutais, in order to illustrate how badly 
indebted his partner was, Guerin points out that Lajutais did not even have the thirty 
livres necessary to pay their foragers or root gatherers (chercheurs de racines).88 
 The most information on the questions of where and by whom the plant was 
actually gathered can be found in Lajutais’ oral deposition (interrogatoire), beginning 
June 8, 1738. Even more importantly, the questions furnished by Guerin that formed the 
basis of the interrogation, suggests that they finally recovered the true secret of Guiller’s 
poudre fébrifuge only after they began producing it for the army. The commission’s 
reporter, Le Roux, began by asking Lajutais if it is true that he employed a number of 
workers in 1735 to collect the roots necessary to produce their remedy. Lajutais 
confirmed that this is true, and was careful to note that they were paid from his accounts, 
not those of Guerin. Lajutais obviously assumed that the question was targeted at his 
finances and the sharing of costs and expenses, but Le Roux unexpectedly followed up 
                                                 
 87 See the following amusing annecdote from one of the questions Guerin furnished to Le Roux to 
be read to Lajutais during his interrogatoire (on which see below): “Sieurs Guerin et la Jutais eurent 
conjointement fait leurs soumissions pour fournir la poudre febrifuge aux hopitaux d’Italie ils n’en auroient 
qu’une foible quantité et qu’ils se transportent l’un et l’autre au bois de Boulogne pour chercher la plante 
propre a composer la nouvelle poudre et que dans le choix que le Sieur de la Jutais fit d’abord il tomba dans 
une telle erreur qu’en ostant l’ecorse de la plante qu’il avoit mal choisie il en fait incommodé au visage et 
aux autres endroits de son corps qu’il en avoit frotté,” Interrogatoire 7v°. Lajutais for his part admits to 
going with Guerin to the Bois de Boulogne, but as usual, he categorically denies having made any errors on 
the identity of the plant, and in fact observes that he did not find the plante fébrifuge there at all. 




with a different question about one of the women he had employed to collect the roots, 
the wife of one Pelletier of Champigny:  
Is it true that in August of 1735 the aforementioned wife of Pelletier of 
Champigny told Sieur Guerin that she would bring him a species of root 
which a chevalier wearing a blond wig had ordered be collected in 
Champigny and which he used to make powders, with this difference: that he 
only used this species?89 
 
Lajutais replied that he does not remember, but Le Roux pressed him on the question, 
asking if he recalled having questioned this woman with Guerin, after the latter brought 
her to his attention. Again Lajutais said he had no such recollection, so Le Roux asked 
again, providing further details from Guerin: 
Is it true that the woman Pelletier told Sieur Guerin and Sieur Lajutais that 
twenty-two or twenty-three years earlier, a Monsieur whose name she could 
no longer remember had come to live in Champigny, and that he had built a 
furnace in his home, and that he employed little children to peel the rind from 
roots similar to those which she had just brought, and that at that time Guerin 
told Lajutais that this was the species of tithymal that they needed? 90 
 
It should of course be remembered that Guerin is the author of this question. 
Unsurprisingly, Lajutais denies any memory of the events described, but he does not call 
it a lie or a slander (injure), as he does with most of Guerin’s other accusations. Although 
it is never made explicit, the implication seems to be that the man with the blonde wig 
and the house with the furnace was the Chevallier de Guiller himself, and that this 
unnamed woman, described only as the “sister of one Belleville and the wife of one 
                                                 
 89 “Interrogé d’office s’il n’est pas vray qu’au mois d’aoust mil sept cent trente-cinq la nommée 
Pelletier de Champigny dit au sieur Guerin qu’elle luy apportoit une espece de racine qu’un chevalier 
portant perruque blonde faisoit ramasser a Champigny et s’en servoit à faire des poudres avec cette 
difference : qu’il ne se servoit que de cette espece,”AN V7 246, (6), cotte 2e, 1738 Interrogatoire, fol. 14v°-
15r°. 
 90 “Interrogé d’office s’il n’est pas vray que la Pelletier dit au Sr Guerin et a luy Sr de la Jutais 
qu’il y avoit vingt-deux ou vingt-trois ans qu’un Monsieur dont elle ne se ressouvenoit pas du nom estoit 
venu demeurer a Champigny, qu’il avoit fait batir un four dans cette maison, qu’il occupoit de petits 
enfants a oster l’ecorce des racines semblablement a celles qu’elle venoit d’aporter et qu’alors le Sr Guerin 




Pelletier of Champigny,” happened to be one of the children that Guiller had employed 
more than two decades earlier to peel the bark from the plants necessary to make his 
powder.91 
Thus, in Guerin’s version of events, even as late as August 1735, he and Lajutais 
still had not succeeded in replicating Guiller’s powder, and Guerin finally discovered the 
true secret by chance from one of their root gatherers. There can be no way of knowing 
with certainty, but this telling of events seems more plausible: if Guerin were simply 
interested in making himself the true discoverer of the secret, why would he admit that he 
still had not yet identified the plant in 1735? Further, why would he credit its discovery to 
a chance encounter with a root gatherer, rather than to his own ingenuity? If indeed this 
was how the secret was recovered, then the story has an important irony: the key to 
unlocking the secret of the plante fébrifuge did not come from printed herbals (which are 
curiously nowhere mentioned throughout the surviving evidence) or Guerin’s inquiries 
with the learned botanists of the Jardin du Roi, but rather from the childhood memories of 
an herb woman. 
4. The legacy of the poudre fébrifuge, 1735-1808 
 In 1735, after years of work, Lajutais and Guerin finally began to reap their 
rewards from the royal coffers. The scale of their operation is made clear by an extrait 
from the registers of the Extraordinaire des guerres, the financial body which managed 
war-related expenditures. Its treasurer, de Launay, provided the commission with a 
                                                 
 91 On the prominent role of herb women in disclosing secrets and an insightful discussion of their 
similarities with colonial informants, see Londa Schiebinger, Plants and Empire: Colonial Bioprospecting 




statement of how much of the poudre fébrifuge the army had bought in 1735 as part of 
their audit of Guerin and Lajutais accounts.  
 Restricting ourselves to their confirmed sales, from February to November 1735, 
the Extrordinaire des guerres paid out 10,025 livres to Guerin and Lajutais for 28,050 
prises of their poudre (see Appendix 3, Figure 15).92 This figure for their military 
contract dwarfs the total retail figures for the drug’s sales, both by Lajutais personally 
and by their Parisian agent, which amount to less than 4,000 prises for an overlapping but 
longer period. As we shall see in chapter 6, the only sales volumes that compare to the 
military contract are those to other bulk purchasers, namely the navy and the East Indies 
Company. Add to this the fact that Guerin and Lajutais sold to the military at a 
discounted rate, roughly 7 sols per prise, as compared to 10 sols on retail. In spite of the 
fact that Guerin and Lajutais made considerably more per dose at retail prices, the vast 
majority of both their production and revenues were coming from their military 
contract.93 
                                                 
 92 AN V7 246 (6), dossier 2, “Extrait du registre journal de Recette et Depense tenu par M. de 
Launay tresorier general de l’Extraordinaire des guerres pour l’armée xvii et trente cinq” (February 7 to 
November 4, 1735).  
 In February 1735, they sent 7,050 prises to Alsace (at a cost of 3,525 livres); another 3,000 prises 
were sent the following month to Metz (at a cost of 1,500 livres); 2,000 prises to Strasbourg in June (at a 
cost of 1,000 livres); 8,000 more prises to Metz (at a cost of 1,000 livres); and finally 8,000 prises for Metz 
and Strasbourg in November (at a cost of 3,000 livres). As there are 20 sols in a livre, this averages to a 
price of 7 sols per prise (or 0.35 livres), although it should be noted that the rate they were paid by prise 
fluctuated in this period. For details on the army sale as well as Guerin and Lajutais other clients, see also 
Appendix 3, Figure 15 and ch. 6, sect. 3. 
 93 AN V7 246 (6), “Etat des poudres febrifuges que j’ay reçu de Messieurs De la Jutaye et Guerin 
et de ce que je leurs ay payé” (enclosed in Le Blanc poudre fébrifgue register). It should also be mentioned 
that Le Blanc took a 5% consignment on sales, so in total Guerin and Lajutais made 1,376 livres through 
him, 381 livres of which were deducted to pay off an initial advance (assumedly as a deposit in exchange 
for the supply of the poudre or to secure their business), leaving 949 livres. 
Some cautions on these figures: although these revenue figures are likely accurate as they are 
based on verified receipts from the drug’s purchasers, there are no similarly complete expense ledgers 
covering labour, equipment, supplies, rent, transportation, and storage. It is therefore impossible to know 
what proportion of these revenues were profit. It should also be remembered that those expense ledgers that 





 These sums seem to have been too large for Guerin and Lajutais to continue an 
honest collaboration, and soon their mutual distrust produced a sequence of legal actions 
that ultimately led to the formation of a special commission of the Conseil privé, the 
highest court of appeal in France, to settle their affairs. By 1736, Lajutais was arguing 
that Guerin had not followed through on a notarized agreement they had made to recover 
Guiller’s pension and had since ceased providing him with accounts of his share of the 
sales of the poudre fébrifuge, which, he claimed, exceeded 12,000 livres.94 Guerin for his 
part learned that Lajutais had retaliated by removing large quantities of the drug from 
their common stockpile in Vincennes, so he proceeded to the Prévôté de l’Hôtel, the legal 
jurisdiction covering the royal household and all royally privileged merchants, and 
secured a summons and court seizure of all “poudres et ustancilles” still in Lajutais’ 
hands. Lajutais responded in kind by proceeding to another tribunal, the Châtelet, where 
he argued that Guerin was merely his agent, not a full partner or associé, and that the 
dispute did not concern his privilege per se. Lajutais thus secured an évocation (transfer) 
of the case to the jurisdiction of the Châtelet Parc civil. Continuing the jurisdictional tug 
of war, Guerin then upped the ante by going all the way to the Grand conseil, where he 
made a requeste arguing that Lajutais’ brevet should be cancelled because he himself was 
the one who recovered the secret and the privilege for the poudre fébrifuge. A règlement 
des juges at the Chancellerie was then required to determine a definitive jurisdiction for 
their lawsuit.  
                                                                                                                                                 
contain exaggerations designed to secure a bigger piece of the pie in the ultimate settlement (see most 
notably the 1,513 livre “bribe ledger” in Guerin’s expense claims, entitled “Differents debourses secretes 
que le rendant a fair dans la veüe de se faire des amis et des protecteurs pour le bien de la Societe”). Indeed, 
if we take Guerin’s expense claims seriously, the total revenues would only just cover the cost of his 
various movements on behalf of the society from 1732-1734. 




 This eventually led to the August 4, 1736 Arrêt du Conseil d’État creating a 
commission extraordinaire.95 The principal question to be settled, according to the arrêts, 
was whether or not there was in fact a société between Lajutais and Guerin (that is, 
whether they had formed a legal company or firm). The commissioners collected a large 
volume of evidence from both parties, which provides the basis for much of this chapter. 
Their jugement, rendered on June 3, 1737, ruled a compromise primarily in favour of 
Lajutais. No official notarized contract establishing a société between the two men could 
be found, in spite of the fact that Guerin produced several documents where he and 
Lajutais were referred to as associés. Lajutais was also confirmed as the rightful holder of 
the brevet which, although it was secured almost entirely through Guerin’s efforts, was 
still in Lajutais’ name. The concession to Guerin was that both men needed to furnish 
their accounts to the commission so that their profits up to the beginning of their 
contestations could be split equally. After which time, Guerin was prohibited from 
troubling Lajutais in his exercise of the privilege, and ordered to neither counterfeit, sell, 
or otherwise distribute the poudre fébrifuge, under the penalties indicated in the brevet, 
namely, a hefty 1,000 livre fine.  
 In spite of this ruling, the case continued to drag along, first by Guerin’s request 
that the basis of the brevet be re-examined, and then by the conflict between their 
respective expense claims. The commission was periodically reconvened all the way up 
to 1743, when the issue of their accounts were settled. The following year a new dispute 
began when Lajutais ordered a new seizure of Guerin’s “poudres, racines, et tablettes”: it 
                                                 
 95 The memers of the commission were: the Sieurs de Lieu and Le Roux, councillors at the Grand 
conseil, and the sieur Montclas, councilor in the Chambre des comptes, Cour des aydes et finances de 




seems that Guerin had devised a drug of his own, which he called the tablette fébrifuge, 
for which he too had secured a military contract via Chicoyneau following trials at the 
Invalides. Lajutais quite naturally argued that these tablettes fébrifuges were clear 
counterfeits of his own poudre fébrifuge, and brought a new suit against Guerin as a 
counterfeiter.96 I have found no final judgement for the case, although it is clear that 
Guerin continued to produce his tablette fébrifuge into the 1750s.97 Despite having been 
edged out by Lajutais, we see here that Guerin was able to draw some benefits from all of 
his travails at the royal court and his close relationship with Chicoyneau. 
 Pierre Brodin de Lajutais appears to have continued exploiting his privilege for 
the remainder of his days. Before his death, he turned his attention to agronomy, 
publishing a book in 1752 on the use of saltpeter as fertilizer, calling it the “true 
philosophers’ stone.”98 He renewed his privilege one last time with Chicoyneau’s 
successor, the first physician Jean-Baptiste Sénac (1693-1770), but after his death it was 
no longer sold and fell into disuse.99 This prompted the inquiry by the anonymous 
Avignon physician and the subsequent response from the Marquis de Chambray in the 
1768 Mercure de France, which opened this chapter. A few years later, in May 1772, 
another reader of the Mercure, who signed only as R.L.V., published a follow-up to the 
                                                 
 96 Etienne Guerin and Rouseel (avocat), A nosseigneurs les commissaires du conseil, Députez pour 
juger en dernier ressort les Contestation qui se sont ci-devant élevées entre les sieurs Guerin et la Jutais 
[…] signifié 20 mars 1744 (Paris: veuve Merge, 1744). 
 97 François Chicoyneau, Lettre de Monsieur le premier medecin du Roy, au sujet des Tablettes 
fébrifuges du sieur Guerin (Paris: s.n. 1743); and Manière de se servir des tablettes fébrifuges [du sieur 
Guérin], distribuées par ordre du Roi dans les hôpitaux (Paris : Imprimerie royal, 1757). 
 98 Pierre Brodin de La Jutais, L’abondance ou véritable pierre philosophale, qui consiste 
seulement à la multiplication de toutes sortes de grains, de fruits, de fleurs et généralement de tous les 
végetatifs (Paris: Delaguette, 1752). 
 99 AN V7 246 (6). Lajutais was 92 years old at his death; this and other details are from the preface 
to the 1805 edition of Lajutais’ principal published work, a treatise on agronomy, republished in 
Philadelphia by his son-in-law: see Pierre Brodin de la Jutais, L’abondance, ou, La véritable pierre 
philosophale consistant en un moyen de multiplier abondamment les grains, les fruits, les fleurs, et tous les 




1768 article: he had personally gone to the original address of Lajutais, indicated on the 
pamphlets to the poudre fébrifuge, and found his widow and two daughters. He reported 
that they still possessed the secret.100 
 Alerted to the continued commercial potential of their inheritance, the Lajutais 
sisters, Marie-Victoire and Marie-Thérèse, appealed to the recently re-established 
Commission des remèdes secrets in order to request a renewed brevet for the poudre 
fébrifuge.101 Their request was denied by the commissioners, for reasons we shall see in a 
moment, but the Lajutais sisters did not stop there. Much of the correspondence on their 
behalf is written by one M. De Moulinot, the husband of the elder daughter, Marie-
Victoire. De Moulinot was a former infantry captain and First Lieutenant of the King’s 
Wolf-Catchery (louvetrie), an office of the royal household which seems to have afforded 
his family important connections.102 Together with De Moulinot, the Lajutais sisters 
sought assistance from a higher power, namely Louis Phélypeaux, Duc de La Vrillière, 
the Secretary of State for the King’s Household, the official who, as we have seen, was 
ultimately responsible for dispatching brevets. 
 In their extensive mémoire, which was later forwarded to the Commission, the 
Lajutais sisters pleaded with La Vrillière concerning their difficulties. They implied that 
the commission was exceeding its powers and defying the wishes of the king by “seeking 
to suppress a remedy precious to the State and to Humanity, and whose goodness, 
efficacy, and utility have been observed by sixty years of continued success” and 
                                                 
 100 Mercure de France (May 1772), 201-202. 
 101 See above, ch. 3, sect. 5 for the role of women in the orviétan privilege and comparisons to 
cases in Bologna, Venice, and London. 




repeatedly approved by royal physicians from Fagon to Sénac.103 They documented these 
claims with a series of pièces justificatives, preserved in their family papers or 
painstakingly transcribed from the government archives, literally chronicling the entire 
history of the poudre. By the 1770s, the legacy of the poudre from generation to 
generation had itself become the most effective argument in its favor. The Lajutais sisters 
included their father’s privileges from 1733, 1743, and 1753, the recommendations of 
Fagon and Boudin from 1713, as well as other attestations documenting the more recent 
history of the poudre’s use by the French army and the East India Company—these 
include an attestation by Chicoyneau to its utility in the campaigns of 1735 and 1736. 
Chicoyneau cites numerous surgeons’ attestations of its efficacy in the field, and a 1737 
letter from the Conseil supérieure de Sénégal underlining its utility against fevers in West 
Africa.104 
 La Vrillière was persuaded by their arguments. He sent repeated letters to the 
commission and to specific members, inquiring as to their motives in refusing such an 
evidently successful drug. He also had the royal first surgeon, Germain Pichault de La 
Martinière (1697-1783), perform an independent evaluation of the drug. La Martinière 
reported finding nothing dangerous to health, and found that the plant that was its main 
ingredient was well-suited to curing fevers. This was more than enough to convince La 
Vrillière: in spite of the commission’s objections, he informed them by letter that given 
the long history of the drug and the support of La Martinière, he would still grant the 
                                                 
 103 ANM SRM 111B d 29, “Mémoire des Demoiselles Lajutais.” 




brevet—which he did, on July 4, 1775105—and that they should register it. As a final 
reminder of his ultimate authority as Secretary of State in actually issuing brevets, La 
Vrillière also specified that his letter should be read aloud at their next meeting.106 
 The force of the drug’s long history of attestations had prevailed in favor of the 
Lajutais sisters, and a privilege for the poudre fébrifuge was granted once again, for the 
fifth time. But what about the objections of the commissioners? Only a summary of the 
original 1772 rejection has survived, probably based on a draft by Gérard Louis Deslon 
de Lassaigne, the commissioner in charge of examining the drug: 
The poudre fébrifuge of the Demoiselles de la Jutais, has been viewed as 
suspect and dangerous, having been drawn from the root of a plant which 
abounds in a very bitter, burning milky sap (suc laiteux), apt to inflame the 
mouth, and which violently purges by vomit and stool.107 
 
Whatever the treatment they had applied to the root, the commissioners argued, it had not 
sufficiently moderated these attributes. After a second test, and the complaints of one 
member who had witnessed the ill effects of the drug on patients, the Lajutais sisters’ 
petition was denied. The commissioners’ concerns, particularly those surrounding the 
“milky sap” or latex, were forwarded to La Vrillière, who rejected them based on the 
testimony of La Martinière. We see here, almost fifty years later, the same criticisms that 
were first voiced in 1714 by Boizard at the Port Louis naval hospital: far from a 
febrifuge, the drug was merely a violent purgative. In spite of these objections, it was still 
granted a new privilege through the intervention of the Secretary of State with the 
                                                 
105 See also the broadside version of their brevet, preserved with a host of other such 
advertisements in ANM 108011: Brevet qui permet aux demoiselles de la Jutais […] de vendre […] une 
poudre royale fébrifuge (Paris: L. Cellot, 1775). 
106 ANM SRM 111B d 30 La Vrillière to Alléaume (July 15, 1775). 




medical support of a senior royal practitioner (the first surgeon rather than the first 
physician in this case), just as it had been in 1713 and 1733. 
 Marie-Victoire was widowed and remarried one Joachim Noël Famin, dit Faming, 
merchant, and died in 1811.108 Faming, who owned properties across the Atlantic in 
Savannah, Georgia, appears to have taken an active interest in the legacy of his father in 
law. In 1805 he republished Lajutais’ treatise on fertilizers in Philadelphia dedicating it to 
the President, Thomas Jefferson.109 In 1808 he was back in Paris, where he took out a 
patent for a “procedure for improving the quality of bread,” which also appears to have 
been a secret devised by Lajutais.110 He appears not to have taken out a patent on the 
poudre fébrifuge—although we do know that in 1808 he was selling it at 90 rue Blanche 
de Castille on the Ile Saint-Louis, and that he was registered with the Police Sanitaire as 
“médecin-naturaliste à Paris” between 1806 and 1809.111 Like Helvétius’ remedies, the 
Guiller-Lajutais poudre fébrifuge survived beyond the Revolution and travelled well 
beyond metropolitan France. 
5. Conclusion: Continuity and change 
This chapter has followed a single drug from the time of Louis XIV to the end of 
the Ancien Régime and beyond. By looking closely at the medical trials that formed an 
                                                 
108 MC/ET/XLII/750, May 20, 1811, Inventaire de Mme. Faming (Marie-Victoire Brodin de 
Lajutais). 
 109 Brodin de la Jutais, L’abondance, ou, La véritable pierre philosophale consistant en un moyen 
de multiplier abondamment les grains, les fruits, les fleurs, et tous les végétaux généralement. The 
dedication is to “Son Excellence des John [sic] Jefferson, Président des États-Unis de l’Amérique.”  In spite 
of the error in name, the book still made its way into Jefferson’s library: see E. Millicent Sowerby, ed., 
Catalogue of the Library of Thomas Jefferson (Washington: The Library of Congress, 1952), 1:722. 
110 Archives des Decouvertes et des inventions nouvelles, faites dans les sciences, les arts et les 
manufactures, tant en France que dans les pays etrangers (Paris: Treuttel et Würtz, 1809), 233–234. 
111 See the éphémérides notice in La Cité: bulletin de la Société historique et archéologique du IVe 
arrondisement de Paris, vol. 7, no. 25 (1908) : 366; Faming is also listed in Alexandre Labat et al., Police 
sanitaire XVIIe siècle-1923: État numérique détaillé de la sous-série F8 (Paris : Archives nationales, 
2008), 198: “Faming de la Jutais, médecin-naturaliste à Paris (1806-1809).” I plan to investigate the post-




important part of how privileges were allotted, it demonstrates that in spite of repeated 
reforms, the granting of pharmaceutical privileges remained contingent upon the personal 
authority and support of the royal first physician. The authority of the secret remedies 
commission could be overridden by the actual officials charged with recommending and 
granting privileges. 
The case of the poudre fébrifuge also shows that medical trials under the personal 
supervision of the first physician played a crucial but largely undocumented role in 
building confidence in a new drug. Although it was destined for use by large numbers of 
soldiers in the field, there was no appeal to large numbers of subjects or rudimentary 
statistics. Indeed, no burden of proof or reasoned reports from the first physician appear 
to have been necessary at all: these would imply a higher medical authority in need of 
convincing. Instead, it seems that the personal judgment of a man who had literally been 
entrusted with the health of the monarch was quite sufficient in deciding whether or not a 
drug “worked,” whether it was useful to the interests of the fiscal-military state, and 
whether it should be rewarded with a privilege. Fagon and Chicoyneau served as medical 
brokers, mediating between the interests of the state—represented by the Secretary of 
State for War, the Navy, and the Royal Household—and those of medical entrepreneurs 
like Guiller and Lajutais.112  
 Personal attestations from other sources also played a crucial role in legitimating 
the poudre fébrifuge. Over the course of sixty years, Guiller, Lajutais, and his daughters 
assembled a veritable archive of positive attestations from a variety of medical, civil, 
                                                 
 112 On the role of brokers in mediating between patrons and clients of different ranks, occupational 
spheres, and geographic origins, see Sharon Kettering, Patrons, Brokers, and Clients in Seventeenth-




ecclesiastic, and military authorities. By the end of the eighteenth century, the 
accumulated weight of earlier written testimony of the drug’s efficacy, coupled with 
powerful patronage, could actually trump new medical trials of the drug that found it to 
be ineffective and even dangerous. Throughout the eighteenth century, the medical 
legitimation for a proprietary drug did not depend upon reports of large-scale institutional 
trials or “disinterested” testing: rather, it was contingent upon a highly personal variety of 
authority, judgement, and recommendation. Some efforts toward large-scale tests were 
apparent, most notably Pontchartrain’s circulation of the poudre fébrifgue to the Atlantic 
port hospitals in 1714, but on the whole, personal brokerage and patron-client 
relationships continued to hold far more sway than bureaucratic testing. 
 Although the history of the poudre fébrifuge is unique for the number of medical 
trials spread out over a long span of time, it also accentuates several themes that have 
appeared in the previous case-study chapters. Like orviétan, the story of the poudre 
fébrifuge shows that medical secrecy was rife with pitfalls. In this case, secrecy was a 
double-edged sword that could both help and hinder the commercial exploitation of a 
drug: it could provoke “succession crises” in the medical dynasticism characteristic of the 
early privilege system, foster uncertainty between partners, and force the one generation 
to literally reinvent the remedies of the past. While the Contugi case shows us what 
happened when a family medical secret was revealed to the public, the Guiller-Lajutais 
case shows us what could happen when a secret was lost. 
Finally, as in the case of Helvétius, the Guiller-Lajutais dynasty offers us a 
window onto the emergence of the proto-industrial production of a new class of uniform 




success of both the 1713 and the 1733 brevet bids were heavily conditioned by a need for 
one-size-fits-all medicinal specifics that could furnish solutions to pressing military 
health problems. This was already apparent in the case of Helvétius’ dysentery remedy, 
but the poudre fébrifuge shows that even when a reputedly effective medicinal specific 
such as cinchona was available, there was still an interest in finding another that was 
cheaper and more readily available. In both the Helvétius and Guiller-Lajutais cases, 
however, the radical increase in the scale of production was not matched by a rupture 
with earlier modes of medical legitimation. Despite attempts to create a more 
bureaucratized testing regime, medical privileges and military supply contracts continued 
to hinge upon the personal authority of the first physician within the wider culture of 





Corporate Consumers and the Global Circulation of Proprietary Medicines 
 
Louis Laneau, Apostolic Vicar of Siam and member of the Paris Foreign Missions 
Society (Société des Missions étrangères de Paris, MEP), wrote a letter to the Society’s 
directors on November 14, 1693, in order to acknowledge the receipt of a supply of drugs 
for the society’s missionaries in Ayutthaya. The drugs in question were Adrien Helvétius’ 
proprietary remède spécifique against dysentery. According to Laneau, bowel flux (cours 
de ventre) and its more serious manifestation, dysentery, was the leading killer of 
missionaries in Siam.1 As such, considerable expenses could be justified in attempts to 
relieve it: 
If these remedies are as infallible as is marked, then they are just what 
we’ll need in these countries, where these ills are very frequent, 
protracted, and often deadly. No missionaries should be allowed to leave 
without being equipped with them, for though they cost dearly, the travels 
of a missionary and his life cost even more.2 
 
Laneau thus acknowledged that spending money on expensive remedies like those of 
Helvétius and shipping them to Southeast Asia was justifiable and even necessary, not 
only given the inherent value of human life, but also the overall expense which would be 
shouldered by the MEP in transporting (and assumedly training) new missionaries to 
replace them. As a matter of corporate policy, the MEP fathers should all be equipped 
with such medications, assuming of course that they were as “as infallible” as advertised. 
                                                 
1 Cours and flux are synonymous. See Le Dictionnaire de l’Académie française (Paris: Coignard, 
Paris, 1694), 1:270. Helvétius for his part classes the flux de sang (bloody flux) and dysenterie as especially 
severe stages of cours de ventre: see Traité des maladies les plus frequentes (1703 ed.), 262. 
 2 AME 881 (Siam), 171-172, Laneau to the MEP Directors (November 14, 1693). “Nous venons 
de recevoir certains remèdes pour le cours de ventre, s’ils sont infaillibles comme il est marqué, c’est 
justement ce qu’il faut dans ces pais cy, ou toutes ces maux sont très fréquents, très longs et très souvent 
mortels, il ne faudroit point laisser partir de missionnaires sans les pourvoir, car bien qu’ils coûtent cher, les 
voyages d’un Missionnaire et sa vie coûtent encore bien d’avantage.” 
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 Implicitly, Laneau has in mind here the overall goals of the MEP mission, which 
at the time of his writing had recently faced a near-catastrophic setback in the form of the 
coup that elevated the staunchly anti-European Phetracha to the throne of Siam in 1688. 
Following the French military’s attempt to seize the port of Bangkok, Laneau, eight MEP 
fathers, and their thirteen indigenous seminarians were all imprisoned.3 These 
seminarians were the embodiments of the MEP’s main objective, that of establishing an 
indigenous clergy and episcopal structure in Southeast Asia. They were eventually 
released, and over the following decades, Helvétius’ drugs were purchased in bulk by the 
MEP and shipped halfway across the world to Siam as well as to adjoining MEP missions 
in Tonkin and Cochinchina (the northern and southern halves of modern Vietnam) in 
order to provide crucial medical support for this missionary project. Although these drugs 
were destined for use by the missionaries and their indigenous seminarians and 
parishioners, they were purchased in Europe not by individual consumers in the 
marketplace, but by the MEP as a “corporate consumer” looking out for the health of its 
agents overseas. 
As a “corporate consumer” purchasing drugs in bulk for its overseas agents, the 
MEP was not alone. Wherever French soldiers, sailors, missionaries, and traders went in 
the world, they brought remedies with them. Although many of these were medicinal 
simples, transported across the ocean to be consumed or compounded upon arrival, a 
growing number were pre-packaged proprietary drugs compounded in Europe. 
“Corporate consumers” like the MEP often served as crucial intermediaries between the 
European producers of these remedies and the sick patients who actually ingested them. 
                                                 
3 On this period of the MEP mission in Siam, see Alain Forest, Les missionnaires français au 
Tonkin et au Siam, XVIIe-XVIIIe siècles : analyse comparée d’un relatif succès et d’un total échec, vol. 1 
(Paris: L’Harmattan, 1998), 236–248. 
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This chapter will argue that the peculiar needs, constraints, and objectives of European 
overseas corporations—namely the missionary societies and joint-stock trading 
companies which played a crucial role in building the first global era—made them 
particularly well-suited customers for the standardized, one-size-fits all proprietary drugs 
developed by vendors like the Helvétius and Guiller-Lajutais monopolies.  
The preceding chapters provided multi-generational case studies of three of these 
proprietary drugs: the Contugi family’s orviétan, the Helvétius family’s dysentery 
spécifique, and the Guiller-Lajutais poudre fébrifuge. They followed the careers of the 
vendors, their monopoly privileges, and where possible delved into the medical secrets of 
their drugs. But with the exception of a few forays into the French provinces, the focus 
was on actors and events at Paris and Versailles, the primary loci of the “court 
capitalism” in which pharmaceutical monopolies were enmeshed under the Old Regime.  
This final chapter will follow the same three drugs as they travelled outside of 
France in the hands of corporate consumers, to consider the role each played in French 
military, missionary, and commercial endeavors, from the 1680s to the 1730s. Its primary 
aim is to illustrate the hitherto unrecognized importance of what I call “corporate 
consumers” in distributing French proprietary drugs overseas. In the seventeenth and 
eighteenth centuries, the most prominent classes of long-distance corporations were, on 
the one hand, the globalizing missionary orders and societies, particularly those of 
Catholicism, and, on the other, the great Western European overseas trading companies.4 
                                                 
4 See above, ch. 1, sect. 1. A “corporation” or “corps” in the Ancien Régime context could of 
course refer to any group individuals, most notably craft guilds, who had collectively been granted a 
privilege by a sovereign or a local civil authority which recognized them as a collective legal entity. In this 
chapter I will be focusing not on those corporations whose privileges were bounded by city walls or the 
borders of a kingdom, but rather on what Steven J. Harris calls “long-distance corporations” whose 
privileges and networks extended overseas. See Steven J. Harris, “Long-Distance Corporations, Big 
Sciences, and the Geography of Knowledge,” Configurations 6, no. 2 (1998): 276–279; Lucien Bély, 
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In this chapter I explore how French exemplars of both types of corporation, namely the 
Paris Foreign Missions Society (MEP), and the French East Indies Company (Compagnie 
des Indes orientales), became important consumers of proprietary drugs in the decades 
around 1700. 
Steven J. Harris has pointed to the critical role of the overseas networks of these 
long-distance corporations in European knowledge production, as well as their potential 
utility in solving problems in the scale of historical analysis by providing a “meso-level” 
subject of inquiry for global history, an intermediate scale of analysis between highly 
local (micro-level) case studies and rarefied historical metanarratives (the macro-level), 
which tend to privilege the state, macroeconomics, and international politics.5 The 
networks of early modern European knowledge production and the varieties of exchange 
with indigenous knowledge traditions, has received considerable attention over the past 
two decades, with botany and colonial bioprospecting playing a significant role.6 While 
the colonial state and metropolitan state-sponsored institutions remain a privileged sphere 
of inquiry, some long-distance corporations, particularly the Society of Jesus, have also 
                                                                                                                                                 
“Corps, Compagnies, Communautés,” Dictionnaire de l’Ancien Régime (Paris: Presses Universitaires de 
France, 2010); Philippe Haudrère, “Compagnies de Commerce,” Dictionnaire de l’Ancien Régime (Paris: 
Presses Universitaires de France, 2010). Although overseas trading companies, guilds (communautés d’arts 
or jurandes), and religious societies like the MEP all have important organizational differences, they share 
one common basis: their legal existence is recognized by the monarch through the granting of privileges, 
usually in the form of letters patent. 
5 Harris, “Long-Distance Corporations, Big Sciences, and the Geography of Knowledge,” 299–
304. 
6 The literature is vast, but see esp. Londa Schiebinger, Plants and Empire: Colonial 
Bioprospecting in the Atlantic World (Cambridge, Mass.: Harvard University Press, 2004); Londa 
Schiebinger and Claudia Swan, Colonial Botany: Science, Commerce, and Politics in the Early Modern 
World (Philadelphia: University of Pennsylvania Press, 2005); Harold J. Cook, Matters of Exchange 
Commerce, Medicine, and Science in the Dutch Golden Age (New Haven: Yale University Press, 2007); 
James E. McClellan and François Regourd, The Colonial Machine: French Science and Overseas 
Expansion in the Old Regime (Turnhout: Brepols, 2011), 287–302. 
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gained prominence in accounts of the production and circulation of knowledge.7 My goal 
here however is not to explore the role of corporations as producers of medical or 
scientific knowledge, but rather to look at them as consumers of medical goods. 
Following this line of inquiry takes us beyond the “inflow” of reports and 
specimens into Europe to also consider the ways in which this knowledge was capitalized 
upon by European entrepreneurs. In the case of medicine, this means moving from 
colonial bioprospecting to explore how indigenous European substances and exotic non-
European therapeutic substances whose value and utility had been recognized by 
Europeans were transformed and commodified. As Chapters 2 and 3 have already 
suggested, the processing, compounding, and chemical transformation of these 
substances in Europe, coupled with their branding and packaging and their intellectual 
incorporation into European medicine, renders the binary between exotic and indigenous 
drugs problematic. The ipecacuanha that formed the basis of the Helvétius family’s 
fortune was collected in Brazil, but only reached its users after first passing through his 
laboratory in Paris, where it was transformed into his proprietary poudre spécifique 
                                                 
 7 On the Jesuits and the global circulation of materia medica, see Sabine Anagnostou, “Jesuit 
Missionaries in Spanish America and the Transfer of Medical-Pharmaceutical Knowledge,” Archives 
Internationales d’histoire des Sciences 52 (2002): 176–97; Sabine Anagnostou, “Jesuits in Spanish 
America: Contributions to the Exploration of the American Materia Medica,” Pharmacy in History 47, no. 
1 (January 1, 2005): 3–17; Ines G. Županov, Missionary Tropics: The Catholic Frontier in India, 16th-17th 
Centuries (Ann Arbor: University of Michigan Press, 2005), esp. ch. 6; Claudia von Collani, “Mission and 
Medicine: Between Canon Law, Charity and Science,” in History of Catechesis in China, ed. Staf 
Vloeberghs (Leuven: Ferdinand Verbiest Institute, 2008), 37–68; Patrícia Albano Maia, “Práticas de Cura 
No Encontro de Culturas:  Jesuítas E a Circulação de Receitas Médicas,” in Anais Do XXVI Simpósio 
Nacional de História – ANPUH (São Paulo, 2011), 13; Charlotte de Castelnau-L’Estoile et al., eds., 
Missions d’évangélisation et circulation des savoirs, XVIe-XVIIIe siècle (Madrid: Casa de Velázquez, 
2011); Beatriz Puente-Ballesteros, “Jesuit Medicine in the Kangxi Court (1662-1722): Imperial Networks 
and Patronage,” East Asian Science, Technology, and Medicine 34 (2012): 86–162; Amy Buono, 
“Interpretative Ingredients: Formulating Art and Natural History in Early Modern Brazil,” Journal of Art 
Historiography, no. 11 (2014): 1; Sabine Anagnostou, “Forming, Transfer and Globalization of Medical-
Pharmaceutical Knowledge in South East Asian Missions (17th to 18th C.) – Historical Dimensions and 
Modern Perspectives,” Journal of Ethnopharmacology, Potent Substances: On the Boundaries of Food and 
Medicine, 167 (June 5, 2015): 78–85. See also Puente-Ballesteros forthcoming monograph, “The Naked 
Emperor: Jesuit Surgeons, Physicians and Apothecaries in the Service of the Kangxi Court (1662-1722),” 
in preparation for Brill. 
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against dysentery.8 Likewise, the search for indigenous European alternatives to exotic, 
expensive, and difficult to secure supplies of simples like cinchona bark, also 
problematizes the indigenous and exotic binary: the common European wood spurge 
tithymalus amigdaloïdes could emerge as the proprietary poudre fébrifuge only in direct 
comparison to (and competition with) cinchona.9 
Whatever the exotic or indigenous origin of these substances, in many cases the 
story of their transformation into a European proprietary drug does not end in Europe: 
rather, there was also an “outflow” of substances that were exported (or re-exported) for 
use elsewhere in the world in their new, transformed states. Some of these proprietary 
drugs travelled across oceans in the hands of individual consumers, as is the case with 
orviétan, or were sent in wholesale quantities to local apothecaries who would then sell 
them to individual consumers, as is the case with most English proprietary drugs in North 
America.10 The first section will explore how instances of individual consumption and 
successful use could elevate a drug to consideration as an object of corporate 
consumption through the example of orviétan in North America. Sections two and three 
will focus on concrete examples of corporate consumption in the global distribution of 
French proprietary drugs, following the drugs of Helvétius and Lajutais through the 
overseas networks of the MEP and the French East Indies Company. 
1. Prospects for corporate consumption: Orviétan and the poisons of North America 
In the final decades of the seventeenth century, French military and trading 
interests endeavored to build a network of fortified posts in the continental interior, with 
                                                 
 8 See above, ch. 4. 
 9 See above, ch. 5. 
 10 Renate Wilson, “Trading in Drugs through Philadelphia in the Eighteenth Century: A 
Transatlantic Enterprise,” Social History of Medicine 26, no. 3 (2013): 352–63. 
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the dual goal of bolstering Louis XIV’s territorial claims to the continental interior and of 
defending the fur trade with indigenous peoples against the two-pronged encroachment of 
the New England colonies and the newly-formed Hudson’s Bay Company. The most 
conspicuous remède secret to play a role in these endeavors is, without a doubt, the 
poison antidote orviétan. Orviétan served as a vital medical asset to several of the most 
prominent French agents who were working to extend French influence into the vast 
lands between Hudson Bay and the Gulf of Mexico. For the purposes of this chapter, 
orviétan is especially interesting because it was first recognized as an important 
therapeutic asset in North America through instances of individual consumption, likely 
having been purchased by agents themselves. By the end of the 1680s, however, its 
reputation led it to be framed as a crucial part of the medical equipment of larger 
expeditions, financed and organized by “corporate consumers” such as the military and 
trading companies.  
References to orviétan are sprinkled across the far-flung travel narratives of 
figures such as René-Robert Cavelier de La Salle, Henri de Tonty, Louis Hennepin, 
Pierre-Esprit Radisson, and the Baron de Lahontan, which are replete with various forms 
of poisoning through spoiled food, toxic plants, and rattlesnake venom, all of which fell 
within orviétan’s purview as an antidote.11 European agents recognized these lands as 
inherently hostile climates filled with poisons known and unknown, and an antidote like 
orviétan, which could be used to guard against a wide variety of potential poisons, was a 
                                                 
11 On the various uses of orviétan and on early modern definitions of poison or venenum, see 
above, ch. 3. See also Frederick W. Gibbs, “Specific Form and Poisonous Properties: Understanding Poison 
in the Fifteenth Century,” Preternature: Critical and Historical Studies on the Preternatural 2, no. 1 
(2013): 19–46. Note once again that this does not make orviétan a panacea: it merely shows that poison or 
venenum was a broad pathological category. Orviétan was explicitly advertised as an antidote against a 
variety of “vénins,” stretching from the venom of vipers and scorpions and poisonous mushrooms to the 
bites of rabid dogs and even plague. 
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particularly desirable item of materia medica to have brought along. It is not clear in all 
cases whether the orviétan in question was that produced by the Contugi family: the 
drug’s North American users never specify which vendor they purchased it from, and, as 
Chapter 3 has shown, the Contugi trade had to compete with several rival producers by 
the 1680s, following the publication of the drug’s secret recipe. Whatever the specific 
vendor in each case, it is nonetheless remarkable that orviétan appears to have been 
preferred even above officinal antidotes with similarly broad applicability, notably 
theriac. Indeed, the proliferation of interlopers on the Contugi orviétan monopoly at 
almost exactly this time and the popularity of orviétan over theriac are likely related 
phenomena.12 
The rationale for bringing orviétan to North America in the first place probably 
originates in a fear of rattlesnakes—virtually a leitmotif in French North American travel 
narratives. The sight alone of three large rattlesnakes crossing his path while climbing a 
rock face was enough to give La Salle a fever in 1669 and convince him to abandon the 
expedition he was accompanying and return to Montreal.13 We know from Henri de 
Tonty that a supply of orviétan was among the equipment that La Salle’s expedition 
brought with them during their explorations down the Mississippi.14 The Recollect Friar 
Louis Hennepin, also a member of the Mississippi expedition, likewise reported many 
                                                 
12 See the Boulogne episode described above, ch. 3, sect. 3. 
13 Gabriel Nadeau, “Le grand électuaire de l’orviétan au pays de la Nouvelle-France,” L’Union 
médicale du Canada 105 (1976): 674. These were probably Massassauga rattlesnakes, now an endangered 
species in Ontario. The expedition La Salle was accompanying was that of the Sulpicians François Dollier 
de Casson and René Bréhant de Galinée, who went on (minus La Salle) to be the first French missionaries 
to take the lower lakes route (rather than the Ottawa River) to Lake Huron. See James H. Coyne, ed. 
Exploration of the Great Lakes 1669-1670: Galinée’s Narrative and Map with an English Version 
(Toronto: Ontario Historical Society, 1903), 40-41. 
14 “Je fus frappé d’un poison, mais, ayant recours à l’orvietan, Dieu me renvoya le santé,” Pierre 
Margry, Mémoires et documents pour servirà l’histoire des origines francaises des pays d’outre-mer. 
Découvertes et établissements des Francais dans l’ouest et dans le sud de l’Amérique Septentrionale 
(1614-1754). (Paris: Maisonneuve et cie., 1879), 1:557; Nadeau, “Le grand électuaire de l’orviétan au pays 
de la Nouvelle-France,” 693. 
329 
 
close-calls with rattlesnakes. He describes a particularly memorable episode in which he 
and one of his French companions witnessed an especially large rattlesnake slithering its 
way up the face of a cliff, eating eggs from birds’ nests as it went. The snake eventually 
fell to its death, but the horror of the scene led both Hennepin and his companion to 
suffer from frequent nightmares, both during and after their ventures in the upper 
Mississippi valley.15 The similarities between rattlesnakes and vipers, which as we have 
seen were intimately associated with orviétan, was likely crucial in motivating La Salle 
and Hennepin to bring orviétan with them: vipers were one of the drug’s main ingredients 
as well as being part of its printed advertising and the associated stage-show, where the 
“charlatan” vendor was often bitten by a viper and then saved by consuming the antidote. 
While the fear of rattlesnake bites may have provided the initial impetus to bring 
along orviétan, the durable lead cases in which orviétan was sold,16 its alleged twenty-
five year shelf life, and the multitude of uses to which it could be put as an antidote no 
doubt played a role in this choice. The most diverse account of these uses during French 
explorations down the Mississippi valley comes from the Recollect Hennepin. As 
Hennepin’s account demonstrates, orviétan not only served immediate medical purposes 
for the members of the expedition, but also played a crucial role in their relations with the 
Santee Sioux.  
In 1680 La Salle sent Hennepin and two other Frenchmen down the Illinois River 
to where it joins the Mississippi. Loaded down with furs, they were unexpectedly taken 
captive by a Santee Sioux war party and forced to come far north to their village near 
                                                 
15 Louis Hennepin, Nouvelle decouverte d’un tres grand pays situé dans l’Amérique entre le 
Nouveau Mexique, et la mer glaciale (Utrecht: G. Broedelet, 1697), 385–386. 
16 See above, ch. 3, and appendix 2 for images; see also below, sect. 3, on how Helvétius’ cheap 
paper packaging could impede the global circulation of his remedies. 
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Mille Lacs, in present-day Wisconsin.17 There Hennepin was adopted by the village 
chief, Aquipaguetin, and by his own account, his life and those of his companions were 
preserved through the barber-surgeon-like services he was able to provide in the form of 
a razor used for bloodletting and shaving, on the one hand, and a stock of orviétan and 
other medications on the other. He explicitly mentions using orviétan to save young 
Santee men who had been bitten by rattlesnakes, and also mentions using theriac to 
revive a Santee woman who had attempted to commit suicide.18 Unable to appeal to their 
souls for salvation, Hennepin explains that he instead appealed to their bodily animal 
natures through these services, a theme we shall see again with the MEP in Southeast 
Asia (sect. 2). By his own account he also tried to leverage these services with his two 
French companions, who once tried to abandon him eight hundred leagues from Canada 
because their canoe was half-rotted and, in their eyes, he added unnecessary weight and 
slowed their paddling. Hennepin pleaded with them, arguing that without the credit he 
had obtained for all of them through his medical services to the Santee, they would all 
have been lengthily tortured and killed.19 
Orviétan was not only handy in treating snakebites among the Santee, however. It 
is also cited for twice saving Hennepin himself and one of his French companions from 
                                                 
17 Hennepin calls them Nadeoüessans or Nadouessioux (Sioux), or more specifically les Issati 
(Santee or Isáŋyáthi). See Patricia C. Albers, “Santee,”.Handbook of North American Indians vol. 15, The 
High Plains, pt. 2 (Washington: Smithsonian Institution, 2001), 761-776. 
18 Hennepin, Nouvelle decouverte d’un tres grand pays, 378; Louis Hennepin, Description de la 
Louisiane : nouvellement decouverte au sud’oüest de la Nouvelle France, par ordre du roy. Avec la carte 
du pays: Les moeurs & la maniere de vivre des sauvages. (Paris: veuve Sebastien Huré, 1683), “Mœurs” 
36. Following the common usage with orviétan, Hennepin probably sucked out the venom and then applied 
the powder to the wound, after scarifying it with his razor. 
19 Louis Hennepin, Description de la Louisiane : nouvellement decouverte au sud’oüest de la 
Nouvelle France, par ordre du roy. Avec la carte du pays: Les moeurs & la maniere de vivre des sauvages. 
(Paris: veuve Sebastien Huré, 1683), 263–264; cf. Louis Hennepin, Nouvelle decouverte d’un tres grand 
pays situé dans l’Amérique entre le Nouveau Mexique, et la mer glaciale (Utrecht: G. Broedelet, 1697), 
378–379. Hennepin’s companions, Michel Accault (or Ako) and Antoine Auguelle (called Picard Le 
Guay), were unmoved: they abandoned him in spite of his pleadings, and he was rescued only by the 
intervention of a Santee warrior chief. 
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the dangerous foods they were forced to eat in order to avoid starvation in the wilderness: 
after eating haws (senelles), currants (groseiles), and other wild berries in desperation, he 
observed “I am persuaded that without powdered orviétan, which we had used to correct 
bad [or spoiled] foods, we would have run a great risk to our lives.”20 In a later episode 
while still on the point of starvation, Hennepin explains how he finally stumbled upon a 
herd of buffalo crossing a river, one of which was killed by his companion. The pair 
became very sick after eating it, and were again saved “by means of powdered orviétan, 
which had often been a great help to us in our voyage.”21 As such Hennepin explicitly 
made use of orviétan on multiple occasions, with himself, his French companions, and 
his Santee captors, treating ailments as diverse as dangerous berries, bad meat, and 
rattlesnake venom.  
How did French orviétan compare to locally available simples and indigenous 
cures? Although he credited orviétan with saving his own life and that of others on 
numerous occasions, Hennepin considered it to be inferior to some native simples in the 
treatment of snakebites. He mentions herbs used by the Illinois “which are far more 
assured than theriac and orviétan,”22 a development which he credits to their experience 
in dealing with snakes, which are so common in their country, particularly in rocky areas. 
Nearer to the core of the French colony in Québec, the surgeon and academician Michel 
Sarrazin mentions a scenario wherein orviétan was privileged over a native plant, known 
to the Canadians as l’herbe du serpent à sonnette (Botrypus virginanum, rattlesnake fern) 
                                                 
20 “Je suis persuadé que sans l’Orviétan en poudre, dont nous nous servions pour corriger la 
mauvaise nourriture, nous eussions couru grand danger de la vie,” Hennepin, Nouvelle decouverte d’un tres 
grand pays, 381. 
21 “…par le moien de l’Orvietan en poudre, qui nous vint souvent à grand secours dans le 
voyage,”Ibid., 392. 
22 “…dont l’usage est beaucoup plus assuré que celle du Theriaque et de l’Orviétan,” Ibid., 220. 
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which the Iroquois used to combat rattlesnake venom. He describes one native man who 
took this plant after being bitten on the ankle by a rattlesnake, but was still sufficiently 
concerned that he ran eight or ten leagues to Sarrazin in order to obtain a more certain 
cure. He gave the man a few doses of orviétan mixed with eau-de-vie (alcohol), and also 
applied some directly to the bite and put a ligature above it. The man survived. The 
account itself was attached to the sample of the plant Sarrazin sent to Paris, which he 
suspects was ineffective against rattlesnake venom.23 
In all of these cases, it seems likely that the orviétan was either bought directly by 
individual French agents like Hennepin, Tonty, and La Salle, or that it was given by their 
individual backers at court (La Salle once mentions having received the antidote “from 
friends”), and that it came to be recognized as a valuable remedy against North American 
poisons through this usage. Possibly as a result of its reputation, orviétan seems to have 
been purchased by a corporate interest to equip one of its expeditions, namely, the newly 
formed Compagnie du Nord, a joint-stock company formed to counter the English 
Hudson’s Bay Company. In 1682 the Compagnie had entrusted two veteran fur traders, 
Pierre-Esprit Radisson and Médard Chouart des Grosseliers, with the project of founding 
a trading post at the mouth of the Nelson River, a location of vital importance to the 
North American fur trade for the access it provided to the continental interior. The vast 
territories surrounding Hudson Bay were disputed between France and England, and 
although he was serving France in this particular episode, Radisson would switch 
allegiances between French and English interests throughout his life, and had informed 
both of the attractiveness of this locale for the fur trade. Shortly before entering the arctic 
                                                 
23 Bernard Boivin, “La flore du Canada en 1708. Étude et publication d’un manuscrit de Michel 
Sarrasin et Sébastien Vaillant,” Études littéraires 10, no. 1–2 (1977): 260. 
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waters of Hudson Bay, however, Radisson reports that some of his men killed a large 
white bear (a polar bear), ate its flesh to excess, and became sick to the point of death 
with headaches and violent evacuations: 
I was forced to make a signal to my brother-in-law [Des Grosseliers, on 
the other barque] to advise him of this accident and to get help. Orviétan 
and sweating pulled these poor unfortunates through, but all their skin had 
peeled off. We have since learned from the Indians [sauvages] that this 
species of white bear has a venom in its liver that spreads to all of the 
flesh, and causes similar accidents when eaten.24 
 
The local “sauvages” (Inuit or Cree) were well aware of the poisonous nature of polar 
bear liver,25 but Radisson and des Grosselier’s party learned of this only after the fact. 
While indigenous knowledge might have spared Radisson and des Grosselier’s party, 
events led them to draw recourse to their supply of orviétan, which had likely been part 
of the “equipment and stocks of food” that the Compagnie du Nord, under the direction 
of the Québec financier Charles Aubert de La Chesnaye, had purchased for the 
expedition.  
 Orviétan’s transition from a drug that was carried by individual agents for 
personal use to one which should be part of the general equipment of larger French 
expeditions is also apparent from a prescriptive text, namely the counsels for future 
exploratory and colonial expeditions which the Baron de Lahontan offers at the end of his 
                                                 
24 “Je fus oblige de faire signal à mon beau-frère pour luy donner advis de cet accident afin d’estre 
secouru. L’orvietan et les sueurs tirerent ces pauvres mal-heureux d’affaire, mais ils ont tous changé de 
peau, nous ayons apris dépuis par les sauvages que cette espece d’ours blancs a du venin dans le foye qui se 
communique à toute la chair, et cause de pareils accidents quand on en mange,” Germaine Warkentin, ed., 
Pierre-Esprit Radisson: The Collected Writings, Volume 2: The Port Nelson Relations, Miscellaneous 
Writings, and Related Documents (Montréal and Kingston: McGill-Queen’s University Press, 2014), 20. 
25 Without delving too deeply into the fraught territory of retrospective diagnosis, Radisson’s men 
may have been suffering from the toxic effects of Hypervitaminosis A, a condition which produces skin 
peeling and is associated with eating the livers of polar bear, which contain large amounts of Vitamin A 
due to their near-exclusive diet of fish-eating carnivores. See K. Rodahl and T. Moore, “The Vitamin A 
Content and Toxicity of Bear and Seal Liver,” Biochemical Journal 37, no. 2 (July 1943): 166–68. 
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1705 Voyages.26 Lahontan, who had himself served in the French army in Canada and 
explored lands west of Michilimackinac from 1687-1689, advises that any future 
expeditions should learn from the failures of earlier expeditions, notably those of La 
Salle, and provides extensive practical advice on how to manage men in the wilderness, 
where their inclination to rebel is “unrestrained due to their distance from settlements,” 
and on which equipment to bring. In this account, which he calls his “pédagogie de la 
découverte,” he proposed an organized military party of between three and four hundred 
men, embarked in longboats (chaloupes) which can brave the waves of the Great Lakes, 
and equipped with all the tools and equipment necessary to navigate and build camps, 
including compass, astrolabe, paper as well as hand mills for grinding corn, nails, pikes, 
spades, axes, fishhooks, soap, candles, even trumpets and violins (to entertain the troops 
and the native guests), and trade goods like tobacco, alcohol, scissors and needles. He 
cautions against bringing ecclesiastics, who he believes weaken the men with 
superstitions, fears, and timidity, and instead to ensure that men from various trades are 
found among the company, including carpenters, gunsmiths, sawyers, hunters and fishers 
by profession, and, of course, surgeons. These surgeons should be “equipped with a full 
kit, of unguents for wounds, drugs for various illness, but above all, orviétan and 
senna.”27 In this respect at least, Lahontan’s “pédagogie de la découverte” is in agreement 
with the practice of La Salle, Tonty, and Hennepin, in fact extending it to cover the whole 
expedition, pointing out that this list of items is based on the one he was provided when 
                                                 
26 Louis Armand de Lom d’Arce Lahontan, Nouveaux voyages de Mr. le baron de Lahontan dans 
l’Amérique Septentrionale (The Hague: frères l’Honoré, 1703). Lahontan is perhaps best known to 
posterity as one of the originators of the Enlightenment noble savage figure, in the form of the interlocutor 
Adario in his later Dialogues avec un Sauvage (1704). 
27 Ibid., 257. “…et des Chirurgiens munis d’un étuit complet, d’onguens pour les blessures, de 
drogues pour les maladies, mais sur tout d’Orviétan et de Sené” 
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he took command at Michilimackinac.28 Given the size of the expedition that Lahontan 
recommends (three to four hundred men) he likely imagined the purchase of a sizable 
quantity of the drug, which otherwise seems to have made its way to North America 
primarily through the hands of individual agents, or in Radisson’s case, through the 
Compagnie du Nord.  
Lahontan’s lavish proposals for how to provision exploratory expeditions and 
build fortified trading posts went unheeded, and there is no evidence that the military 
ever purchased orviétan in bulk, be it in France or in its colonies. This may have more to 
do with the scale of France’s North American operations and the relative lack of interest 
of metropolitan officials than with the value of the drug for such purposes: until the 
Seven Years War, French military operations in North America would remain relatively 
small. The drug’s persistent supporting role in North American French expansion 
nonetheless provides a window into how a proprietary drug, purchased by individual 
agents, might accumulate a reputation over time that would lead it to be considered an 
indispensable provision for larger expeditions, like those actually undertaken by Radisson 
and des Grosseillers in the service of the Compagnie du Nord, and those proposed by 
Lahontan. Moving from North America to the Indian Ocean, the cases of the MEP and 
the French East Indies Company allow us to see fully realized models of “corporate 
consumption” in action. 
 
2. Helvétius’ Remedies and the Paris Foreign Missions Society in Southeast Asia 
Unlike orviétan, Helvétius’ remedy did not “go global” by trickling out to French 
colonies and outposts after a prolonged period of use in France. Rather, it was a “born 
                                                 
28 Ibid., 258. 
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global” drug in both supply and demand: Brazilian ipecacuanha, shipped across the 
Atlantic, was its active ingredient, and Helvétius’ finished, compounded drug was almost 
immediately dispatched abroad from France. Within eight months of having received his 
privilege on August 23, 1688, Helvétius’ dysentery remedy was being requested in bulk 
quantities to bolster French military and missionary interests on three continents: (1) 
Louis XIV’s War Minister, the Marquis de Louvois, was requesting it for use in France’s 
European armies, then mobilizing for what would become the War of the League of 
Augsburg (1688–1697);29 (2) Louis-Hector de Callière, Governor of Montréal, had 
earmarked it as critical to the medical support of his planned invasion of New York in 
America (February 1689);30 and (3) the French navy squadron being dispatched to the 
Indian Ocean under the command of Abraham Duquesne-Guiton,31 as well as the Paris 
Foreign Missions Society. By 1709, when Helvétius proposed the creation of a royal 
office of Distributor General of Remedies (Distributeur général de remèdes), he could 
brag that, in addition to their widespread dissemination in metropolitan France both to the 
army and in rural poor relief efforts, his drugs had also been used in Siam, Canada, and 
China through the MEP.32 
 The cases of Louvois and Callière for the French armies in Europe and Canada fit 
neatly within the relationship Helvétius built with the military, detailed at length in 
chapter 4. This section will focus on the supply relationship Helvétius built with a 
                                                 
29 SHD A1 811, fol. 6, Louvois to Helvétius (October 18, 1688). 
30 Gabriel Nadeau, “Les remèdes des Helvétius dans la Nouvelle France,” Bulletin de 
l’Association des  médecins de langue française de l’Amérique du Nord / L’Union médicale du Canada 74, 
no. 5 (May 1945): 621–35; Pierre-Georges Roy, “Le projet de conquête de la Nouvelle-York de M. de 
Callières en 1689 (suite),” Bulletin des recherches historiques 24, no. 12 (1918): 353–67. See 356-357 for 
Helvétius’ remedy. 
31 AN MARINE B2 69, fol. 173 (March 13, 1689); Maurice Chiray, “La famille des Helvétius,” 
Paris médicale 42 (1921): 3; Lafond, Dynastie des Helvétius 46. 
 32 See above, ch. 4, sect. 4, and AN G7 716, Adrien Helvétius, “Placet à M. Desmaretz,” fol. 23r°. 
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different kind of organization, the Paris Foreign Missions Society or MEP, founded in 
1663 by Alexandre de Rhodes and active in Southeast Asia in this period.33 Although not 
technically a religious order, the MEP was made up primarily of French secular priests 
who had come to Southeast Asia to establish a traditional episcopal structure and 
indigenous parish clergy there. The Propaganda Fide, the papal congregation charged 
with overseeing the spread of Catholicism globally, appointed three Vicars Apostolic to 
direct the missions in Southeast Asia, all of whom were French and drawn from the MEP 
rather than the Society of Jesus, marking a challenge to Portuguese Padroado and Jesuit 
interests. These Apostolic Vicars, including Louis Laneau (whose letter opens this 
chapter) were also there to assert papal control over the heterogeneous collection of 
missionaries from various orders and that were already on the ground, including Spanish 
and Portuguese Franciscans, Dominicans, Augustinians, and of course the Jesuits. The 
Vicars and the MEP missionaries initially based themselves at Ayutthaya (Siam), where 
they established a seminary under the protection of King Narai, who favored the French 
Catholic missionaries and forged diplomatic links with the court of Louis XIV in the 
1680s.34  
 How did Helvétius establish a relationship with this relatively new missionary 
society, so favoured by the Propaganda Fide? In much the same way, it seems, as he had 
built links with the military: namely, through private practice in élite Parisian circles. The 
social commentator Bonaventure d’Argonne mentions that one of Helvétius’ early 
                                                 
 33 On the MEP in Southeast Asia, the best survey is Forest, Les missionnaires français au Tonkin 
et au Siam, 3vols.; see also Catherine Marin, ed., La Société des Missions Etrangères de Paris: 350 ans à 
la rencontre de l’Asie : 1658-2008 : colloque à l’Institut Catholique de Paris (4 et 5 avril 2008) (Paris: 
Karthala, 2011). For an older institutional history, see Henri Alexander Chappoulie, Aux origines d’une 
église. Rome et les missions d’Indochine au XVIIe siècle, 2 vols. (Paris: Bloud et Gay, 1943-1948). 
 34 Tara Alberts, Conflict and Conversion: Catholicism in Southeast Asia, 1500-1700 (Oxford: 
Oxford University Press, 2013), 36–37. 
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patients was Jacques-Charles Brisacier, Superior of the Foreign Missions Society 
Seminary, the organization which trained MEP priests. Helvétius may also have attracted 
attention through his own charitable practice at his residence on the rue Serpente in Paris, 
where he daily provided free consultations to the destitute, even handing out doses of his 
remedies. His charitable dispensation of the drug was known to Laneau, the head of the 
mission in Siam in 1693, as we have already seen. As Bonaventure d’Argonne tells it, La 
Chaise had Helvétius provide some of his remedy to a (“Père Beize”) who was preparing 
to go on mission, almost certainly the same Père de Bèze who accompanied the Jesuit 
Guy Tachard on the second French embassy to Siam.35 
The effects of the drug were so remarkable that La Chaise informed the king, who 
in turn ordered the Navy Secretary Seignelay and the royal first physician Daquin to 
organize the 1688 hospital trial.36 As such, in the chain of patients that referred Helvétius 
to higher and higher echelons of the French élite, it was in fact Brisacier that brought him 
to the attention of Père Lachaise, which prompted the hospital trials ordered by 
Seignelay, intended to determine the utility of the drug for use in the navy, which 
eventually led to its widespread use in the army at the beginning of the War of the 
League of Augsburg (1688-1697). In this sense, then, it was the patronage of powerful 
clerics and missionaries that recommended Helvétius’ to the military. 
 The earliest supply of Helvétius’ remedies to reach Southeast Asia likewise show 
a close link between his military and missionaries connections, in this case with the 
Jesuits rather than the MEP. The Jesuit Tachard’s account of the second French embassy 
to Siam shows that Helvétius’ remedy was already being sent overseas, probably in small 
                                                 
35 Bonaventure d’Argonne, Mélanges d’histoire et de littérature recueillis par M. De Vigneul 
Marville. Nouvelle édition, revûë, corrigée, et augmentée, vol. 1 (Paris: Claude Prudhomme, 1713), 51. 
36 Ibid., 1:52. See above, ch. 4, sect. 1. 
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quantities, in 1687, even before the Parisian hospital trials which led to his monopoly 
privilege.37  Here some background is useful. Tachard had accompanied the first French 
embassy to Siam in 1685, but at that time he and the other Jesuits accompanying him had 
been en route to China. During their time in Ayutthaya, however, they sufficiently 
impressed the Siamese King Narai, particularly with their astronomical skills, that the 
king requested a company of Jesuits join the next embassy. Tachard took on the role of 
Narai’s envoy to Louis XIV and to Pope Innocent XI, and so became a figure of 
considerable importance in relations between Versailles and the court of King Narai.38 
This led to a brief period of intensified relations between Versailles and the Siamese 
court at Ayutthaya, which was itself looking for a counter-weight to Dutch influence in 
the region and had become receptive to French overtures through the influence of the 
prominent courtier and “quasi-minster” Constance Phaulkon, himself a Levantine Greek 
who sought to profit from French influence in the region for his own ends.39 
Tachard’s account of the 1687 voyage to Siam incorporates a letter from the 
aforementioned Père Bèze, who Bonaventure d’Argonne describes as having received a 
supply of Helvétius’s drug while preparing to go on mission. The letter describes a climb 
the Jesuits made up the Table Mountain while the squadron made port at the Dutch 
colony of Cape Town. While the letter is mainly of interest for its observations on the 
Khoikhoi (Hottentots) and its comments on the tide markings and seashells up on the 
                                                 
37 The squadron carrying the embassy sailed March 1, 1687, and Seignelay’s orders for the 
hospital trails are from July of 1687. 
38 Michael Smithies has argued that Tachard was an overactive agent whose actions often 
frustrated French interests: see Michael Smithies, ed., Mission Made Impossible: The Second French 
Embassy to Siam, 1687 (Chiang Mai, Thailand: Silkworm Books, 2002), 1–8; for a more favourable view 
of Tachard, see Raphaël Vongsuravatana, Un jésuite à la Cour de Siam (Paris: Editions France-Empire, 
1992); and Michael Smithies reply, “Saint Tachard? A Rejoinder to Vongsuravatana,” Journal of the Siam 
Society 82, no. 2 (1994): 175–78. 
 39On Phaulkon see Luang Sitsayamkan, The Greek Favourite of the King of Siam (Singapore: 
Donald Moore Press, 1967). 
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cliffs (taken as proof that the top of the mountain was once at sea level), Bèze also 
mentions that several of the Jesuits were already sick by the time of the arrival at the 
Cape:  
We worked to restore a few of our fathers who had arrived sick [at the 
Cape], and I made some contribution through the remedies that the 
Marquis de Seignelay had the goodness to have given to us, and by some 
specifics that Monsieur Helvétius and the Brother of the Sun [the Duke of 
Orléans] had put into my hands.40 
 
Although nominally an embassy, the 1687 expedition also included a military contingent 
intended to seize the ports of Mergui and Bangkok, regardless of the outcome of the 
negotiations. Was the drug among the medical supplies intended to support the military 
contingent, or was it held by the Jesuits? Bèze’s wording suggests the spécifique was 
given directly to him via Helvétius and Philippe II Duke of Orléans (whom Helvétius 
served as physician in ordinary). The mention of Seignelay, Secretary of the Navy, points 
in the other direction: it was Seignelay who later ordered the hospital trials, with 
explicitly military ends in mind, and Seignelay would order a large supply of Helvétius’ 
drug for the Duquesne-Guiton expedition to Siam a few years later, this time explicitly 
for the soldiers and sailors.41 
 French gains during the 1687 embassy were mixed: a new trade treaty (deemed to 
be mediocre), but no conversion from Narai, nor any other official support for 
                                                 
40 “Nous avions travaillé à rétablir quelques uns de nos Pères qui étoient arrivez malades, et j’y 
avois un peu contribué par les remedes que M. le Marquis de Seignelay avoit eu la bonté de nous faire 
donner, et par quelques specifiques (58) que Monsieur Helvetius et le frere du Soleil m’avoient mis entre 
les mains,” Guy Tachard, Second voyage du pere Tachard et des jesuites envoyez par le roy au royaume de 
Siam: Contenant diverses remarques d’histoire, de physique, de geographie, et d’astronomie. (Paris: 
Daniel Horthemels, 1689), 57–58. 
41 On March 13, 1689, Seignelay requested that Helvétius supply him with enough of his remedy 
to provide three doses (prises) to three hundred patients, as part of the cargo of the ship L’Oyseau for 
Abraham Duquesne-Guiton’s expedition to Siam. See AN MARINE B2 69, fol. 173 (March 13, 1689); 




Catholicism. In 1688 the growing French influence at Ayutthaya, coupled with the 
presence of a foreign military force and resentment against Phaulkon, eventually 
produced a palace coup led by the staunchly anti-French Phetracha, who executed 
Phaulkon and his allies as well as Narai’s heirs apparent, expelled the French, and 
declared himself king on Narai’s death.42 Although these events marked the end of direct 
French colonial designs on Southeast Asia until the nineteenth century, the MEP 
missionaries, who had been in Siam since the 1660s, remained and through them 
Helvétius’ dysentery remedy and later his other drugs came to be distributed in Southeast 
Asia. 
 Although the Superior of the MEP seminary was one of the prominent patients 
that Helvétius treated early in his career (and may stand at or near the root of the 
connections he forged with the MEP), Helvétius’ first formal business dealings with the 
MEP fathers were not until 1689, after he had secured his monopoly privilege. Their 
surviving accounts show that by March 1689, Helvétius was already providing them with 
shipments of his poudre spécifique, and that it was destined for Siam.43 Mention of the 
                                                 
42 For a summaries of these events, see David K. Wyatt, Thailand: A Short History (New Haven: 
Yale University Press, 1984), 95–104; and Anthony Reid, Southeast Asia in the Age of Commerce, 1450-
1680, vol. 2. Expansion and Crisis (New Haven, Conn.: Yale University Press, 1988), 307; for European 
primary accoutns, see Michael Smithies, ed., Witnesses to a revolution: Siam, 1688 : twelve key texts 
describing the events and consequences of the Phetracha coup d’état and the withdrawal of French forces 
from the country (Bangkok: Siam Society, 2004); and E. W Hutchinson, ed., 1688 Revolution in Siam: The 
Memoir of Father de Bèze. (Hong Kong: University Press, 1968); for debate over the consequences of the 
1688 revolution and the supposed isolationism that came in its wake, see Victor B. Lieberman, Strange 
Parallels Southeast Asia in Global Context, c 800-1830, vol. 1, Integration on the Mainland, 2 vols. 
(Cambridge: Cambridge University Press, 2003): 288–291. 
 43 AME 1537, “Recettes et dépenses des missions, 1687-1697,” 28. The ledger shows that 225 
livres were paid to Helvétius for an unspecified quantity of his dysentery remedy, to be sent to Siam 
(March 1689). If the drug was sold at the standard price of 3 louis d’or (1 louis = 3 livres), which seems 
likely, then the MEP fathers bought 25 boxes (each containing the sixteen alphanumerically labelled 
packets that make up a full course of treatment, see ch. 4.  
Unfortunately no further expense registers exist for the period in question, thus preventing me 
from charting the purchases of Helvétius’ drugs after this point. The missionary correspondence 
demonstrates however that shipments continued to be sent, particularly to Tonkin and Cochinchina, into the 
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drug recurs in the missionary correspondence over the following decades, not only in 
Siam but also in Tonkin and Cochinchina, where the MEP was also very active during 
this period. 
As suggested by comments by Louis Laneau which open this chapter, Helvétius’ 
remedies were an important expense for the MEP. If we compare the price of the drugs 
purchased in March of 1689 to other medical expenses, we see that the supply of drugs 
from Helvétius cost more than seven times the two surgeon’s kits the MEP had purchased 
for the Siam mission in the same month.44 As we have already seen, the price of the drug 
was particularly high during the early years of Helvétius’ monopoly, before he 
streamlined the regimen instructions and developed the smaller uniform dosage scheme 
that enabled him to sell it in bulk more cheaply. Reading the printed instructions that 
accompanied the drug, however, Laneau knew that Helvétius also sometimes dispensed 
the drug charitably to the poor, and expressed his wishes that this charity should extend to 
the missions in Siam, and so spare the MEP the expense of purchasing such an expensive 
drug. Like most of the drug’s users, Laneau was almost certainly unaware that its active 
ingredient, ipecacuanha, was the ground root of a plant which had been collected in 
Brazil (quite literally on the opposite side of the planet from Siam), which had then been 
transformed in Helvétius’ Parisian lab, and then packaged and boxed with a small set of 
                                                                                                                                                 
1730s. Some points on search methodology: it being impracticable to go through whole correspondence, I 
scanned through the (admittedly limited) manuscript finding aids for correspondence from Tonkin, Siam, 
Canada, Cochinchina, China, and Pondichéry, looking for references to medicine generally and to 
Helvétius’ remedies in particular, or for correspondence from figures I knew were connected to him. The 
references that did yield results were often brief, couched in paragraphs dealing with other matters, or 
placed as if by afterthought at the end of letters (e.g. among requests for other materials), and may not have 
always struck the eye of the archivist as an item worth noting in the descriptions. The results are presented 
here, in full admission of the fragmentary nature of the picture that emerges from them. 
44 AME 1537, p. 28. The figures are 225 livres for Helvétius remedy vs. 32 livres for the surgeon’s 
kits to a M. Alet. The only medical expense that exceeds it is 431 livres paid to a physician, M. Vincent, for 
services rendered, probably in Siam. The roughly bi-annual payments to the, M. Alet, never exceed 37 
livres; he appears to have served as surgeon for the seminarists in Paris. 
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ancillary drugs and printed instruction sheets, to be sent to Siam by the MEP directors.45 
Ignoring the accumulated expenses in shipping, and the value added by Helvétius’ 
chymical transformation, Laneau could only express his wish that Helvétius might 
instruct the MEP fathers on how to produce a less expensive, even if “less infallible,” 
substitute that they might compound locally. He acknowledged that this would need to be 
done without assuming the availability of most common European simples, as in Siam 
these could only be bought at great expense from European merchants and 
apothecaries.46 
As Helvétius found ways to make his drug cheaper and easier to use, Laneau’s 
wish would eventually be fulfilled: we have already seen that, over the course of the 
1690s and 1700 it became cheaper and appealed more and more to bulk purchasers, 
notably the French army and state-funded poor relief efforts. The MEP, which had been 
purchasing Helvétius’ remedies as early as 1689, would also benefit from this 
transformation. Even in 1693, when a full regime of Helvétius’ drug still cost a whopping 
5 louis d’or, Laneau still felt that the price remedy could be justified, as we have already 
seen, given the much greater expense of training and transporting missionaries. 
 Lanneau’s ambivalence about the expense of Helvétius remedies would be shared 
by other missionaries in the coming decades, in spite of both the fact that they became 
cheaper and that the MEP fathers came to see medicine as a crucial support for their 
missionary goals. Alain Forest has suggested that the emphasis on medicine through the 
                                                 
45 For curious readers who have not looked at chapter 4: this mainly involved treating it with a 
coating to minimize its recognized emetic properties in order to enable its users to better keep it down and 
benefit fully from the exercise of its other, hitherto unrecognized virtues against flux and dysentery. It was 
placed in a series of alphanumerically labelled packages which contained mixtures of variable 
concentrations, along with a series of ancillary drugs, and boxed along with instruction sheets which would 
guide the patient or the administering practitioner through the drug’s regimen. 
 46 AME 881 (Siam), 171-172, Lanneau aux directeurs (14 novembre 1693). 
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establishment of hospices and the distribution of holy water and medication is a peculiar 
feature of the MEP missions, as contrasted with the Jesuit emphasis on impressing court 
elites with mathematical and astronomical skill.47 Recent scholarship however has 
demonstrated the importance of medicine to the Jesuit mission to China as well.48 French 
Jesuits at the court of the Kangxi emperor not only facilitated the exchange of medical 
knowledge, for instance bringing knowledge of European anatomy to China and Chinese 
acupuncture to Europe, but also the introduction of therapeutic substances. In addition to 
the well-known example of cinchona,49 some of these were even French proprietary 
medicines: the “pastes medicinales” which Kangxhi dubbed “Chin-yo” and which, 
according to the account of Jean de Fontaney, were distributed to the poor of France by 
Louis XIV, may have been the remedies of the state medical supplier, Pierre-Jean-
Baptiste Chomel, who as we have already seen, supplied pastilles and onguent divin 
alongside Helvétius’ shipments to the rural poor in the French provinces.50 Among the 
                                                 
47 Forest, Les missionnaires français au Tonkin et au Siam, 1:210. 
 48 See von Collani, “Mission and Medicine”; Puente-Ballesteros, “Jesuit Medicine in the Kangxi 
Court.” See also Puente-Ballesteros forthcoming monograph, “The Naked Emperor: Jesuit Surgeons, 
Physicians and Apothecaries in the Service of the Kangxi Court (1662-1722),” in preparation for Brill. 
 49 Marta Hanson, “Jesuits and Medicine in the Kangxi Court (1662–1722),” Pacific Rim Report 43 
(2007): 1–10; Harold J. Cook, “Testing the Effects of Jesuit’s Bark in the Chinese Emperor’s Court,” 
Journal of the Royal Society of Medicine 107, no. 8 (August 1, 2014): 326–27; Puente-Ballesteros, “Jesuit 
Medicine in the Kangxi Court.” 
 It is of course possible that the Jesuits received one of Robert Talbor or even Helvétius’ 
proprietary preparations of cinchona, which were included in his standard boëtes; but it seems more likely 
that they used raw cinchona and prepared it themselves following a recipe. The text refers to the 
distribution of cinchona among the poor in France, the rewards given the man who “possessed the secret” 
(Talbor, see above, ch. 2), describes a pound of cinchona being sent from a Jesuit Father Dolu in 
Pondichéry, and to instructions on its use printed by order of the king: this could be a reference to Blégny’s 
book disclosing the secret, or to the short printed pamphlets that accompany Helvétius’ remedy. My leaning 
is to the Jesuits using raw cinchona and processing it themselves, possibly following the instructions in 
Blégny’s book, described in chapter 2. 
 50 Jean de Fontaney, “Lettre du Pere de Fontaney, Missionnaire de la Compagnie de Jesus à la 
Chine, au R. Pere de la Chaize de la mesme Compagnie, confesseur du Roy. A Tchou-Chan Port de la 
Chine dans le Province de Tche-kiam à 18 lieuës de Nimpo, le 15 de Février 1703.,” in Lettres edifiantes et 
curieuses, ecrites des missions etrangeres, par quelques missionnaires de la Compagnie de Jesus, vol. 7 (A 
Paris: Nicolas Le Clerc, 1707), 222–231. See the following link to photographs of this source appended to a 
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medicines recommended by the Jesuit Joachim Bouvet, which should be carried in 
medicine chests by missionaries, we find simples and officinal compounds like theriac, 
Queen of Hungary water, capillary syrups, confection of hyacinth, and bezoar stone, but 
also orviétan, described as “another kind of theriac.”51 
Despite long-standing canon law prohibitions against surgery, care for the sick fit 
within traditional Catholic pastoral and charitable imperatives from the perspective of the 
missionaries, and opened a space for proselytization and baptism. Likewise, populations 
in Southeast Asia, like those in Europe, were accustomed to connecting spiritual with 
bodily health, and proselytization was also linked with care for the sick in the more 
locally familiar Buddhist tradition: there was as such little barrier to their perceiving the 
new missionaries coming from Europe as a variety of healer.52 
But if missionaries were also to be healers of the body, they needed medicines. 
Requests for medicines, recipes, and secrets are a persistent feature of the MEP 
missionary correspondence. In his correspondence from Cochinchina, the missionary 
Pierre Langlois repeatedly extols the importance of medical work to the mission and in 
his letters back to the Directors of the Society in Paris asked for “good recipes or secrets 
that will be easy to execute.”53 He also asked for medical books, often specified titles,54 
and expressed his hope that one of his nephews would come join him in his mission, as 
he was growing old, and that his nephew might study pharmacy, surgery, or medicine, 
                                                                                                                                                 
short article by Hal Cook on this episode for the James Lind Library: http://www.jameslindlibrary.org/de-
fontaney-f-1703/ (July 14 2015). 
 On Chomel, see above, ch. 4, sect. 4. 
 51 von Collani, “Mission and Medicine,” 58–60. 
52 On missionaries as healers in Southeast Asia in this period, see esp. Alberts, Conflict and 
Conversion, 109–119. 
53 AME 726, fol. 277, Langlois to the Directors (February 8, 1699). 
54 AME 713, fol. 132, Langlois to Langlois (August 2, 1698). The books requested include “M. 
Dubé, Le médecin et chirurgien des pauvres, La Chimie de Glaser ou autre.” 
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“for this will serve him well in working to save souls by healing bodies.”55 Other 
missionaries likewise wrote of the importance of a supply of both skilled practitioners 
and medicines in keeping up relations with the “mandarins” and other local elites.56  
What role did proprietary remedies play in this combined medical and religious 
economy?  The correspondence provides some indicative hints. In 1699 colleague Père 
Capponi made specific requests for different substances, such as aloe, senna, cream of 
tartar, and theriac, but also requested a supply of a proprietary drug, l’onguent divin, 
produced by the médecin du roi Jean-Baptiste Chomel (1639-1720) and his son Pierre-
Jean-Baptiste (1671-1740).57 We see here that requests for proprietary drugs were mixed 
with more conventional simples, compounds, and chemical substances. It will be recalled 
that Chomel’s onguent and pastilles were distributed to the rural poor in the provinces 
through a system which antedated that of Helvétius and may even have furnished the 
latter with his distribution model (see chapter 4). The presence of the onguent in the 
missionary correspondence suggests that Chomel was also involved in supplying drugs to 
the missionaries, and that Helvétius was thus not the only vendor of proprietary remedies 
that had established a relationship with the MEP in Southeast Asia. 
While Helvétius’ early shipments to Siam appear only to have contained the 
dysentery specific, later shipments to Tonkin (northern Vietnam) in the 1720s appear to 
have been the same as the chests (boëtes) sent out the provincial intendants in France, 
including a full range of drugs with printed instruction sheets. The Tonkin missionary 
correspondence points to some of the inherent challenges in shipping proprietary drugs 
                                                 
55 AME 726, fol. 259, Langlois to Langlois (February 8, 1699). 
56 AME 725, fol. 8, Capponi to the Directors (February 10, 1699); AME 737, fol. 240, Capponi to 
the 
Directors (May 12, 1692).  
57 AME 725, fol. 7, Capponi to the Directors, 10 February, 1699. 
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overseas as well as preserving and using them in tropical environments. Père Cordier, 
writing October 29, 1729, almost forty years after Helvétius’ earliest shipments to 
Southeast Asia, observed that “In our experience the medicines of Helvétius are very 
good even in this country” and requested that his superiors send more.58 He observed 
however a number of material problems with packaging and spoilage: although the 
dysentery specific apparently travelled well, several of the other powders and pills 
included in the chests had a tendency to melt or become moist (humide) and soak through 
the paper envelopes that contained them: “When they are wrapped in paper they soak up 
water and loose their virtues and should instead be kept in small faience pots, sealed with 
small piece of pine or cork, and with several doubled-over layers of paper [assumedly as 
a cushion].”59 The balms and sudorific pastes by contrast had the opposite problem: they 
would dry out in the heat of the local climate. Cordier made other points which 
emphasize the difficulties of adapting the drugs in Helvétius’ chest to local conditions. 
These parallel the feedback mechanisms in place in the French provinces, whereby the 
intendants and their subdelegates would have the substances and quantities in each chest 
tailored to meet their specific deeds. Cordier advised, for instance, that the alum could be 
dispensed with as it was easily available at low cost in Tonkin, but requested a common 
European purgative, senna, be included in the next shipment. Likewise following the 
practice of the provincial intendants, he offered up a detailed description of specific local 
medical problems that were not addressed by the box’s standard therapeutic 
armamentarium, in the hopes that Helvétius might devise a new specific: “If Monsieur 
Helvétius could communicate some remedies to us which would be easy to put into use, 
                                                 




he would do us a service and could save the lives of many of our Christians.”60 The 
condition afflicted women after they delivered babies, and struck them so suddenly that 
the fathers scarcely had time to give them last rites: “Decorum does not permit us to 
inform ourselves in detail on this disease, but what our Tonkinois usually tell us is that 
blood comes back up and suffocates them [the mothers] so promptly that in just a few 
hours they expire.”61 At this point, production of the medicine chests was being overseen 
by Adrien Helvétius’ son Jean-Claude-Adrien, and it is impossible to say whether 
Cordier’s request ever reached him, and the subsequent surviving correspondence makes 
no further reference to the condition Cordier observed. The request does however 
demonstrate that, just as they did in France, the immediate consumers and dispensers of 
the drugs took the time to provide Helvétius with feedback on both their effects and 
advice on tailoring the content of the shipments to local conditions. Likewise, the 
description of the local “epidemic conditions” shows that whether they were a Daughter 
of Charity in Brittany, an intendant in Auvergne, or a missionary Tonkin, the people who 
received and dispensed Helvetius’ drugs did not simply see him as a distant and 
impersonal purveyor of medical supplies: rather, they conceived of him as a kind of 
lifeline of medical expertise whom they could contact personally. 
Cordier was also not the first to complain about packaging and damage in 
transport: Lanneau in Siam had brought up similar problems, being particularly vexed by 
a discordance between the drugs containers—which were unlabeled by the time they 
reached him—and the references to alphanumeric labels in the accompanying instruction 
                                                 
60 “Si M. Helvetius pouvoit nous communiquer quelques remedes qui fût facile mettre en usage, il 
nous rendroit service et sauveroit peut être la vie a bien de nos chrétiens,” Ibid. 
61 “La bien sceance ne nous permet pas de nous informer en detail de cette maladie, ce que nos 
Tonquinois nous dissent ordinairement c’est que le sang remonte et suffoque si promptement qu’en tres peu 
d’heures elles expirent,” Ibid., fol. 306. 
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sheets. It is possible that the labels had become detached, or the drugs had at some point 
been repackaged (or even adulterated); either way, he asked the directors to sort this out, 
until which time “he would not dare to use them.”62  
The MEP missionaries combined bodily healing with their spiritual aims in 
Southeast Asia, and consistently expressed the need for remedies, both for the 
preservation of their own health as well as for making inroads with the local populations. 
Alongside more traditional simples and compounds shipped from Europe, the proprietary 
drugs of Helvétius as well as his forerunner Chomel helped furnish the missionaries with 
the means to their medical and ultimately spiritual ends. This linkage of the spiritual and 
the temporal was not universally seen as fitting for missionaries, however, and at least 
one missionary, Louis Néez, criticized the mingling of medicine with the religious 
mission and singled out Helvétius’ drugs in particular as an unnecessary expense: 
Mr. Guetti has sent us [...] a box of Helvétius’ medicines, which are of little 
use to us here in Tonkin, where everyone dabbles in medicine except us (as 
we have other things to do). When we ourselves are sick, we draw recourse to 
the physicians of the land.63 
 
Alongside casting the utility of Helvétius’ drugs into doubt, we find here an implicit 
condemnation of missionary medical practice and unique praise for the indigenous 
medical tradition as perfectly sufficient to the missionaries’ needs. Resources could be 
better allocated: as the rest of the letter makes clear, Néez felt the directors should send 
fewer of Helvétius’ remedies and more money for them to buy food. 
                                                 
62 AME 881, fol. 172, Lanneau to the Directors (November 14, 1699). 
63 AME 655, fol. 367, Néez to Brisacier and Tiberge (December 15, 1721). “M. Guetti nous a fait 
venir de la côte […] une boëte de medecines de M. Helvetius qui nous sont de peu d’usage icy au Tonquin; 
ou tout le monde se mêle de medecines excepté nous qui avons autre chose à faire, et quand nous sommes 
malades nous-mêmes nous avous recours aux medecins du païs.”  
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To summarize, it seems that Helvétius gained the patronage of the MEP in much 
the same way as he had made inroads with the state: namely, through private practice on 
high-ranking patients. The case of the Jesuits, the French military, and the MEP 
demonstrate that the connections Helvétius forged with these “corporate consumers” 
were derived from the patronage of a small set of actors at the highest levels of the 
French court and ecclesiastical hierarchy. The evidence I have assembled demonstrates 
that the MEP recognized dysentery as an important threat to their missions in Southeast 
Asia, and were willing to pay for Helvétius’ drug, even in its most expensive phase. It 
also shows that there were problems inherent in shipping compounded drugs overseas for 
use in a radically different climate, and that the drugs’ users hoped that their individual 
feedback, questions, and requests could be relayed by the corporate consumer to the 
drug’s producer, even though there is no evidence that the message ever reached 
Helvétius in the case of the MEP. Finally, the missionary correspondence shows that 
Helvétius’ drugs played only one role in a broader economy of medical support being 
provided to the missionaries, one which included at least one other proprietary, Chomel’s 
onguent, as well as simples, recipes, and printed books. The mention of Chomel’s 
onguent is of particular interest, as it suggests that Helvétius was not alone among 
proprietary vendors in sending his remedies to the MEP in Southeast Asia, and offers 
another example of how his operation was paralleled by that of Chomel.64 
In the case of Helvétius as a producer, the fragmentary state of the archival record 
prevents us from saying how much business he conducted with the MEP in terms of the 
volume or regularity of shipments: no receipts or expense records survive past the 1690s, 
even though the drugs are periodically mentioned in the correspondence between the 
                                                 
 64 See above, ch. 4, sect. 4. 
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missionaries and the MEP directors in Paris. Nor can we say how regularly his drugs 
were supplied to Siam, Tonkin and Cochinchina across this rather long period, from the 
earliest mentions in the 1690s correspondence to later references in the 1720s. While we 
can assume that the volumes Helvétius was shipping to Southeast Asia were quite small 
in comparison to the thousands of doses of his poudre spécifique that were sent into the 
army hospitals in Alsace in 1690, not to mention the tens of thousands of doses in 
medicine chests sent by the French state to the provinces from the 1700s onward, his 
business with the MEP nonetheless shows that his provision of uniform, pre-packaged 
drugs had global reach. Beyond Southeast Asia, he also claims to have exported them to 
MEP missionaries in China (a claim which I have unfortunately been unable to verify, 
but which is quite plausible), and by 1753, at the end of the French Regime in Canada, 
they were also being sent to Québec.65 The evidence permits us to make a number of 
statements about the global reach of Helvétius’ pharmaceutical network, but the lack of 
actual receipts and accounts allows us to say almost nothing about the relative importance 
of given channels within it. Fortunately, this is not the case with the Guiller-Lajutais 
poudre fébrifuge, where the accounts have survived as evidence collected during lawsuits 
over the sharing of profits. They permit us, at least for a few short years, to have a 
relatively complete picture of their overall pharmaceutical business with different 
consumers, both individual and corporate.  
3.  Lajutais’ poudre fébrifuge and the French East Indies Company 
 
We have already seen how Ferdinand de Guiller and his putative successor Pierre 
Brodin de Lajutais followed the path blazed by Adrien Helvétius in building on their 
royal monopoly privileges to gain lucrative military supply contracts. Lajutais also 
                                                 
65 Nadeau, “Les remèdes des Helvétius dans la Nouvelle France,” 627. 
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followed Helvétius in finding other corporate consumers who would buy his drugs in 
bulk, but rather than extending his operation to supply missionaries, Lajutais appears to 
have leveraged his personal connections and those of his one-time agent/associé Etienne 
Guerin with the financial world of the General Farm (Ferme général), the outsourced tax 
agency of the French state, to supply the poudre fébrifuge to the French East Indies 
Company (Compagnie des indes orientales). As we have already seen in the previous 
chapter, both men were senior officials at the Mondragon snuff works, which processed 
tobacco for the Farmer’s state tobacco monopoly. This employment had acquainted them 
not only with the large-scale processing of plant substances that was crucial to the 
production of large volumes of their poudre, but also provided them with connections to 
the world of “court capitalism” at Versailles.66  
Despite the lack of documentation surrounding how Lajutais came to supply the 
Company, the rare survival of his account book and various receipts in the case of the 
poudre fébrifuge allows us to make quantitative statements about the total volume of 
Lajutais’ business in 1735-1736 and the distribution of sales between the Company and 
other consumers. As the following charts make clear, the vast bulk (over 2/3) of Lajutais’ 
total sales in these years went to the French army, which, as we have already seen, was 
mobilizing for the War of the Polish Succession. After this, the next largest purchaser by 
                                                 
66 While the surviving correspondence between Guerin and Lajutais does not include any direct 
evidence of their negotiations with the Company in the form of an adjudication de fourniture (supply 
contract negotiation), it does demonstrate that their work in Mondragon had put both men in contact with a 
“M. Dupleix,” probably Charles-Claude-Ange Dupleix, one of the Farmers, son of René François, former 
controller of the East Indies Company and the elder brother of Joseph François Dupleix, governor of 
Pondichéry and commandant general of the French posts in India. See esp. AN V7 246 (6), dossier 1, item 
1, Guerin to Lajutais (21 June 1732). Incidentally, the mention of Dupleix in this letter pertains to the non-
poudre-related business which crops up frequently in Guerin’s earliest letters to Lajutais. In this particular 
case, Guerin agitatedly expresses his hope that Lajutais can secure the return of an account book from 
Dupleix, which, I suspect, pertains to his work in managing the Mondragon manufacture and, based on his 
concern, may have implicated him in some financial malfeasance. 
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far was the French East Indies Company, receiving over 6,300 prises (packaged doses) of 
the drug in the years 1735-1736. While this pales when compared to the 28,000 prises 
that were supplied to the army, it also exceeds the total retail sales of the drug, both by 
Lajutais personally and by Blanc, his Parisian agent, which amount to less than 4,000 
prises.67 Indeed, retail sales in the traditional urban marketplace sense make up only a 
small fraction of the overall sales of the poudre fébrifuge (see Appendix 3, Figure 15). 
How do these figures compare to those of other proprietary medicine vendors 
from this period? Unfortunately, the extremely limited number of surviving account 
books from such vendors makes it difficult to know the extent to which this distribution 
was normal or exceptional. Indeed, the lack of surviving accounts for after the period of 
Lajutais’ lawsuit with Guerin even makes it impossible to know how typical the years 
1735-1736 were for his own operation. Chronologically, the nearest point of comparison 
is furnished by the accounts for Anthony Daffy’s elixir and the various Francke 
Foundation medicines. Both cases show that the export of proprietary drugs, particularly 
to the British colonies in North America, was far more common than one might expect, 
and offer an instructive parallel to that of Lajutais or even Helvétius. 
As with those of Lajutais, we owe the survival of Daffy’s accounts to their being 
deposited as evidence during disputes over the distribution of profits and legal rights.68 
Daffy shipped an average of 9,000 half-pint bottles of his elixir per year between 1678-
                                                 
67 I should remind the reader here that it is impossible to know what portion of this was profit due 
to the near-total lack of documentation on production costs in the surviving documents (esp. raw simples, 
other materials, equipment, and labour). While all revenues were disputed between Guerin and Lajutais, 
expenses played a much smaller part in their legal dispute, and consequently, little evidence on them 
survives, with the exception of a few expenses on advertising (painted signage and printed pamphlets).  On 
all of this, see above, ch. 5. 
68 David Boyd Haycock and Patrick Wallis, Quackery and Commerce in Seventeenth-Century 
London: The Proprietary Medicine Business of Anthony Daffy (London: Wellcome Trust Centre for the 
History of Medicine at UCL, 2005), 2. 
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1693, at a price of 2 shillings 6 pennies per bottle. While a considerable volume was 
shipped beyond England, most of this was to Daffy’s agents in other European countries, 
such as Scotland, France, Ireland, Holland, and Portugal. Comparatively small quantities 
reached North America and the West Indies, and only two shipments were sent to the 
Indian Ocean: one a shipment of 80 half pints shipped to Fort St George, the English East 
Indies Company’s trading post at Madras in 1677; and the other a shipment of 36 half-
pints sent to one Caleb Travers of Bombay in 1682.69 These quantities are in the same 
ballpark as Helvétius’ early shipments to Southeast Asia, at 25 boxes of his dysentery 
specific, which occurred in roughly the same period (1677 and 1682 for Daffy’s 
shipments to India vs. 1689 for Helvétius’ shipments to Southeast Asia), but are dwarfed 
by the over 6,000 doses sent by Lajutais four decades later, which approaches Daffy’s 
total annual sales in Europe. 
The German context provides an even more interesting basis for comparison in 
the form of what we might call a “corporate producer,” namely, the philanthropic 
Francke Foundations of Halle, recently detailed by Renate Wilson.70 As we have seen in 
chapter 4, the standardized medicine chests of the Foundations provide a parallel to those 
of Helvétius, and were developed at almost the exact same time, ca. 1700-1705.71 The 
Foundations financed an orphanage and educational activities through the sale of 
proprietary drugs, which they distributed not only in the Holy Roman Empire, but also in 
Russia and across the Atlantic, where they were also distributed through an extensive 
network of German Pietist clients in Britain’s North American colonies, as well as to 
                                                 
69 Ibid., 145, 195. 
70 Renate Wilson, Pious Traders in Medicine: A German Pharmaceutical Network in Eighteenth-
Century North America (University Park, Pa.: Pennsylvania State University Press, 2000). 
 71 See above, ch. 4, sect. 4. 
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Pietist missions in the Danish Tranquebar colony in India. In many ways their business 
stands as an inversion of the Helvétius or Lajutais model: they were a corporate producer 
that catered to individual consumers, selling primarily to individual clients; whereas 
Helvétius and Lajutais were individual pharmaceutical entrepreneurs, (employing of 
course various workers to produce their medications) which they then sold to corporate 
consumers.72 
When Lajutais’ sales are examined from the point of view of revenue, however, 
an important drawback of his business with the East Indies Company immediately 
becomes clear: while he was paid in full for the 600 prises he sent to their hospital in 
Lorient (the Company’s metropolitan port in Brittany) he was only paid for half of the 
much larger shipment of 6,300 prises that was dispatched to ten East Indies Company 
ships bound for their colonies and comptoirs. In this case and possibly others, as the 
similar terms for the antivenereal pills suggest, the risks in such overseas commerce were 
shouldered by the producers of the drug, not the consumers. According to a note in his 
accounts, the Company alleged that half of this massive order spoiled aboard ship: “they 
allege that the greater part of the poudre fébrifuge distributed aboard ten ships were found 
wet and moldy upon arrival at some of their colonies, despite being found well packaged 
at others, where they were perfectly successful.”73 Spoilage as we have seen was likewise 
                                                 
72 On a financial level, Wilson provides detailed information on the net profits of the Francke 
pharmaceuticals over the course of the eighteenth century, but nothing that would enable a comparison to 
either Helvétius and Lajutais, as my information includes only sales by unit and by revenue, but not profits, 
which in both cases would require information on production costs, which is unfortunately absent. Wilson 
is undoubtedly correct, however, that their net profits, which varied between 20,000 and 35,000 
Reichsthaler per annum, must have put them in the highest tier of European pharmaceutical production in 
this period. Wilson, Pious Traders in Medicine, 90. 
73 AN V7 246 (6), cotte 3e, “Journal en forme de compte que rend le Sr Lajutais au Sr Guerin cy 
devant son agent, ainsi ordonné par jugement de Mgrs les Commissaires généraux du Conseil,” 2. “Elle 
prétend que la plus grande partie des poudres febrifuge distribuée sur dix vaisseaux se sont trouvées 
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a problem with Helvetius’ remedies sent to Vietnam. Lajutais does not specify how many 
prises this order entailed, but based on his usual pricing it would have been in the order 
of 6,300. Following the terms of his contract, he shouldered half of the loss: the original 
3,150 livres due to him from the Company was reduced to 1,181 livres.74 These losses 
from the perspective of Lajutais may have discouraged him from subsequent dealings 
with the Company, as we shall see. 
 How were these drugs distributed by the Company? Most were sent to port 
hospitals in the network of French posts that dotted the Indian Ocean. Isle de France 
(Mauritius), Bourbon (Réunion), and Pondichéry all had standing East Indies Company 
hospitals, the latter two (which will concern this section) dating respectively from 1683 
and 1701. These hospitals served the stable company personnel at each comptoir (trading 
post), but also had to contend with regular waves of sick sailors arriving aboard Company 
ships. Each was equipped with permanent surgeons-major, but only Bourbon had an 
apothecary, starting in 1735, just a few years prior to the first poudre fébrifuge 
shipments.75 
                                                                                                                                                 
mouillées, et moisies arrivant a quelques unes de leurs Colonies quoy que bien conditionnées dans les 
autres, ou elles ont eu un parfait success.” 
 74 Ibid., 1-2: “300 livres reçue comtant de la compagnie des Indes pour vente de 600 prises a 
l'usage de son hopital d’Orient [Lorient]. De la somme 1,181 livres 5 sols duë par la Compagnie des Indes, 
provenant de sa reconnoissance de la somme de 3,150 livres qu’elle reduit à moitié, attendu qu’elle prétend 
que la plus grande partie des poudres febrifuge distribuée sur dix vaisseaux se sont trouvées mouillées, et 
moisies arrivant a quelques unes de leurs Colonies, quoy que bien conditionnées dans les autres, ou elles on 
eu un parfait succès. Laquelle moitié estat celle de 1,575 livres sur la quelle est osté le quart que l’arrest du 
Parlement accorde a Made. Rivoire (?), en ce qu’il est jugé que l’envoy a esté fait par son Canal, il reste la 
premiere somme de onze cents quatre vingt une livres cinq sols.” I am uncertain as to Lajutais’s relation 
with this “Mme. Rivoire,” but she appears to have been the channel (“canal”) by which the drugs were 
delivered to the Company. Mention of an arrêt from the Parlement suggests that there was a dispute 
between her and Lajutais, the settlement of which required him to pay her one quarter of his profits. 
 75 Yannick Romieux, De la hune au mortier, ou, L’histoire des compagnies des Indes : leurs 
apothicaires et leurs remèdes (Nantes: Editions ACL, 1986), 263, 269; Alfred Bigot, “La médecine 
française à Pondichéry aux XVIIIe et XIXe siècles,” in Comptes rendus du 91e Congrès national des 




 Lacking apothecaries in the Indian Ocean, the majority of their drugs came from 
Europe. Many likely originated in the central “Apothicairerie” of the port of Lorient, the 
metropolitan port of the Company. This “Apothicairerie” was created in 1725 as a cost 
saving measure, with the company following the French navy in abolishing the traditional 
practice of contracting apothicaire-fournisseurs on an ad hoc basis, instead giving the 
responsibility to a single apothecary who was charged with producing medicine chests to 
be used by the surgeons aboard Company ships and in the comptoirs.76 In this sense it 
was born of much she same frustration with fournisseurs as the army’s decision to 
purchase Helvétius’ drugs in bulk.77 But even with this drive to compound medicines 
centrally and internally within the Company, the letters and inventories of requested 
drugs sent by the Superior councils of the comptoirs demonstrate that the Company relied 
on proprietary vendors to supply a number of drugs, including Lajutais. It is unclear 
whether this is the result of the central apothecary’s inability to fill orders, the specific 
nature of the drugs in question (that is, the proprietary poudre fébrifuge may have been 
deemed superior to available officinal alternatives, justifying its purchase), or the 
inherent drawbacks of not having compounding apothecaries on the ground at the 
comptoir hospitals in the Indian Ocean. 
 Whatever the precise rationale for the corporate purchase of the poudre fébrifuge, 
in some cases it is possible to follow shipments of these from the port of Lorient all the 
way to the comptoirs in the Indian Ocean. In most cases the references in question are 
only brief mentions of the drug in official Company correspondence (usually 
acknowledgements of the receipt of a shipment), or the presence of the drug on lists of 
                                                 
 76 Romieux, De la hune au mortier, 129–130; Édouard Guéguen, “Les apothicaires des 
Compagnies des Indes,” Revue d’histoire de la pharmacie 58, no. 206 (1970): 150–154. 
 77 See above, ch. 4, sect. 3. 
358 
 
requested medications. The most interesting is from the Superior Council at Pondichéry, 
the central Indian comptoir of the French Company.78 In the fall of 1736, 600 prises of 
the poudre fébrifuge were shipped there, and the Directors of the Company charged the 
Pondichéry Council with the task of evaluating their efficacy, providing explicit 
instructions on how to do so: 
The good effects here produced by a poudre fébrifuge invented by the 
Sieur de la Jutais have convinced us to send you two parcels, each 
containing 300 doses. The printed sheets will instruct you on the drug’s 
qualities, use, operation, and the dosage that should be taken. You will 
take care as soon as they arrive to inform the surgeon-major to make 
several trials [épreuves] on the sick attacked by several illnesses; you will 
order him to draw up a memorandum with exact details on the uses he has 
made of it and the effects that it has produced, which you will submit to us 
in two certified copies, and in the case that this powder does not have all 
the success that we would hope it to, you will have him draw up a legal 
statement [procès-verbal] in the proper form which you will then submit in 
duplicate, and send back to us aboard the same ships whatever remains of 
this powder so that it can be returned to the Sieur La Jutais at his 
requisition and at whose risk we shall let it pass through on your behalf.79 
 
The implication of this final sentence is that the efficacy of the drugs was an important 
condition of the contract: if they were deemed ineffective, a legal account (procès-verbal) 
was to be produced of the assessment of the surgeon major, and the drugs were to be sent 
back to France and returned to Lajutais, who would shoulder risk of loss on their long 
                                                 
78 On medicine at Pondichéry see Bigot, “La médecine française à Pondichéry aux XVIIIe et XIXe 
siècles.” Bigot mentions that Lajutais poudre was among the drugs sent to the hospital there. 
79 Compagnie au Conseil supérieur de Pondichéry (October 30, 1736), in Alfred Martineau, ed., 
Correspondance du Conseil supérieur de Pondichéry et de la Compagnie, vol. 2 (1736–38) (Pondichéry: 
Sociéte de l’histoire de lʹInde française., 1920), 66–67.  
“Les bons effets que l’on débite icy d’une poudre fébrifuge de l’invention du sieur de la Jutais 
nous ont déterminés à vous en envoyer deux pacquets contenant chacun 300 prises; les imprimés qui y sont 
vous instruiront de ses qualités, de son usage, de son opération et de la dose qu’il en faut prendre. Vous 
observerez aussitôt qu’elle vous sera parvenue d’ordonner au chirurgien major d’en faire plusieurs épreuves 
sur des malades attaqués de diverses maladies; vous lui ordonnerez de dresser un mémoire exactement 
circonstancié de l’employ qu’il en aura fait et des effets qu’elle aura produits, dont vous nous en remettrés 
deux copies certifiées, et au cas que cette poudre n’ait point le succès que l’on doit en espérer, vous en ferés 
dresser un procès-verbal en bonne forme que vous nous remettreés par duplicata et nous renvoyerez par ces 
mêmes vaisseaux ce qui vous restera de cette poudre pour la rendre au sieur La Jutais à la [sic, “sa”] 
réquisition et aux risques duquel nous vous la faisons passer.” 
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journey as well. This provision appears not to have been unique: a similar report on 
another proprietary drug, referred to in the correspondence as the pillules 
antivénériennes, 3,600 of which were sent to Pondichéry aboard the same ship, was also 
requested. 
 The response of the Pondichéry Council shows that the poudre fébrifuge was not, 
in fact, deemed by their surgeon-major to be effective. A detailed report by the surgeon-
major, Ferrier, was attached to the correspondence but has unfortunately not survived. 
Based on the Council’s summary, the suggestion seems to have been that the drug’s 
inefficacy may be due to differences between the climate of France and India:  
Our surgeons have not found that these powders have the same good 
effects in India as they do in France. The same is true of the antivenereal 
pills. We are sending the certificate drawn up by surgeon-major, the Sieur 
Ferrier, to the Company; the Company will also observe that these drugs 
did not have any greater success at Mahé.80 
 
This response suggests a shipment of the drug was also sent to the French comptoir at 
Mahé on the (opposite) Mallabar coast, possibly with similar instructions to assess its 
efficacy and report back.81 This of course raises an interesting question: was Lajutais 
only paid for half of the shipment of his drug because they “spoiled” aboard ship, or 
because, based on the assessment of the surgeon majors at Pondichéry, Mahé, and other 
comptoirs, they were deemed to be ineffective? The statements in Lajutais’ own accounts 
point to spoilage, but the two explanations need not be mutually exclusive: we have 
                                                 
80 Réponse du Conseil Supérieur de Pondichéry au Compagnie (January 2, 1738), in Ibid. “Nos 
chirurgiens n’ont pas trouvé que cette poudre eut aux Indes les bons effets qu’elle a en France; il en est de 
même des pilules antivénériennes. Nous envoyons à la Compagnie le certificat qu’en a dressé le sieur 
Ferrier, chirurgien major; la Compagnie y verra que ces drogues n’ont pas eu plus de succès à Mahé.” 
81 This suggests the two posts were communicating regarding the efficacy of the drug, or at least 
that the Council at Pondichéry received the Mahé correspondence before it was dispatched to France. 
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already seen Ferdnand de Guiller attribute the failure of his poudre during the first trials 
in 1713 to spoilage en route. 
 Whatever the relationship between the perceived failure of the poudre in 
Pondichéry and the Company only paying Lajutais for half of the shipment, this episode 
shows that the Company was a very savvy corporate consumer: provisions surrounding 
the failure of a drug to function as promised were included in their supply contract, and 
their orders show close attention to legally documenting such a failure so that it would 
stand up in the case of a lawsuit. Like the War Office bureaucrats who initiated the 
distribution of Helvétius drugs in the 1690s, the administrators of the Company was not 
just throwing money at what seemed to be a quick fix to a large-scale health problem: 
they wanted documented proof of efficacy from medical personnel on the ground, and 
were very careful not to be swindled by a wily medical entrepreneur like Lajutais. 
 The poudre fébrifuge crops up from time to time in the official correspondence of 
some of the other Indian Ocean posts. The Superior Council of Ile Bourbon (modern 
Réunion) for instance requested a new shipment of the poudre and other proprietary 
drugs in 1741: the Copmany agreed to send them 2,000 pillules de Chabert, “but as 
regards those of Petit, and the poudre fébrifuge of Lajutais, we will not send you any.” 
This refusal could be a response to the failure of the drug at Pondichéry and Mahé: the 
Company may have decided not to contract Lajutais for another supply. As with the 
initial naval trials of Guiller’s version of the drug in the 1710s, it seems that opinion on 
the efficacy of the drug was mixed.82  
                                                 
82 AD Réunion, C° 86, Directeurs de la Compagnie des Indes au Conseil supérieur à l’Isle de 
Bourbon (March 25, 1741). This letter has been published in Albert Lougnon, ed., Correspondance du 
Conseil supérieur de Bourbon et de la Compagnie des Indes, 23 janvier 1736 - 9 mai 1741, vol. 3.1 (Saint-
Denis, Réunion: Gastron Daudé, 1935), 183 for the reference to the poudre; see also Albert Lougnon, 
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 The last site where the poudre fébrifuge crops up in this period is the port of 
Saint-Louis in Sénégal, an important center in the Atlantic slave trade. Lajutais appears to 
have secured an official copy of a letter from the Superior Council of Sénégal to the East 
Indies Company, which was later used by his daughters to provide documentation of the 
drug’s long history of use when they worked to renew their father’s privilege in 1775.83 
The Council reported, “Our surgeons have employed the poudre fébrifuge which you had 
the kindness to send us with the last case of remedies to great success; as such we ask you 
to include them in subsequent cases.”84 The copy of the letter, attested as authentic by the 
Company syndics, goes on to specify that Lajutais had supplied them with another 1,000 
prises in November of 1738. Other evidence of the use of the poudre fébrifuge in Sénégal 
a few years later survives in the form of an “État des remèdes qui sont les plus 
nécessaires au Sénégal,” prepared by agents in Saint-Louis for the directors of the 
Senegal Company (Compagnie du Sénégal).85 The main interest of the Company was in 
gum (a substance which had a wide variety of commercial uses, most notably in textile 
dying), and in supplying slaves to France’s sugar islands in the Caribbean.86 The 
extensive list includes hundreds of drugs in high volumes, with the poudre fébrifuge 
mentioned prominently on the first page. The agents in Senegal requested a total of 800 
                                                                                                                                                 
Classement et inventaire du Fonds de la Compagnie des Indes des Archives Départementales de La 
Réunion. Série C°. (Nérac: Impr. G. Couderc, 1956), 22. 
 83 See above, ch. 5, sect. 4. 
84 ANM SRM 111B d 29, Mémoire et copies des pièces originales, No. 5, Extrait de la lettre du 
Conseil Superieur du Senegal écrite à la Compagnie des Indes (August 24, 1737). “Nos Chirurgiens ont 
employé avec succes la poudre fébrifuge que vous avez eu la bonté de faire envoyer avec les derniers 
caisses de remèdes; ainsy nous vous prions d’en joindre aux nouvelles caisses.” 
 85 ANOM COL C6 12, item 16 : État des remèdes qui sont les plus nécessaires au Sénégal, 30 
juillet 1742. 
 86 On the Compagnie du Sénégal, see Kenneth J. Banks, “Financiers, Factors, and French 
Proprietary Companies in West Africa, 1664-1713,” in Constructing Early Modern Empires: Proprietary 
Ventures in the Atlantic World, 1500-1750, ed. Louis H. Roper and Bertrand Van Ruymbeke (Leiden: Brill, 




prises of the poudre, along with large quantities of other drugs (e.g. 20 pounds each of 
theriac, confection of hyacinth, and alkermes, 25 pounds of capillary syrup, etc.). The 
“État” was attached to a letter, which includes explanations for many of the items being 
requested, including various trade goods for the slave trade itself. Among these 
explanations is the following, likely intended to justify the long list of medicines 
requested: “We assure you that we have always taken particular care to let no sick blacks 
embark among the cargoes we send to the American Isles.”87 This suggests that the 
medications being requested were not only meant for company personnel, but may also 
have been intended to preserve the health of slaves destined to be sent to plantations in 
the West Indies.88 
 The case of a standardized proprietary drug like Lajutais’ poudre fébrifuge being 
used to treat slaves in Senegal poses an important challenge to the view that proprietary 
drugs were “branded” luxury or “semi-luxury” products catering to the interests and 
purchasing power of metropolitan consumers in the urban medical marketplace.89 While 
admittedly extreme, it nonetheless fits within the established trends described here and in 
the preceding two chapters: slaves, like soldiers, sailors, peasants, and even distant 
converts to Catholicism, all represented collections of people whose health was worth 
preserving from the perspective of various state and corporate interests, but whose 
                                                 
87 ANOM COL C6 12, item 77, Letter to the Compagnie (August 1, 1742), article 26. “Nous 
pouvons vous assurer Messieurs que nous avons toujours eû une attention particulière à ne laisser 
embarquer aucun noir malade dans les cargaisons que nous envoyons aux Isles de l’Amérique.” 
 88 While the medical dimension of slavery in the Caribbean and British North America has seen a 
great deal of scholarly attention, the medical dimension of the transatlantic slave trade, particularly the 
metropolitan European and indigenous West African supply of pharmaceuticals, remains understudied. 
Carolyn Roberts’ dissertation in progress, provisionally entitled “Surgeon, Fetish Woman, Apothecary, 
Slave: The Medical Culture, Labor, and Economy of the British Slave Trade, 1680-1807,” promises to fill 
this lacuna in the case of the British slave trade. 
 89 Haycock and Wallis, Quackery and Commerce, 2; John Styles, “Product Innovation in Early 
Modern London,” Past & Present 168, no. 1 (August 1, 2000): 124–69. 
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individual conditions and constitutions were either assumed to be basically homogenous 
(with some allowances in dosage for age and sex), or at the very least, economically and 
medically impractical to consider seriously. Rather than catering to the burgeoning 
market of affluent consumers of health care, able to pick and choose from a panoply of 
available cures in the marketplace, these proprietary drugs were purchased on the behalf 
of patients with little to no buying power whatsoever as individual consumers, often 
living in hostile or isolated environments at a considerable distance from the metropolitan 
marketplace. Their bodies were still the ones that ingested the drugs, of course, but in the 
economic field of the medical marketplace, their needs were assessed and represented by 
the corporate consumers who had taken an interest in their collective (rather than 
individual) health, and so purchased drugs on their behalf.  
 Following on the success of his initial military contract, Lajutais appears to have 
found a niche with another corporate consumer for his drugs, namely the French East 
Indies Company. The surviving accounts of his pharmaceutical enterprise show that, at 
least in 1735-1736, the volume of his business with the Company was second only to his 
business with the army, and also outstripped his retail sales by a considerable margin. 
Despite this, his relationship with the Company appears to have been somewhat mixed: 
he was only paid for half of what he supplied, owing either to perceived inefficacy of the 
drug on the ground in the Company’s Indian Ocean trading posts, to spoilage en route, or 
to some combination of both. The Company for its part emerges as a shrewd consumer of 
pharmaceuticals, and seems to have included a clause on the need for the drug to be 
deemed effective by its surgeon majors in local port hospitals in order for Lajutais to 
receive payment in full. In spite of being questioned at some ports, such as Pondichéry 
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and Mahé, it was seen as effective at others, such as Ile Bourbon and Saint-Louis. The 
drug also likely played a role in the medical support for the French slave trade in Senegal. 
 The ambivalent history of the poudre fébrifuge in Senegal and the Indian Ocean 
suggests that metropolitan proprietary drugs played a larger role in the medical economy 
of European commercial expansion. Indeed, the drugs that one finds mentioned alongside 
the poudre reinforce this claim: one common feature across the sources from Pondichéry, 
Réunion, and Sénégal is that Lajutais’ poudre fébrifuge is never the only proprietary drug 
mentioned in requests for medical supplies: it is always mentioned alongside those of 
other vendors, such as Auguste Belloste’s mercurial pills or Mrs. Stephen’s pills for the 
stone.90 These drugs are of course often listed alongside simples such as senna and some 
standard officinal compounds like theriac, but the presence of so many proprietaries 
suggests that the foundations of a global trade in proprietary drugs were already in place 
by the 1730s, and that this trade occurred primarily (at least in the French case) with 
corporate, rather than individual, consumers. 
4. Conclusion 
The trade in proprietary pharmaceuticals to French “corporate consumers” in the 
Indian Ocean has gone wholly unnoticed by the existing historiography of medicine, 
which when treating proprietary drugs, has tended to focus on metropolitan advertising 
and regulation.91 Although the evidence I have assembled is suggestive, it is also 
important to acknowledge some of the limitations of this chapter’s foray outside of 
                                                 
 90 On these vendors, see Pascal Clair and Jean-Marie Le Minor, “Augustin Belloste (1654-1730), 
de la chirurgie militaire à la thérapeutique mercurielle,” Revue d’histoire de la pharmacie 89, no. 331 
(2001): 369–80; Arthur J. Viseltear, “Joanna Stephens and the Eighteenth Century Lithontriptics; a 
Misplaced Chapter in the History of Therapeutics,” Bulletin of the History of Medicine 42, no. 3 (1968): 
199–220. Following an extensive series of medical tests, in 1740 Joanna Stephens was awarded £5,000 by 
the British state to disclose her cure for bladder stones. 
91 Haycock and Wallis, Quackery and Commerce, 1–2. 
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metropolitan France.  To begin, while I have been able to follow the three drugs detailed 
in this dissertation out into the wider world, a more exhaustive study of the supply of all 
medicines to the East Indies Company, as well as medical references in the 
correspondence of the MEP, would be required to make a more definitive case for the 
prominence of proprietary drugs at French outposts on the Indian Ocean. Comparisons to 
other corporate actors, for example other missionary orders like the Jesuits, and the 
trading companies of other European powers, would also be needed to establish whether 
(or to what degree) the large-scale supply of proprietary drugs overseas may be a French 
peculiarity. In some ways, these corporate purchasers, with their relatively intact 
archives, may provide better documentation for overseas circulation of medicines than 
environments which depended more on private retail and wholesale trade: as Renate 
Wilson has demonstrated, focusing on the British colonies in North America, medicines, 
even in substantial quantities, could go “under the radar” of customs, the most systematic 
type of record that could provide a window onto their trade. Such records are often 
fragmentary even for large-scale staples and commodities, and medicines, which required 
comparably little space and were difficult to price in declarations, were often carried 
privately, undeclared, or even smuggled.92 As such, historians should guard against the 
potential “survival bias” that likely exists in the documentation, with private trade being 
less likely to be documented than the varieties of “corporate consumption” described 
here. 
On the whole, however, I maintain that the task of building a clearer picture of 
“corporate consumption” in pharmaceuticals, as well as the “state consumption” met by 
entrepreneurs who supplied pharmaceuticals in bulk to the military, both offer rich 
                                                 
92 Wilson, “Trading in Drugs through Philadelphia,” 355–356. 
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avenues for research on late seventeenth- and early-eighteenth-century medicine, one 
which my dissertation has only begun to explore. On the level of the broader history of 
pharmaceutical monopolies in this period, it seems probable that Helvétius, Lajutais, and 
the Francke Foundations stood in an intermediate position between what we might call 
“private monopolists” who sold their proprietaries to retailers, and the even larger state 
medical monopolies (Daffy provides an instructive example), on the one hand, and the 
great state monopolies over medicinal simples of the later eighteenth century on the 
other, namely the Spanish state monopoly on cinchona, and the Russian state monopoly 
on Chinese rhubarb, which in their scope and aim to monopolize all sale and production 
of a plant within a given territory, may in fact be more comparable to the tobacco 
monopolies organized by various early modern states in the same period.93 
Beyond the ambit of the history of pharmacy, it also bears mention that corporate 
or institutional consumers of all kinds have long been overlooked in the history of 
consumption, which tends to focus on the social, cultural, and economic dimensions of 
private acts of purchase in the marketplace.94 This is certainly the case with much of the 
history of early modern medicine, in which the model of a “medical marketplace” where 
individual patients had a wide variety of options of recourse to different types of 
practitioner, is still dominant. Like much of the historiography of consumption, this 
                                                 
93 On the Spanish cinchona monopoly in the later eighteenth century, see Matthew James 
Crawford, “Empire’s Experts : The Politics of Knowledge in Spain’s Royal Monopoly of Quina (1751-
1808)” (Dissertation, University of California, San Diego, 2009); on the Russian state monopoly on 
Chinese rhubarb, see Erika Monahan, “Locating Rhubarb: Early Modernity’s Relevant Obscurity,” in Early 
Modern Things: Objects and Their Histories, 1500-1800, ed. Paula Findlen (New York: Routledge, 2012); 
Clifford M. Foust, Rhubarb: The Wondrous Drug (Princeton: Princeton University Press, 1992), 46–78. 
94 This point has been made by Frank Trentmann, “Introduction,” in The Oxford Handbook of the 
History of Consumption (Oxford: Oxford University Press, 2012), 16: “Consumption today is so widely 
associated with the private act of purchase in the market that it is easy to forget that huge chunks have been 
public (and in many ways continue to be)—in public hospitals, armies, schools, subsidized university 




model implicitly assumes individual actors in a marketplace setting. It has been recently 
challenged on several grounds, notably by Patrick Wallis and Mark Jenner, who have 
pointed to its multitude of meanings and consequent vagueness as an analytical category 
as well as its seemingly paradoxical tendency to obscure the economy of medicine: more 
often than not it is simply used as a synonym for medical pluralism, wherein a wide 
variety of different healers exist (and compete) in a context where the influence of 
regulatory authorities are non-hegemonic. In this usage, it implicitly stands as an early 
modern counterpoint to a regulated, professionalized medicine identified as a feature of 
medical modernity.95 The medical marketplace model has also been criticized for 
obscuring or marginalizing other forms of healing which occur outside of the 
transactional nexus and marketplace competition or which served as a mediator between 
a patient and the market, most notably domestic and communal health care, which are 
assumed to fall to the wayside in the face of a commercializing medical marketplace,96 
and are often relegated to the position of “first port of call” in the so-called “hierarchy of 
resort” (with the implicit assumption that they could only serve as a prelude to more 
“serious” or important acts of private or household medical consumption in the 
                                                 
95 Mark S. R Jenner and Patrick Wallis, “The Medical Marketplace,” in Medicine and the Market 
in England and Its Colonies, c.1450-c.1850 (New York: Palgrave Macmillan, 2007), 1–23. On the 
“pluralistic diversity” of practitioners as the “dominant usage” of the term see page 4; on its status as an 
“underspecified counterpoint to domestic and professionalized medicine,” see page 6. Jenner and Wallis 
also point to the potentially misleading “Friedmanite echoes” of using free market language to describe 
early modern medicine, which of course was strongly influenced by regulation (and in which, I would add, 
monopolies could be pervasive) (p. 13), while acknowledging its utility in escaping narratives which 
projected normative views of profession, ethics, and authority into the past (p. 3), and emphasizes the 
patient’s agency as a consumer of health care. They also point to its continued value in current 
historiography, particularly if it moves beyond mere “linguistic nods” to the economy of health with an 
attention to the “ethical and political dimensions of using this kind of language” (p.7). 
96 Ibid., 5. 
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marketplace).97 At the opposite end of the scale, in this chapter I have sought to illustrate 
some of the ways the individualistic focus of the marketplace also fails to encompass 
certain large-scale transactions which, by the eighteenth century, were playing an 
increasingly important role in the circulation of therapeutic substances. 
The historiography on proprietary drugs is predicated on a similar assumption, 
namely that such drugs were objects of private consumption. With their flashy print 
advertising and prominent branding, many were undoubtedly targeted to a marketplace 
consumer, particularly in England from the Regency onward, as the recent work of 
Patrick Wallis and John Styles has illustrated.98 This tendency toward individual 
consumption is also apparent in France toward the end of the eighteenth century, as Colin 
Jones has shown.99 My contention here is that there was also another kind of proprietary 
vendor, one that targeted a corporate, rather than individual, consumer, which became 
prominent in the decades between 1680 and 1720. Given the close links many of these 
vendors cultivated with the French state, which was undoubtedly their largest customer, 
this phenomenon may be tied to the peculiar conditions of absolutism, and the 
monopolistic privileges which characterized the “court capitalism” of Old Regime 
France. 
  Even when these proprietary drugs would have been expensive goods for the 
individual urban consumer, in bulk quantities they could still fall within the purchasing 
range of corporate consumers. Further, the claims to uniformity and consistency of 
                                                 
97 For counter-examples to the relegation of domestic and communal medicine as a mere “first 
port of call,” see Seth Stein LeJacq, “The Bounds of Domestic Healing: Medical Recipes, Storytelling and 
Surgery in Early Modern England,” Social History of Medicine 26, no. 3 (August 1, 2013): 451–68. 
 98 Haycock and Wallis, Quackery and Commerce; Styles, “Product Innovation in Early Modern 
London.” 
 99 Colin Jones, “The Great Chain of Buying: Medical Advertisement, the Bourgeois Public Sphere, 




product made by such proprietaries were perhaps even more important to the interests of 
corporate consumers—who wanted a stable therapeutic substance that would work 
consistently across large numbers of individuals wherever they happened to be—than 
they were to individual consumers. Harold J. Cook has suggested that the mechanisms of 
a proto-capitalist marketplace in the eighteenth century encouraged producers to offer a 
recognizable, uniform product, preferably a medicinal specific that could appeal to any 
individual consumer suffering from a defined pathological condition. In his view, these 
market forces tended toward a de-individualization of the human body.100 While Cook 
acknowledges the role of state-sponsored experimentation on military populations as an 
important part of this phenomenon, this role stops at the “research and development” 
phase, after which time we return to a more conventional view of the medical 
marketplace.101 Cook is obviously correct when he observes that “moving from 
considerations of the body individual to the body universal had advantages in the medical 
marketplace,” but this chapter shows that such advantages served vendors not only in 
accessing individual consumers, but also corporate ones.102 In this way, de-
individualization was also propelled by the new, population-scale needs of the military 
and long-distance corporations. In their medical needs and interests, corporations bear 
important similarities with the military organizations discussed in the previous chapters: 
all were interested in finding effective, consistent solutions to health problems for their 
specific populations—be they missionaries or converts, sailors or slaves—in order to 
better attain their overall aims. 
                                                 
100 Harold J. Cook, “Markets and Cultures: Medical Specifics and the Reconfiguration of the Body 
in Early Modern Europe,” Transactions of the Royal Historical Society 21 (2011): 123–45. 
 101 Ibid., 141–143. 





 This dissertation demonstrates that prototypes of large-scale pharmaceutical 
production can be found in France in the years 1680‒1735. The centralizing state of 
Louis XIV played an important role in fostering this development, first serving as 
guarantor of monopolies through royal privileges, and then serving as a bulk consumer of 
the drugs it had so licensed. Two broader trends converged to produce this development: 
the first is the import of exotic medicinal plants to Europe, the most notable being two 
South American plants, cinchona and ipecacuanha. The second trend was the decline of 
Galenic pharmacy and the growing prominence of chymical medicine, which exercised 
an important influence in two related ways: through developments in practical pharmacy 
(drying, grinding, infusion, and distillation), and through the reelaboration of the concept 
of medicinal specifics, a potentiality which had been latent within the Western medical 
tradition since the time of Avicenna. These trends were capitalized upon by a new class 
of pharmaceutical entrepreneurs who transformed medicinal specifics from objects of 
knowledge into globally circulating proprietary drugs. In addition to being consumed by 
soldiers, sailors, and peasants in metropolitan France, these drugs were also distributed 
throughout the world by French mercantile and missionary endeavors. 
These findings demand a reevaluation of existing historical models of medical 
practice in the early modern period. In the first place, they challenge core-periphery 
models, which tend to privilege the perspective of a medically orthodox learned élite by 
placing it at the “core” while consigning chymical physicians, empirics, charlatans, and 
“popular medicine” to the margins. It is an old truism that historians tell us about the past, 
but also about their own present. Such models are historiographic offshoots of the 
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professionalization process itself, and the tendency of the medical professionals of the 
nineteenth and twentieth century to see their own reflection in the learned physicians of 
the past. Historians who lean toward the underdog or popular culture can of course 
reverse the valence of this relation by affirming the dignity of the (supposedly) 
marginalized.  This rescues the medical “fringe” from “the enormous condescension of 
posterity,” but leaves the essential binary intact. As I have argued here, the Faculties and 
colleges were not always successful in seizing regulatory authority from the municipal 
and royal government, and quite far from being marginalized, an important subset of 
particularly entrepreneurial “empirics” walked the corridors of power at Versailles, were 
closely entwined with the bureaucracy of the central state, and saw the learned physicians 
less as threats or rivals and more as potential allies against their real competitors—rival 
entrepreneurs.  
The notion of a “medical marketplace” has often been invoked to challenge core-
periphery models. In the medical marketplace, we are told, early modern patients had a 
wide range of choice among various kinds of medical practitioners and could take their 
custom wherever they liked. We find two broad variants of this model: the first privileges 
the agency of the patient, the second stresses competition between rival practitioners or 
groups of practitioners.  Here too we hear echoes of the historian’s present: the first view, 
centered on the concept of patient agency, bears a more than passing resemblance to the 
consumer movement and advocacy of patient-centered care; the second, where 
competition is stressed, consciously or unconsciously evokes the neoliberal rhetoric of 
the “free market.”1 
                                                 
 1 I draw here on the excellent review of Mark S.R. Jenner and Patrick Wallis, who have likewise 
pointed out the potentially misleading “Friedmanite echoes” of using free market language to describe early 
372 
 
Physician-dominated medical regulation was far from hegemonic, where it existed 
at all, and there can be little doubt that early modern patients had access to a plurality of 
different health-care solutions. But this does not mean that the playing field was even. Far 
from being a sphere of “free” competition, the Ancien Régime medical marketplace was 
structured by monopoly, privilege, and differing sources of legitimation, most of which 
remained tied to kinship or highly personal patronage relations. In Ancien Régime 
France, the last word on medical regulation was not in the hands of the Faculty. Rather, it 
was a prerogative of senior state officials like Louvois, Seignelay, and Pontchartrain, who 
held the reins of power and were perfectly willing to collaborate with empirics to cover 
the medical dimensions of their larger projects. The state, then as now, could choose 
winners in the marketplace: it could provide entrepreneurs with a protected market and 
even serve as the principal consumer of their products. 
 By both complementing and challenging existing accounts of a pluralistic, 
predominately urban medical marketplace of private consumption, my research points to 
the unrecognized importance of state-sponsored monopolies and globally-active 
corporate consumers in early modern medicine. The state and other corporate actors 
could in fact serve as intermediaries for patients who lacked individual access to the 
medical marketplace by purchasing remedies in bulk on their behalf. The standardized 
medicine chests of Helvétius and the packets of Guiller’s poudre fébrifuge were a new 
kind of pharmaceutical resource for socially disadvantaged but numerically significant 
patient populations: peasants of the French provinces, sailors aboard French East India 
Company ships, and inmates of the French army’s campaign hospitals. Further, in the 
                                                                                                                                                 
modern medicine: Mark S. R Jenner and Patrick Wallis, “The Medical Marketplace,” in Medicine and the 
Market in England and Its Colonies, c.1450-c.1850 (New York: Palgrave Macmillan, 2007), 13. 
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hands of missionaries, explorers, and slave traders, these medicine chests even entered 
the medical worlds of Southeast Asia, North America, and Africa. 
 Pharmaceutical monopolies could be highly lucrative in these contexts, but they 
were also inherently fragile, as my research results demonstrate. Medical secrets could be 
counterfeited, stolen, or reverse-engineered by rivals. While a monopoly privilege 
provided legal grounds for prosecuting competitors, actual litigation in the courts could 
be costly and time-consuming. Medical secrets could also be disclosed to the public: this 
might be planned, as in the case of Robert Talbor, whose secret was purchased by Louis 
XIV but revealed only posthumously. But their divulgation might also take the form of a 
kind of “genericide,” as happened when the Contugi family faced the challenge posed by 
the inclusion of orviétan recipes in the pharmacopoeias. Rival vendors and apothecaries 
could then argue that the preparation of the drug was public knowledge, and that they had 
the right to produce their own versions of it, which forced the Contugi family to re-
formulate its privilege as a defense of a trade-mark and exclusive point of sale, as we 
have seen. 
 Moreover, the survival of a monopoly across multiple generations was subject to 
numerous pitfalls. Breaks in the transmission of a privilege or the medical secret on 
which it was based could present serious challenges to would-be inheritors. As Jean 
Verdier pointed out, many useful medical secrets failed to enrich medicine, sinking into 
oblivion after the death of their authors, who had not transmitted them to future 
generations.2 The secret of Guiller’s poudre fébrifuge was almost lost in this way, and 
was only recovered through the considerable efforts of Lajutais and Guerin. Privileges 
                                                 




and secrets alike were also vulnerable to “succession crises” in which a medical 
“dynasty”—like a royal dynasty—faced the uncertainties of a possible break in the 
transmission of the monopoly. The fact that most secrets and privileges were transmitted 
bilaterally—that is, through both men and women—did give them some degree of 
flexibility. We have seen that the “succession crises” of the Contugi and Guiller-Lajutais 
monopolies produced a variety of familial arrangements, which put the privilege in the 
hands of mothers, widows, and sisters. Similar cases existed in other monopolies, for 
example the gouttes of General La Motte, which were sold for decades by his widow.3 
Although it was not possible to explore this subject in detail here, a closer study of the 
role of women in these monopolies and a comparison to their role in the craft guilds 
would make an important contribution to the history of women’s medical work in the 
early modern period.4 In addition to these problems of transmission, it should also be 
remembered that monopoly rights did not in themselves guarantee the sales or the 
popularity of the drug. The best perspective of profit in the world of secret remedies was 
to supplement a monopoly privilege with the acquisition of a government supply 
contract. It is no accident that the most extensive monopoly here described, that of 
Helvétius père et fils, was also the most thoroughly integrated with the structures of the 
fiscal-military state. Fortunately for would-be monopolists, the source of both 
                                                 
3 See above, ch. 1, sect. 5 
 4 The cases of the Grimaldi electuary in Bologna and the Colochi plague remedy in Venice 
provide comparable cases demonstrating the prominent of women in multi-generational monopolies. On the 
Grimaldi electuary, see David Gentilcore, Medical Charlatanism in Early Modern Italy (Oxford: Oxford 
University Press, 2006), 66–78; and Gianna Pomata, “Practicing between Earth and Heaven: Women 
Healers in Seventeenth-Century Bologna,” Dynamis 19 (1999): 119–43. On the Colochi plague remedy, see 
Jane Stevens Crawshaw, “Families, Medical Secrets and Public Health in Early Modern Venice,” 
Renaissance Studies 28, no. 4 (2014): 597–618. For surveys of the history of women’s medical work, see 
Leigh Whaley, Women and the Practice of Medical Care in Early Modern Europe, 1400-1800 
(Houndmills: Palgrave Macmillan, 2011); Susan Broomhall, Women’s Medical Work in Early Modern 
France (Manchester: Manchester University Press, 2004).  
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monopolies and contracts was the same: the royal court. The detailed case of Guerin’s 
negotiations at Versailles in 1733 demonstrates how closely intertwined those 
negotiations could be. 
 Another question that emerges from this dissertation is the applicability of the 
concept of proto-industrialization to early modern pharmaceutical production. “Proto-
industrialization”was originally linked to developmental models aimed at explaining a 
“first step” in European industrialization and the transition to modern capitalism. Today, 
historians use it less schematically to describe various forms of expansion in domestic 
industries that did not centralize in factories and produced goods for export markets 
rather than local consumption. It is often but not always linked to rural settings beyond 
the pale of urban craft guild regulations.5 
 Could the monopolies of the Contugi, Helvétius, and Guiller-Lajutais families be 
seen as pharmaceutical proto-industries? The scale of their operations itself poses the 
question. Although quantitative data on the Contugi orviétan monopoly are lacking, this 
dissertation shows that Adrien Helvétius sold an average of over 50,000 prises 
(individually packaged doses) of his various proprietary remedies to the French state 
annually in the 1710s, a figure which doubled by the 1720s to reach 100,000 prises. 
Similarly, in 1735 alone, Pierre Brodin de Lajutais sold almost 40,000 prises of his 
poudre fébrifuge to the army, the navy, and the French East Indies Company.6 These 
levels of pharmaceutical production were quite high for this period and were likely 
                                                 
5 For an excellent introduction, see Sheilagh C. Ogilvie and Markus Cerman, European Proto-
Industrialization: An Introductory Handbook (Cambridge: Cambridge University Press, 1996); the concept 
was first introduced by Franklin F. Mendels, “Proto-Industrialization: The First Phase of the 
Industrialization Process,” The Journal of Economic History 32, no. 01 (March 1972): 241–61. 
 6 In the 1720s, “Helvétius père et fils” were being paid over 30,000 livres annually by the 
Controller General of Finances, and in 1735 Lajutais’s revenue exceeded 14,000 livres, 10,000 of which 




matched by only a handful of other producers elsewhere in Europe, most notably the 
Francke Foundations of Halle.7 
 The three monopolies I have described share some features with the proto-
industrialization model. They emerged from domestic settings but expanded to meet 
demand in export markets. They managed to escape guild regulation, which gave them a 
free hand to innovate. Unfortunately, very little detail has survived on their actual 
production processes. We can say almost nothing about the Contugi or Helvétius 
laboratories or labor, although we do know that Guiller and later Guerin and Lajutais 
based their own operation in Champigny and Vincennes, respectively, both of which 
were beyond the walls of Paris. We also know that Guiller employed children to peel the 
skin from the tithymal that formed the key ingredient of his poudre fébrifuge, and that 
Guerin and Lajutais employed a group of herb gatherers to collect the plant on their 
behalf. We know that Guiller had a chymical furnace in his home, and that Guerin and 
Lajutais fought one another over the ownership of chymical equipment used in the 
production of the poudre, as well as other items which are harder to categorize, including 
“two big wooden machines lined with tin and four copper rollers.”8 It also goes without 
saying that the ingredients of their drug had to be processed, compounded, and packaged 
in paper envelopes with printed instructions sheets. These details are suggestive, and, 
coupled with the large production figures numbering in the tens of thousands, they point 
in the direction of a proto-industry. Helvétius’ operation is even more obscure, but based 
on its variety and total output—which reached 100,000 packaged doses per year—was 
                                                 
 7 Renate Wilson, Pious Traders in Medicine: A German Pharmaceutical Network in Eighteenth-
Century North America (University Park, Pa.: Pennsylvania State University Press, 2000). 
8 “Deux grandes machines de bois doubles de fer blanc et quatre roulettes de cuivre” AN V7 246 
(6), dossier 2, “Compte de recette et dépense que rend le S. Guerin au S. de Lajutais,”18r-v. 
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likely even more complex than that of the poudre fébrifuge. Sources may yet emerge 
which could shed more light on production practices, which could then be compared to 
the more customized and locally-oriented craft production prevalent among urban 
apothecaries. 
 The question of whether these monopolies constituted a pharmaceutical proto-
industry is closely tied to a woefully neglected subject in the history of military medicine: 
namely, the critical role played by pharmacy in the support of the ever growing armies 
and navies of early modern Europe. Pharmacy and drugs are mostly ignored in most 
surveys of the history of army medicine, which focus overwhelmingly on surgeons, 
surgery, hospital organization, and the “proto-public health” of hygiene, nutrition, and 
preventative medicine. The link between wartime needs and pharmaceutical 
developments has long been clear to historians of the nineteenth-century American 
pharmaceutical industry, who have often pointed to military spending during the 
American Civil War (1861-1865) as a watershed in the development of the industry, 
although relatively few detailed studies exist.9 Somewhat closer to the period in question, 
Erica Charters has recently pointed to the role of medical trials organized by the Sick and 
Hurt Board of the Royal Navy during the Seven Years’ War (1754-1763) in response to 
the problem of scurvy.10 The cases outlined in my dissertation show that much the same 
is true of the later seventeenth century and the first decades of the eighteenth. In spite of 
                                                 
 9 Michael A Flannery, Civil War Pharmacy: A History of Drugs, Drug Supply and Provision, and 
Therapeutics for the Union and Confederacy (New York: Pharmaceutical Products Press, 2004); George 
Winston Smith, Medicines for the Union Army: The United States Army Laboratories during the Civil War 
(New York: Pharmaceutical Products Press, 2001); Jonathan Liebenau, Medical Science and Medical 
Industry: The Formation of the American Pharmaceutical Industry (Baltimore: Johns Hopkins University 
Press, 1987), 17–20; Edward Kremers and George Urdang, Kremers and Urdang’s History of Pharmacy, 
ed. Glenn Sonnedecker, 4th ed (Philadelphia: Lippincott, 1976), 327–329. 
 10 Erica Charters, Disease, War, and the Imperial State: The Welfare of the British Armed Forces 
during the Seven Years’ War (Chicago: University of Chicago Press, 2014), chaps. 4, 120–141. 
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the absence of testing-oriented bureaucratic structures like those which Charters 
highlights, French officials at the highest levels of military administration—most notably 
the War Secretary Louvois and the Navy Secretary Pontchatrain—were keenly interested 
in finding drugs that could solve strategic medical problems like intermittent fevers and 
dysentery. Lower-ranking officials, notably the clerks (commis) of the Bureau de Guerre, 
were also strongly aware of corruption and inefficiencies with the existing practices of 
out-contracting, and tried to develop alternatives. It is to be hoped that medical 
entrepreneurs-fournisseurs will attract some interest in the wider renewal of scholarship 
around the role of out-contracting in the rise of the fiscal-military state.11 
 The widespread popularization of medicinal specifics described in my dissertation 
is also part of a longer lineage of “mass medicine,” and the development of de-
individualized therapies, which took on a particular importance in the eighteenth century. 
Later episodes in the eighteenth-century history of “mass medicine” likewise point to the 
importance of “empirics” and familial monopolies. Take for example the case of 
smallpox inoculation, first pioneered for large-scale use in England around 1760 by a 
dynasty of inoculators, Robert (1708-1788) and Daniel Sutton (1735-1819).12 We already 
know that empirics and entrepreneurs played an important role in English army and navy 
medicine.13 A greater attention to such apparently peripheral figures, and an assessment 
                                                 
 11 Once again, for an excellent review of the state of research on this question, see Jeff Fynn-Paul, 
Marjolein ’t Hart, and Griet Vermeesch, “Entrepreneurs, Military Supply, and State Formation in the Late 
Medieval and Early Modern Periods: New Directions,” in War, Entrepreneurs, and the State in Europe and 
the Mediterranean, 1300-1800, ed. Jeff Fynn-Paul (Leiden: Brill, 2014), 1–12. 
12 John Robert Smith, The Speckled Monster: Smallpox in England, 1670-1970, with Particular 
Reference to Essex (Chelmsford: Essex Record Office, 1987), esp. ch. 4, “The impact of Daniel Sutton.” 
 13 Harold J. Cook, “Practical Medicine and the British Armed Forces after the ‘Glorious 
Revolution,’” Medical History 34, no. 1 (1990): 1–26; Harold J. Cook, “Sir John Colbatch and Augustan 




of their differences and similarities across time and place, has the potential to reorient the 
history of therapeutic innovation and “mass medicine” in the early modern period.  
 This history also extends back in time: “mass medicine” has of course existed in 
one form or another since antiquity. The Roman encyclopedist Cornelius Celsus, for 
example, pointed out that an appreciation for the peculiarity of individual constitutions 
was impractical when treating large numbers of patients. In such circumstances it was 
better to do as the empirics did, and look for common characteristics, in the same way as 
one would when dealing with soldiers, slaves, or livestock.14 At the end of the 
seventeenth century, the medical needs of large numbers of soldiers, sailors, missionaries, 
and peasants came to be recognized as a problem by the state and other corporate bodies. 
The élites at the head of these institutions turned to their own practitioners for solutions—
most notably the physicians of the court—and these physicians brokered relationships 
between empirics and the state.  
 Does this mean that the popularization of medicinal specifics was simply a 
consequence of these new demands? Harold J. Cook has posed this question in a 
provocative article on medicinal specifics. In it he argues that the rise of specifics was a 
result of “a decline of learned medicine due to market forces, which created 
commonalities among consumers.”15 While prudently cautioning against economic 
reductionism, Cook stresses the importance of the arrival of new therapeutic substances 
in Europe and their subsequent commodification within a consumer marketplace.16  But 
though he points to the importance of large-scale trials on military populations, Cook 
                                                 
 14 Celsus, De medicina, trans. W.G. Spencer, Loeb Classical Library (London: W. Heinemann 
Ltd., 1935), 1.17–18. 
 15 Harold J. Cook, “Markets and Cultures: Medical Specifics and the Reconfiguration of the Body 
in Early Modern Europe,” Transactions of the Royal Historical Society 21 (2011): 143. 
 16 Ibid., 129–130. 
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does not view the military itself as a market player, focusing instead on the marketplace 
of individual consumers.17 I would argue, in contrast, that the fiscal-military state played 
a critical role at every stage: not just at the level of the testing and licensing of drugs, but 
also fundamentally in their consumption.  
 In addition to highlighting the critical role of the fiscal-military state, I have also 
suggested that intellectual developments played a key role in the emergence of medicinal 
specifics. There can be little doubt that medicinal specifics contributed to the decline of 
what Owsei Temkin called “physiological” views of disease implicit within the humoral 
theory of orthodox Galenism, and that this occurred alongside the rise of the more 
“ontological” views of disease promoted by Paracelsus and especially Van Helmont.18 A 
full appreciation of these intellectual developments would necessitate a broader re-
assessment of the impact of chymical medicine, one which would go beyond the 
doctrines and “schools” of the most prominent theorists and would not focus narrowly 
only on the use of mineral substances in medicine. By the end of the seventeenth century, 
the ideas of Van Helmont in particular had taken a variety of permutations, including the 
“materialist” versions of which the acid-alkali theory was the most prominent. 
Adequately reconstructing these developments would not be an easy task: as Evan 
Ragland has shown, the sources of these theories have long been misunderstood in the 
                                                 
 17 Ibid., 141–142. 
 18 Broadly, the “physiological” view points to disease as a result of disturbances in the natural 
order of an individual’s internal processes (e.g. humoral imbalance in Galenism) while the “ontological” 
view treats disease as the result of a distinct entity which enters the individual (e.g. the Helmontian 
peregrinus exoticus). The physiological model tends to emphasize the particularities of the individual case, 
while the ontological model looks for commonalities—the pathological entity—across cases. See Owsei 
Temkin, “The Scientific Approach to Disease: Specific Entity and Individual Sickness,” in The Double 
Face of Janus and Other Essays in the History of Medicine (Baltimore: Johns Hopkins University Press, 
1977), 441–55; Walter Pagel, “Van Helmont’s Concept of Disease - To Be or Not To Be? The Influence of 
Paracelsus,” Bulletin of the History of Medicine 46, no. 5 (1972): 419–54; Walter Pagel, Joan Baptista van 




historiography, and a better idea of their diffusion would necessitate a return to the 
sources.19 A better appreciation of chymical theory would also need to be complemented 
by a better understanding of the diffusion of chymical practices, particularly in pharmacy, 
a potential direction that has been opened by the recent revival of interest in the history of 
materials and concrete practices in early modern science.20 
 In this perspective, a stronger effort to combine intellectual and economic history 
would be very useful, and I believe that this is one of the methodological lessons to be 
drawn from my research results. I have endeavored to show that intellectual and 
economic factors were deeply intertwined in the history of secret remedies. Cinchona and 
ipecacuanha offer two prominent examples. The material presence in Europe of cinchona 
bark was the basic precondition for its commodification, but its use and circulation 
stagnated for decades, due to the skepticism of the medical establishment. As we have 
seen, this skepticism had both clinical and theoretical motivations: it was related to the 
uncertainty of the drug’s effects on patients (the relapse problem) and its incompatibility 
with Galenic pharmacology. Practical and theoretical developments in medicine were 
necessary to lift cinchona out of this impasse: on the practical level, it took a new 
pharmaceutical preparation of the bark in the form of Robert Talbor’s remède anglois, 
held to be much more successful than those already in circulation; on the theoretical 
level, it took a revised chymical account of the drug’s action, partnered with an 
                                                 
 19 Evan R. Ragland, “Experimenting with Chemical Bodies: Science, Medicine, and Philosophy in 
the Long History of Reinier de Graaf’s Experiments on Digestion, from Harvey and Descartes to Claude 
Bernard” (PhD dissertation, Indiana University, 2012). 
 20 Pamela H. Smith, “In the Workshop of History: Making, Writing, and Meaning,” West 86th: A 
Journal of Decorative Arts, Design History, and Material Culture 19 (2012): 4–31; Pamela H. Smith, Amy 
R. W. Meyers, and Harold J. Cook, Ways of Making and Knowing: The Material Culture of Empirical 
Knowledge (Ann Arbor: University of Michigan Press, 2014); Lawrence M. Principe, “‘Chemical 
Translation’ and the Role of Impurities in Alchemy: Examples from Basil Valentine’s Triumph-Wagen,” 
Ambix 34, no. 1 (1987): 21–30. 
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increasing dissatisfaction with the limits of Galenic pharmacology and the Aristotelian 
qualities themselves. These intellectual forces interacted with the material world of 
economics, triggering a market rush to purchase all the cinchona available and an effort 
to duplicate the new preparation. This wave of experiment and reverse engineering, in 
turn, generated a corresponding wave of learned publication on the medical virtues of the 
bark in the intellectual domain. 
 As we have seen, this phenomenon repeated itself in the case of Helvétius’ 
popularization of ipecacuanha. On the theoretical level, Adrien Helvétius drew on the 
case of cinchona and fevers as a model problem solution: he took a root that had 
previously been disregarded as a dangerous emetic and recognized its virtues as a specific 
against dysentery. On a practical level, he developed a preparation that reduced 
ipecacuanha’s emetic effects so that it would stay inside the patient’s digestive tract, a 
condition that he saw as critical for the drug’s efficacy against dysentery. Here again 
practical and theoretical transformations of the drug had an impact on the world of the 
market: equipped with his awareness of the drug’s virtues and of a useful method for 
preparing it in such a way as to enhance them, Helvétius availed himself of this 
“information asymmetry” in the market to purchase as much of the drug as possible at 
low cost from merchants and apothecaries who had not recognized its real value. As such, 
practical and theoretical transformations—the proper objects of the intellectual history of 
medicine—stand at the origin of Helvétius’ entire monopoly, prior to his negotiations at 
court, his military contracts, and his innovative distribution system.  
 These cases stand as a reminder of the critical insights that intellectual history can 
offer to our understanding of the market forces in medicine, particularly the forces that 
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enabled the prototypes of large-scale pharmaceutical production that are the object of this 
study. They show us that practical and theoretical developments in medical therapeutics 
played a critical role in the long chain of events that brought a South American root like 
ipecacuanha to the army hospitals of the Rhineland and the peasants of the French 
provinces, transforming a raw plant substance into a drug and enabling it to travel from 




Appendix 1: Tables 
 
Table 1:  
Exclusive-sale privileges, by date (total: 46) 
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Distillateur Sirop capillaire, eaux de la 
reine de Hongrie, l’huile de 
petroleum de Gabian 
8 August 
1678 







Remèdes 17 January 
1681 
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Alleaume  Eaux minérales 20 January 
1694 
V3 190 129v 
Contugy, 
Jean-Louis 
 Orviétan 24 April 
1694 
O1 38 109r-v 
Daumont, 
Jean-Baptiste 
 Eaux minérales 1694 V3 190 128v 
Danet, 
Guillaume 
 Eaux minérales 1698 V3 190 149 
Gerauldy Opérateur pour 
les dents 
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Remède contre les callosités et 





V3 191 141r 
Contugy  Orviétan 10 May 
1716 













 Antidote ou contrepoison 3 August 
1716 
V 1252 43r 
Fournier de la 
Flotte, Jacob 
 Antidote de France 5 
November 
1716 
V 1252 47v-48r 
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Table 2:  
Laboratory privileges, by date (total: 10) 
 
Name Occupation Date Cote fol. 
de Rochas, Henri Médecin ordinaire du roi 1646 Z 84 101 A 
Charpentier, 
Marguerite 
 15 March 1663 Arsenal 
ms 10357 
p. 522, 524 
Barré, Cosme 
Damien 
Chirurgien du garde robe et 
distillateur suivant la cour 
15 January 1678 V3 189 15r-16r 
Barré, Cosme 
Damien 
Chirurgien du garde robe et 
distillateur suivant la cour 




Docteur en médecine 31 January 1685 O1 29 92r-v 
Lémery, Nicolas Docteur en médecine 8 April 1686 O1 30 132r-v 
Helvétius, 
Adrien 
Docteur en médecine 24 August 1688 O1 32 224r-225r 
Aignan, Nicolas 
and Rousseau de 
Montbazon 
 11 July 1690 O1 34 194r-v 
Fronville  30 October 1700 O1 44 546r-v 
Helvétius, 
Adrien 
Docteur en medicine 7 October 1703 G7 716 Placet 
Name Occupation Remedy Date Cote fol. 





O1 66 459r 




V3 192 48r 
Gerauldy  Antidote theriacal 1 August 
1721 
O1 65 174r 
Bols “Anglais” Remède pour la guérison des 




O1 69 273r-v 
Granger, 
Pierre 















O1 66 447-448 
Barbey Veuve du sieur 
Garrus 














V3 192 48v 
Toscano, 
Gregoire 












O1 71 76-77 
Barbey Veuve Garrus Élixir du sieur Garrus 21 October 
1727 




Pensions, by date (total: 6) 
 





Philippe de la 
Remède spécifique 
pour les fièvres 
9 September 
1680 
1,200 O1 24 233r-v 
Talbor, Robert Remède anglois 13 November 
1680 
2,000 O1 24 196v 
Alliot Remède contre le 
cancer 
4 April 1683 2,400 O1 27 88r 
Guiller, 
Ferdinand 
Racines de febrifuge 13 February 
1713 
1,200 O1 57 20r-v 
Martin 
Blumantié, sieur 
de la Ligerie 




Elixir de Garus 9 April 1723 1,000 O1 67 332 
 
Table 4: 
Exclusive sales privileges: 
Fines for counterfeiters 
 
 Table 5: 
Exclusive sales privileges:  
Distribution of fines for counterfeiters 
Fine  
(livres tournois)           
No. of 
privileges 
 Fine distribution pattern               No. of 
privileges 
1,000 6  1/3 each for king + vendor + hospital 5 
1,500 2  1/3 each for informer + vendor + hospital 3 
3,000 10  1/2 each for vendor +  hospital 6 
Total specifying fine: 18  Total with a divided fine: 14 
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Appendix 2: Research methodology and sources for Tables 1-3 
 Before the bureaucratization of privilege-granting for secret remedies under the 
Société royale de médecine, all letters patent and brevets were granted through the 
authority of the Secretary of State of the Royal Household on behalf of the king on the 
recommendation of the first physician. I have found no documented efforts to develop 
systematic process of examination before 1728. The nature of the records generated by 
this form of licensing has presented special challenges: in the absence of bureaucratic 
procedures or records, the corpus of privileges I have assembled represents a series of ad 
hoc permissions granted by arbitrary authority which I have had to painstakingly extract 
from the voluminous dispatch registers of the Secretary of State (AN series O1 1-128). 
Within these registers, which themselves have only survived partially for the period from 
1669 onward, medical privileges appear sporadically, organized only by order of date. 
Indexes are provided at the beginning of each volume but they often only class them as 
“brevet,” “permission,” or “pension” with the name of the recipient, making no mention 
of their specifically medical nature and classing them alongside documents of the same 
type alongside a plethora of other kinds of non-medical “brevets,” “permissions,” or 
“pensions” granted to individuals. These non-medical brevets include, naturalisation 
letters; pensions; orders to imprison, exile, or pardon convicted criminals; dispensations 
for the sale of seigniorial lands; and provisions of every kind of office or position within 
the royal household. Checking through thousands of pages of these systematically to see 
any are medical privileges would be impractical, so I have instead relied on the only 
finding aid for the fonds. This finding aid, a twenty-six volume (7,997-page) typewritten 
alphabetical index of the recipients of all royal letters or brevets with a brief description 
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of the nature of the entry (noting, for instance, if the letters, brevet, or pension is for a 
remedy), was compiled by several generations of archivists and appears to be of uneven 
quality. I scanned systematically (entry-by-entry) through volumes 1-6 and 10-12 of this 
index. For the remaining volumes I was able to make use of keyword searches as this 
finding aid was digitized and OCRed while the project was already underway.1 I have 
also made more localized searches based on lists of vendors of proprietary remedies 
which I have assembled based on other sources, notably the various articles by Maurice 
Bouvet (see bibliography), and the Essais de médecine of Jean Bernier, which include 
dozens of pages listing various Paris “empirics” and “charlatans.”2 Their names are often 
enciphered through anagrams in Bernier’s Essais, but the copy at the Bibliothèque de 
l’Arsenal includes manuscript annotations which decode the anagrams (accurately, I 
believe). 
 To complicate matters further, not all brevets and letters patent appear to have 
been copied into the surviving dispatch registers: many only appear in the registres 
d’enregistrement of various courts, where privilege-holders would often submit their 
documents to be verified and registered in order to make them binding (exécutoire) in a 
given jurisdiction.3 Whenever I locate a letter or brevet that has been registered in the V3 
                                                 
 1 The following search terms were used: remède, spécifique, médicament, drogue,  maladie, 
malade, laboratoire, fourneau/fourneaux. 
 2 Jean Bernier, Essais de medecine, où il est traité de l’histoire de medecine et des medecins 
(Paris: Simon Langronne, 1689), 415–526, ch. XVI, “Des charlatans pretendus Medecins, et des Medecins 
Charlatans.” 
 3 This of course raises an important question: could some of the letters and brevets which appear 
in registres d’enregistrement but not in the Secretary of State’s dispatch register be counterfeits? It is 
certainly possible, but two other possibilities should also be considered: some may simply have never been 
copied into the dispatch registers through plain neglect. They were, it must be admitted, not the most 
important letters being dispatched by the Secretary of State. It is also possible that copies of these letters 
and brevets do in fact exist in the surviving dispatch registries but have not been properly entered into the 
indexes of the registers and, consequently, do not appear in the finding aids for the fonds. In cases where 
the date of letters or a brevet is known from another source (e.g. a printed handbill, a notarial act) it would 
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(Prévôté de l’hôtel) or V5 (Grand conseil) registres d’enregistrement, I cross-check the 
series O1 finding aid (the alphabetical index to the dispatch registers) to see if I can locate 
the name of the holder there. In some cases I have even checked the register itself to see 
if I can find the privilege transcribed at the date of its granting. In the vast majority of 
cases, however, these exercises have been fruitless, which suggests the surviving dispatch 
registers are incomplete. This hypothesis is confirmed by the fact that several of the 
original register “tables de matières” actually signal that there is an additional dispatch 
register “sous-coté,” but these seem not to have survived. As such, although all of the 
privileges ultimately originate either with the Secretary of State or the first physician, 
there is no single, stable source base to collect privileges. 
 How representative is this corpus? Several of the letters and brevets refer to 
earlier privileges which have not survived. A notable example of this problem is the oft-
cited first letters patent granted to Christophle Contugy for the sale of orviétan on April 9, 
1647. This privilege is attested to by numerous other sources subsequent letters patent 
granted to his descendants: in the 1648 Commentaires of the Paris Faculty, where the 
Dean Piètre explicitly states that he examined it. I have noted twelve similar instances for 
the pre-1728 period alone, wherein a reputable source, either a publication (e.g. the 
Mercure Gallant) or a subsequent legal document (an arrêt, or a renewed patent letter), 
refers directly to a brevet or letter which I have not been able to locate at the archives. If 
we add these twelve reliably attested letters and brevets to the existing pre-1728 corpus, 
we reach a total of sixty-nine, of which only fifty-six have survived for inclusion into my 
corpus, which suggests I am missing, at minimum, 19% of those that we can say with 
                                                                                                                                                 
be possible to check the registers for the corresponding date, but even this poses problems as brevets and 
letters sometimes appear out of sequence in the registers. 
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certainty were granted. As such, the figures I provide above, although revealing, should 
not be taken as complete: the phenomenon which they document was likely much 








Ferdinand de Guiller’s 1713 brevet. Parchment. 50x35cm. AN V7 246 (6) dossier 3, item 






   
 Figure 3 
 Photograph of an intact orviétan pot. Source: The Bridgeman Art Library, 
 http://www.bridgemanart.com/de/asset/236384/french-school-18th-
 century/box-for-orvietan-lead (accessed 24 November 2013). Original 





     Figure 4 
 
 
       Figure 5 
 
Source for Figure 4 and Figure 5: Photos of “Vrai Orvietan de Rome” lids/caps posted by 
users “Mlesplomb” and “Prusse du sud,” on the online forum “Échange-passion: Forum 
privé consacré à l'échange (Monnaies, Objects, Pierres),” http://www.echange-






 Figure 6 
 Christophle Contugy Orviétan broadsheet. Woodcut. Source: Collection Michel 
 Hennin. Estampes relatives à l’Histoire de France, vol. 39, p. 28.  





(detail of Figure 6 top-center) 
 
 
 Figure 8     Figure 9 
 
  
  SOL    SOLUS   UT 
Figure 10 
 
Source for Figures 8-10: Photos posted by users terremythe, identified as orviétan 
pots/lids by user Alice25, on “la-detection.com - Forum de discussion, identification 
trouvailles, detecteur de metaux,” http://www.la-detection.com/dp/message-75142.htm 








Theodore Rombouts, “The tooth-puller” (ca. 1635). Source: Baroque in the Southern 
Netherlands Online Museum (http://barokinvlaanderen.vlaamsekunstcollectie.be/en, 
accessed December 15, 2015). Original: Museum of Fine Arts Ghent. Note the folded 








Etching. Francesco Curti after Giuseppe Maria Mitelli from L’arti per via 







Detail from Le Charlatan françois, 1777. Engraving. Isidore-Stanislas Helman after Jean-
Duplessis Bertaux. Source: Gallica. Original: Collection Michel Hennin. BnF Richelieu, 








Detail from Le Charlatan, 1785. Hand coloured etching and aquatint. Antoine Borel after 






Figure 15: Lajtuais revenues 
 
 
The reason for distinguishing between sales by volume and by revenue is to take into account the 
20% discount received by the French army. Figure 2 also includes the full quantity of poudre that 
was shipped by the Compagnie des Indes to its colonies: many of these shipments spoiled, so the 
Compagnie paid Lajutais for only half of the total shipment. This chart thus shows that both the 
French army and the Compagnie des Indes were even more significant in the total supply volume 
than the previous chart, which includes only receipts, would suggest. 
 
NB: Blanc is the Parisian retailer for the poudre fébrifuge, but appears to have been Lajutais’ 








1735-1736 Sales by revenue (in livres tournois) of the poudre 
fébrifuge (Total: 14,373 livres)







1735-1736 Sales by volume (in prises, individually packaged doses) 
of the poudre fébrifuge (Total: 39,894 prises)




Chronological table of the King’s First Physicians 
and Secretaries of State for the Royal Household 
1675–1775 
 
Secretaries of State for the Royal Household (Secrétaires d’État de la Maison du roi)1 
 
1672–1690  Jean-Baptiste Colbert, marquis de Seignelay 
  (also Navy Secretary) 
 
1690–1699  Louis Phélypeaux, comte de Pontchartrain  
  (also Controller General and Navy Secretary, later Chancellor)  
 
1699–1715 Jérôme Phélypeaux, comte de Pontchartrain  
  (also Navy Secretary) 
 
1715–1718 Louis Phélypeaux, marquis de La Vrillière  
 
1718–1749 Jean-Frédéric Phélypeaux, comte de Maurepas 
 
1749–1775 Louis Phélypeaux, comte de Saint-Florentin, duc de la Vrillière 
 
Royal First Physicians (Premiers médecins du roi)2 
 
1671–1693 Antoine Daquin 
 
1693–1715 Guy-Crescent Fagon 
 
1715–1718 Louis Poirier  
 
1718–1730 Claude-Jean-Baptiste Dodart  
 
1731–1732 Pierre Chirac  
 
1732–1752 François Chicoyneau  
 
1752–1770 Jean-Baptiste Sénac  
 
1774–1780 Joseph Lieutaud  
 
1780–1788 Joseph-Marie-François Lassone  
                                                 
 1 Source: Bernard Barbiche, Les institutions de la monarchie française à l’époque moderne (XVIe 
- XVIIIe siècle) (Paris: Presses Universitaires de France, 2012), 240. 
 2 Source: Paul Delaunay, Le monde médical parisien au dix-huitième siècle. (Paris: J. Rousset, 





AAP-HP Archives de l’Assistance publique – Hôpitaux de Paris 
 
AD  Archives départementales 
   Puy-de-dôme (Clermont-Ferand) 
   Ille-et-Vilaine (Rennes) 
Yvelines (Saint-Quentin-en-Yvelines) 
 
AME  Archives des Missions Etrangères de Paris (MEP) 
 
AN  Archives nationales  
  (Centre d’accueil et de recherche des Archives nationales, Paris) 
AE  Affaires étrangères (consulats) 
G7  Contrôle général des finances 
MARINE Fonds de la Marine 
MC  Minutier central des notaires de Paris 
O1  Maison du Roi 
V3  Prévôté de l’Hôtel 
V5  Grand conseil 
X  Parlement de Paris 
Y  Châtelet 
 
ANM   Académie nationale de médecine 
 SRM  Fonds du Société royale de médecine 
 
BM   Bibliothèque municipale 
  Reims, Bibliothèque Carnegie 
 
BIUS  Bibliothèque interuniversitaire de santé – Université Paris Descartes 
Pharmacie = Pôle Pharmacie 




Médecine = Pôle Médecine 
 
BnF  Bibliothèque nationale de France 
 
SHD  Service historique de la Défense (Vincennes) 
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